INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34001, 25481, 'Budesonide (nasal)', 'Adrenocortical Hyperfunction', 'The use of inhaled and nasal corticosteroids may rarely precipitate or aggravate conditions of hyperadrenocorticism.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during inhaled or nasal corticosteroid therapy may indicate excessive use.', '2', 'Kimmerle R, Rolla AR "Iatrogenic Cushing''s syndrome due to dexamethasone nasal drops." Am J Med 79 (1985):  535-7|Monk B, Cunliffe WJ, Layton AM, Rhodes DJ "Acne induced by inhaled corticosteroids." Clin Exp Dermatol 18 (1993):  148-50|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Clark TJ "Safety of inhaled corticosteroids." Eur J Respir Dis Suppl 122 (1982):  235-42|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|van As A, Bronsky E, Grossman J, Meltzer E, Ratner P, Reed C "Dose tolerance study of fluticasone propionate aqueous nasal spray in patients with seasonal allergic rhinitis." Ann Allergy 67 (1991):  156-62|Stevens DJ "Cushing''s syndrome due to the abuse of betamethasone nasal drops." J Laryngol Otol 102 (1988):  219-21|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Robinson DS, Geddes DM "Inhaled corticosteroids: benefits and risks." J Asthma 33 (1996):  5-16|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34002, 25482, 'Budesonide (nasal)', 'Adrenocortical Hyperfunction', 'The use of inhaled and nasal corticosteroids may rarely precipitate or aggravate conditions of hyperadrenocorticism.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during inhaled or nasal corticosteroid therapy may indicate excessive use.', '2', 'Kimmerle R, Rolla AR "Iatrogenic Cushing''s syndrome due to dexamethasone nasal drops." Am J Med 79 (1985):  535-7|Monk B, Cunliffe WJ, Layton AM, Rhodes DJ "Acne induced by inhaled corticosteroids." Clin Exp Dermatol 18 (1993):  148-50|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Clark TJ "Safety of inhaled corticosteroids." Eur J Respir Dis Suppl 122 (1982):  235-42|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|van As A, Bronsky E, Grossman J, Meltzer E, Ratner P, Reed C "Dose tolerance study of fluticasone propionate aqueous nasal spray in patients with seasonal allergic rhinitis." Ann Allergy 67 (1991):  156-62|Stevens DJ "Cushing''s syndrome due to the abuse of betamethasone nasal drops." J Laryngol Otol 102 (1988):  219-21|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Robinson DS, Geddes DM "Inhaled corticosteroids: benefits and risks." J Asthma 33 (1996):  5-16|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34003, 26038, 'Budesonide (nasal)', 'Adrenocortical Hyperfunction', 'The use of inhaled and nasal corticosteroids may rarely precipitate or aggravate conditions of hyperadrenocorticism.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during inhaled or nasal corticosteroid therapy may indicate excessive use.', '2', 'Kimmerle R, Rolla AR "Iatrogenic Cushing''s syndrome due to dexamethasone nasal drops." Am J Med 79 (1985):  535-7|Monk B, Cunliffe WJ, Layton AM, Rhodes DJ "Acne induced by inhaled corticosteroids." Clin Exp Dermatol 18 (1993):  148-50|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Clark TJ "Safety of inhaled corticosteroids." Eur J Respir Dis Suppl 122 (1982):  235-42|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|van As A, Bronsky E, Grossman J, Meltzer E, Ratner P, Reed C "Dose tolerance study of fluticasone propionate aqueous nasal spray in patients with seasonal allergic rhinitis." Ann Allergy 67 (1991):  156-62|Stevens DJ "Cushing''s syndrome due to the abuse of betamethasone nasal drops." J Laryngol Otol 102 (1988):  219-21|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Robinson DS, Geddes DM "Inhaled corticosteroids: benefits and risks." J Asthma 33 (1996):  5-16|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34004, 26039, 'Budesonide (nasal)', 'Adrenocortical Hyperfunction', 'The use of inhaled and nasal corticosteroids may rarely precipitate or aggravate conditions of hyperadrenocorticism.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during inhaled or nasal corticosteroid therapy may indicate excessive use.', '2', 'Kimmerle R, Rolla AR "Iatrogenic Cushing''s syndrome due to dexamethasone nasal drops." Am J Med 79 (1985):  535-7|Monk B, Cunliffe WJ, Layton AM, Rhodes DJ "Acne induced by inhaled corticosteroids." Clin Exp Dermatol 18 (1993):  148-50|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Clark TJ "Safety of inhaled corticosteroids." Eur J Respir Dis Suppl 122 (1982):  235-42|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|van As A, Bronsky E, Grossman J, Meltzer E, Ratner P, Reed C "Dose tolerance study of fluticasone propionate aqueous nasal spray in patients with seasonal allergic rhinitis." Ann Allergy 67 (1991):  156-62|Stevens DJ "Cushing''s syndrome due to the abuse of betamethasone nasal drops." J Laryngol Otol 102 (1988):  219-21|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Robinson DS, Geddes DM "Inhaled corticosteroids: benefits and risks." J Asthma 33 (1996):  5-16|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34005, 1780, 'Budesonide (nasal)', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Horton DJ, Spector SL "Clinical pulmonary tuberculosis in an asthmatic patient using a steroid aerosol." Chest 71 (1977):  540-2|Carrel TP, Schaffner A, Schmid ER, Schneider J, Bauer EP, Laske A, von Segesser LK, Turina MI "Fatal fungal pericarditis after cardiac surgery and immunosuppression." J Thorac Cardiovasc Surg 101 (1991):  161-4|Vogt FC "The incidence of oral candidiasis with use of inhaled corticosteroids." Ann Allergy 43 (1979):  205-10|Milne LJ, Crompton GK "Beclomethasone dipropionate and oropharyngeal candidiasis." Br Med J 3 (1974):  797-8|Toogood JH, Jennings B, Greenway RW, Chuang L "Candidiasis and dysphonia complicating beclomethasone treatment of asthma." J Allergy Clin Immunol 65 (1980):  145-53|Webb EL "Nasal candidiasis in a patient on long-term topical intranasal corticosteroid therapy." J Allergy Clin Immunol 91 (1993):  680-1|Shaikh WA "Pulmonary tuberculosis in patients treated with inhaled beclomethasone." Allergy 47 (1992):  327-30|Kesten S, Hyland RH, Pruzanski WR, Kortan PP "Esophageal candidiasis associated with beclomethasone dipropionate aerosol therapy." Drug Intell Clin Pharm 22 (1988):  568-9|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993):  223-8|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34006, 2048, 'Budesonide (nasal)', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Horton DJ, Spector SL "Clinical pulmonary tuberculosis in an asthmatic patient using a steroid aerosol." Chest 71 (1977):  540-2|Carrel TP, Schaffner A, Schmid ER, Schneider J, Bauer EP, Laske A, von Segesser LK, Turina MI "Fatal fungal pericarditis after cardiac surgery and immunosuppression." J Thorac Cardiovasc Surg 101 (1991):  161-4|Vogt FC "The incidence of oral candidiasis with use of inhaled corticosteroids." Ann Allergy 43 (1979):  205-10|Milne LJ, Crompton GK "Beclomethasone dipropionate and oropharyngeal candidiasis." Br Med J 3 (1974):  797-8|Toogood JH, Jennings B, Greenway RW, Chuang L "Candidiasis and dysphonia complicating beclomethasone treatment of asthma." J Allergy Clin Immunol 65 (1980):  145-53|Webb EL "Nasal candidiasis in a patient on long-term topical intranasal corticosteroid therapy." J Allergy Clin Immunol 91 (1993):  680-1|Shaikh WA "Pulmonary tuberculosis in patients treated with inhaled beclomethasone." Allergy 47 (1992):  327-30|Kesten S, Hyland RH, Pruzanski WR, Kortan PP "Esophageal candidiasis associated with beclomethasone dipropionate aerosol therapy." Drug Intell Clin Pharm 22 (1988):  568-9|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993):  223-8|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34007, 2413, 'Budesonide (nasal)', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Horton DJ, Spector SL "Clinical pulmonary tuberculosis in an asthmatic patient using a steroid aerosol." Chest 71 (1977):  540-2|Carrel TP, Schaffner A, Schmid ER, Schneider J, Bauer EP, Laske A, von Segesser LK, Turina MI "Fatal fungal pericarditis after cardiac surgery and immunosuppression." J Thorac Cardiovasc Surg 101 (1991):  161-4|Vogt FC "The incidence of oral candidiasis with use of inhaled corticosteroids." Ann Allergy 43 (1979):  205-10|Milne LJ, Crompton GK "Beclomethasone dipropionate and oropharyngeal candidiasis." Br Med J 3 (1974):  797-8|Toogood JH, Jennings B, Greenway RW, Chuang L "Candidiasis and dysphonia complicating beclomethasone treatment of asthma." J Allergy Clin Immunol 65 (1980):  145-53|Webb EL "Nasal candidiasis in a patient on long-term topical intranasal corticosteroid therapy." J Allergy Clin Immunol 91 (1993):  680-1|Shaikh WA "Pulmonary tuberculosis in patients treated with inhaled beclomethasone." Allergy 47 (1992):  327-30|Kesten S, Hyland RH, Pruzanski WR, Kortan PP "Esophageal candidiasis associated with beclomethasone dipropionate aerosol therapy." Drug Intell Clin Pharm 22 (1988):  568-9|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993):  223-8|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34008, 2424, 'Budesonide (nasal)', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Horton DJ, Spector SL "Clinical pulmonary tuberculosis in an asthmatic patient using a steroid aerosol." Chest 71 (1977):  540-2|Carrel TP, Schaffner A, Schmid ER, Schneider J, Bauer EP, Laske A, von Segesser LK, Turina MI "Fatal fungal pericarditis after cardiac surgery and immunosuppression." J Thorac Cardiovasc Surg 101 (1991):  161-4|Vogt FC "The incidence of oral candidiasis with use of inhaled corticosteroids." Ann Allergy 43 (1979):  205-10|Milne LJ, Crompton GK "Beclomethasone dipropionate and oropharyngeal candidiasis." Br Med J 3 (1974):  797-8|Toogood JH, Jennings B, Greenway RW, Chuang L "Candidiasis and dysphonia complicating beclomethasone treatment of asthma." J Allergy Clin Immunol 65 (1980):  145-53|Webb EL "Nasal candidiasis in a patient on long-term topical intranasal corticosteroid therapy." J Allergy Clin Immunol 91 (1993):  680-1|Shaikh WA "Pulmonary tuberculosis in patients treated with inhaled beclomethasone." Allergy 47 (1992):  327-30|Kesten S, Hyland RH, Pruzanski WR, Kortan PP "Esophageal candidiasis associated with beclomethasone dipropionate aerosol therapy." Drug Intell Clin Pharm 22 (1988):  568-9|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993):  223-8|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34009, 4183, 'Budesonide (nasal)', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Horton DJ, Spector SL "Clinical pulmonary tuberculosis in an asthmatic patient using a steroid aerosol." Chest 71 (1977):  540-2|Carrel TP, Schaffner A, Schmid ER, Schneider J, Bauer EP, Laske A, von Segesser LK, Turina MI "Fatal fungal pericarditis after cardiac surgery and immunosuppression." J Thorac Cardiovasc Surg 101 (1991):  161-4|Vogt FC "The incidence of oral candidiasis with use of inhaled corticosteroids." Ann Allergy 43 (1979):  205-10|Milne LJ, Crompton GK "Beclomethasone dipropionate and oropharyngeal candidiasis." Br Med J 3 (1974):  797-8|Toogood JH, Jennings B, Greenway RW, Chuang L "Candidiasis and dysphonia complicating beclomethasone treatment of asthma." J Allergy Clin Immunol 65 (1980):  145-53|Webb EL "Nasal candidiasis in a patient on long-term topical intranasal corticosteroid therapy." J Allergy Clin Immunol 91 (1993):  680-1|Shaikh WA "Pulmonary tuberculosis in patients treated with inhaled beclomethasone." Allergy 47 (1992):  327-30|Kesten S, Hyland RH, Pruzanski WR, Kortan PP "Esophageal candidiasis associated with beclomethasone dipropionate aerosol therapy." Drug Intell Clin Pharm 22 (1988):  568-9|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993):  223-8|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34010, 8162, 'Budesonide (nasal)', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Horton DJ, Spector SL "Clinical pulmonary tuberculosis in an asthmatic patient using a steroid aerosol." Chest 71 (1977):  540-2|Carrel TP, Schaffner A, Schmid ER, Schneider J, Bauer EP, Laske A, von Segesser LK, Turina MI "Fatal fungal pericarditis after cardiac surgery and immunosuppression." J Thorac Cardiovasc Surg 101 (1991):  161-4|Vogt FC "The incidence of oral candidiasis with use of inhaled corticosteroids." Ann Allergy 43 (1979):  205-10|Milne LJ, Crompton GK "Beclomethasone dipropionate and oropharyngeal candidiasis." Br Med J 3 (1974):  797-8|Toogood JH, Jennings B, Greenway RW, Chuang L "Candidiasis and dysphonia complicating beclomethasone treatment of asthma." J Allergy Clin Immunol 65 (1980):  145-53|Webb EL "Nasal candidiasis in a patient on long-term topical intranasal corticosteroid therapy." J Allergy Clin Immunol 91 (1993):  680-1|Shaikh WA "Pulmonary tuberculosis in patients treated with inhaled beclomethasone." Allergy 47 (1992):  327-30|Kesten S, Hyland RH, Pruzanski WR, Kortan PP "Esophageal candidiasis associated with beclomethasone dipropionate aerosol therapy." Drug Intell Clin Pharm 22 (1988):  568-9|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993):  223-8|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34011, 9114, 'Budesonide (nasal)', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Horton DJ, Spector SL "Clinical pulmonary tuberculosis in an asthmatic patient using a steroid aerosol." Chest 71 (1977):  540-2|Carrel TP, Schaffner A, Schmid ER, Schneider J, Bauer EP, Laske A, von Segesser LK, Turina MI "Fatal fungal pericarditis after cardiac surgery and immunosuppression." J Thorac Cardiovasc Surg 101 (1991):  161-4|Vogt FC "The incidence of oral candidiasis with use of inhaled corticosteroids." Ann Allergy 43 (1979):  205-10|Milne LJ, Crompton GK "Beclomethasone dipropionate and oropharyngeal candidiasis." Br Med J 3 (1974):  797-8|Toogood JH, Jennings B, Greenway RW, Chuang L "Candidiasis and dysphonia complicating beclomethasone treatment of asthma." J Allergy Clin Immunol 65 (1980):  145-53|Webb EL "Nasal candidiasis in a patient on long-term topical intranasal corticosteroid therapy." J Allergy Clin Immunol 91 (1993):  680-1|Shaikh WA "Pulmonary tuberculosis in patients treated with inhaled beclomethasone." Allergy 47 (1992):  327-30|Kesten S, Hyland RH, Pruzanski WR, Kortan PP "Esophageal candidiasis associated with beclomethasone dipropionate aerosol therapy." Drug Intell Clin Pharm 22 (1988):  568-9|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993):  223-8|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34012, 10589, 'Budesonide (nasal)', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Horton DJ, Spector SL "Clinical pulmonary tuberculosis in an asthmatic patient using a steroid aerosol." Chest 71 (1977):  540-2|Carrel TP, Schaffner A, Schmid ER, Schneider J, Bauer EP, Laske A, von Segesser LK, Turina MI "Fatal fungal pericarditis after cardiac surgery and immunosuppression." J Thorac Cardiovasc Surg 101 (1991):  161-4|Vogt FC "The incidence of oral candidiasis with use of inhaled corticosteroids." Ann Allergy 43 (1979):  205-10|Milne LJ, Crompton GK "Beclomethasone dipropionate and oropharyngeal candidiasis." Br Med J 3 (1974):  797-8|Toogood JH, Jennings B, Greenway RW, Chuang L "Candidiasis and dysphonia complicating beclomethasone treatment of asthma." J Allergy Clin Immunol 65 (1980):  145-53|Webb EL "Nasal candidiasis in a patient on long-term topical intranasal corticosteroid therapy." J Allergy Clin Immunol 91 (1993):  680-1|Shaikh WA "Pulmonary tuberculosis in patients treated with inhaled beclomethasone." Allergy 47 (1992):  327-30|Kesten S, Hyland RH, Pruzanski WR, Kortan PP "Esophageal candidiasis associated with beclomethasone dipropionate aerosol therapy." Drug Intell Clin Pharm 22 (1988):  568-9|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993):  223-8|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34013, 13149, 'Budesonide (nasal)', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Horton DJ, Spector SL "Clinical pulmonary tuberculosis in an asthmatic patient using a steroid aerosol." Chest 71 (1977):  540-2|Carrel TP, Schaffner A, Schmid ER, Schneider J, Bauer EP, Laske A, von Segesser LK, Turina MI "Fatal fungal pericarditis after cardiac surgery and immunosuppression." J Thorac Cardiovasc Surg 101 (1991):  161-4|Vogt FC "The incidence of oral candidiasis with use of inhaled corticosteroids." Ann Allergy 43 (1979):  205-10|Milne LJ, Crompton GK "Beclomethasone dipropionate and oropharyngeal candidiasis." Br Med J 3 (1974):  797-8|Toogood JH, Jennings B, Greenway RW, Chuang L "Candidiasis and dysphonia complicating beclomethasone treatment of asthma." J Allergy Clin Immunol 65 (1980):  145-53|Webb EL "Nasal candidiasis in a patient on long-term topical intranasal corticosteroid therapy." J Allergy Clin Immunol 91 (1993):  680-1|Shaikh WA "Pulmonary tuberculosis in patients treated with inhaled beclomethasone." Allergy 47 (1992):  327-30|Kesten S, Hyland RH, Pruzanski WR, Kortan PP "Esophageal candidiasis associated with beclomethasone dipropionate aerosol therapy." Drug Intell Clin Pharm 22 (1988):  568-9|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993):  223-8|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34014, 14925, 'Budesonide (nasal)', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Horton DJ, Spector SL "Clinical pulmonary tuberculosis in an asthmatic patient using a steroid aerosol." Chest 71 (1977):  540-2|Carrel TP, Schaffner A, Schmid ER, Schneider J, Bauer EP, Laske A, von Segesser LK, Turina MI "Fatal fungal pericarditis after cardiac surgery and immunosuppression." J Thorac Cardiovasc Surg 101 (1991):  161-4|Vogt FC "The incidence of oral candidiasis with use of inhaled corticosteroids." Ann Allergy 43 (1979):  205-10|Milne LJ, Crompton GK "Beclomethasone dipropionate and oropharyngeal candidiasis." Br Med J 3 (1974):  797-8|Toogood JH, Jennings B, Greenway RW, Chuang L "Candidiasis and dysphonia complicating beclomethasone treatment of asthma." J Allergy Clin Immunol 65 (1980):  145-53|Webb EL "Nasal candidiasis in a patient on long-term topical intranasal corticosteroid therapy." J Allergy Clin Immunol 91 (1993):  680-1|Shaikh WA "Pulmonary tuberculosis in patients treated with inhaled beclomethasone." Allergy 47 (1992):  327-30|Kesten S, Hyland RH, Pruzanski WR, Kortan PP "Esophageal candidiasis associated with beclomethasone dipropionate aerosol therapy." Drug Intell Clin Pharm 22 (1988):  568-9|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993):  223-8|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34015, 15551, 'Budesonide (nasal)', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Horton DJ, Spector SL "Clinical pulmonary tuberculosis in an asthmatic patient using a steroid aerosol." Chest 71 (1977):  540-2|Carrel TP, Schaffner A, Schmid ER, Schneider J, Bauer EP, Laske A, von Segesser LK, Turina MI "Fatal fungal pericarditis after cardiac surgery and immunosuppression." J Thorac Cardiovasc Surg 101 (1991):  161-4|Vogt FC "The incidence of oral candidiasis with use of inhaled corticosteroids." Ann Allergy 43 (1979):  205-10|Milne LJ, Crompton GK "Beclomethasone dipropionate and oropharyngeal candidiasis." Br Med J 3 (1974):  797-8|Toogood JH, Jennings B, Greenway RW, Chuang L "Candidiasis and dysphonia complicating beclomethasone treatment of asthma." J Allergy Clin Immunol 65 (1980):  145-53|Webb EL "Nasal candidiasis in a patient on long-term topical intranasal corticosteroid therapy." J Allergy Clin Immunol 91 (1993):  680-1|Shaikh WA "Pulmonary tuberculosis in patients treated with inhaled beclomethasone." Allergy 47 (1992):  327-30|Kesten S, Hyland RH, Pruzanski WR, Kortan PP "Esophageal candidiasis associated with beclomethasone dipropionate aerosol therapy." Drug Intell Clin Pharm 22 (1988):  568-9|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993):  223-8|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34016, 15552, 'Budesonide (nasal)', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Horton DJ, Spector SL "Clinical pulmonary tuberculosis in an asthmatic patient using a steroid aerosol." Chest 71 (1977):  540-2|Carrel TP, Schaffner A, Schmid ER, Schneider J, Bauer EP, Laske A, von Segesser LK, Turina MI "Fatal fungal pericarditis after cardiac surgery and immunosuppression." J Thorac Cardiovasc Surg 101 (1991):  161-4|Vogt FC "The incidence of oral candidiasis with use of inhaled corticosteroids." Ann Allergy 43 (1979):  205-10|Milne LJ, Crompton GK "Beclomethasone dipropionate and oropharyngeal candidiasis." Br Med J 3 (1974):  797-8|Toogood JH, Jennings B, Greenway RW, Chuang L "Candidiasis and dysphonia complicating beclomethasone treatment of asthma." J Allergy Clin Immunol 65 (1980):  145-53|Webb EL "Nasal candidiasis in a patient on long-term topical intranasal corticosteroid therapy." J Allergy Clin Immunol 91 (1993):  680-1|Shaikh WA "Pulmonary tuberculosis in patients treated with inhaled beclomethasone." Allergy 47 (1992):  327-30|Kesten S, Hyland RH, Pruzanski WR, Kortan PP "Esophageal candidiasis associated with beclomethasone dipropionate aerosol therapy." Drug Intell Clin Pharm 22 (1988):  568-9|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993):  223-8|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34017, 15553, 'Budesonide (nasal)', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Horton DJ, Spector SL "Clinical pulmonary tuberculosis in an asthmatic patient using a steroid aerosol." Chest 71 (1977):  540-2|Carrel TP, Schaffner A, Schmid ER, Schneider J, Bauer EP, Laske A, von Segesser LK, Turina MI "Fatal fungal pericarditis after cardiac surgery and immunosuppression." J Thorac Cardiovasc Surg 101 (1991):  161-4|Vogt FC "The incidence of oral candidiasis with use of inhaled corticosteroids." Ann Allergy 43 (1979):  205-10|Milne LJ, Crompton GK "Beclomethasone dipropionate and oropharyngeal candidiasis." Br Med J 3 (1974):  797-8|Toogood JH, Jennings B, Greenway RW, Chuang L "Candidiasis and dysphonia complicating beclomethasone treatment of asthma." J Allergy Clin Immunol 65 (1980):  145-53|Webb EL "Nasal candidiasis in a patient on long-term topical intranasal corticosteroid therapy." J Allergy Clin Immunol 91 (1993):  680-1|Shaikh WA "Pulmonary tuberculosis in patients treated with inhaled beclomethasone." Allergy 47 (1992):  327-30|Kesten S, Hyland RH, Pruzanski WR, Kortan PP "Esophageal candidiasis associated with beclomethasone dipropionate aerosol therapy." Drug Intell Clin Pharm 22 (1988):  568-9|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993):  223-8|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34018, 15555, 'Budesonide (nasal)', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Horton DJ, Spector SL "Clinical pulmonary tuberculosis in an asthmatic patient using a steroid aerosol." Chest 71 (1977):  540-2|Carrel TP, Schaffner A, Schmid ER, Schneider J, Bauer EP, Laske A, von Segesser LK, Turina MI "Fatal fungal pericarditis after cardiac surgery and immunosuppression." J Thorac Cardiovasc Surg 101 (1991):  161-4|Vogt FC "The incidence of oral candidiasis with use of inhaled corticosteroids." Ann Allergy 43 (1979):  205-10|Milne LJ, Crompton GK "Beclomethasone dipropionate and oropharyngeal candidiasis." Br Med J 3 (1974):  797-8|Toogood JH, Jennings B, Greenway RW, Chuang L "Candidiasis and dysphonia complicating beclomethasone treatment of asthma." J Allergy Clin Immunol 65 (1980):  145-53|Webb EL "Nasal candidiasis in a patient on long-term topical intranasal corticosteroid therapy." J Allergy Clin Immunol 91 (1993):  680-1|Shaikh WA "Pulmonary tuberculosis in patients treated with inhaled beclomethasone." Allergy 47 (1992):  327-30|Kesten S, Hyland RH, Pruzanski WR, Kortan PP "Esophageal candidiasis associated with beclomethasone dipropionate aerosol therapy." Drug Intell Clin Pharm 22 (1988):  568-9|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993):  223-8|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34019, 15556, 'Budesonide (nasal)', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Horton DJ, Spector SL "Clinical pulmonary tuberculosis in an asthmatic patient using a steroid aerosol." Chest 71 (1977):  540-2|Carrel TP, Schaffner A, Schmid ER, Schneider J, Bauer EP, Laske A, von Segesser LK, Turina MI "Fatal fungal pericarditis after cardiac surgery and immunosuppression." J Thorac Cardiovasc Surg 101 (1991):  161-4|Vogt FC "The incidence of oral candidiasis with use of inhaled corticosteroids." Ann Allergy 43 (1979):  205-10|Milne LJ, Crompton GK "Beclomethasone dipropionate and oropharyngeal candidiasis." Br Med J 3 (1974):  797-8|Toogood JH, Jennings B, Greenway RW, Chuang L "Candidiasis and dysphonia complicating beclomethasone treatment of asthma." J Allergy Clin Immunol 65 (1980):  145-53|Webb EL "Nasal candidiasis in a patient on long-term topical intranasal corticosteroid therapy." J Allergy Clin Immunol 91 (1993):  680-1|Shaikh WA "Pulmonary tuberculosis in patients treated with inhaled beclomethasone." Allergy 47 (1992):  327-30|Kesten S, Hyland RH, Pruzanski WR, Kortan PP "Esophageal candidiasis associated with beclomethasone dipropionate aerosol therapy." Drug Intell Clin Pharm 22 (1988):  568-9|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993):  223-8|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34020, 18134, 'Budesonide (nasal)', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Horton DJ, Spector SL "Clinical pulmonary tuberculosis in an asthmatic patient using a steroid aerosol." Chest 71 (1977):  540-2|Carrel TP, Schaffner A, Schmid ER, Schneider J, Bauer EP, Laske A, von Segesser LK, Turina MI "Fatal fungal pericarditis after cardiac surgery and immunosuppression." J Thorac Cardiovasc Surg 101 (1991):  161-4|Vogt FC "The incidence of oral candidiasis with use of inhaled corticosteroids." Ann Allergy 43 (1979):  205-10|Milne LJ, Crompton GK "Beclomethasone dipropionate and oropharyngeal candidiasis." Br Med J 3 (1974):  797-8|Toogood JH, Jennings B, Greenway RW, Chuang L "Candidiasis and dysphonia complicating beclomethasone treatment of asthma." J Allergy Clin Immunol 65 (1980):  145-53|Webb EL "Nasal candidiasis in a patient on long-term topical intranasal corticosteroid therapy." J Allergy Clin Immunol 91 (1993):  680-1|Shaikh WA "Pulmonary tuberculosis in patients treated with inhaled beclomethasone." Allergy 47 (1992):  327-30|Kesten S, Hyland RH, Pruzanski WR, Kortan PP "Esophageal candidiasis associated with beclomethasone dipropionate aerosol therapy." Drug Intell Clin Pharm 22 (1988):  568-9|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993):  223-8|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34021, 25479, 'Budesonide (nasal)', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Horton DJ, Spector SL "Clinical pulmonary tuberculosis in an asthmatic patient using a steroid aerosol." Chest 71 (1977):  540-2|Carrel TP, Schaffner A, Schmid ER, Schneider J, Bauer EP, Laske A, von Segesser LK, Turina MI "Fatal fungal pericarditis after cardiac surgery and immunosuppression." J Thorac Cardiovasc Surg 101 (1991):  161-4|Vogt FC "The incidence of oral candidiasis with use of inhaled corticosteroids." Ann Allergy 43 (1979):  205-10|Milne LJ, Crompton GK "Beclomethasone dipropionate and oropharyngeal candidiasis." Br Med J 3 (1974):  797-8|Toogood JH, Jennings B, Greenway RW, Chuang L "Candidiasis and dysphonia complicating beclomethasone treatment of asthma." J Allergy Clin Immunol 65 (1980):  145-53|Webb EL "Nasal candidiasis in a patient on long-term topical intranasal corticosteroid therapy." J Allergy Clin Immunol 91 (1993):  680-1|Shaikh WA "Pulmonary tuberculosis in patients treated with inhaled beclomethasone." Allergy 47 (1992):  327-30|Kesten S, Hyland RH, Pruzanski WR, Kortan PP "Esophageal candidiasis associated with beclomethasone dipropionate aerosol therapy." Drug Intell Clin Pharm 22 (1988):  568-9|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993):  223-8|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34022, 25480, 'Budesonide (nasal)', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Horton DJ, Spector SL "Clinical pulmonary tuberculosis in an asthmatic patient using a steroid aerosol." Chest 71 (1977):  540-2|Carrel TP, Schaffner A, Schmid ER, Schneider J, Bauer EP, Laske A, von Segesser LK, Turina MI "Fatal fungal pericarditis after cardiac surgery and immunosuppression." J Thorac Cardiovasc Surg 101 (1991):  161-4|Vogt FC "The incidence of oral candidiasis with use of inhaled corticosteroids." Ann Allergy 43 (1979):  205-10|Milne LJ, Crompton GK "Beclomethasone dipropionate and oropharyngeal candidiasis." Br Med J 3 (1974):  797-8|Toogood JH, Jennings B, Greenway RW, Chuang L "Candidiasis and dysphonia complicating beclomethasone treatment of asthma." J Allergy Clin Immunol 65 (1980):  145-53|Webb EL "Nasal candidiasis in a patient on long-term topical intranasal corticosteroid therapy." J Allergy Clin Immunol 91 (1993):  680-1|Shaikh WA "Pulmonary tuberculosis in patients treated with inhaled beclomethasone." Allergy 47 (1992):  327-30|Kesten S, Hyland RH, Pruzanski WR, Kortan PP "Esophageal candidiasis associated with beclomethasone dipropionate aerosol therapy." Drug Intell Clin Pharm 22 (1988):  568-9|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993):  223-8|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34023, 25481, 'Budesonide (nasal)', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Horton DJ, Spector SL "Clinical pulmonary tuberculosis in an asthmatic patient using a steroid aerosol." Chest 71 (1977):  540-2|Carrel TP, Schaffner A, Schmid ER, Schneider J, Bauer EP, Laske A, von Segesser LK, Turina MI "Fatal fungal pericarditis after cardiac surgery and immunosuppression." J Thorac Cardiovasc Surg 101 (1991):  161-4|Vogt FC "The incidence of oral candidiasis with use of inhaled corticosteroids." Ann Allergy 43 (1979):  205-10|Milne LJ, Crompton GK "Beclomethasone dipropionate and oropharyngeal candidiasis." Br Med J 3 (1974):  797-8|Toogood JH, Jennings B, Greenway RW, Chuang L "Candidiasis and dysphonia complicating beclomethasone treatment of asthma." J Allergy Clin Immunol 65 (1980):  145-53|Webb EL "Nasal candidiasis in a patient on long-term topical intranasal corticosteroid therapy." J Allergy Clin Immunol 91 (1993):  680-1|Shaikh WA "Pulmonary tuberculosis in patients treated with inhaled beclomethasone." Allergy 47 (1992):  327-30|Kesten S, Hyland RH, Pruzanski WR, Kortan PP "Esophageal candidiasis associated with beclomethasone dipropionate aerosol therapy." Drug Intell Clin Pharm 22 (1988):  568-9|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993):  223-8|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34024, 25482, 'Budesonide (nasal)', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Horton DJ, Spector SL "Clinical pulmonary tuberculosis in an asthmatic patient using a steroid aerosol." Chest 71 (1977):  540-2|Carrel TP, Schaffner A, Schmid ER, Schneider J, Bauer EP, Laske A, von Segesser LK, Turina MI "Fatal fungal pericarditis after cardiac surgery and immunosuppression." J Thorac Cardiovasc Surg 101 (1991):  161-4|Vogt FC "The incidence of oral candidiasis with use of inhaled corticosteroids." Ann Allergy 43 (1979):  205-10|Milne LJ, Crompton GK "Beclomethasone dipropionate and oropharyngeal candidiasis." Br Med J 3 (1974):  797-8|Toogood JH, Jennings B, Greenway RW, Chuang L "Candidiasis and dysphonia complicating beclomethasone treatment of asthma." J Allergy Clin Immunol 65 (1980):  145-53|Webb EL "Nasal candidiasis in a patient on long-term topical intranasal corticosteroid therapy." J Allergy Clin Immunol 91 (1993):  680-1|Shaikh WA "Pulmonary tuberculosis in patients treated with inhaled beclomethasone." Allergy 47 (1992):  327-30|Kesten S, Hyland RH, Pruzanski WR, Kortan PP "Esophageal candidiasis associated with beclomethasone dipropionate aerosol therapy." Drug Intell Clin Pharm 22 (1988):  568-9|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993):  223-8|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34025, 26038, 'Budesonide (nasal)', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Horton DJ, Spector SL "Clinical pulmonary tuberculosis in an asthmatic patient using a steroid aerosol." Chest 71 (1977):  540-2|Carrel TP, Schaffner A, Schmid ER, Schneider J, Bauer EP, Laske A, von Segesser LK, Turina MI "Fatal fungal pericarditis after cardiac surgery and immunosuppression." J Thorac Cardiovasc Surg 101 (1991):  161-4|Vogt FC "The incidence of oral candidiasis with use of inhaled corticosteroids." Ann Allergy 43 (1979):  205-10|Milne LJ, Crompton GK "Beclomethasone dipropionate and oropharyngeal candidiasis." Br Med J 3 (1974):  797-8|Toogood JH, Jennings B, Greenway RW, Chuang L "Candidiasis and dysphonia complicating beclomethasone treatment of asthma." J Allergy Clin Immunol 65 (1980):  145-53|Webb EL "Nasal candidiasis in a patient on long-term topical intranasal corticosteroid therapy." J Allergy Clin Immunol 91 (1993):  680-1|Shaikh WA "Pulmonary tuberculosis in patients treated with inhaled beclomethasone." Allergy 47 (1992):  327-30|Kesten S, Hyland RH, Pruzanski WR, Kortan PP "Esophageal candidiasis associated with beclomethasone dipropionate aerosol therapy." Drug Intell Clin Pharm 22 (1988):  568-9|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993):  223-8|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34026, 26039, 'Budesonide (nasal)', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with an infection, particularly active or quiescent tuberculosis infection of the respiratory tract or any untreated systemic fungal, bacterial, parasitic, or viral infection.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Horton DJ, Spector SL "Clinical pulmonary tuberculosis in an asthmatic patient using a steroid aerosol." Chest 71 (1977):  540-2|Carrel TP, Schaffner A, Schmid ER, Schneider J, Bauer EP, Laske A, von Segesser LK, Turina MI "Fatal fungal pericarditis after cardiac surgery and immunosuppression." J Thorac Cardiovasc Surg 101 (1991):  161-4|Vogt FC "The incidence of oral candidiasis with use of inhaled corticosteroids." Ann Allergy 43 (1979):  205-10|Milne LJ, Crompton GK "Beclomethasone dipropionate and oropharyngeal candidiasis." Br Med J 3 (1974):  797-8|Toogood JH, Jennings B, Greenway RW, Chuang L "Candidiasis and dysphonia complicating beclomethasone treatment of asthma." J Allergy Clin Immunol 65 (1980):  145-53|Webb EL "Nasal candidiasis in a patient on long-term topical intranasal corticosteroid therapy." J Allergy Clin Immunol 91 (1993):  680-1|Shaikh WA "Pulmonary tuberculosis in patients treated with inhaled beclomethasone." Allergy 47 (1992):  327-30|Kesten S, Hyland RH, Pruzanski WR, Kortan PP "Esophageal candidiasis associated with beclomethasone dipropionate aerosol therapy." Drug Intell Clin Pharm 22 (1988):  568-9|Brogden RN, Heel RC, Speight TM, Avery GS "Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis." Drugs 28 (1984):  99-126|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Executive Committee American Academy of Allergy and Immunology "Inhaled corticosteroids and severe viral infections." J Allergy Clin Immunol 92 (1993):  223-8|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34027, 1780, 'Budesonide (nasal)', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34028, 2048, 'Budesonide (nasal)', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34029, 2413, 'Budesonide (nasal)', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34030, 2424, 'Budesonide (nasal)', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34031, 4183, 'Budesonide (nasal)', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34032, 8162, 'Budesonide (nasal)', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34033, 9114, 'Budesonide (nasal)', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34034, 10589, 'Budesonide (nasal)', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34035, 13149, 'Budesonide (nasal)', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34036, 14925, 'Budesonide (nasal)', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34037, 15551, 'Budesonide (nasal)', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34038, 15552, 'Budesonide (nasal)', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34039, 15553, 'Budesonide (nasal)', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34040, 15555, 'Budesonide (nasal)', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34041, 15556, 'Budesonide (nasal)', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34042, 18134, 'Budesonide (nasal)', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34043, 25479, 'Budesonide (nasal)', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34044, 25480, 'Budesonide (nasal)', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34045, 25481, 'Budesonide (nasal)', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34046, 25482, 'Budesonide (nasal)', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34047, 26038, 'Budesonide (nasal)', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34048, 26039, 'Budesonide (nasal)', 'Keratitis, Herpetic', 'Pharmacologic dosages of corticosteroids may increase the risk of corneal perforation in patients with ocular herpes simplex.  Therapy with inhaled and nasal corticosteroids should be administered cautiously in such patients.', '2', '"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34049, 1780, 'Budesonide (nasal)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Fraunfelder FT, Meyer SM "Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids." Am J Ophthalmol 109 (1990):  489-90|Karim AK, Thompson GM, Jacob TJ "Steroid aerosols and cataract formation." BMJ 299 (1989):  918|Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen B "Steroid aerosols and cataract formation." BMJ 299 (1989):  432-3|Kewley GD "Possible association between beclomethasone diproprionate aerosol and cataracts." Aust Paediatr J 16 (1980):  117-8|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Ghanchi F "Young patients on inhaled steroids and cataract." Lancet 342 (1993):  1306-7|Dreyer EB "Inhaled steroid use and glaucoma." N Engl J Med 329 (1993):  1822|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Spaeth GL, Rodrigues MM, Weinreb S "Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects." Trans Am Ophthalmol Soc 75 (1977):  353-81|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997):  722-7|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Cumming RG, Mitchell P, Leeder SR "Use of inhaled corticosteroids and the risk of cataracts." N Engl J Med 337 (1997):  8-14|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Agertoft L, Larsen FE, Pedersen S "Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide." Eur Resp J 12 (1998):  130-5|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34050, 2048, 'Budesonide (nasal)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Fraunfelder FT, Meyer SM "Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids." Am J Ophthalmol 109 (1990):  489-90|Karim AK, Thompson GM, Jacob TJ "Steroid aerosols and cataract formation." BMJ 299 (1989):  918|Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen B "Steroid aerosols and cataract formation." BMJ 299 (1989):  432-3|Kewley GD "Possible association between beclomethasone diproprionate aerosol and cataracts." Aust Paediatr J 16 (1980):  117-8|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Ghanchi F "Young patients on inhaled steroids and cataract." Lancet 342 (1993):  1306-7|Dreyer EB "Inhaled steroid use and glaucoma." N Engl J Med 329 (1993):  1822|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Spaeth GL, Rodrigues MM, Weinreb S "Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects." Trans Am Ophthalmol Soc 75 (1977):  353-81|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997):  722-7|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Cumming RG, Mitchell P, Leeder SR "Use of inhaled corticosteroids and the risk of cataracts." N Engl J Med 337 (1997):  8-14|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Agertoft L, Larsen FE, Pedersen S "Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide." Eur Resp J 12 (1998):  130-5|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34051, 2413, 'Budesonide (nasal)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Fraunfelder FT, Meyer SM "Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids." Am J Ophthalmol 109 (1990):  489-90|Karim AK, Thompson GM, Jacob TJ "Steroid aerosols and cataract formation." BMJ 299 (1989):  918|Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen B "Steroid aerosols and cataract formation." BMJ 299 (1989):  432-3|Kewley GD "Possible association between beclomethasone diproprionate aerosol and cataracts." Aust Paediatr J 16 (1980):  117-8|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Ghanchi F "Young patients on inhaled steroids and cataract." Lancet 342 (1993):  1306-7|Dreyer EB "Inhaled steroid use and glaucoma." N Engl J Med 329 (1993):  1822|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Spaeth GL, Rodrigues MM, Weinreb S "Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects." Trans Am Ophthalmol Soc 75 (1977):  353-81|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997):  722-7|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Cumming RG, Mitchell P, Leeder SR "Use of inhaled corticosteroids and the risk of cataracts." N Engl J Med 337 (1997):  8-14|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Agertoft L, Larsen FE, Pedersen S "Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide." Eur Resp J 12 (1998):  130-5|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34052, 2424, 'Budesonide (nasal)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Fraunfelder FT, Meyer SM "Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids." Am J Ophthalmol 109 (1990):  489-90|Karim AK, Thompson GM, Jacob TJ "Steroid aerosols and cataract formation." BMJ 299 (1989):  918|Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen B "Steroid aerosols and cataract formation." BMJ 299 (1989):  432-3|Kewley GD "Possible association between beclomethasone diproprionate aerosol and cataracts." Aust Paediatr J 16 (1980):  117-8|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Ghanchi F "Young patients on inhaled steroids and cataract." Lancet 342 (1993):  1306-7|Dreyer EB "Inhaled steroid use and glaucoma." N Engl J Med 329 (1993):  1822|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Spaeth GL, Rodrigues MM, Weinreb S "Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects." Trans Am Ophthalmol Soc 75 (1977):  353-81|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997):  722-7|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Cumming RG, Mitchell P, Leeder SR "Use of inhaled corticosteroids and the risk of cataracts." N Engl J Med 337 (1997):  8-14|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Agertoft L, Larsen FE, Pedersen S "Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide." Eur Resp J 12 (1998):  130-5|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34053, 4183, 'Budesonide (nasal)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Fraunfelder FT, Meyer SM "Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids." Am J Ophthalmol 109 (1990):  489-90|Karim AK, Thompson GM, Jacob TJ "Steroid aerosols and cataract formation." BMJ 299 (1989):  918|Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen B "Steroid aerosols and cataract formation." BMJ 299 (1989):  432-3|Kewley GD "Possible association between beclomethasone diproprionate aerosol and cataracts." Aust Paediatr J 16 (1980):  117-8|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Ghanchi F "Young patients on inhaled steroids and cataract." Lancet 342 (1993):  1306-7|Dreyer EB "Inhaled steroid use and glaucoma." N Engl J Med 329 (1993):  1822|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Spaeth GL, Rodrigues MM, Weinreb S "Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects." Trans Am Ophthalmol Soc 75 (1977):  353-81|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997):  722-7|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Cumming RG, Mitchell P, Leeder SR "Use of inhaled corticosteroids and the risk of cataracts." N Engl J Med 337 (1997):  8-14|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Agertoft L, Larsen FE, Pedersen S "Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide." Eur Resp J 12 (1998):  130-5|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34054, 8162, 'Budesonide (nasal)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Fraunfelder FT, Meyer SM "Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids." Am J Ophthalmol 109 (1990):  489-90|Karim AK, Thompson GM, Jacob TJ "Steroid aerosols and cataract formation." BMJ 299 (1989):  918|Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen B "Steroid aerosols and cataract formation." BMJ 299 (1989):  432-3|Kewley GD "Possible association between beclomethasone diproprionate aerosol and cataracts." Aust Paediatr J 16 (1980):  117-8|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Ghanchi F "Young patients on inhaled steroids and cataract." Lancet 342 (1993):  1306-7|Dreyer EB "Inhaled steroid use and glaucoma." N Engl J Med 329 (1993):  1822|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Spaeth GL, Rodrigues MM, Weinreb S "Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects." Trans Am Ophthalmol Soc 75 (1977):  353-81|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997):  722-7|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Cumming RG, Mitchell P, Leeder SR "Use of inhaled corticosteroids and the risk of cataracts." N Engl J Med 337 (1997):  8-14|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Agertoft L, Larsen FE, Pedersen S "Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide." Eur Resp J 12 (1998):  130-5|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34055, 9114, 'Budesonide (nasal)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Fraunfelder FT, Meyer SM "Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids." Am J Ophthalmol 109 (1990):  489-90|Karim AK, Thompson GM, Jacob TJ "Steroid aerosols and cataract formation." BMJ 299 (1989):  918|Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen B "Steroid aerosols and cataract formation." BMJ 299 (1989):  432-3|Kewley GD "Possible association between beclomethasone diproprionate aerosol and cataracts." Aust Paediatr J 16 (1980):  117-8|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Ghanchi F "Young patients on inhaled steroids and cataract." Lancet 342 (1993):  1306-7|Dreyer EB "Inhaled steroid use and glaucoma." N Engl J Med 329 (1993):  1822|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Spaeth GL, Rodrigues MM, Weinreb S "Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects." Trans Am Ophthalmol Soc 75 (1977):  353-81|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997):  722-7|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Cumming RG, Mitchell P, Leeder SR "Use of inhaled corticosteroids and the risk of cataracts." N Engl J Med 337 (1997):  8-14|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Agertoft L, Larsen FE, Pedersen S "Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide." Eur Resp J 12 (1998):  130-5|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34056, 10589, 'Budesonide (nasal)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Fraunfelder FT, Meyer SM "Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids." Am J Ophthalmol 109 (1990):  489-90|Karim AK, Thompson GM, Jacob TJ "Steroid aerosols and cataract formation." BMJ 299 (1989):  918|Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen B "Steroid aerosols and cataract formation." BMJ 299 (1989):  432-3|Kewley GD "Possible association between beclomethasone diproprionate aerosol and cataracts." Aust Paediatr J 16 (1980):  117-8|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Ghanchi F "Young patients on inhaled steroids and cataract." Lancet 342 (1993):  1306-7|Dreyer EB "Inhaled steroid use and glaucoma." N Engl J Med 329 (1993):  1822|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Spaeth GL, Rodrigues MM, Weinreb S "Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects." Trans Am Ophthalmol Soc 75 (1977):  353-81|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997):  722-7|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Cumming RG, Mitchell P, Leeder SR "Use of inhaled corticosteroids and the risk of cataracts." N Engl J Med 337 (1997):  8-14|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Agertoft L, Larsen FE, Pedersen S "Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide." Eur Resp J 12 (1998):  130-5|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34057, 13149, 'Budesonide (nasal)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Fraunfelder FT, Meyer SM "Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids." Am J Ophthalmol 109 (1990):  489-90|Karim AK, Thompson GM, Jacob TJ "Steroid aerosols and cataract formation." BMJ 299 (1989):  918|Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen B "Steroid aerosols and cataract formation." BMJ 299 (1989):  432-3|Kewley GD "Possible association between beclomethasone diproprionate aerosol and cataracts." Aust Paediatr J 16 (1980):  117-8|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Ghanchi F "Young patients on inhaled steroids and cataract." Lancet 342 (1993):  1306-7|Dreyer EB "Inhaled steroid use and glaucoma." N Engl J Med 329 (1993):  1822|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Spaeth GL, Rodrigues MM, Weinreb S "Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects." Trans Am Ophthalmol Soc 75 (1977):  353-81|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997):  722-7|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Cumming RG, Mitchell P, Leeder SR "Use of inhaled corticosteroids and the risk of cataracts." N Engl J Med 337 (1997):  8-14|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Agertoft L, Larsen FE, Pedersen S "Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide." Eur Resp J 12 (1998):  130-5|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34058, 14925, 'Budesonide (nasal)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Fraunfelder FT, Meyer SM "Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids." Am J Ophthalmol 109 (1990):  489-90|Karim AK, Thompson GM, Jacob TJ "Steroid aerosols and cataract formation." BMJ 299 (1989):  918|Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen B "Steroid aerosols and cataract formation." BMJ 299 (1989):  432-3|Kewley GD "Possible association between beclomethasone diproprionate aerosol and cataracts." Aust Paediatr J 16 (1980):  117-8|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Ghanchi F "Young patients on inhaled steroids and cataract." Lancet 342 (1993):  1306-7|Dreyer EB "Inhaled steroid use and glaucoma." N Engl J Med 329 (1993):  1822|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Spaeth GL, Rodrigues MM, Weinreb S "Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects." Trans Am Ophthalmol Soc 75 (1977):  353-81|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997):  722-7|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Cumming RG, Mitchell P, Leeder SR "Use of inhaled corticosteroids and the risk of cataracts." N Engl J Med 337 (1997):  8-14|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Agertoft L, Larsen FE, Pedersen S "Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide." Eur Resp J 12 (1998):  130-5|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34059, 15551, 'Budesonide (nasal)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Fraunfelder FT, Meyer SM "Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids." Am J Ophthalmol 109 (1990):  489-90|Karim AK, Thompson GM, Jacob TJ "Steroid aerosols and cataract formation." BMJ 299 (1989):  918|Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen B "Steroid aerosols and cataract formation." BMJ 299 (1989):  432-3|Kewley GD "Possible association between beclomethasone diproprionate aerosol and cataracts." Aust Paediatr J 16 (1980):  117-8|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Ghanchi F "Young patients on inhaled steroids and cataract." Lancet 342 (1993):  1306-7|Dreyer EB "Inhaled steroid use and glaucoma." N Engl J Med 329 (1993):  1822|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Spaeth GL, Rodrigues MM, Weinreb S "Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects." Trans Am Ophthalmol Soc 75 (1977):  353-81|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997):  722-7|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Cumming RG, Mitchell P, Leeder SR "Use of inhaled corticosteroids and the risk of cataracts." N Engl J Med 337 (1997):  8-14|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Agertoft L, Larsen FE, Pedersen S "Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide." Eur Resp J 12 (1998):  130-5|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34060, 15552, 'Budesonide (nasal)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Fraunfelder FT, Meyer SM "Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids." Am J Ophthalmol 109 (1990):  489-90|Karim AK, Thompson GM, Jacob TJ "Steroid aerosols and cataract formation." BMJ 299 (1989):  918|Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen B "Steroid aerosols and cataract formation." BMJ 299 (1989):  432-3|Kewley GD "Possible association between beclomethasone diproprionate aerosol and cataracts." Aust Paediatr J 16 (1980):  117-8|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Ghanchi F "Young patients on inhaled steroids and cataract." Lancet 342 (1993):  1306-7|Dreyer EB "Inhaled steroid use and glaucoma." N Engl J Med 329 (1993):  1822|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Spaeth GL, Rodrigues MM, Weinreb S "Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects." Trans Am Ophthalmol Soc 75 (1977):  353-81|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997):  722-7|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Cumming RG, Mitchell P, Leeder SR "Use of inhaled corticosteroids and the risk of cataracts." N Engl J Med 337 (1997):  8-14|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Agertoft L, Larsen FE, Pedersen S "Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide." Eur Resp J 12 (1998):  130-5|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34061, 15553, 'Budesonide (nasal)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Fraunfelder FT, Meyer SM "Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids." Am J Ophthalmol 109 (1990):  489-90|Karim AK, Thompson GM, Jacob TJ "Steroid aerosols and cataract formation." BMJ 299 (1989):  918|Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen B "Steroid aerosols and cataract formation." BMJ 299 (1989):  432-3|Kewley GD "Possible association between beclomethasone diproprionate aerosol and cataracts." Aust Paediatr J 16 (1980):  117-8|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Ghanchi F "Young patients on inhaled steroids and cataract." Lancet 342 (1993):  1306-7|Dreyer EB "Inhaled steroid use and glaucoma." N Engl J Med 329 (1993):  1822|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Spaeth GL, Rodrigues MM, Weinreb S "Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects." Trans Am Ophthalmol Soc 75 (1977):  353-81|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997):  722-7|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Cumming RG, Mitchell P, Leeder SR "Use of inhaled corticosteroids and the risk of cataracts." N Engl J Med 337 (1997):  8-14|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Agertoft L, Larsen FE, Pedersen S "Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide." Eur Resp J 12 (1998):  130-5|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34062, 15555, 'Budesonide (nasal)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Fraunfelder FT, Meyer SM "Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids." Am J Ophthalmol 109 (1990):  489-90|Karim AK, Thompson GM, Jacob TJ "Steroid aerosols and cataract formation." BMJ 299 (1989):  918|Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen B "Steroid aerosols and cataract formation." BMJ 299 (1989):  432-3|Kewley GD "Possible association between beclomethasone diproprionate aerosol and cataracts." Aust Paediatr J 16 (1980):  117-8|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Ghanchi F "Young patients on inhaled steroids and cataract." Lancet 342 (1993):  1306-7|Dreyer EB "Inhaled steroid use and glaucoma." N Engl J Med 329 (1993):  1822|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Spaeth GL, Rodrigues MM, Weinreb S "Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects." Trans Am Ophthalmol Soc 75 (1977):  353-81|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997):  722-7|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Cumming RG, Mitchell P, Leeder SR "Use of inhaled corticosteroids and the risk of cataracts." N Engl J Med 337 (1997):  8-14|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Agertoft L, Larsen FE, Pedersen S "Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide." Eur Resp J 12 (1998):  130-5|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34063, 15556, 'Budesonide (nasal)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Fraunfelder FT, Meyer SM "Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids." Am J Ophthalmol 109 (1990):  489-90|Karim AK, Thompson GM, Jacob TJ "Steroid aerosols and cataract formation." BMJ 299 (1989):  918|Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen B "Steroid aerosols and cataract formation." BMJ 299 (1989):  432-3|Kewley GD "Possible association between beclomethasone diproprionate aerosol and cataracts." Aust Paediatr J 16 (1980):  117-8|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Ghanchi F "Young patients on inhaled steroids and cataract." Lancet 342 (1993):  1306-7|Dreyer EB "Inhaled steroid use and glaucoma." N Engl J Med 329 (1993):  1822|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Spaeth GL, Rodrigues MM, Weinreb S "Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects." Trans Am Ophthalmol Soc 75 (1977):  353-81|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997):  722-7|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Cumming RG, Mitchell P, Leeder SR "Use of inhaled corticosteroids and the risk of cataracts." N Engl J Med 337 (1997):  8-14|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Agertoft L, Larsen FE, Pedersen S "Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide." Eur Resp J 12 (1998):  130-5|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34064, 18134, 'Budesonide (nasal)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Fraunfelder FT, Meyer SM "Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids." Am J Ophthalmol 109 (1990):  489-90|Karim AK, Thompson GM, Jacob TJ "Steroid aerosols and cataract formation." BMJ 299 (1989):  918|Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen B "Steroid aerosols and cataract formation." BMJ 299 (1989):  432-3|Kewley GD "Possible association between beclomethasone diproprionate aerosol and cataracts." Aust Paediatr J 16 (1980):  117-8|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Ghanchi F "Young patients on inhaled steroids and cataract." Lancet 342 (1993):  1306-7|Dreyer EB "Inhaled steroid use and glaucoma." N Engl J Med 329 (1993):  1822|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Spaeth GL, Rodrigues MM, Weinreb S "Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects." Trans Am Ophthalmol Soc 75 (1977):  353-81|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997):  722-7|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Cumming RG, Mitchell P, Leeder SR "Use of inhaled corticosteroids and the risk of cataracts." N Engl J Med 337 (1997):  8-14|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Agertoft L, Larsen FE, Pedersen S "Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide." Eur Resp J 12 (1998):  130-5|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34065, 25479, 'Budesonide (nasal)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Fraunfelder FT, Meyer SM "Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids." Am J Ophthalmol 109 (1990):  489-90|Karim AK, Thompson GM, Jacob TJ "Steroid aerosols and cataract formation." BMJ 299 (1989):  918|Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen B "Steroid aerosols and cataract formation." BMJ 299 (1989):  432-3|Kewley GD "Possible association between beclomethasone diproprionate aerosol and cataracts." Aust Paediatr J 16 (1980):  117-8|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Ghanchi F "Young patients on inhaled steroids and cataract." Lancet 342 (1993):  1306-7|Dreyer EB "Inhaled steroid use and glaucoma." N Engl J Med 329 (1993):  1822|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Spaeth GL, Rodrigues MM, Weinreb S "Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects." Trans Am Ophthalmol Soc 75 (1977):  353-81|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997):  722-7|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Cumming RG, Mitchell P, Leeder SR "Use of inhaled corticosteroids and the risk of cataracts." N Engl J Med 337 (1997):  8-14|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Agertoft L, Larsen FE, Pedersen S "Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide." Eur Resp J 12 (1998):  130-5|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34066, 25480, 'Budesonide (nasal)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Fraunfelder FT, Meyer SM "Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids." Am J Ophthalmol 109 (1990):  489-90|Karim AK, Thompson GM, Jacob TJ "Steroid aerosols and cataract formation." BMJ 299 (1989):  918|Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen B "Steroid aerosols and cataract formation." BMJ 299 (1989):  432-3|Kewley GD "Possible association between beclomethasone diproprionate aerosol and cataracts." Aust Paediatr J 16 (1980):  117-8|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Ghanchi F "Young patients on inhaled steroids and cataract." Lancet 342 (1993):  1306-7|Dreyer EB "Inhaled steroid use and glaucoma." N Engl J Med 329 (1993):  1822|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Spaeth GL, Rodrigues MM, Weinreb S "Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects." Trans Am Ophthalmol Soc 75 (1977):  353-81|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997):  722-7|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Cumming RG, Mitchell P, Leeder SR "Use of inhaled corticosteroids and the risk of cataracts." N Engl J Med 337 (1997):  8-14|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Agertoft L, Larsen FE, Pedersen S "Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide." Eur Resp J 12 (1998):  130-5|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34067, 25481, 'Budesonide (nasal)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Fraunfelder FT, Meyer SM "Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids." Am J Ophthalmol 109 (1990):  489-90|Karim AK, Thompson GM, Jacob TJ "Steroid aerosols and cataract formation." BMJ 299 (1989):  918|Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen B "Steroid aerosols and cataract formation." BMJ 299 (1989):  432-3|Kewley GD "Possible association between beclomethasone diproprionate aerosol and cataracts." Aust Paediatr J 16 (1980):  117-8|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Ghanchi F "Young patients on inhaled steroids and cataract." Lancet 342 (1993):  1306-7|Dreyer EB "Inhaled steroid use and glaucoma." N Engl J Med 329 (1993):  1822|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Spaeth GL, Rodrigues MM, Weinreb S "Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects." Trans Am Ophthalmol Soc 75 (1977):  353-81|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997):  722-7|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Cumming RG, Mitchell P, Leeder SR "Use of inhaled corticosteroids and the risk of cataracts." N Engl J Med 337 (1997):  8-14|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Agertoft L, Larsen FE, Pedersen S "Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide." Eur Resp J 12 (1998):  130-5|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34068, 25482, 'Budesonide (nasal)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Fraunfelder FT, Meyer SM "Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids." Am J Ophthalmol 109 (1990):  489-90|Karim AK, Thompson GM, Jacob TJ "Steroid aerosols and cataract formation." BMJ 299 (1989):  918|Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen B "Steroid aerosols and cataract formation." BMJ 299 (1989):  432-3|Kewley GD "Possible association between beclomethasone diproprionate aerosol and cataracts." Aust Paediatr J 16 (1980):  117-8|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Ghanchi F "Young patients on inhaled steroids and cataract." Lancet 342 (1993):  1306-7|Dreyer EB "Inhaled steroid use and glaucoma." N Engl J Med 329 (1993):  1822|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Spaeth GL, Rodrigues MM, Weinreb S "Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects." Trans Am Ophthalmol Soc 75 (1977):  353-81|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997):  722-7|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Cumming RG, Mitchell P, Leeder SR "Use of inhaled corticosteroids and the risk of cataracts." N Engl J Med 337 (1997):  8-14|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Agertoft L, Larsen FE, Pedersen S "Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide." Eur Resp J 12 (1998):  130-5|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34069, 26038, 'Budesonide (nasal)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Fraunfelder FT, Meyer SM "Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids." Am J Ophthalmol 109 (1990):  489-90|Karim AK, Thompson GM, Jacob TJ "Steroid aerosols and cataract formation." BMJ 299 (1989):  918|Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen B "Steroid aerosols and cataract formation." BMJ 299 (1989):  432-3|Kewley GD "Possible association between beclomethasone diproprionate aerosol and cataracts." Aust Paediatr J 16 (1980):  117-8|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Ghanchi F "Young patients on inhaled steroids and cataract." Lancet 342 (1993):  1306-7|Dreyer EB "Inhaled steroid use and glaucoma." N Engl J Med 329 (1993):  1822|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Spaeth GL, Rodrigues MM, Weinreb S "Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects." Trans Am Ophthalmol Soc 75 (1977):  353-81|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997):  722-7|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Cumming RG, Mitchell P, Leeder SR "Use of inhaled corticosteroids and the risk of cataracts." N Engl J Med 337 (1997):  8-14|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Agertoft L, Larsen FE, Pedersen S "Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide." Eur Resp J 12 (1998):  130-5|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34070, 26039, 'Budesonide (nasal)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with inhaled and nasal corticosteroids has only rarely produced these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure.  Although adverse effects of corticosteroids may be minimized by local rather than systemic administration, the risks are not entirely abolished.  Inhaled and nasally applied drug may be absorbed into the circulation, especially when large doses are used.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Fraunfelder FT, Meyer SM "Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids." Am J Ophthalmol 109 (1990):  489-90|Karim AK, Thompson GM, Jacob TJ "Steroid aerosols and cataract formation." BMJ 299 (1989):  918|Allen MB, Ray SG, Leitch AG, Dhillon B, Cullen B "Steroid aerosols and cataract formation." BMJ 299 (1989):  432-3|Kewley GD "Possible association between beclomethasone diproprionate aerosol and cataracts." Aust Paediatr J 16 (1980):  117-8|Messerli C, Studer H, Scherrer M "Systemic side effects of beclomethasone dipropionate aerosols (becotide, aldecine, sanasthmyl) in otherwise non steroid treated asthmatic patients." Pneumonologie 153 (1975):  29-42|Ghanchi F "Young patients on inhaled steroids and cataract." Lancet 342 (1993):  1306-7|Dreyer EB "Inhaled steroid use and glaucoma." N Engl J Med 329 (1993):  1822|"Product Information. Beclovent (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. Vancenase (beclomethasone)." Glaxo Wellcome  (2001):|"Product Information. AeroBid (flunisolide)." Forest Pharmaceuticals  (2022):|"Product Information. Nasalide (flunisolide)." Syntex Laboratories Inc  (2001):|Spaeth GL, Rodrigues MM, Weinreb S "Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure B. Histopathological aspects." Trans Am Ophthalmol Soc 75 (1977):  353-81|Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|"Product Information. Flonase (fluticasone)." Glaxo Wellcome  (2001):|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|"Product Information. Rhinocort (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Garbe E, LeLorier J, Boivin JF, Suissa S "Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma." JAMA 277 (1997):  722-7|"Product Information. Flovent (fluticasone)." Glaxo Wellcome  (2001):|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Cumming RG, Mitchell P, Leeder SR "Use of inhaled corticosteroids and the risk of cataracts." N Engl J Med 337 (1997):  8-14|"Product Information. Nasonex (mometasone nasal)." Scherer Laboratories Inc|"Product Information. Pulmicort Turbuhaler (budesonide)." Astra-Zeneca Pharmaceuticals  (2001):|Agertoft L, Larsen FE, Pedersen S "Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide." Eur Resp J 12 (1998):  130-5|"Product Information. Azmacort (triamcinolone)." Rhone Poulenc Rorer  (2001):|"Product Information. Nasacort (triamcinolone nasal)." Rhone Poulenc Rorer  (2001):|Wales D, Makker H, Kane J, McDowell P, ODriscoll BR "Systemic bioavailability and potency of high-dose inhaled corticosteroids - A comparison of four inhaler devices and three drugs in healthy adult volunteers." Chest 115 (1999):  1278-84|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|"Product Information. Alvesco (ciclesonide)." Nycomed USA  (2008):|"Product Information. Omnaris (ciclesonide nasal)." Sepracor Inc  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34071, 1780, 'Budesonide (nasal)', 'Osteoporosis', 'Prolonged use of inhaled corticosteroids may be associated with a reduction in bone density.  This effect appears to be dose-related and has been reported primarily with high dosages (>= 800 mcg/day of beclomethasone or equivalent for >= 1 year).  Reduced levels of total body calcium have also been demonstrated in patients receiving lower dosages.  Long-term therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with osteoporosis.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Toogood JH, Crilly RG, Jones G, Nadeau J, Wells GA "Effect of high-dose inhaled budesonide on calcium and phosphate metabolism and the risk of osteoporosis." Am Rev Respir Dis 138 (1988):  57-61|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|Konig P, Hillman L, Cervantes C, Levine C, Maloney C, Douglass B, Johnson L, Allen S "Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate." J Pediatr 122 (1993):  219-26|Kinberg KA, Hopp RJ, Biven RE, Gallagher JC "Bone mineral density in normal and asthmatic children." J Allergy Clin Immunol 94 (1994):  490-7|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|Toogood JH, Baskerville JC, Markov AE, Hodsman AB, Fraher LJ, Jennings B, Haddad RG, Drost D "Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma." J Allergy Clin Immunol 96 (1995):  157-66|Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S "Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids." J Allergy Clin Immunol 96 (1995):  571-9|Martinati LC, Bertoldo F, Gasperi E, Micelli S, Boner AL "Effect on cortical and trabecular bone mass of different anti-inflammatory treatments in preadolescent children with chronic asthma." Am J Respir Crit Care Med 153 (1996):  232-6|Packe GE, Douglas JG, McDonald AF, Robins SP, Reid DM "Bone density in asthmatic patients taking high dose inhaled beclomethasone diproprionate and intermittent systemic corticosteroids." Thorax 47 (1992):  414-7|Reid DM, Nicoll JJ, Smith MA, Higgins B, Tothill P, Nuki G "Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica." BMJ 293 (1986):  1463-6|Ali NJ, Capewell S, Ward MJ "Bone turnover during high dose inhaled corticosteroid treatment." Thorax 46 (1991):  160-4|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Packe GE, Robb O, Robins SP, Reid DM, Douglas JG "Bone density in asthmatic patients taking inhaled corticosteroids: comparison of budesonide and beclomethasone dipropionate." J R Coll Physicians Lond 30 (1996):  128-32|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|Luengo M, delRio L, Pons F, Picado C "Bone mineral density in asthmatic patients treated with inhaled corticosteroids: a case-control study." Eur Respir J 10 (1997):  2110-3|Wisniewski AF, Lewis SA, Green DJ, Maslanka W, Burrell H, Tattersfield AE "Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma." Thorax 52 (1997):  853-60|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|Wong CA, Walsh LJ, Smith CJP, Wisniewski AF, Lewis SA, Hubbard R, Cawte S, Green DJ, Pringle M, Tattersfield AE "Inhaled corticosteroid use and bone-mineral density in patients with asthma." Lancet 355 (2000):  1399-403|Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS "Effects of inhaled glucocorticoids on bone density in premenopausal women." N Engl J Med 345 (2001):  941-7|Sharma PK, Malhotra S, Pandhi P, Kumar N "Effect of inhaled steroids on bone mineral density: a meta-analysis." J Clin Pharmacol 43 (2003):  193-7|Boulet LP, Milot J, Gagnon L, Poubelle PE, Brown J "Long-term influence of inhaled corticosteroids on bone metabolism and density. Are biological markers predictors of bone loss?" Am J Respir Crit Care Med 159 (1999):  838-44', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34072, 2048, 'Budesonide (nasal)', 'Osteoporosis', 'Prolonged use of inhaled corticosteroids may be associated with a reduction in bone density.  This effect appears to be dose-related and has been reported primarily with high dosages (>= 800 mcg/day of beclomethasone or equivalent for >= 1 year).  Reduced levels of total body calcium have also been demonstrated in patients receiving lower dosages.  Long-term therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with osteoporosis.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Toogood JH, Crilly RG, Jones G, Nadeau J, Wells GA "Effect of high-dose inhaled budesonide on calcium and phosphate metabolism and the risk of osteoporosis." Am Rev Respir Dis 138 (1988):  57-61|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|Konig P, Hillman L, Cervantes C, Levine C, Maloney C, Douglass B, Johnson L, Allen S "Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate." J Pediatr 122 (1993):  219-26|Kinberg KA, Hopp RJ, Biven RE, Gallagher JC "Bone mineral density in normal and asthmatic children." J Allergy Clin Immunol 94 (1994):  490-7|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|Toogood JH, Baskerville JC, Markov AE, Hodsman AB, Fraher LJ, Jennings B, Haddad RG, Drost D "Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma." J Allergy Clin Immunol 96 (1995):  157-66|Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S "Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids." J Allergy Clin Immunol 96 (1995):  571-9|Martinati LC, Bertoldo F, Gasperi E, Micelli S, Boner AL "Effect on cortical and trabecular bone mass of different anti-inflammatory treatments in preadolescent children with chronic asthma." Am J Respir Crit Care Med 153 (1996):  232-6|Packe GE, Douglas JG, McDonald AF, Robins SP, Reid DM "Bone density in asthmatic patients taking high dose inhaled beclomethasone diproprionate and intermittent systemic corticosteroids." Thorax 47 (1992):  414-7|Reid DM, Nicoll JJ, Smith MA, Higgins B, Tothill P, Nuki G "Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica." BMJ 293 (1986):  1463-6|Ali NJ, Capewell S, Ward MJ "Bone turnover during high dose inhaled corticosteroid treatment." Thorax 46 (1991):  160-4|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Packe GE, Robb O, Robins SP, Reid DM, Douglas JG "Bone density in asthmatic patients taking inhaled corticosteroids: comparison of budesonide and beclomethasone dipropionate." J R Coll Physicians Lond 30 (1996):  128-32|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|Luengo M, delRio L, Pons F, Picado C "Bone mineral density in asthmatic patients treated with inhaled corticosteroids: a case-control study." Eur Respir J 10 (1997):  2110-3|Wisniewski AF, Lewis SA, Green DJ, Maslanka W, Burrell H, Tattersfield AE "Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma." Thorax 52 (1997):  853-60|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|Wong CA, Walsh LJ, Smith CJP, Wisniewski AF, Lewis SA, Hubbard R, Cawte S, Green DJ, Pringle M, Tattersfield AE "Inhaled corticosteroid use and bone-mineral density in patients with asthma." Lancet 355 (2000):  1399-403|Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS "Effects of inhaled glucocorticoids on bone density in premenopausal women." N Engl J Med 345 (2001):  941-7|Sharma PK, Malhotra S, Pandhi P, Kumar N "Effect of inhaled steroids on bone mineral density: a meta-analysis." J Clin Pharmacol 43 (2003):  193-7|Boulet LP, Milot J, Gagnon L, Poubelle PE, Brown J "Long-term influence of inhaled corticosteroids on bone metabolism and density. Are biological markers predictors of bone loss?" Am J Respir Crit Care Med 159 (1999):  838-44', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34073, 2413, 'Budesonide (nasal)', 'Osteoporosis', 'Prolonged use of inhaled corticosteroids may be associated with a reduction in bone density.  This effect appears to be dose-related and has been reported primarily with high dosages (>= 800 mcg/day of beclomethasone or equivalent for >= 1 year).  Reduced levels of total body calcium have also been demonstrated in patients receiving lower dosages.  Long-term therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with osteoporosis.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Toogood JH, Crilly RG, Jones G, Nadeau J, Wells GA "Effect of high-dose inhaled budesonide on calcium and phosphate metabolism and the risk of osteoporosis." Am Rev Respir Dis 138 (1988):  57-61|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|Konig P, Hillman L, Cervantes C, Levine C, Maloney C, Douglass B, Johnson L, Allen S "Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate." J Pediatr 122 (1993):  219-26|Kinberg KA, Hopp RJ, Biven RE, Gallagher JC "Bone mineral density in normal and asthmatic children." J Allergy Clin Immunol 94 (1994):  490-7|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|Toogood JH, Baskerville JC, Markov AE, Hodsman AB, Fraher LJ, Jennings B, Haddad RG, Drost D "Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma." J Allergy Clin Immunol 96 (1995):  157-66|Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S "Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids." J Allergy Clin Immunol 96 (1995):  571-9|Martinati LC, Bertoldo F, Gasperi E, Micelli S, Boner AL "Effect on cortical and trabecular bone mass of different anti-inflammatory treatments in preadolescent children with chronic asthma." Am J Respir Crit Care Med 153 (1996):  232-6|Packe GE, Douglas JG, McDonald AF, Robins SP, Reid DM "Bone density in asthmatic patients taking high dose inhaled beclomethasone diproprionate and intermittent systemic corticosteroids." Thorax 47 (1992):  414-7|Reid DM, Nicoll JJ, Smith MA, Higgins B, Tothill P, Nuki G "Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica." BMJ 293 (1986):  1463-6|Ali NJ, Capewell S, Ward MJ "Bone turnover during high dose inhaled corticosteroid treatment." Thorax 46 (1991):  160-4|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Packe GE, Robb O, Robins SP, Reid DM, Douglas JG "Bone density in asthmatic patients taking inhaled corticosteroids: comparison of budesonide and beclomethasone dipropionate." J R Coll Physicians Lond 30 (1996):  128-32|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|Luengo M, delRio L, Pons F, Picado C "Bone mineral density in asthmatic patients treated with inhaled corticosteroids: a case-control study." Eur Respir J 10 (1997):  2110-3|Wisniewski AF, Lewis SA, Green DJ, Maslanka W, Burrell H, Tattersfield AE "Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma." Thorax 52 (1997):  853-60|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|Wong CA, Walsh LJ, Smith CJP, Wisniewski AF, Lewis SA, Hubbard R, Cawte S, Green DJ, Pringle M, Tattersfield AE "Inhaled corticosteroid use and bone-mineral density in patients with asthma." Lancet 355 (2000):  1399-403|Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS "Effects of inhaled glucocorticoids on bone density in premenopausal women." N Engl J Med 345 (2001):  941-7|Sharma PK, Malhotra S, Pandhi P, Kumar N "Effect of inhaled steroids on bone mineral density: a meta-analysis." J Clin Pharmacol 43 (2003):  193-7|Boulet LP, Milot J, Gagnon L, Poubelle PE, Brown J "Long-term influence of inhaled corticosteroids on bone metabolism and density. Are biological markers predictors of bone loss?" Am J Respir Crit Care Med 159 (1999):  838-44', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34074, 2424, 'Budesonide (nasal)', 'Osteoporosis', 'Prolonged use of inhaled corticosteroids may be associated with a reduction in bone density.  This effect appears to be dose-related and has been reported primarily with high dosages (>= 800 mcg/day of beclomethasone or equivalent for >= 1 year).  Reduced levels of total body calcium have also been demonstrated in patients receiving lower dosages.  Long-term therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with osteoporosis.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Toogood JH, Crilly RG, Jones G, Nadeau J, Wells GA "Effect of high-dose inhaled budesonide on calcium and phosphate metabolism and the risk of osteoporosis." Am Rev Respir Dis 138 (1988):  57-61|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|Konig P, Hillman L, Cervantes C, Levine C, Maloney C, Douglass B, Johnson L, Allen S "Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate." J Pediatr 122 (1993):  219-26|Kinberg KA, Hopp RJ, Biven RE, Gallagher JC "Bone mineral density in normal and asthmatic children." J Allergy Clin Immunol 94 (1994):  490-7|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|Toogood JH, Baskerville JC, Markov AE, Hodsman AB, Fraher LJ, Jennings B, Haddad RG, Drost D "Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma." J Allergy Clin Immunol 96 (1995):  157-66|Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S "Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids." J Allergy Clin Immunol 96 (1995):  571-9|Martinati LC, Bertoldo F, Gasperi E, Micelli S, Boner AL "Effect on cortical and trabecular bone mass of different anti-inflammatory treatments in preadolescent children with chronic asthma." Am J Respir Crit Care Med 153 (1996):  232-6|Packe GE, Douglas JG, McDonald AF, Robins SP, Reid DM "Bone density in asthmatic patients taking high dose inhaled beclomethasone diproprionate and intermittent systemic corticosteroids." Thorax 47 (1992):  414-7|Reid DM, Nicoll JJ, Smith MA, Higgins B, Tothill P, Nuki G "Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica." BMJ 293 (1986):  1463-6|Ali NJ, Capewell S, Ward MJ "Bone turnover during high dose inhaled corticosteroid treatment." Thorax 46 (1991):  160-4|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Packe GE, Robb O, Robins SP, Reid DM, Douglas JG "Bone density in asthmatic patients taking inhaled corticosteroids: comparison of budesonide and beclomethasone dipropionate." J R Coll Physicians Lond 30 (1996):  128-32|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|Luengo M, delRio L, Pons F, Picado C "Bone mineral density in asthmatic patients treated with inhaled corticosteroids: a case-control study." Eur Respir J 10 (1997):  2110-3|Wisniewski AF, Lewis SA, Green DJ, Maslanka W, Burrell H, Tattersfield AE "Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma." Thorax 52 (1997):  853-60|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|Wong CA, Walsh LJ, Smith CJP, Wisniewski AF, Lewis SA, Hubbard R, Cawte S, Green DJ, Pringle M, Tattersfield AE "Inhaled corticosteroid use and bone-mineral density in patients with asthma." Lancet 355 (2000):  1399-403|Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS "Effects of inhaled glucocorticoids on bone density in premenopausal women." N Engl J Med 345 (2001):  941-7|Sharma PK, Malhotra S, Pandhi P, Kumar N "Effect of inhaled steroids on bone mineral density: a meta-analysis." J Clin Pharmacol 43 (2003):  193-7|Boulet LP, Milot J, Gagnon L, Poubelle PE, Brown J "Long-term influence of inhaled corticosteroids on bone metabolism and density. Are biological markers predictors of bone loss?" Am J Respir Crit Care Med 159 (1999):  838-44', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34075, 4183, 'Budesonide (nasal)', 'Osteoporosis', 'Prolonged use of inhaled corticosteroids may be associated with a reduction in bone density.  This effect appears to be dose-related and has been reported primarily with high dosages (>= 800 mcg/day of beclomethasone or equivalent for >= 1 year).  Reduced levels of total body calcium have also been demonstrated in patients receiving lower dosages.  Long-term therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with osteoporosis.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Toogood JH, Crilly RG, Jones G, Nadeau J, Wells GA "Effect of high-dose inhaled budesonide on calcium and phosphate metabolism and the risk of osteoporosis." Am Rev Respir Dis 138 (1988):  57-61|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|Konig P, Hillman L, Cervantes C, Levine C, Maloney C, Douglass B, Johnson L, Allen S "Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate." J Pediatr 122 (1993):  219-26|Kinberg KA, Hopp RJ, Biven RE, Gallagher JC "Bone mineral density in normal and asthmatic children." J Allergy Clin Immunol 94 (1994):  490-7|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|Toogood JH, Baskerville JC, Markov AE, Hodsman AB, Fraher LJ, Jennings B, Haddad RG, Drost D "Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma." J Allergy Clin Immunol 96 (1995):  157-66|Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S "Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids." J Allergy Clin Immunol 96 (1995):  571-9|Martinati LC, Bertoldo F, Gasperi E, Micelli S, Boner AL "Effect on cortical and trabecular bone mass of different anti-inflammatory treatments in preadolescent children with chronic asthma." Am J Respir Crit Care Med 153 (1996):  232-6|Packe GE, Douglas JG, McDonald AF, Robins SP, Reid DM "Bone density in asthmatic patients taking high dose inhaled beclomethasone diproprionate and intermittent systemic corticosteroids." Thorax 47 (1992):  414-7|Reid DM, Nicoll JJ, Smith MA, Higgins B, Tothill P, Nuki G "Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica." BMJ 293 (1986):  1463-6|Ali NJ, Capewell S, Ward MJ "Bone turnover during high dose inhaled corticosteroid treatment." Thorax 46 (1991):  160-4|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Packe GE, Robb O, Robins SP, Reid DM, Douglas JG "Bone density in asthmatic patients taking inhaled corticosteroids: comparison of budesonide and beclomethasone dipropionate." J R Coll Physicians Lond 30 (1996):  128-32|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|Luengo M, delRio L, Pons F, Picado C "Bone mineral density in asthmatic patients treated with inhaled corticosteroids: a case-control study." Eur Respir J 10 (1997):  2110-3|Wisniewski AF, Lewis SA, Green DJ, Maslanka W, Burrell H, Tattersfield AE "Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma." Thorax 52 (1997):  853-60|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|Wong CA, Walsh LJ, Smith CJP, Wisniewski AF, Lewis SA, Hubbard R, Cawte S, Green DJ, Pringle M, Tattersfield AE "Inhaled corticosteroid use and bone-mineral density in patients with asthma." Lancet 355 (2000):  1399-403|Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS "Effects of inhaled glucocorticoids on bone density in premenopausal women." N Engl J Med 345 (2001):  941-7|Sharma PK, Malhotra S, Pandhi P, Kumar N "Effect of inhaled steroids on bone mineral density: a meta-analysis." J Clin Pharmacol 43 (2003):  193-7|Boulet LP, Milot J, Gagnon L, Poubelle PE, Brown J "Long-term influence of inhaled corticosteroids on bone metabolism and density. Are biological markers predictors of bone loss?" Am J Respir Crit Care Med 159 (1999):  838-44', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34076, 8162, 'Budesonide (nasal)', 'Osteoporosis', 'Prolonged use of inhaled corticosteroids may be associated with a reduction in bone density.  This effect appears to be dose-related and has been reported primarily with high dosages (>= 800 mcg/day of beclomethasone or equivalent for >= 1 year).  Reduced levels of total body calcium have also been demonstrated in patients receiving lower dosages.  Long-term therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with osteoporosis.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Toogood JH, Crilly RG, Jones G, Nadeau J, Wells GA "Effect of high-dose inhaled budesonide on calcium and phosphate metabolism and the risk of osteoporosis." Am Rev Respir Dis 138 (1988):  57-61|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|Konig P, Hillman L, Cervantes C, Levine C, Maloney C, Douglass B, Johnson L, Allen S "Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate." J Pediatr 122 (1993):  219-26|Kinberg KA, Hopp RJ, Biven RE, Gallagher JC "Bone mineral density in normal and asthmatic children." J Allergy Clin Immunol 94 (1994):  490-7|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|Toogood JH, Baskerville JC, Markov AE, Hodsman AB, Fraher LJ, Jennings B, Haddad RG, Drost D "Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma." J Allergy Clin Immunol 96 (1995):  157-66|Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S "Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids." J Allergy Clin Immunol 96 (1995):  571-9|Martinati LC, Bertoldo F, Gasperi E, Micelli S, Boner AL "Effect on cortical and trabecular bone mass of different anti-inflammatory treatments in preadolescent children with chronic asthma." Am J Respir Crit Care Med 153 (1996):  232-6|Packe GE, Douglas JG, McDonald AF, Robins SP, Reid DM "Bone density in asthmatic patients taking high dose inhaled beclomethasone diproprionate and intermittent systemic corticosteroids." Thorax 47 (1992):  414-7|Reid DM, Nicoll JJ, Smith MA, Higgins B, Tothill P, Nuki G "Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica." BMJ 293 (1986):  1463-6|Ali NJ, Capewell S, Ward MJ "Bone turnover during high dose inhaled corticosteroid treatment." Thorax 46 (1991):  160-4|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Packe GE, Robb O, Robins SP, Reid DM, Douglas JG "Bone density in asthmatic patients taking inhaled corticosteroids: comparison of budesonide and beclomethasone dipropionate." J R Coll Physicians Lond 30 (1996):  128-32|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|Luengo M, delRio L, Pons F, Picado C "Bone mineral density in asthmatic patients treated with inhaled corticosteroids: a case-control study." Eur Respir J 10 (1997):  2110-3|Wisniewski AF, Lewis SA, Green DJ, Maslanka W, Burrell H, Tattersfield AE "Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma." Thorax 52 (1997):  853-60|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|Wong CA, Walsh LJ, Smith CJP, Wisniewski AF, Lewis SA, Hubbard R, Cawte S, Green DJ, Pringle M, Tattersfield AE "Inhaled corticosteroid use and bone-mineral density in patients with asthma." Lancet 355 (2000):  1399-403|Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS "Effects of inhaled glucocorticoids on bone density in premenopausal women." N Engl J Med 345 (2001):  941-7|Sharma PK, Malhotra S, Pandhi P, Kumar N "Effect of inhaled steroids on bone mineral density: a meta-analysis." J Clin Pharmacol 43 (2003):  193-7|Boulet LP, Milot J, Gagnon L, Poubelle PE, Brown J "Long-term influence of inhaled corticosteroids on bone metabolism and density. Are biological markers predictors of bone loss?" Am J Respir Crit Care Med 159 (1999):  838-44', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34077, 9114, 'Budesonide (nasal)', 'Osteoporosis', 'Prolonged use of inhaled corticosteroids may be associated with a reduction in bone density.  This effect appears to be dose-related and has been reported primarily with high dosages (>= 800 mcg/day of beclomethasone or equivalent for >= 1 year).  Reduced levels of total body calcium have also been demonstrated in patients receiving lower dosages.  Long-term therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with osteoporosis.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Toogood JH, Crilly RG, Jones G, Nadeau J, Wells GA "Effect of high-dose inhaled budesonide on calcium and phosphate metabolism and the risk of osteoporosis." Am Rev Respir Dis 138 (1988):  57-61|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|Konig P, Hillman L, Cervantes C, Levine C, Maloney C, Douglass B, Johnson L, Allen S "Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate." J Pediatr 122 (1993):  219-26|Kinberg KA, Hopp RJ, Biven RE, Gallagher JC "Bone mineral density in normal and asthmatic children." J Allergy Clin Immunol 94 (1994):  490-7|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|Toogood JH, Baskerville JC, Markov AE, Hodsman AB, Fraher LJ, Jennings B, Haddad RG, Drost D "Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma." J Allergy Clin Immunol 96 (1995):  157-66|Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S "Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids." J Allergy Clin Immunol 96 (1995):  571-9|Martinati LC, Bertoldo F, Gasperi E, Micelli S, Boner AL "Effect on cortical and trabecular bone mass of different anti-inflammatory treatments in preadolescent children with chronic asthma." Am J Respir Crit Care Med 153 (1996):  232-6|Packe GE, Douglas JG, McDonald AF, Robins SP, Reid DM "Bone density in asthmatic patients taking high dose inhaled beclomethasone diproprionate and intermittent systemic corticosteroids." Thorax 47 (1992):  414-7|Reid DM, Nicoll JJ, Smith MA, Higgins B, Tothill P, Nuki G "Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica." BMJ 293 (1986):  1463-6|Ali NJ, Capewell S, Ward MJ "Bone turnover during high dose inhaled corticosteroid treatment." Thorax 46 (1991):  160-4|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Packe GE, Robb O, Robins SP, Reid DM, Douglas JG "Bone density in asthmatic patients taking inhaled corticosteroids: comparison of budesonide and beclomethasone dipropionate." J R Coll Physicians Lond 30 (1996):  128-32|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|Luengo M, delRio L, Pons F, Picado C "Bone mineral density in asthmatic patients treated with inhaled corticosteroids: a case-control study." Eur Respir J 10 (1997):  2110-3|Wisniewski AF, Lewis SA, Green DJ, Maslanka W, Burrell H, Tattersfield AE "Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma." Thorax 52 (1997):  853-60|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|Wong CA, Walsh LJ, Smith CJP, Wisniewski AF, Lewis SA, Hubbard R, Cawte S, Green DJ, Pringle M, Tattersfield AE "Inhaled corticosteroid use and bone-mineral density in patients with asthma." Lancet 355 (2000):  1399-403|Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS "Effects of inhaled glucocorticoids on bone density in premenopausal women." N Engl J Med 345 (2001):  941-7|Sharma PK, Malhotra S, Pandhi P, Kumar N "Effect of inhaled steroids on bone mineral density: a meta-analysis." J Clin Pharmacol 43 (2003):  193-7|Boulet LP, Milot J, Gagnon L, Poubelle PE, Brown J "Long-term influence of inhaled corticosteroids on bone metabolism and density. Are biological markers predictors of bone loss?" Am J Respir Crit Care Med 159 (1999):  838-44', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34078, 10589, 'Budesonide (nasal)', 'Osteoporosis', 'Prolonged use of inhaled corticosteroids may be associated with a reduction in bone density.  This effect appears to be dose-related and has been reported primarily with high dosages (>= 800 mcg/day of beclomethasone or equivalent for >= 1 year).  Reduced levels of total body calcium have also been demonstrated in patients receiving lower dosages.  Long-term therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with osteoporosis.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Toogood JH, Crilly RG, Jones G, Nadeau J, Wells GA "Effect of high-dose inhaled budesonide on calcium and phosphate metabolism and the risk of osteoporosis." Am Rev Respir Dis 138 (1988):  57-61|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|Konig P, Hillman L, Cervantes C, Levine C, Maloney C, Douglass B, Johnson L, Allen S "Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate." J Pediatr 122 (1993):  219-26|Kinberg KA, Hopp RJ, Biven RE, Gallagher JC "Bone mineral density in normal and asthmatic children." J Allergy Clin Immunol 94 (1994):  490-7|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|Toogood JH, Baskerville JC, Markov AE, Hodsman AB, Fraher LJ, Jennings B, Haddad RG, Drost D "Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma." J Allergy Clin Immunol 96 (1995):  157-66|Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S "Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids." J Allergy Clin Immunol 96 (1995):  571-9|Martinati LC, Bertoldo F, Gasperi E, Micelli S, Boner AL "Effect on cortical and trabecular bone mass of different anti-inflammatory treatments in preadolescent children with chronic asthma." Am J Respir Crit Care Med 153 (1996):  232-6|Packe GE, Douglas JG, McDonald AF, Robins SP, Reid DM "Bone density in asthmatic patients taking high dose inhaled beclomethasone diproprionate and intermittent systemic corticosteroids." Thorax 47 (1992):  414-7|Reid DM, Nicoll JJ, Smith MA, Higgins B, Tothill P, Nuki G "Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica." BMJ 293 (1986):  1463-6|Ali NJ, Capewell S, Ward MJ "Bone turnover during high dose inhaled corticosteroid treatment." Thorax 46 (1991):  160-4|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Packe GE, Robb O, Robins SP, Reid DM, Douglas JG "Bone density in asthmatic patients taking inhaled corticosteroids: comparison of budesonide and beclomethasone dipropionate." J R Coll Physicians Lond 30 (1996):  128-32|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|Luengo M, delRio L, Pons F, Picado C "Bone mineral density in asthmatic patients treated with inhaled corticosteroids: a case-control study." Eur Respir J 10 (1997):  2110-3|Wisniewski AF, Lewis SA, Green DJ, Maslanka W, Burrell H, Tattersfield AE "Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma." Thorax 52 (1997):  853-60|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|Wong CA, Walsh LJ, Smith CJP, Wisniewski AF, Lewis SA, Hubbard R, Cawte S, Green DJ, Pringle M, Tattersfield AE "Inhaled corticosteroid use and bone-mineral density in patients with asthma." Lancet 355 (2000):  1399-403|Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS "Effects of inhaled glucocorticoids on bone density in premenopausal women." N Engl J Med 345 (2001):  941-7|Sharma PK, Malhotra S, Pandhi P, Kumar N "Effect of inhaled steroids on bone mineral density: a meta-analysis." J Clin Pharmacol 43 (2003):  193-7|Boulet LP, Milot J, Gagnon L, Poubelle PE, Brown J "Long-term influence of inhaled corticosteroids on bone metabolism and density. Are biological markers predictors of bone loss?" Am J Respir Crit Care Med 159 (1999):  838-44', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34079, 13149, 'Budesonide (nasal)', 'Osteoporosis', 'Prolonged use of inhaled corticosteroids may be associated with a reduction in bone density.  This effect appears to be dose-related and has been reported primarily with high dosages (>= 800 mcg/day of beclomethasone or equivalent for >= 1 year).  Reduced levels of total body calcium have also been demonstrated in patients receiving lower dosages.  Long-term therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with osteoporosis.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Toogood JH, Crilly RG, Jones G, Nadeau J, Wells GA "Effect of high-dose inhaled budesonide on calcium and phosphate metabolism and the risk of osteoporosis." Am Rev Respir Dis 138 (1988):  57-61|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|Konig P, Hillman L, Cervantes C, Levine C, Maloney C, Douglass B, Johnson L, Allen S "Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate." J Pediatr 122 (1993):  219-26|Kinberg KA, Hopp RJ, Biven RE, Gallagher JC "Bone mineral density in normal and asthmatic children." J Allergy Clin Immunol 94 (1994):  490-7|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|Toogood JH, Baskerville JC, Markov AE, Hodsman AB, Fraher LJ, Jennings B, Haddad RG, Drost D "Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma." J Allergy Clin Immunol 96 (1995):  157-66|Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S "Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids." J Allergy Clin Immunol 96 (1995):  571-9|Martinati LC, Bertoldo F, Gasperi E, Micelli S, Boner AL "Effect on cortical and trabecular bone mass of different anti-inflammatory treatments in preadolescent children with chronic asthma." Am J Respir Crit Care Med 153 (1996):  232-6|Packe GE, Douglas JG, McDonald AF, Robins SP, Reid DM "Bone density in asthmatic patients taking high dose inhaled beclomethasone diproprionate and intermittent systemic corticosteroids." Thorax 47 (1992):  414-7|Reid DM, Nicoll JJ, Smith MA, Higgins B, Tothill P, Nuki G "Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica." BMJ 293 (1986):  1463-6|Ali NJ, Capewell S, Ward MJ "Bone turnover during high dose inhaled corticosteroid treatment." Thorax 46 (1991):  160-4|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Packe GE, Robb O, Robins SP, Reid DM, Douglas JG "Bone density in asthmatic patients taking inhaled corticosteroids: comparison of budesonide and beclomethasone dipropionate." J R Coll Physicians Lond 30 (1996):  128-32|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|Luengo M, delRio L, Pons F, Picado C "Bone mineral density in asthmatic patients treated with inhaled corticosteroids: a case-control study." Eur Respir J 10 (1997):  2110-3|Wisniewski AF, Lewis SA, Green DJ, Maslanka W, Burrell H, Tattersfield AE "Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma." Thorax 52 (1997):  853-60|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|Wong CA, Walsh LJ, Smith CJP, Wisniewski AF, Lewis SA, Hubbard R, Cawte S, Green DJ, Pringle M, Tattersfield AE "Inhaled corticosteroid use and bone-mineral density in patients with asthma." Lancet 355 (2000):  1399-403|Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS "Effects of inhaled glucocorticoids on bone density in premenopausal women." N Engl J Med 345 (2001):  941-7|Sharma PK, Malhotra S, Pandhi P, Kumar N "Effect of inhaled steroids on bone mineral density: a meta-analysis." J Clin Pharmacol 43 (2003):  193-7|Boulet LP, Milot J, Gagnon L, Poubelle PE, Brown J "Long-term influence of inhaled corticosteroids on bone metabolism and density. Are biological markers predictors of bone loss?" Am J Respir Crit Care Med 159 (1999):  838-44', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34080, 14925, 'Budesonide (nasal)', 'Osteoporosis', 'Prolonged use of inhaled corticosteroids may be associated with a reduction in bone density.  This effect appears to be dose-related and has been reported primarily with high dosages (>= 800 mcg/day of beclomethasone or equivalent for >= 1 year).  Reduced levels of total body calcium have also been demonstrated in patients receiving lower dosages.  Long-term therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with osteoporosis.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Toogood JH, Crilly RG, Jones G, Nadeau J, Wells GA "Effect of high-dose inhaled budesonide on calcium and phosphate metabolism and the risk of osteoporosis." Am Rev Respir Dis 138 (1988):  57-61|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|Konig P, Hillman L, Cervantes C, Levine C, Maloney C, Douglass B, Johnson L, Allen S "Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate." J Pediatr 122 (1993):  219-26|Kinberg KA, Hopp RJ, Biven RE, Gallagher JC "Bone mineral density in normal and asthmatic children." J Allergy Clin Immunol 94 (1994):  490-7|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|Toogood JH, Baskerville JC, Markov AE, Hodsman AB, Fraher LJ, Jennings B, Haddad RG, Drost D "Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma." J Allergy Clin Immunol 96 (1995):  157-66|Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S "Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids." J Allergy Clin Immunol 96 (1995):  571-9|Martinati LC, Bertoldo F, Gasperi E, Micelli S, Boner AL "Effect on cortical and trabecular bone mass of different anti-inflammatory treatments in preadolescent children with chronic asthma." Am J Respir Crit Care Med 153 (1996):  232-6|Packe GE, Douglas JG, McDonald AF, Robins SP, Reid DM "Bone density in asthmatic patients taking high dose inhaled beclomethasone diproprionate and intermittent systemic corticosteroids." Thorax 47 (1992):  414-7|Reid DM, Nicoll JJ, Smith MA, Higgins B, Tothill P, Nuki G "Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica." BMJ 293 (1986):  1463-6|Ali NJ, Capewell S, Ward MJ "Bone turnover during high dose inhaled corticosteroid treatment." Thorax 46 (1991):  160-4|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Packe GE, Robb O, Robins SP, Reid DM, Douglas JG "Bone density in asthmatic patients taking inhaled corticosteroids: comparison of budesonide and beclomethasone dipropionate." J R Coll Physicians Lond 30 (1996):  128-32|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|Luengo M, delRio L, Pons F, Picado C "Bone mineral density in asthmatic patients treated with inhaled corticosteroids: a case-control study." Eur Respir J 10 (1997):  2110-3|Wisniewski AF, Lewis SA, Green DJ, Maslanka W, Burrell H, Tattersfield AE "Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma." Thorax 52 (1997):  853-60|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|Wong CA, Walsh LJ, Smith CJP, Wisniewski AF, Lewis SA, Hubbard R, Cawte S, Green DJ, Pringle M, Tattersfield AE "Inhaled corticosteroid use and bone-mineral density in patients with asthma." Lancet 355 (2000):  1399-403|Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS "Effects of inhaled glucocorticoids on bone density in premenopausal women." N Engl J Med 345 (2001):  941-7|Sharma PK, Malhotra S, Pandhi P, Kumar N "Effect of inhaled steroids on bone mineral density: a meta-analysis." J Clin Pharmacol 43 (2003):  193-7|Boulet LP, Milot J, Gagnon L, Poubelle PE, Brown J "Long-term influence of inhaled corticosteroids on bone metabolism and density. Are biological markers predictors of bone loss?" Am J Respir Crit Care Med 159 (1999):  838-44', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34081, 15551, 'Budesonide (nasal)', 'Osteoporosis', 'Prolonged use of inhaled corticosteroids may be associated with a reduction in bone density.  This effect appears to be dose-related and has been reported primarily with high dosages (>= 800 mcg/day of beclomethasone or equivalent for >= 1 year).  Reduced levels of total body calcium have also been demonstrated in patients receiving lower dosages.  Long-term therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with osteoporosis.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Toogood JH, Crilly RG, Jones G, Nadeau J, Wells GA "Effect of high-dose inhaled budesonide on calcium and phosphate metabolism and the risk of osteoporosis." Am Rev Respir Dis 138 (1988):  57-61|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|Konig P, Hillman L, Cervantes C, Levine C, Maloney C, Douglass B, Johnson L, Allen S "Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate." J Pediatr 122 (1993):  219-26|Kinberg KA, Hopp RJ, Biven RE, Gallagher JC "Bone mineral density in normal and asthmatic children." J Allergy Clin Immunol 94 (1994):  490-7|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|Toogood JH, Baskerville JC, Markov AE, Hodsman AB, Fraher LJ, Jennings B, Haddad RG, Drost D "Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma." J Allergy Clin Immunol 96 (1995):  157-66|Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S "Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids." J Allergy Clin Immunol 96 (1995):  571-9|Martinati LC, Bertoldo F, Gasperi E, Micelli S, Boner AL "Effect on cortical and trabecular bone mass of different anti-inflammatory treatments in preadolescent children with chronic asthma." Am J Respir Crit Care Med 153 (1996):  232-6|Packe GE, Douglas JG, McDonald AF, Robins SP, Reid DM "Bone density in asthmatic patients taking high dose inhaled beclomethasone diproprionate and intermittent systemic corticosteroids." Thorax 47 (1992):  414-7|Reid DM, Nicoll JJ, Smith MA, Higgins B, Tothill P, Nuki G "Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica." BMJ 293 (1986):  1463-6|Ali NJ, Capewell S, Ward MJ "Bone turnover during high dose inhaled corticosteroid treatment." Thorax 46 (1991):  160-4|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Packe GE, Robb O, Robins SP, Reid DM, Douglas JG "Bone density in asthmatic patients taking inhaled corticosteroids: comparison of budesonide and beclomethasone dipropionate." J R Coll Physicians Lond 30 (1996):  128-32|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|Luengo M, delRio L, Pons F, Picado C "Bone mineral density in asthmatic patients treated with inhaled corticosteroids: a case-control study." Eur Respir J 10 (1997):  2110-3|Wisniewski AF, Lewis SA, Green DJ, Maslanka W, Burrell H, Tattersfield AE "Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma." Thorax 52 (1997):  853-60|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|Wong CA, Walsh LJ, Smith CJP, Wisniewski AF, Lewis SA, Hubbard R, Cawte S, Green DJ, Pringle M, Tattersfield AE "Inhaled corticosteroid use and bone-mineral density in patients with asthma." Lancet 355 (2000):  1399-403|Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS "Effects of inhaled glucocorticoids on bone density in premenopausal women." N Engl J Med 345 (2001):  941-7|Sharma PK, Malhotra S, Pandhi P, Kumar N "Effect of inhaled steroids on bone mineral density: a meta-analysis." J Clin Pharmacol 43 (2003):  193-7|Boulet LP, Milot J, Gagnon L, Poubelle PE, Brown J "Long-term influence of inhaled corticosteroids on bone metabolism and density. Are biological markers predictors of bone loss?" Am J Respir Crit Care Med 159 (1999):  838-44', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34082, 15552, 'Budesonide (nasal)', 'Osteoporosis', 'Prolonged use of inhaled corticosteroids may be associated with a reduction in bone density.  This effect appears to be dose-related and has been reported primarily with high dosages (>= 800 mcg/day of beclomethasone or equivalent for >= 1 year).  Reduced levels of total body calcium have also been demonstrated in patients receiving lower dosages.  Long-term therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with osteoporosis.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Toogood JH, Crilly RG, Jones G, Nadeau J, Wells GA "Effect of high-dose inhaled budesonide on calcium and phosphate metabolism and the risk of osteoporosis." Am Rev Respir Dis 138 (1988):  57-61|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|Konig P, Hillman L, Cervantes C, Levine C, Maloney C, Douglass B, Johnson L, Allen S "Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate." J Pediatr 122 (1993):  219-26|Kinberg KA, Hopp RJ, Biven RE, Gallagher JC "Bone mineral density in normal and asthmatic children." J Allergy Clin Immunol 94 (1994):  490-7|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|Toogood JH, Baskerville JC, Markov AE, Hodsman AB, Fraher LJ, Jennings B, Haddad RG, Drost D "Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma." J Allergy Clin Immunol 96 (1995):  157-66|Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S "Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids." J Allergy Clin Immunol 96 (1995):  571-9|Martinati LC, Bertoldo F, Gasperi E, Micelli S, Boner AL "Effect on cortical and trabecular bone mass of different anti-inflammatory treatments in preadolescent children with chronic asthma." Am J Respir Crit Care Med 153 (1996):  232-6|Packe GE, Douglas JG, McDonald AF, Robins SP, Reid DM "Bone density in asthmatic patients taking high dose inhaled beclomethasone diproprionate and intermittent systemic corticosteroids." Thorax 47 (1992):  414-7|Reid DM, Nicoll JJ, Smith MA, Higgins B, Tothill P, Nuki G "Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica." BMJ 293 (1986):  1463-6|Ali NJ, Capewell S, Ward MJ "Bone turnover during high dose inhaled corticosteroid treatment." Thorax 46 (1991):  160-4|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Packe GE, Robb O, Robins SP, Reid DM, Douglas JG "Bone density in asthmatic patients taking inhaled corticosteroids: comparison of budesonide and beclomethasone dipropionate." J R Coll Physicians Lond 30 (1996):  128-32|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|Luengo M, delRio L, Pons F, Picado C "Bone mineral density in asthmatic patients treated with inhaled corticosteroids: a case-control study." Eur Respir J 10 (1997):  2110-3|Wisniewski AF, Lewis SA, Green DJ, Maslanka W, Burrell H, Tattersfield AE "Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma." Thorax 52 (1997):  853-60|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|Wong CA, Walsh LJ, Smith CJP, Wisniewski AF, Lewis SA, Hubbard R, Cawte S, Green DJ, Pringle M, Tattersfield AE "Inhaled corticosteroid use and bone-mineral density in patients with asthma." Lancet 355 (2000):  1399-403|Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS "Effects of inhaled glucocorticoids on bone density in premenopausal women." N Engl J Med 345 (2001):  941-7|Sharma PK, Malhotra S, Pandhi P, Kumar N "Effect of inhaled steroids on bone mineral density: a meta-analysis." J Clin Pharmacol 43 (2003):  193-7|Boulet LP, Milot J, Gagnon L, Poubelle PE, Brown J "Long-term influence of inhaled corticosteroids on bone metabolism and density. Are biological markers predictors of bone loss?" Am J Respir Crit Care Med 159 (1999):  838-44', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34083, 15553, 'Budesonide (nasal)', 'Osteoporosis', 'Prolonged use of inhaled corticosteroids may be associated with a reduction in bone density.  This effect appears to be dose-related and has been reported primarily with high dosages (>= 800 mcg/day of beclomethasone or equivalent for >= 1 year).  Reduced levels of total body calcium have also been demonstrated in patients receiving lower dosages.  Long-term therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with osteoporosis.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Toogood JH, Crilly RG, Jones G, Nadeau J, Wells GA "Effect of high-dose inhaled budesonide on calcium and phosphate metabolism and the risk of osteoporosis." Am Rev Respir Dis 138 (1988):  57-61|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|Konig P, Hillman L, Cervantes C, Levine C, Maloney C, Douglass B, Johnson L, Allen S "Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate." J Pediatr 122 (1993):  219-26|Kinberg KA, Hopp RJ, Biven RE, Gallagher JC "Bone mineral density in normal and asthmatic children." J Allergy Clin Immunol 94 (1994):  490-7|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|Toogood JH, Baskerville JC, Markov AE, Hodsman AB, Fraher LJ, Jennings B, Haddad RG, Drost D "Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma." J Allergy Clin Immunol 96 (1995):  157-66|Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S "Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids." J Allergy Clin Immunol 96 (1995):  571-9|Martinati LC, Bertoldo F, Gasperi E, Micelli S, Boner AL "Effect on cortical and trabecular bone mass of different anti-inflammatory treatments in preadolescent children with chronic asthma." Am J Respir Crit Care Med 153 (1996):  232-6|Packe GE, Douglas JG, McDonald AF, Robins SP, Reid DM "Bone density in asthmatic patients taking high dose inhaled beclomethasone diproprionate and intermittent systemic corticosteroids." Thorax 47 (1992):  414-7|Reid DM, Nicoll JJ, Smith MA, Higgins B, Tothill P, Nuki G "Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica." BMJ 293 (1986):  1463-6|Ali NJ, Capewell S, Ward MJ "Bone turnover during high dose inhaled corticosteroid treatment." Thorax 46 (1991):  160-4|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Packe GE, Robb O, Robins SP, Reid DM, Douglas JG "Bone density in asthmatic patients taking inhaled corticosteroids: comparison of budesonide and beclomethasone dipropionate." J R Coll Physicians Lond 30 (1996):  128-32|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|Luengo M, delRio L, Pons F, Picado C "Bone mineral density in asthmatic patients treated with inhaled corticosteroids: a case-control study." Eur Respir J 10 (1997):  2110-3|Wisniewski AF, Lewis SA, Green DJ, Maslanka W, Burrell H, Tattersfield AE "Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma." Thorax 52 (1997):  853-60|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|Wong CA, Walsh LJ, Smith CJP, Wisniewski AF, Lewis SA, Hubbard R, Cawte S, Green DJ, Pringle M, Tattersfield AE "Inhaled corticosteroid use and bone-mineral density in patients with asthma." Lancet 355 (2000):  1399-403|Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS "Effects of inhaled glucocorticoids on bone density in premenopausal women." N Engl J Med 345 (2001):  941-7|Sharma PK, Malhotra S, Pandhi P, Kumar N "Effect of inhaled steroids on bone mineral density: a meta-analysis." J Clin Pharmacol 43 (2003):  193-7|Boulet LP, Milot J, Gagnon L, Poubelle PE, Brown J "Long-term influence of inhaled corticosteroids on bone metabolism and density. Are biological markers predictors of bone loss?" Am J Respir Crit Care Med 159 (1999):  838-44', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34084, 15555, 'Budesonide (nasal)', 'Osteoporosis', 'Prolonged use of inhaled corticosteroids may be associated with a reduction in bone density.  This effect appears to be dose-related and has been reported primarily with high dosages (>= 800 mcg/day of beclomethasone or equivalent for >= 1 year).  Reduced levels of total body calcium have also been demonstrated in patients receiving lower dosages.  Long-term therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with osteoporosis.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Toogood JH, Crilly RG, Jones G, Nadeau J, Wells GA "Effect of high-dose inhaled budesonide on calcium and phosphate metabolism and the risk of osteoporosis." Am Rev Respir Dis 138 (1988):  57-61|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|Konig P, Hillman L, Cervantes C, Levine C, Maloney C, Douglass B, Johnson L, Allen S "Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate." J Pediatr 122 (1993):  219-26|Kinberg KA, Hopp RJ, Biven RE, Gallagher JC "Bone mineral density in normal and asthmatic children." J Allergy Clin Immunol 94 (1994):  490-7|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|Toogood JH, Baskerville JC, Markov AE, Hodsman AB, Fraher LJ, Jennings B, Haddad RG, Drost D "Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma." J Allergy Clin Immunol 96 (1995):  157-66|Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S "Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids." J Allergy Clin Immunol 96 (1995):  571-9|Martinati LC, Bertoldo F, Gasperi E, Micelli S, Boner AL "Effect on cortical and trabecular bone mass of different anti-inflammatory treatments in preadolescent children with chronic asthma." Am J Respir Crit Care Med 153 (1996):  232-6|Packe GE, Douglas JG, McDonald AF, Robins SP, Reid DM "Bone density in asthmatic patients taking high dose inhaled beclomethasone diproprionate and intermittent systemic corticosteroids." Thorax 47 (1992):  414-7|Reid DM, Nicoll JJ, Smith MA, Higgins B, Tothill P, Nuki G "Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica." BMJ 293 (1986):  1463-6|Ali NJ, Capewell S, Ward MJ "Bone turnover during high dose inhaled corticosteroid treatment." Thorax 46 (1991):  160-4|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Packe GE, Robb O, Robins SP, Reid DM, Douglas JG "Bone density in asthmatic patients taking inhaled corticosteroids: comparison of budesonide and beclomethasone dipropionate." J R Coll Physicians Lond 30 (1996):  128-32|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|Luengo M, delRio L, Pons F, Picado C "Bone mineral density in asthmatic patients treated with inhaled corticosteroids: a case-control study." Eur Respir J 10 (1997):  2110-3|Wisniewski AF, Lewis SA, Green DJ, Maslanka W, Burrell H, Tattersfield AE "Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma." Thorax 52 (1997):  853-60|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|Wong CA, Walsh LJ, Smith CJP, Wisniewski AF, Lewis SA, Hubbard R, Cawte S, Green DJ, Pringle M, Tattersfield AE "Inhaled corticosteroid use and bone-mineral density in patients with asthma." Lancet 355 (2000):  1399-403|Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS "Effects of inhaled glucocorticoids on bone density in premenopausal women." N Engl J Med 345 (2001):  941-7|Sharma PK, Malhotra S, Pandhi P, Kumar N "Effect of inhaled steroids on bone mineral density: a meta-analysis." J Clin Pharmacol 43 (2003):  193-7|Boulet LP, Milot J, Gagnon L, Poubelle PE, Brown J "Long-term influence of inhaled corticosteroids on bone metabolism and density. Are biological markers predictors of bone loss?" Am J Respir Crit Care Med 159 (1999):  838-44', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34085, 15556, 'Budesonide (nasal)', 'Osteoporosis', 'Prolonged use of inhaled corticosteroids may be associated with a reduction in bone density.  This effect appears to be dose-related and has been reported primarily with high dosages (>= 800 mcg/day of beclomethasone or equivalent for >= 1 year).  Reduced levels of total body calcium have also been demonstrated in patients receiving lower dosages.  Long-term therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with osteoporosis.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Toogood JH, Crilly RG, Jones G, Nadeau J, Wells GA "Effect of high-dose inhaled budesonide on calcium and phosphate metabolism and the risk of osteoporosis." Am Rev Respir Dis 138 (1988):  57-61|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|Konig P, Hillman L, Cervantes C, Levine C, Maloney C, Douglass B, Johnson L, Allen S "Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate." J Pediatr 122 (1993):  219-26|Kinberg KA, Hopp RJ, Biven RE, Gallagher JC "Bone mineral density in normal and asthmatic children." J Allergy Clin Immunol 94 (1994):  490-7|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|Toogood JH, Baskerville JC, Markov AE, Hodsman AB, Fraher LJ, Jennings B, Haddad RG, Drost D "Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma." J Allergy Clin Immunol 96 (1995):  157-66|Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S "Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids." J Allergy Clin Immunol 96 (1995):  571-9|Martinati LC, Bertoldo F, Gasperi E, Micelli S, Boner AL "Effect on cortical and trabecular bone mass of different anti-inflammatory treatments in preadolescent children with chronic asthma." Am J Respir Crit Care Med 153 (1996):  232-6|Packe GE, Douglas JG, McDonald AF, Robins SP, Reid DM "Bone density in asthmatic patients taking high dose inhaled beclomethasone diproprionate and intermittent systemic corticosteroids." Thorax 47 (1992):  414-7|Reid DM, Nicoll JJ, Smith MA, Higgins B, Tothill P, Nuki G "Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica." BMJ 293 (1986):  1463-6|Ali NJ, Capewell S, Ward MJ "Bone turnover during high dose inhaled corticosteroid treatment." Thorax 46 (1991):  160-4|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Packe GE, Robb O, Robins SP, Reid DM, Douglas JG "Bone density in asthmatic patients taking inhaled corticosteroids: comparison of budesonide and beclomethasone dipropionate." J R Coll Physicians Lond 30 (1996):  128-32|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|Luengo M, delRio L, Pons F, Picado C "Bone mineral density in asthmatic patients treated with inhaled corticosteroids: a case-control study." Eur Respir J 10 (1997):  2110-3|Wisniewski AF, Lewis SA, Green DJ, Maslanka W, Burrell H, Tattersfield AE "Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma." Thorax 52 (1997):  853-60|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|Wong CA, Walsh LJ, Smith CJP, Wisniewski AF, Lewis SA, Hubbard R, Cawte S, Green DJ, Pringle M, Tattersfield AE "Inhaled corticosteroid use and bone-mineral density in patients with asthma." Lancet 355 (2000):  1399-403|Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS "Effects of inhaled glucocorticoids on bone density in premenopausal women." N Engl J Med 345 (2001):  941-7|Sharma PK, Malhotra S, Pandhi P, Kumar N "Effect of inhaled steroids on bone mineral density: a meta-analysis." J Clin Pharmacol 43 (2003):  193-7|Boulet LP, Milot J, Gagnon L, Poubelle PE, Brown J "Long-term influence of inhaled corticosteroids on bone metabolism and density. Are biological markers predictors of bone loss?" Am J Respir Crit Care Med 159 (1999):  838-44', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34086, 18134, 'Budesonide (nasal)', 'Osteoporosis', 'Prolonged use of inhaled corticosteroids may be associated with a reduction in bone density.  This effect appears to be dose-related and has been reported primarily with high dosages (>= 800 mcg/day of beclomethasone or equivalent for >= 1 year).  Reduced levels of total body calcium have also been demonstrated in patients receiving lower dosages.  Long-term therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with osteoporosis.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Toogood JH, Crilly RG, Jones G, Nadeau J, Wells GA "Effect of high-dose inhaled budesonide on calcium and phosphate metabolism and the risk of osteoporosis." Am Rev Respir Dis 138 (1988):  57-61|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|Konig P, Hillman L, Cervantes C, Levine C, Maloney C, Douglass B, Johnson L, Allen S "Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate." J Pediatr 122 (1993):  219-26|Kinberg KA, Hopp RJ, Biven RE, Gallagher JC "Bone mineral density in normal and asthmatic children." J Allergy Clin Immunol 94 (1994):  490-7|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|Toogood JH, Baskerville JC, Markov AE, Hodsman AB, Fraher LJ, Jennings B, Haddad RG, Drost D "Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma." J Allergy Clin Immunol 96 (1995):  157-66|Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S "Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids." J Allergy Clin Immunol 96 (1995):  571-9|Martinati LC, Bertoldo F, Gasperi E, Micelli S, Boner AL "Effect on cortical and trabecular bone mass of different anti-inflammatory treatments in preadolescent children with chronic asthma." Am J Respir Crit Care Med 153 (1996):  232-6|Packe GE, Douglas JG, McDonald AF, Robins SP, Reid DM "Bone density in asthmatic patients taking high dose inhaled beclomethasone diproprionate and intermittent systemic corticosteroids." Thorax 47 (1992):  414-7|Reid DM, Nicoll JJ, Smith MA, Higgins B, Tothill P, Nuki G "Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica." BMJ 293 (1986):  1463-6|Ali NJ, Capewell S, Ward MJ "Bone turnover during high dose inhaled corticosteroid treatment." Thorax 46 (1991):  160-4|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Packe GE, Robb O, Robins SP, Reid DM, Douglas JG "Bone density in asthmatic patients taking inhaled corticosteroids: comparison of budesonide and beclomethasone dipropionate." J R Coll Physicians Lond 30 (1996):  128-32|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|Luengo M, delRio L, Pons F, Picado C "Bone mineral density in asthmatic patients treated with inhaled corticosteroids: a case-control study." Eur Respir J 10 (1997):  2110-3|Wisniewski AF, Lewis SA, Green DJ, Maslanka W, Burrell H, Tattersfield AE "Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma." Thorax 52 (1997):  853-60|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|Wong CA, Walsh LJ, Smith CJP, Wisniewski AF, Lewis SA, Hubbard R, Cawte S, Green DJ, Pringle M, Tattersfield AE "Inhaled corticosteroid use and bone-mineral density in patients with asthma." Lancet 355 (2000):  1399-403|Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS "Effects of inhaled glucocorticoids on bone density in premenopausal women." N Engl J Med 345 (2001):  941-7|Sharma PK, Malhotra S, Pandhi P, Kumar N "Effect of inhaled steroids on bone mineral density: a meta-analysis." J Clin Pharmacol 43 (2003):  193-7|Boulet LP, Milot J, Gagnon L, Poubelle PE, Brown J "Long-term influence of inhaled corticosteroids on bone metabolism and density. Are biological markers predictors of bone loss?" Am J Respir Crit Care Med 159 (1999):  838-44', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34087, 25479, 'Budesonide (nasal)', 'Osteoporosis', 'Prolonged use of inhaled corticosteroids may be associated with a reduction in bone density.  This effect appears to be dose-related and has been reported primarily with high dosages (>= 800 mcg/day of beclomethasone or equivalent for >= 1 year).  Reduced levels of total body calcium have also been demonstrated in patients receiving lower dosages.  Long-term therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with osteoporosis.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Toogood JH, Crilly RG, Jones G, Nadeau J, Wells GA "Effect of high-dose inhaled budesonide on calcium and phosphate metabolism and the risk of osteoporosis." Am Rev Respir Dis 138 (1988):  57-61|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|Konig P, Hillman L, Cervantes C, Levine C, Maloney C, Douglass B, Johnson L, Allen S "Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate." J Pediatr 122 (1993):  219-26|Kinberg KA, Hopp RJ, Biven RE, Gallagher JC "Bone mineral density in normal and asthmatic children." J Allergy Clin Immunol 94 (1994):  490-7|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|Toogood JH, Baskerville JC, Markov AE, Hodsman AB, Fraher LJ, Jennings B, Haddad RG, Drost D "Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma." J Allergy Clin Immunol 96 (1995):  157-66|Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S "Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids." J Allergy Clin Immunol 96 (1995):  571-9|Martinati LC, Bertoldo F, Gasperi E, Micelli S, Boner AL "Effect on cortical and trabecular bone mass of different anti-inflammatory treatments in preadolescent children with chronic asthma." Am J Respir Crit Care Med 153 (1996):  232-6|Packe GE, Douglas JG, McDonald AF, Robins SP, Reid DM "Bone density in asthmatic patients taking high dose inhaled beclomethasone diproprionate and intermittent systemic corticosteroids." Thorax 47 (1992):  414-7|Reid DM, Nicoll JJ, Smith MA, Higgins B, Tothill P, Nuki G "Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica." BMJ 293 (1986):  1463-6|Ali NJ, Capewell S, Ward MJ "Bone turnover during high dose inhaled corticosteroid treatment." Thorax 46 (1991):  160-4|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Packe GE, Robb O, Robins SP, Reid DM, Douglas JG "Bone density in asthmatic patients taking inhaled corticosteroids: comparison of budesonide and beclomethasone dipropionate." J R Coll Physicians Lond 30 (1996):  128-32|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|Luengo M, delRio L, Pons F, Picado C "Bone mineral density in asthmatic patients treated with inhaled corticosteroids: a case-control study." Eur Respir J 10 (1997):  2110-3|Wisniewski AF, Lewis SA, Green DJ, Maslanka W, Burrell H, Tattersfield AE "Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma." Thorax 52 (1997):  853-60|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|Wong CA, Walsh LJ, Smith CJP, Wisniewski AF, Lewis SA, Hubbard R, Cawte S, Green DJ, Pringle M, Tattersfield AE "Inhaled corticosteroid use and bone-mineral density in patients with asthma." Lancet 355 (2000):  1399-403|Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS "Effects of inhaled glucocorticoids on bone density in premenopausal women." N Engl J Med 345 (2001):  941-7|Sharma PK, Malhotra S, Pandhi P, Kumar N "Effect of inhaled steroids on bone mineral density: a meta-analysis." J Clin Pharmacol 43 (2003):  193-7|Boulet LP, Milot J, Gagnon L, Poubelle PE, Brown J "Long-term influence of inhaled corticosteroids on bone metabolism and density. Are biological markers predictors of bone loss?" Am J Respir Crit Care Med 159 (1999):  838-44', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34088, 25480, 'Budesonide (nasal)', 'Osteoporosis', 'Prolonged use of inhaled corticosteroids may be associated with a reduction in bone density.  This effect appears to be dose-related and has been reported primarily with high dosages (>= 800 mcg/day of beclomethasone or equivalent for >= 1 year).  Reduced levels of total body calcium have also been demonstrated in patients receiving lower dosages.  Long-term therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with osteoporosis.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Toogood JH, Crilly RG, Jones G, Nadeau J, Wells GA "Effect of high-dose inhaled budesonide on calcium and phosphate metabolism and the risk of osteoporosis." Am Rev Respir Dis 138 (1988):  57-61|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|Konig P, Hillman L, Cervantes C, Levine C, Maloney C, Douglass B, Johnson L, Allen S "Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate." J Pediatr 122 (1993):  219-26|Kinberg KA, Hopp RJ, Biven RE, Gallagher JC "Bone mineral density in normal and asthmatic children." J Allergy Clin Immunol 94 (1994):  490-7|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|Toogood JH, Baskerville JC, Markov AE, Hodsman AB, Fraher LJ, Jennings B, Haddad RG, Drost D "Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma." J Allergy Clin Immunol 96 (1995):  157-66|Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S "Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids." J Allergy Clin Immunol 96 (1995):  571-9|Martinati LC, Bertoldo F, Gasperi E, Micelli S, Boner AL "Effect on cortical and trabecular bone mass of different anti-inflammatory treatments in preadolescent children with chronic asthma." Am J Respir Crit Care Med 153 (1996):  232-6|Packe GE, Douglas JG, McDonald AF, Robins SP, Reid DM "Bone density in asthmatic patients taking high dose inhaled beclomethasone diproprionate and intermittent systemic corticosteroids." Thorax 47 (1992):  414-7|Reid DM, Nicoll JJ, Smith MA, Higgins B, Tothill P, Nuki G "Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica." BMJ 293 (1986):  1463-6|Ali NJ, Capewell S, Ward MJ "Bone turnover during high dose inhaled corticosteroid treatment." Thorax 46 (1991):  160-4|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Packe GE, Robb O, Robins SP, Reid DM, Douglas JG "Bone density in asthmatic patients taking inhaled corticosteroids: comparison of budesonide and beclomethasone dipropionate." J R Coll Physicians Lond 30 (1996):  128-32|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|Luengo M, delRio L, Pons F, Picado C "Bone mineral density in asthmatic patients treated with inhaled corticosteroids: a case-control study." Eur Respir J 10 (1997):  2110-3|Wisniewski AF, Lewis SA, Green DJ, Maslanka W, Burrell H, Tattersfield AE "Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma." Thorax 52 (1997):  853-60|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|Wong CA, Walsh LJ, Smith CJP, Wisniewski AF, Lewis SA, Hubbard R, Cawte S, Green DJ, Pringle M, Tattersfield AE "Inhaled corticosteroid use and bone-mineral density in patients with asthma." Lancet 355 (2000):  1399-403|Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS "Effects of inhaled glucocorticoids on bone density in premenopausal women." N Engl J Med 345 (2001):  941-7|Sharma PK, Malhotra S, Pandhi P, Kumar N "Effect of inhaled steroids on bone mineral density: a meta-analysis." J Clin Pharmacol 43 (2003):  193-7|Boulet LP, Milot J, Gagnon L, Poubelle PE, Brown J "Long-term influence of inhaled corticosteroids on bone metabolism and density. Are biological markers predictors of bone loss?" Am J Respir Crit Care Med 159 (1999):  838-44', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34089, 25481, 'Budesonide (nasal)', 'Osteoporosis', 'Prolonged use of inhaled corticosteroids may be associated with a reduction in bone density.  This effect appears to be dose-related and has been reported primarily with high dosages (>= 800 mcg/day of beclomethasone or equivalent for >= 1 year).  Reduced levels of total body calcium have also been demonstrated in patients receiving lower dosages.  Long-term therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with osteoporosis.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Toogood JH, Crilly RG, Jones G, Nadeau J, Wells GA "Effect of high-dose inhaled budesonide on calcium and phosphate metabolism and the risk of osteoporosis." Am Rev Respir Dis 138 (1988):  57-61|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|Konig P, Hillman L, Cervantes C, Levine C, Maloney C, Douglass B, Johnson L, Allen S "Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate." J Pediatr 122 (1993):  219-26|Kinberg KA, Hopp RJ, Biven RE, Gallagher JC "Bone mineral density in normal and asthmatic children." J Allergy Clin Immunol 94 (1994):  490-7|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|Toogood JH, Baskerville JC, Markov AE, Hodsman AB, Fraher LJ, Jennings B, Haddad RG, Drost D "Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma." J Allergy Clin Immunol 96 (1995):  157-66|Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S "Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids." J Allergy Clin Immunol 96 (1995):  571-9|Martinati LC, Bertoldo F, Gasperi E, Micelli S, Boner AL "Effect on cortical and trabecular bone mass of different anti-inflammatory treatments in preadolescent children with chronic asthma." Am J Respir Crit Care Med 153 (1996):  232-6|Packe GE, Douglas JG, McDonald AF, Robins SP, Reid DM "Bone density in asthmatic patients taking high dose inhaled beclomethasone diproprionate and intermittent systemic corticosteroids." Thorax 47 (1992):  414-7|Reid DM, Nicoll JJ, Smith MA, Higgins B, Tothill P, Nuki G "Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica." BMJ 293 (1986):  1463-6|Ali NJ, Capewell S, Ward MJ "Bone turnover during high dose inhaled corticosteroid treatment." Thorax 46 (1991):  160-4|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Packe GE, Robb O, Robins SP, Reid DM, Douglas JG "Bone density in asthmatic patients taking inhaled corticosteroids: comparison of budesonide and beclomethasone dipropionate." J R Coll Physicians Lond 30 (1996):  128-32|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|Luengo M, delRio L, Pons F, Picado C "Bone mineral density in asthmatic patients treated with inhaled corticosteroids: a case-control study." Eur Respir J 10 (1997):  2110-3|Wisniewski AF, Lewis SA, Green DJ, Maslanka W, Burrell H, Tattersfield AE "Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma." Thorax 52 (1997):  853-60|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|Wong CA, Walsh LJ, Smith CJP, Wisniewski AF, Lewis SA, Hubbard R, Cawte S, Green DJ, Pringle M, Tattersfield AE "Inhaled corticosteroid use and bone-mineral density in patients with asthma." Lancet 355 (2000):  1399-403|Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS "Effects of inhaled glucocorticoids on bone density in premenopausal women." N Engl J Med 345 (2001):  941-7|Sharma PK, Malhotra S, Pandhi P, Kumar N "Effect of inhaled steroids on bone mineral density: a meta-analysis." J Clin Pharmacol 43 (2003):  193-7|Boulet LP, Milot J, Gagnon L, Poubelle PE, Brown J "Long-term influence of inhaled corticosteroids on bone metabolism and density. Are biological markers predictors of bone loss?" Am J Respir Crit Care Med 159 (1999):  838-44', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34090, 25482, 'Budesonide (nasal)', 'Osteoporosis', 'Prolonged use of inhaled corticosteroids may be associated with a reduction in bone density.  This effect appears to be dose-related and has been reported primarily with high dosages (>= 800 mcg/day of beclomethasone or equivalent for >= 1 year).  Reduced levels of total body calcium have also been demonstrated in patients receiving lower dosages.  Long-term therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with osteoporosis.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Toogood JH, Crilly RG, Jones G, Nadeau J, Wells GA "Effect of high-dose inhaled budesonide on calcium and phosphate metabolism and the risk of osteoporosis." Am Rev Respir Dis 138 (1988):  57-61|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|Konig P, Hillman L, Cervantes C, Levine C, Maloney C, Douglass B, Johnson L, Allen S "Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate." J Pediatr 122 (1993):  219-26|Kinberg KA, Hopp RJ, Biven RE, Gallagher JC "Bone mineral density in normal and asthmatic children." J Allergy Clin Immunol 94 (1994):  490-7|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|Toogood JH, Baskerville JC, Markov AE, Hodsman AB, Fraher LJ, Jennings B, Haddad RG, Drost D "Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma." J Allergy Clin Immunol 96 (1995):  157-66|Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S "Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids." J Allergy Clin Immunol 96 (1995):  571-9|Martinati LC, Bertoldo F, Gasperi E, Micelli S, Boner AL "Effect on cortical and trabecular bone mass of different anti-inflammatory treatments in preadolescent children with chronic asthma." Am J Respir Crit Care Med 153 (1996):  232-6|Packe GE, Douglas JG, McDonald AF, Robins SP, Reid DM "Bone density in asthmatic patients taking high dose inhaled beclomethasone diproprionate and intermittent systemic corticosteroids." Thorax 47 (1992):  414-7|Reid DM, Nicoll JJ, Smith MA, Higgins B, Tothill P, Nuki G "Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica." BMJ 293 (1986):  1463-6|Ali NJ, Capewell S, Ward MJ "Bone turnover during high dose inhaled corticosteroid treatment." Thorax 46 (1991):  160-4|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Packe GE, Robb O, Robins SP, Reid DM, Douglas JG "Bone density in asthmatic patients taking inhaled corticosteroids: comparison of budesonide and beclomethasone dipropionate." J R Coll Physicians Lond 30 (1996):  128-32|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|Luengo M, delRio L, Pons F, Picado C "Bone mineral density in asthmatic patients treated with inhaled corticosteroids: a case-control study." Eur Respir J 10 (1997):  2110-3|Wisniewski AF, Lewis SA, Green DJ, Maslanka W, Burrell H, Tattersfield AE "Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma." Thorax 52 (1997):  853-60|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|Wong CA, Walsh LJ, Smith CJP, Wisniewski AF, Lewis SA, Hubbard R, Cawte S, Green DJ, Pringle M, Tattersfield AE "Inhaled corticosteroid use and bone-mineral density in patients with asthma." Lancet 355 (2000):  1399-403|Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS "Effects of inhaled glucocorticoids on bone density in premenopausal women." N Engl J Med 345 (2001):  941-7|Sharma PK, Malhotra S, Pandhi P, Kumar N "Effect of inhaled steroids on bone mineral density: a meta-analysis." J Clin Pharmacol 43 (2003):  193-7|Boulet LP, Milot J, Gagnon L, Poubelle PE, Brown J "Long-term influence of inhaled corticosteroids on bone metabolism and density. Are biological markers predictors of bone loss?" Am J Respir Crit Care Med 159 (1999):  838-44', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34091, 26038, 'Budesonide (nasal)', 'Osteoporosis', 'Prolonged use of inhaled corticosteroids may be associated with a reduction in bone density.  This effect appears to be dose-related and has been reported primarily with high dosages (>= 800 mcg/day of beclomethasone or equivalent for >= 1 year).  Reduced levels of total body calcium have also been demonstrated in patients receiving lower dosages.  Long-term therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with osteoporosis.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Toogood JH, Crilly RG, Jones G, Nadeau J, Wells GA "Effect of high-dose inhaled budesonide on calcium and phosphate metabolism and the risk of osteoporosis." Am Rev Respir Dis 138 (1988):  57-61|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|Konig P, Hillman L, Cervantes C, Levine C, Maloney C, Douglass B, Johnson L, Allen S "Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate." J Pediatr 122 (1993):  219-26|Kinberg KA, Hopp RJ, Biven RE, Gallagher JC "Bone mineral density in normal and asthmatic children." J Allergy Clin Immunol 94 (1994):  490-7|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|Toogood JH, Baskerville JC, Markov AE, Hodsman AB, Fraher LJ, Jennings B, Haddad RG, Drost D "Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma." J Allergy Clin Immunol 96 (1995):  157-66|Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S "Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids." J Allergy Clin Immunol 96 (1995):  571-9|Martinati LC, Bertoldo F, Gasperi E, Micelli S, Boner AL "Effect on cortical and trabecular bone mass of different anti-inflammatory treatments in preadolescent children with chronic asthma." Am J Respir Crit Care Med 153 (1996):  232-6|Packe GE, Douglas JG, McDonald AF, Robins SP, Reid DM "Bone density in asthmatic patients taking high dose inhaled beclomethasone diproprionate and intermittent systemic corticosteroids." Thorax 47 (1992):  414-7|Reid DM, Nicoll JJ, Smith MA, Higgins B, Tothill P, Nuki G "Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica." BMJ 293 (1986):  1463-6|Ali NJ, Capewell S, Ward MJ "Bone turnover during high dose inhaled corticosteroid treatment." Thorax 46 (1991):  160-4|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Packe GE, Robb O, Robins SP, Reid DM, Douglas JG "Bone density in asthmatic patients taking inhaled corticosteroids: comparison of budesonide and beclomethasone dipropionate." J R Coll Physicians Lond 30 (1996):  128-32|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|Luengo M, delRio L, Pons F, Picado C "Bone mineral density in asthmatic patients treated with inhaled corticosteroids: a case-control study." Eur Respir J 10 (1997):  2110-3|Wisniewski AF, Lewis SA, Green DJ, Maslanka W, Burrell H, Tattersfield AE "Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma." Thorax 52 (1997):  853-60|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|Wong CA, Walsh LJ, Smith CJP, Wisniewski AF, Lewis SA, Hubbard R, Cawte S, Green DJ, Pringle M, Tattersfield AE "Inhaled corticosteroid use and bone-mineral density in patients with asthma." Lancet 355 (2000):  1399-403|Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS "Effects of inhaled glucocorticoids on bone density in premenopausal women." N Engl J Med 345 (2001):  941-7|Sharma PK, Malhotra S, Pandhi P, Kumar N "Effect of inhaled steroids on bone mineral density: a meta-analysis." J Clin Pharmacol 43 (2003):  193-7|Boulet LP, Milot J, Gagnon L, Poubelle PE, Brown J "Long-term influence of inhaled corticosteroids on bone metabolism and density. Are biological markers predictors of bone loss?" Am J Respir Crit Care Med 159 (1999):  838-44', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34092, 26039, 'Budesonide (nasal)', 'Osteoporosis', 'Prolonged use of inhaled corticosteroids may be associated with a reduction in bone density.  This effect appears to be dose-related and has been reported primarily with high dosages (>= 800 mcg/day of beclomethasone or equivalent for >= 1 year).  Reduced levels of total body calcium have also been demonstrated in patients receiving lower dosages.  Long-term therapy with inhaled and nasal corticosteroids should be administered cautiously in patients with osteoporosis.  It is important that the recommended dosages of the individual products not be exceeded and that the lowest effective dosage be used.', '2', 'Grahnen A, Eckernas SA, Brundin RM, Lingandersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994):  521-5|Toogood JH, Crilly RG, Jones G, Nadeau J, Wells GA "Effect of high-dose inhaled budesonide on calcium and phosphate metabolism and the risk of osteoporosis." Am Rev Respir Dis 138 (1988):  57-61|Edsbacker S, Andersson KE, Ryrfeldt A "Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man." Eur J Clin Pharmacol 29 (1985):  477-81|Konig P, Hillman L, Cervantes C, Levine C, Maloney C, Douglass B, Johnson L, Allen S "Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate." J Pediatr 122 (1993):  219-26|Kinberg KA, Hopp RJ, Biven RE, Gallagher JC "Bone mineral density in normal and asthmatic children." J Allergy Clin Immunol 94 (1994):  490-7|Barnes PJ "Drug therapy: inhaled glucocorticoids for asthma." N Engl J Med 332 (1995):  868-75|Toogood JH, Baskerville JC, Markov AE, Hodsman AB, Fraher LJ, Jennings B, Haddad RG, Drost D "Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma." J Allergy Clin Immunol 96 (1995):  157-66|Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S "Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids." J Allergy Clin Immunol 96 (1995):  571-9|Martinati LC, Bertoldo F, Gasperi E, Micelli S, Boner AL "Effect on cortical and trabecular bone mass of different anti-inflammatory treatments in preadolescent children with chronic asthma." Am J Respir Crit Care Med 153 (1996):  232-6|Packe GE, Douglas JG, McDonald AF, Robins SP, Reid DM "Bone density in asthmatic patients taking high dose inhaled beclomethasone diproprionate and intermittent systemic corticosteroids." Thorax 47 (1992):  414-7|Reid DM, Nicoll JJ, Smith MA, Higgins B, Tothill P, Nuki G "Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica." BMJ 293 (1986):  1463-6|Ali NJ, Capewell S, Ward MJ "Bone turnover during high dose inhaled corticosteroid treatment." Thorax 46 (1991):  160-4|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|Packe GE, Robb O, Robins SP, Reid DM, Douglas JG "Bone density in asthmatic patients taking inhaled corticosteroids: comparison of budesonide and beclomethasone dipropionate." J R Coll Physicians Lond 30 (1996):  128-32|Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren JE "Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects." Br J Clin Pharmacol 43 (1997):  155-61|McEvoy CE, Niewoehner DE "Adverse effects of corticosteroid therapy for COPD - A critical review." Chest 111 (1997):  732-43|Wiseman LR, Benfield P "Intranasal fluticasone propionate: A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis." Drugs 53 (1997):  885-907|Luengo M, delRio L, Pons F, Picado C "Bone mineral density in asthmatic patients treated with inhaled corticosteroids: a case-control study." Eur Respir J 10 (1997):  2110-3|Wisniewski AF, Lewis SA, Green DJ, Maslanka W, Burrell H, Tattersfield AE "Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma." Thorax 52 (1997):  853-60|Derom E, Schoor JV, Verhaeghe W, Vincken W, Pauwels R "Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma." Am J Respir Crit Care Med 160 (1999):  157-61|Wong CA, Walsh LJ, Smith CJP, Wisniewski AF, Lewis SA, Hubbard R, Cawte S, Green DJ, Pringle M, Tattersfield AE "Inhaled corticosteroid use and bone-mineral density in patients with asthma." Lancet 355 (2000):  1399-403|Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS "Effects of inhaled glucocorticoids on bone density in premenopausal women." N Engl J Med 345 (2001):  941-7|Sharma PK, Malhotra S, Pandhi P, Kumar N "Effect of inhaled steroids on bone mineral density: a meta-analysis." J Clin Pharmacol 43 (2003):  193-7|Boulet LP, Milot J, Gagnon L, Poubelle PE, Brown J "Long-term influence of inhaled corticosteroids on bone metabolism and density. Are biological markers predictors of bone loss?" Am J Respir Crit Care Med 159 (1999):  838-44', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34093, 0, 'Brodalumab', 'Crohn Disease', 'The use of brodalumab is contraindicated in patients with Crohn''s disease as this agent may cause worsening of the disease.  It is recommended to discontinue the use of brodalumab if patients develop Crohn''s disease while on treatment.', '3', '"Product Information. Siliq (brodalumab)." Valeant Pharmaceuticals  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34094, 0, 'Brodalumab', 'Depressive Disorder', 'Suicidal ideation and behavior, including completed suicides, have occurred in patients treated with brodalumab.  Patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior.  Prescribers should weigh the potential risks and benefits before using brodalumab in patients with a history of depression or suicidality.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.', '3', '"Product Information. Siliq (brodalumab)." Valeant Pharmaceuticals  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34095, 0, 'Brodalumab', 'Tuberculosis', 'Brodalumab should not be administered to patients with active tuberculosis infection.  It is recommended to evaluate patients for tuberculosis infection prior to initiating treatment with brodalumab and initiate treatment for latent tuberculosis prior to administering this agent.  Consider anti- tuberculosis therapy prior to initiation of therapy in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed.  Closely monitor patients receiving brodalumab for signs and symptoms of active tuberculosis during and after treatment.', '3', '"Product Information. Siliq (brodalumab)." Valeant Pharmaceuticals  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34096, 0, 'Brodalumab', 'Infections', 'The use of brodalumab of may increase the risk of infections.  When using this agent in patients with a chronic infection or a history of recurrent infection, it is recommended to consider the risks and benefits prior to prescribing brodalumab.  Therapy discontinuation may be considered if a patient develops a serious infection or is not responding to standard therapy for the infection.  Care should be exercised when prescribing this agent to patients with an existing infection.', '2', '"Product Information. Siliq (brodalumab)." Valeant Pharmaceuticals  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34097, 1420, 'Activated charcoal', 'Intestinal Obstruction', 'Charcoal (with or without sorbitol) should not be used in the presence of a stomach or intestinal obstruction or absence of active bowel sounds.  Delayed GI transit time or constipation can result in failure to excrete a drug- charcoal complex and may result in increased toxicity.', '3', '"Product Information. Actidose-Aqua (charcoal)." Paddock Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34098, 3724, 'Activated charcoal', 'Intestinal Obstruction', 'Charcoal (with or without sorbitol) should not be used in the presence of a stomach or intestinal obstruction or absence of active bowel sounds.  Delayed GI transit time or constipation can result in failure to excrete a drug- charcoal complex and may result in increased toxicity.', '3', '"Product Information. Actidose-Aqua (charcoal)." Paddock Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34099, 7164, 'Activated charcoal', 'Intestinal Obstruction', 'Charcoal (with or without sorbitol) should not be used in the presence of a stomach or intestinal obstruction or absence of active bowel sounds.  Delayed GI transit time or constipation can result in failure to excrete a drug- charcoal complex and may result in increased toxicity.', '3', '"Product Information. Actidose-Aqua (charcoal)." Paddock Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34100, 7165, 'Activated charcoal', 'Intestinal Obstruction', 'Charcoal (with or without sorbitol) should not be used in the presence of a stomach or intestinal obstruction or absence of active bowel sounds.  Delayed GI transit time or constipation can result in failure to excrete a drug- charcoal complex and may result in increased toxicity.', '3', '"Product Information. Actidose-Aqua (charcoal)." Paddock Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34101, 32053, 'Activated charcoal', 'Intestinal Obstruction', 'Charcoal (with or without sorbitol) should not be used in the presence of a stomach or intestinal obstruction or absence of active bowel sounds.  Delayed GI transit time or constipation can result in failure to excrete a drug- charcoal complex and may result in increased toxicity.', '3', '"Product Information. Actidose-Aqua (charcoal)." Paddock Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34102, 1420, 'Activated charcoal', 'Seizures', 'Charcoal should not be administered in poison victims that are unconscious or having convulsions.', '3', '"Product Information. Actidose-Aqua (charcoal)." Paddock Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34103, 3724, 'Activated charcoal', 'Seizures', 'Charcoal should not be administered in poison victims that are unconscious or having convulsions.', '3', '"Product Information. Actidose-Aqua (charcoal)." Paddock Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34104, 7164, 'Activated charcoal', 'Seizures', 'Charcoal should not be administered in poison victims that are unconscious or having convulsions.', '3', '"Product Information. Actidose-Aqua (charcoal)." Paddock Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34105, 7165, 'Activated charcoal', 'Seizures', 'Charcoal should not be administered in poison victims that are unconscious or having convulsions.', '3', '"Product Information. Actidose-Aqua (charcoal)." Paddock Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34106, 32053, 'Activated charcoal', 'Seizures', 'Charcoal should not be administered in poison victims that are unconscious or having convulsions.', '3', '"Product Information. Actidose-Aqua (charcoal)." Paddock Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34107, 684, 'Bromotheophylline', 'Hypokalemia', 'The use of pamabrom (a theobromine derivative) has been associated with the renal elimination of potassium due to its diuretic effects.  Therapy with pamabrom should be administered cautiously in patients with hypokalemia.', '2', 'Niemeyer C, Hasenfub G, Wais U, et al. "Pharmacokinetics of hydrochlorothiazide in relation to renal function." Eur J Clin Pharmacol 24 (1983):  661-5|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Minizide (polythiazide-prazosin)." Pfizer U.S. Pharmaceuticals|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Exna (benzthiazide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34108, 8210, 'Bromotheophylline', 'Hypokalemia', 'The use of pamabrom (a theobromine derivative) has been associated with the renal elimination of potassium due to its diuretic effects.  Therapy with pamabrom should be administered cautiously in patients with hypokalemia.', '2', 'Niemeyer C, Hasenfub G, Wais U, et al. "Pharmacokinetics of hydrochlorothiazide in relation to renal function." Eur J Clin Pharmacol 24 (1983):  661-5|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Minizide (polythiazide-prazosin)." Pfizer U.S. Pharmaceuticals|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Exna (benzthiazide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34109, 11348, 'Bromotheophylline', 'Hypokalemia', 'The use of pamabrom (a theobromine derivative) has been associated with the renal elimination of potassium due to its diuretic effects.  Therapy with pamabrom should be administered cautiously in patients with hypokalemia.', '2', 'Niemeyer C, Hasenfub G, Wais U, et al. "Pharmacokinetics of hydrochlorothiazide in relation to renal function." Eur J Clin Pharmacol 24 (1983):  661-5|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Minizide (polythiazide-prazosin)." Pfizer U.S. Pharmaceuticals|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Exna (benzthiazide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34110, 11349, 'Bromotheophylline', 'Hypokalemia', 'The use of pamabrom (a theobromine derivative) has been associated with the renal elimination of potassium due to its diuretic effects.  Therapy with pamabrom should be administered cautiously in patients with hypokalemia.', '2', 'Niemeyer C, Hasenfub G, Wais U, et al. "Pharmacokinetics of hydrochlorothiazide in relation to renal function." Eur J Clin Pharmacol 24 (1983):  661-5|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Minizide (polythiazide-prazosin)." Pfizer U.S. Pharmaceuticals|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Exna (benzthiazide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34111, 11354, 'Bromotheophylline', 'Hypokalemia', 'The use of pamabrom (a theobromine derivative) has been associated with the renal elimination of potassium due to its diuretic effects.  Therapy with pamabrom should be administered cautiously in patients with hypokalemia.', '2', 'Niemeyer C, Hasenfub G, Wais U, et al. "Pharmacokinetics of hydrochlorothiazide in relation to renal function." Eur J Clin Pharmacol 24 (1983):  661-5|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Minizide (polythiazide-prazosin)." Pfizer U.S. Pharmaceuticals|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Exna (benzthiazide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34112, 11909, 'Bromotheophylline', 'Hypokalemia', 'The use of pamabrom (a theobromine derivative) has been associated with the renal elimination of potassium due to its diuretic effects.  Therapy with pamabrom should be administered cautiously in patients with hypokalemia.', '2', 'Niemeyer C, Hasenfub G, Wais U, et al. "Pharmacokinetics of hydrochlorothiazide in relation to renal function." Eur J Clin Pharmacol 24 (1983):  661-5|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Minizide (polythiazide-prazosin)." Pfizer U.S. Pharmaceuticals|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Exna (benzthiazide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34113, 12208, 'Bromotheophylline', 'Hypokalemia', 'The use of pamabrom (a theobromine derivative) has been associated with the renal elimination of potassium due to its diuretic effects.  Therapy with pamabrom should be administered cautiously in patients with hypokalemia.', '2', 'Niemeyer C, Hasenfub G, Wais U, et al. "Pharmacokinetics of hydrochlorothiazide in relation to renal function." Eur J Clin Pharmacol 24 (1983):  661-5|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Minizide (polythiazide-prazosin)." Pfizer U.S. Pharmaceuticals|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Exna (benzthiazide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34114, 12209, 'Bromotheophylline', 'Hypokalemia', 'The use of pamabrom (a theobromine derivative) has been associated with the renal elimination of potassium due to its diuretic effects.  Therapy with pamabrom should be administered cautiously in patients with hypokalemia.', '2', 'Niemeyer C, Hasenfub G, Wais U, et al. "Pharmacokinetics of hydrochlorothiazide in relation to renal function." Eur J Clin Pharmacol 24 (1983):  661-5|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Minizide (polythiazide-prazosin)." Pfizer U.S. Pharmaceuticals|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Exna (benzthiazide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34115, 14071, 'Bromotheophylline', 'Hypokalemia', 'The use of pamabrom (a theobromine derivative) has been associated with the renal elimination of potassium due to its diuretic effects.  Therapy with pamabrom should be administered cautiously in patients with hypokalemia.', '2', 'Niemeyer C, Hasenfub G, Wais U, et al. "Pharmacokinetics of hydrochlorothiazide in relation to renal function." Eur J Clin Pharmacol 24 (1983):  661-5|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Minizide (polythiazide-prazosin)." Pfizer U.S. Pharmaceuticals|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Exna (benzthiazide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34116, 16323, 'Bromotheophylline', 'Hypokalemia', 'The use of pamabrom (a theobromine derivative) has been associated with the renal elimination of potassium due to its diuretic effects.  Therapy with pamabrom should be administered cautiously in patients with hypokalemia.', '2', 'Niemeyer C, Hasenfub G, Wais U, et al. "Pharmacokinetics of hydrochlorothiazide in relation to renal function." Eur J Clin Pharmacol 24 (1983):  661-5|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Minizide (polythiazide-prazosin)." Pfizer U.S. Pharmaceuticals|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Exna (benzthiazide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34117, 25546, 'Bromotheophylline', 'Hypokalemia', 'The use of pamabrom (a theobromine derivative) has been associated with the renal elimination of potassium due to its diuretic effects.  Therapy with pamabrom should be administered cautiously in patients with hypokalemia.', '2', 'Niemeyer C, Hasenfub G, Wais U, et al. "Pharmacokinetics of hydrochlorothiazide in relation to renal function." Eur J Clin Pharmacol 24 (1983):  661-5|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Minizide (polythiazide-prazosin)." Pfizer U.S. Pharmaceuticals|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Exna (benzthiazide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34118, 25547, 'Bromotheophylline', 'Hypokalemia', 'The use of pamabrom (a theobromine derivative) has been associated with the renal elimination of potassium due to its diuretic effects.  Therapy with pamabrom should be administered cautiously in patients with hypokalemia.', '2', 'Niemeyer C, Hasenfub G, Wais U, et al. "Pharmacokinetics of hydrochlorothiazide in relation to renal function." Eur J Clin Pharmacol 24 (1983):  661-5|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Minizide (polythiazide-prazosin)." Pfizer U.S. Pharmaceuticals|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Exna (benzthiazide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34119, 28102, 'Bromotheophylline', 'Hypokalemia', 'The use of pamabrom (a theobromine derivative) has been associated with the renal elimination of potassium due to its diuretic effects.  Therapy with pamabrom should be administered cautiously in patients with hypokalemia.', '2', 'Niemeyer C, Hasenfub G, Wais U, et al. "Pharmacokinetics of hydrochlorothiazide in relation to renal function." Eur J Clin Pharmacol 24 (1983):  661-5|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Minizide (polythiazide-prazosin)." Pfizer U.S. Pharmaceuticals|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Exna (benzthiazide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34120, 28105, 'Bromotheophylline', 'Hypokalemia', 'The use of pamabrom (a theobromine derivative) has been associated with the renal elimination of potassium due to its diuretic effects.  Therapy with pamabrom should be administered cautiously in patients with hypokalemia.', '2', 'Niemeyer C, Hasenfub G, Wais U, et al. "Pharmacokinetics of hydrochlorothiazide in relation to renal function." Eur J Clin Pharmacol 24 (1983):  661-5|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Minizide (polythiazide-prazosin)." Pfizer U.S. Pharmaceuticals|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Exna (benzthiazide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34121, 28106, 'Bromotheophylline', 'Hypokalemia', 'The use of pamabrom (a theobromine derivative) has been associated with the renal elimination of potassium due to its diuretic effects.  Therapy with pamabrom should be administered cautiously in patients with hypokalemia.', '2', 'Niemeyer C, Hasenfub G, Wais U, et al. "Pharmacokinetics of hydrochlorothiazide in relation to renal function." Eur J Clin Pharmacol 24 (1983):  661-5|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Minizide (polythiazide-prazosin)." Pfizer U.S. Pharmaceuticals|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Exna (benzthiazide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34122, 28107, 'Bromotheophylline', 'Hypokalemia', 'The use of pamabrom (a theobromine derivative) has been associated with the renal elimination of potassium due to its diuretic effects.  Therapy with pamabrom should be administered cautiously in patients with hypokalemia.', '2', 'Niemeyer C, Hasenfub G, Wais U, et al. "Pharmacokinetics of hydrochlorothiazide in relation to renal function." Eur J Clin Pharmacol 24 (1983):  661-5|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Minizide (polythiazide-prazosin)." Pfizer U.S. Pharmaceuticals|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Exna (benzthiazide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34123, 28108, 'Bromotheophylline', 'Hypokalemia', 'The use of pamabrom (a theobromine derivative) has been associated with the renal elimination of potassium due to its diuretic effects.  Therapy with pamabrom should be administered cautiously in patients with hypokalemia.', '2', 'Niemeyer C, Hasenfub G, Wais U, et al. "Pharmacokinetics of hydrochlorothiazide in relation to renal function." Eur J Clin Pharmacol 24 (1983):  661-5|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Minizide (polythiazide-prazosin)." Pfizer U.S. Pharmaceuticals|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Exna (benzthiazide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34124, 28745, 'Bromotheophylline', 'Hypokalemia', 'The use of pamabrom (a theobromine derivative) has been associated with the renal elimination of potassium due to its diuretic effects.  Therapy with pamabrom should be administered cautiously in patients with hypokalemia.', '2', 'Niemeyer C, Hasenfub G, Wais U, et al. "Pharmacokinetics of hydrochlorothiazide in relation to renal function." Eur J Clin Pharmacol 24 (1983):  661-5|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Minizide (polythiazide-prazosin)." Pfizer U.S. Pharmaceuticals|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Exna (benzthiazide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34125, 29717, 'Bromotheophylline', 'Hypokalemia', 'The use of pamabrom (a theobromine derivative) has been associated with the renal elimination of potassium due to its diuretic effects.  Therapy with pamabrom should be administered cautiously in patients with hypokalemia.', '2', 'Niemeyer C, Hasenfub G, Wais U, et al. "Pharmacokinetics of hydrochlorothiazide in relation to renal function." Eur J Clin Pharmacol 24 (1983):  661-5|"Product Information. Lozol (indapamide)." Rhone Poulenc Rorer  (2002):|"Product Information. Thalitone (chlorthalidone)." Monarch Pharmaceuticals Inc  (2001):|"Product Information. Minizide (polythiazide-prazosin)." Pfizer U.S. Pharmaceuticals|"Product Information. Enduron (methyclothiazide)." Abbott Pharmaceutical  (2001):|"Product Information. Diucardin (hydroflumethiazide)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Exna (benzthiazide)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34126, 2948, 'Brivaracetam', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Klonopin (clonazepam)." Roche Laboratories  (2001):|"Product Information. Dilantin (phenytoin)." Parke-Davis  (2001):|"Product Information. Cerebyx (fosphenytoin)." Parke-Davis  (2001):|"Product Information. Mysoline (primidone)." Elan Pharmaceuticals  (2001):|"Product Information. Lyrica (pregabalin)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Sabril (vigabatrin)." Lundbeck Inc  (2009):|"Product Information. Potiga (ezogabine)." GlaxoSmithKline  (2011):|"Product Information. Qsymia (phentermine-topiramate)." Vivus Inc  (2012):|"Product Information. Fycompa (perampanel)." Eisai Inc  (2012):|"Product Information. Briviact (brivaracetam)." UCB Pharma Inc  (2016):|"Product Information. Diacomit (stiripentol)." Biocodex USA  (2018):|"Product Information. Epidiolex (cannabidiol)." Greenwich Biosciences LLC  (2018):|"Product Information. Xcopri (cenobamate)." SK Life Science, Inc.  (2020):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):|"Product Information. Ztalmy (ganaxolone)." Marinus Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34127, 7861, 'Brivaracetam', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Klonopin (clonazepam)." Roche Laboratories  (2001):|"Product Information. Dilantin (phenytoin)." Parke-Davis  (2001):|"Product Information. Cerebyx (fosphenytoin)." Parke-Davis  (2001):|"Product Information. Mysoline (primidone)." Elan Pharmaceuticals  (2001):|"Product Information. Lyrica (pregabalin)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Sabril (vigabatrin)." Lundbeck Inc  (2009):|"Product Information. Potiga (ezogabine)." GlaxoSmithKline  (2011):|"Product Information. Qsymia (phentermine-topiramate)." Vivus Inc  (2012):|"Product Information. Fycompa (perampanel)." Eisai Inc  (2012):|"Product Information. Briviact (brivaracetam)." UCB Pharma Inc  (2016):|"Product Information. Diacomit (stiripentol)." Biocodex USA  (2018):|"Product Information. Epidiolex (cannabidiol)." Greenwich Biosciences LLC  (2018):|"Product Information. Xcopri (cenobamate)." SK Life Science, Inc.  (2020):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):|"Product Information. Ztalmy (ganaxolone)." Marinus Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34128, 10838, 'Brivaracetam', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Klonopin (clonazepam)." Roche Laboratories  (2001):|"Product Information. Dilantin (phenytoin)." Parke-Davis  (2001):|"Product Information. Cerebyx (fosphenytoin)." Parke-Davis  (2001):|"Product Information. Mysoline (primidone)." Elan Pharmaceuticals  (2001):|"Product Information. Lyrica (pregabalin)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Sabril (vigabatrin)." Lundbeck Inc  (2009):|"Product Information. Potiga (ezogabine)." GlaxoSmithKline  (2011):|"Product Information. Qsymia (phentermine-topiramate)." Vivus Inc  (2012):|"Product Information. Fycompa (perampanel)." Eisai Inc  (2012):|"Product Information. Briviact (brivaracetam)." UCB Pharma Inc  (2016):|"Product Information. Diacomit (stiripentol)." Biocodex USA  (2018):|"Product Information. Epidiolex (cannabidiol)." Greenwich Biosciences LLC  (2018):|"Product Information. Xcopri (cenobamate)." SK Life Science, Inc.  (2020):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):|"Product Information. Ztalmy (ganaxolone)." Marinus Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34129, 25731, 'Brivaracetam', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Klonopin (clonazepam)." Roche Laboratories  (2001):|"Product Information. Dilantin (phenytoin)." Parke-Davis  (2001):|"Product Information. Cerebyx (fosphenytoin)." Parke-Davis  (2001):|"Product Information. Mysoline (primidone)." Elan Pharmaceuticals  (2001):|"Product Information. Lyrica (pregabalin)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Sabril (vigabatrin)." Lundbeck Inc  (2009):|"Product Information. Potiga (ezogabine)." GlaxoSmithKline  (2011):|"Product Information. Qsymia (phentermine-topiramate)." Vivus Inc  (2012):|"Product Information. Fycompa (perampanel)." Eisai Inc  (2012):|"Product Information. Briviact (brivaracetam)." UCB Pharma Inc  (2016):|"Product Information. Diacomit (stiripentol)." Biocodex USA  (2018):|"Product Information. Epidiolex (cannabidiol)." Greenwich Biosciences LLC  (2018):|"Product Information. Xcopri (cenobamate)." SK Life Science, Inc.  (2020):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):|"Product Information. Ztalmy (ganaxolone)." Marinus Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34130, 30851, 'Brivaracetam', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Klonopin (clonazepam)." Roche Laboratories  (2001):|"Product Information. Dilantin (phenytoin)." Parke-Davis  (2001):|"Product Information. Cerebyx (fosphenytoin)." Parke-Davis  (2001):|"Product Information. Mysoline (primidone)." Elan Pharmaceuticals  (2001):|"Product Information. Lyrica (pregabalin)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Sabril (vigabatrin)." Lundbeck Inc  (2009):|"Product Information. Potiga (ezogabine)." GlaxoSmithKline  (2011):|"Product Information. Qsymia (phentermine-topiramate)." Vivus Inc  (2012):|"Product Information. Fycompa (perampanel)." Eisai Inc  (2012):|"Product Information. Briviact (brivaracetam)." UCB Pharma Inc  (2016):|"Product Information. Diacomit (stiripentol)." Biocodex USA  (2018):|"Product Information. Epidiolex (cannabidiol)." Greenwich Biosciences LLC  (2018):|"Product Information. Xcopri (cenobamate)." SK Life Science, Inc.  (2020):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):|"Product Information. Ztalmy (ganaxolone)." Marinus Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34131, 32049, 'Brivaracetam', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Klonopin (clonazepam)." Roche Laboratories  (2001):|"Product Information. Dilantin (phenytoin)." Parke-Davis  (2001):|"Product Information. Cerebyx (fosphenytoin)." Parke-Davis  (2001):|"Product Information. Mysoline (primidone)." Elan Pharmaceuticals  (2001):|"Product Information. Lyrica (pregabalin)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Sabril (vigabatrin)." Lundbeck Inc  (2009):|"Product Information. Potiga (ezogabine)." GlaxoSmithKline  (2011):|"Product Information. Qsymia (phentermine-topiramate)." Vivus Inc  (2012):|"Product Information. Fycompa (perampanel)." Eisai Inc  (2012):|"Product Information. Briviact (brivaracetam)." UCB Pharma Inc  (2016):|"Product Information. Diacomit (stiripentol)." Biocodex USA  (2018):|"Product Information. Epidiolex (cannabidiol)." Greenwich Biosciences LLC  (2018):|"Product Information. Xcopri (cenobamate)." SK Life Science, Inc.  (2020):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):|"Product Information. Ztalmy (ganaxolone)." Marinus Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34132, 32050, 'Brivaracetam', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Klonopin (clonazepam)." Roche Laboratories  (2001):|"Product Information. Dilantin (phenytoin)." Parke-Davis  (2001):|"Product Information. Cerebyx (fosphenytoin)." Parke-Davis  (2001):|"Product Information. Mysoline (primidone)." Elan Pharmaceuticals  (2001):|"Product Information. Lyrica (pregabalin)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Sabril (vigabatrin)." Lundbeck Inc  (2009):|"Product Information. Potiga (ezogabine)." GlaxoSmithKline  (2011):|"Product Information. Qsymia (phentermine-topiramate)." Vivus Inc  (2012):|"Product Information. Fycompa (perampanel)." Eisai Inc  (2012):|"Product Information. Briviact (brivaracetam)." UCB Pharma Inc  (2016):|"Product Information. Diacomit (stiripentol)." Biocodex USA  (2018):|"Product Information. Epidiolex (cannabidiol)." Greenwich Biosciences LLC  (2018):|"Product Information. Xcopri (cenobamate)." SK Life Science, Inc.  (2020):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):|"Product Information. Ztalmy (ganaxolone)." Marinus Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34133, 2948, 'Brivaracetam', 'Bronchial Spasm', 'Bronchospasm and angioedema have been reported in patients taking brivaracetam and a hypersensitivity reaction to this agent could predispose patients at risk.  Caution is recommended when using brivaracetam in patients predisposed to bronchospasm and angioedema.', '2', '"Product Information. Briviact (brivaracetam)." UCB Pharma Inc  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34134, 7861, 'Brivaracetam', 'Bronchial Spasm', 'Bronchospasm and angioedema have been reported in patients taking brivaracetam and a hypersensitivity reaction to this agent could predispose patients at risk.  Caution is recommended when using brivaracetam in patients predisposed to bronchospasm and angioedema.', '2', '"Product Information. Briviact (brivaracetam)." UCB Pharma Inc  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34135, 10838, 'Brivaracetam', 'Bronchial Spasm', 'Bronchospasm and angioedema have been reported in patients taking brivaracetam and a hypersensitivity reaction to this agent could predispose patients at risk.  Caution is recommended when using brivaracetam in patients predisposed to bronchospasm and angioedema.', '2', '"Product Information. Briviact (brivaracetam)." UCB Pharma Inc  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34136, 25731, 'Brivaracetam', 'Bronchial Spasm', 'Bronchospasm and angioedema have been reported in patients taking brivaracetam and a hypersensitivity reaction to this agent could predispose patients at risk.  Caution is recommended when using brivaracetam in patients predisposed to bronchospasm and angioedema.', '2', '"Product Information. Briviact (brivaracetam)." UCB Pharma Inc  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34137, 30851, 'Brivaracetam', 'Bronchial Spasm', 'Bronchospasm and angioedema have been reported in patients taking brivaracetam and a hypersensitivity reaction to this agent could predispose patients at risk.  Caution is recommended when using brivaracetam in patients predisposed to bronchospasm and angioedema.', '2', '"Product Information. Briviact (brivaracetam)." UCB Pharma Inc  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34138, 32049, 'Brivaracetam', 'Bronchial Spasm', 'Bronchospasm and angioedema have been reported in patients taking brivaracetam and a hypersensitivity reaction to this agent could predispose patients at risk.  Caution is recommended when using brivaracetam in patients predisposed to bronchospasm and angioedema.', '2', '"Product Information. Briviact (brivaracetam)." UCB Pharma Inc  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34139, 32050, 'Brivaracetam', 'Bronchial Spasm', 'Bronchospasm and angioedema have been reported in patients taking brivaracetam and a hypersensitivity reaction to this agent could predispose patients at risk.  Caution is recommended when using brivaracetam in patients predisposed to bronchospasm and angioedema.', '2', '"Product Information. Briviact (brivaracetam)." UCB Pharma Inc  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34140, 2948, 'Brivaracetam', 'Liver Diseases', 'Brivaracetam is primarily metabolized by hydrolysis in the liver.  A pharmacokinetic study in adult subjects with hepatic cirrhosis, Child-Pugh grades A, B, and C, showed 50%, 57%, and 59% increases in brivaracetam exposure, respectively, compared to matched healthy controls.  Because of increases in brivaracetam exposure, dosage adjustment is recommended for all stages of hepatic impairment as per manufacturer recommendation.  Care and close monitoring is recommended when using this agent in patients with liver disease.', '2', '"Product Information. Briviact (brivaracetam)." UCB Pharma Inc  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34141, 7861, 'Brivaracetam', 'Liver Diseases', 'Brivaracetam is primarily metabolized by hydrolysis in the liver.  A pharmacokinetic study in adult subjects with hepatic cirrhosis, Child-Pugh grades A, B, and C, showed 50%, 57%, and 59% increases in brivaracetam exposure, respectively, compared to matched healthy controls.  Because of increases in brivaracetam exposure, dosage adjustment is recommended for all stages of hepatic impairment as per manufacturer recommendation.  Care and close monitoring is recommended when using this agent in patients with liver disease.', '2', '"Product Information. Briviact (brivaracetam)." UCB Pharma Inc  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34142, 10838, 'Brivaracetam', 'Liver Diseases', 'Brivaracetam is primarily metabolized by hydrolysis in the liver.  A pharmacokinetic study in adult subjects with hepatic cirrhosis, Child-Pugh grades A, B, and C, showed 50%, 57%, and 59% increases in brivaracetam exposure, respectively, compared to matched healthy controls.  Because of increases in brivaracetam exposure, dosage adjustment is recommended for all stages of hepatic impairment as per manufacturer recommendation.  Care and close monitoring is recommended when using this agent in patients with liver disease.', '2', '"Product Information. Briviact (brivaracetam)." UCB Pharma Inc  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34143, 25731, 'Brivaracetam', 'Liver Diseases', 'Brivaracetam is primarily metabolized by hydrolysis in the liver.  A pharmacokinetic study in adult subjects with hepatic cirrhosis, Child-Pugh grades A, B, and C, showed 50%, 57%, and 59% increases in brivaracetam exposure, respectively, compared to matched healthy controls.  Because of increases in brivaracetam exposure, dosage adjustment is recommended for all stages of hepatic impairment as per manufacturer recommendation.  Care and close monitoring is recommended when using this agent in patients with liver disease.', '2', '"Product Information. Briviact (brivaracetam)." UCB Pharma Inc  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34144, 30851, 'Brivaracetam', 'Liver Diseases', 'Brivaracetam is primarily metabolized by hydrolysis in the liver.  A pharmacokinetic study in adult subjects with hepatic cirrhosis, Child-Pugh grades A, B, and C, showed 50%, 57%, and 59% increases in brivaracetam exposure, respectively, compared to matched healthy controls.  Because of increases in brivaracetam exposure, dosage adjustment is recommended for all stages of hepatic impairment as per manufacturer recommendation.  Care and close monitoring is recommended when using this agent in patients with liver disease.', '2', '"Product Information. Briviact (brivaracetam)." UCB Pharma Inc  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34145, 32049, 'Brivaracetam', 'Liver Diseases', 'Brivaracetam is primarily metabolized by hydrolysis in the liver.  A pharmacokinetic study in adult subjects with hepatic cirrhosis, Child-Pugh grades A, B, and C, showed 50%, 57%, and 59% increases in brivaracetam exposure, respectively, compared to matched healthy controls.  Because of increases in brivaracetam exposure, dosage adjustment is recommended for all stages of hepatic impairment as per manufacturer recommendation.  Care and close monitoring is recommended when using this agent in patients with liver disease.', '2', '"Product Information. Briviact (brivaracetam)." UCB Pharma Inc  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34146, 32050, 'Brivaracetam', 'Liver Diseases', 'Brivaracetam is primarily metabolized by hydrolysis in the liver.  A pharmacokinetic study in adult subjects with hepatic cirrhosis, Child-Pugh grades A, B, and C, showed 50%, 57%, and 59% increases in brivaracetam exposure, respectively, compared to matched healthy controls.  Because of increases in brivaracetam exposure, dosage adjustment is recommended for all stages of hepatic impairment as per manufacturer recommendation.  Care and close monitoring is recommended when using this agent in patients with liver disease.', '2', '"Product Information. Briviact (brivaracetam)." UCB Pharma Inc  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34147, 2948, 'Brivaracetam', 'Kidney Diseases', 'No dose adjustments are needed for patients with impaired renal function.  The use of brivaracetam is not recommended in patients with end-stage renal disease undergoing dialysis as there are no data in this patient population.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34148, 7861, 'Brivaracetam', 'Kidney Diseases', 'No dose adjustments are needed for patients with impaired renal function.  The use of brivaracetam is not recommended in patients with end-stage renal disease undergoing dialysis as there are no data in this patient population.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34149, 10838, 'Brivaracetam', 'Kidney Diseases', 'No dose adjustments are needed for patients with impaired renal function.  The use of brivaracetam is not recommended in patients with end-stage renal disease undergoing dialysis as there are no data in this patient population.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34150, 25731, 'Brivaracetam', 'Kidney Diseases', 'No dose adjustments are needed for patients with impaired renal function.  The use of brivaracetam is not recommended in patients with end-stage renal disease undergoing dialysis as there are no data in this patient population.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34151, 30851, 'Brivaracetam', 'Kidney Diseases', 'No dose adjustments are needed for patients with impaired renal function.  The use of brivaracetam is not recommended in patients with end-stage renal disease undergoing dialysis as there are no data in this patient population.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34152, 32049, 'Brivaracetam', 'Kidney Diseases', 'No dose adjustments are needed for patients with impaired renal function.  The use of brivaracetam is not recommended in patients with end-stage renal disease undergoing dialysis as there are no data in this patient population.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34153, 32050, 'Brivaracetam', 'Kidney Diseases', 'No dose adjustments are needed for patients with impaired renal function.  The use of brivaracetam is not recommended in patients with end-stage renal disease undergoing dialysis as there are no data in this patient population.', '2', NULL, 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34154, 14447, 'Bromfenac (ophthalmic)', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34155, 19095, 'Bromfenac (ophthalmic)', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', '"Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn  (2002):|"Product Information. Nalfon (fenoprofen)." Xspire Pharma  (2002):|"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Clinoril (sulindac)." Merck & Co., Inc  (2001):|"Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical  (2001):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Mobic (meloxicam)." Boehringer-Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34156, 3839, 'Bromocriptine', 'Heart Diseases', 'Cardiac irregularities occur infrequently in patients on dopamine agonists.  The initial administration and titration is recommended to occur under close cardiac monitoring in a facility equipped for intensive cardiac care.  Adverse cardiac affects may include palpitation, sinus tachycardia, ventricular tachycardia, extrasystole, atrial flutter or fibrillation, or block of AV conduction.', '3', 'Shah PK, Amin DK, Horn E "Adverse clinical and hemodynamic effects of oral levodopa in chronic  congestive heart failure." Am Heart J 110 (1985):  488-9|Benaim ME "Levodopa and arrhythmias." Br Med J 4 (1972):  50-1|Broderick G, Rajfer SI "The use of levodopa, an oral dopamine precursor, in congestive heart  failure." Basic Res Cardiol 84 (1989):  187-90|Chamsi-Pasha H, Horsley M, Barnes PC "Levodopa and congestive cardiomyopathy." Br J Hosp Med 41 (1989):  489|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34157, 7048, 'Bromocriptine', 'Heart Diseases', 'Cardiac irregularities occur infrequently in patients on dopamine agonists.  The initial administration and titration is recommended to occur under close cardiac monitoring in a facility equipped for intensive cardiac care.  Adverse cardiac affects may include palpitation, sinus tachycardia, ventricular tachycardia, extrasystole, atrial flutter or fibrillation, or block of AV conduction.', '3', 'Shah PK, Amin DK, Horn E "Adverse clinical and hemodynamic effects of oral levodopa in chronic  congestive heart failure." Am Heart J 110 (1985):  488-9|Benaim ME "Levodopa and arrhythmias." Br Med J 4 (1972):  50-1|Broderick G, Rajfer SI "The use of levodopa, an oral dopamine precursor, in congestive heart  failure." Basic Res Cardiol 84 (1989):  187-90|Chamsi-Pasha H, Horsley M, Barnes PC "Levodopa and congestive cardiomyopathy." Br J Hosp Med 41 (1989):  489|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34158, 9648, 'Bromocriptine', 'Heart Diseases', 'Cardiac irregularities occur infrequently in patients on dopamine agonists.  The initial administration and titration is recommended to occur under close cardiac monitoring in a facility equipped for intensive cardiac care.  Adverse cardiac affects may include palpitation, sinus tachycardia, ventricular tachycardia, extrasystole, atrial flutter or fibrillation, or block of AV conduction.', '3', 'Shah PK, Amin DK, Horn E "Adverse clinical and hemodynamic effects of oral levodopa in chronic  congestive heart failure." Am Heart J 110 (1985):  488-9|Benaim ME "Levodopa and arrhythmias." Br Med J 4 (1972):  50-1|Broderick G, Rajfer SI "The use of levodopa, an oral dopamine precursor, in congestive heart  failure." Basic Res Cardiol 84 (1989):  187-90|Chamsi-Pasha H, Horsley M, Barnes PC "Levodopa and congestive cardiomyopathy." Br J Hosp Med 41 (1989):  489|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34159, 12990, 'Bromocriptine', 'Heart Diseases', 'Cardiac irregularities occur infrequently in patients on dopamine agonists.  The initial administration and titration is recommended to occur under close cardiac monitoring in a facility equipped for intensive cardiac care.  Adverse cardiac affects may include palpitation, sinus tachycardia, ventricular tachycardia, extrasystole, atrial flutter or fibrillation, or block of AV conduction.', '3', 'Shah PK, Amin DK, Horn E "Adverse clinical and hemodynamic effects of oral levodopa in chronic  congestive heart failure." Am Heart J 110 (1985):  488-9|Benaim ME "Levodopa and arrhythmias." Br Med J 4 (1972):  50-1|Broderick G, Rajfer SI "The use of levodopa, an oral dopamine precursor, in congestive heart  failure." Basic Res Cardiol 84 (1989):  187-90|Chamsi-Pasha H, Horsley M, Barnes PC "Levodopa and congestive cardiomyopathy." Br J Hosp Med 41 (1989):  489|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34160, 3839, 'Bromocriptine', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34161, 7048, 'Bromocriptine', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34162, 9648, 'Bromocriptine', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34163, 12990, 'Bromocriptine', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34164, 3839, 'Bromocriptine', 'Psychotic Disorders', 'The use of dopamine agonists has been associated with psychiatric effects such as hallucinations, psychosis, confusion, anxiety, mania, hypomania, depression, rapid mood cycling, nightmares, and hypersexuality.  Therapy with dopamine agonists should be administered cautiously in psychotic patients and all patients should be carefully observed for development of depression and suicidal tendencies.', '3', 'Ko GN, Leckman JF, Heninger GR "Induction of rapid mood cycling during L-dopa treatment in a bipolar  patient." Am J Psychiatry 138 (1981):  1624-5|Ryback RS, Schwab RS "Manic response to levodopa therapy. Report of a case." N Engl J Med 285 (1971):  788-9|Banerjee AK, Falkai PG, Savidge M "Visual hallucinations in the elderly associated with the use of  levodopa." Postgrad Med J 65 (1989):  358-61|Vazquez A, Jimenez-Jimenez FJ, Garcia-Ruiz P, Garcia-Urra D ""Panic attacks" in Parkinson''s disease. A long-term complication of  levodopa therapy." Acta Neurol Scand 87 (1993):  14-8|Nausieda PA, Glantz R, Weber S, Baum R, Klawans HL "Psychiatric complications of levodopa therapy of Parkinson''s disease." Adv Neurol 40 (1984):  271-7|Glantz RH, Bieliauskas L, Paleologos N "Behavioral indicators of hallucinosis in levodopa-treated Parkinson''s  disease." Adv Neurol 45 (1987):  417-20|Friedman JH "The management of the levodopa psychoses." Clin Neuropharmacol 14 (1991):  283-95|Harsch HH, Miller M, Young LD "Induction of mania by L-dopa in a nonbipolar patient." J Clin Psychopharmacol 5 (1985):  338-9|Maricle RA, Nutt JG, Carter JH "Mood and anxiety fluctuation in parkinson''s disease associated with levodopa infusion: preliminary findings." Mov Disord 10 (1995):  329-32|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34165, 7048, 'Bromocriptine', 'Psychotic Disorders', 'The use of dopamine agonists has been associated with psychiatric effects such as hallucinations, psychosis, confusion, anxiety, mania, hypomania, depression, rapid mood cycling, nightmares, and hypersexuality.  Therapy with dopamine agonists should be administered cautiously in psychotic patients and all patients should be carefully observed for development of depression and suicidal tendencies.', '3', 'Ko GN, Leckman JF, Heninger GR "Induction of rapid mood cycling during L-dopa treatment in a bipolar  patient." Am J Psychiatry 138 (1981):  1624-5|Ryback RS, Schwab RS "Manic response to levodopa therapy. Report of a case." N Engl J Med 285 (1971):  788-9|Banerjee AK, Falkai PG, Savidge M "Visual hallucinations in the elderly associated with the use of  levodopa." Postgrad Med J 65 (1989):  358-61|Vazquez A, Jimenez-Jimenez FJ, Garcia-Ruiz P, Garcia-Urra D ""Panic attacks" in Parkinson''s disease. A long-term complication of  levodopa therapy." Acta Neurol Scand 87 (1993):  14-8|Nausieda PA, Glantz R, Weber S, Baum R, Klawans HL "Psychiatric complications of levodopa therapy of Parkinson''s disease." Adv Neurol 40 (1984):  271-7|Glantz RH, Bieliauskas L, Paleologos N "Behavioral indicators of hallucinosis in levodopa-treated Parkinson''s  disease." Adv Neurol 45 (1987):  417-20|Friedman JH "The management of the levodopa psychoses." Clin Neuropharmacol 14 (1991):  283-95|Harsch HH, Miller M, Young LD "Induction of mania by L-dopa in a nonbipolar patient." J Clin Psychopharmacol 5 (1985):  338-9|Maricle RA, Nutt JG, Carter JH "Mood and anxiety fluctuation in parkinson''s disease associated with levodopa infusion: preliminary findings." Mov Disord 10 (1995):  329-32|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34166, 9648, 'Bromocriptine', 'Psychotic Disorders', 'The use of dopamine agonists has been associated with psychiatric effects such as hallucinations, psychosis, confusion, anxiety, mania, hypomania, depression, rapid mood cycling, nightmares, and hypersexuality.  Therapy with dopamine agonists should be administered cautiously in psychotic patients and all patients should be carefully observed for development of depression and suicidal tendencies.', '3', 'Ko GN, Leckman JF, Heninger GR "Induction of rapid mood cycling during L-dopa treatment in a bipolar  patient." Am J Psychiatry 138 (1981):  1624-5|Ryback RS, Schwab RS "Manic response to levodopa therapy. Report of a case." N Engl J Med 285 (1971):  788-9|Banerjee AK, Falkai PG, Savidge M "Visual hallucinations in the elderly associated with the use of  levodopa." Postgrad Med J 65 (1989):  358-61|Vazquez A, Jimenez-Jimenez FJ, Garcia-Ruiz P, Garcia-Urra D ""Panic attacks" in Parkinson''s disease. A long-term complication of  levodopa therapy." Acta Neurol Scand 87 (1993):  14-8|Nausieda PA, Glantz R, Weber S, Baum R, Klawans HL "Psychiatric complications of levodopa therapy of Parkinson''s disease." Adv Neurol 40 (1984):  271-7|Glantz RH, Bieliauskas L, Paleologos N "Behavioral indicators of hallucinosis in levodopa-treated Parkinson''s  disease." Adv Neurol 45 (1987):  417-20|Friedman JH "The management of the levodopa psychoses." Clin Neuropharmacol 14 (1991):  283-95|Harsch HH, Miller M, Young LD "Induction of mania by L-dopa in a nonbipolar patient." J Clin Psychopharmacol 5 (1985):  338-9|Maricle RA, Nutt JG, Carter JH "Mood and anxiety fluctuation in parkinson''s disease associated with levodopa infusion: preliminary findings." Mov Disord 10 (1995):  329-32|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34167, 12990, 'Bromocriptine', 'Psychotic Disorders', 'The use of dopamine agonists has been associated with psychiatric effects such as hallucinations, psychosis, confusion, anxiety, mania, hypomania, depression, rapid mood cycling, nightmares, and hypersexuality.  Therapy with dopamine agonists should be administered cautiously in psychotic patients and all patients should be carefully observed for development of depression and suicidal tendencies.', '3', 'Ko GN, Leckman JF, Heninger GR "Induction of rapid mood cycling during L-dopa treatment in a bipolar  patient." Am J Psychiatry 138 (1981):  1624-5|Ryback RS, Schwab RS "Manic response to levodopa therapy. Report of a case." N Engl J Med 285 (1971):  788-9|Banerjee AK, Falkai PG, Savidge M "Visual hallucinations in the elderly associated with the use of  levodopa." Postgrad Med J 65 (1989):  358-61|Vazquez A, Jimenez-Jimenez FJ, Garcia-Ruiz P, Garcia-Urra D ""Panic attacks" in Parkinson''s disease. A long-term complication of  levodopa therapy." Acta Neurol Scand 87 (1993):  14-8|Nausieda PA, Glantz R, Weber S, Baum R, Klawans HL "Psychiatric complications of levodopa therapy of Parkinson''s disease." Adv Neurol 40 (1984):  271-7|Glantz RH, Bieliauskas L, Paleologos N "Behavioral indicators of hallucinosis in levodopa-treated Parkinson''s  disease." Adv Neurol 45 (1987):  417-20|Friedman JH "The management of the levodopa psychoses." Clin Neuropharmacol 14 (1991):  283-95|Harsch HH, Miller M, Young LD "Induction of mania by L-dopa in a nonbipolar patient." J Clin Psychopharmacol 5 (1985):  338-9|Maricle RA, Nutt JG, Carter JH "Mood and anxiety fluctuation in parkinson''s disease associated with levodopa infusion: preliminary findings." Mov Disord 10 (1995):  329-32|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34168, 1168, 'Brompheniramine', 'Anticholinergic Syndrome', 'Antihistamines often have anticholinergic activity, to which elderly patients are particularly sensitive.  Therapy with antihistamines should be administered cautiously, if at all, in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.  Conventional, first-generation antihistamines such as the ethanolamines (bromodiphenhydramine, carbinoxamine, clemastine, dimenhydrinate, diphenhydramine, doxylamine, phenyltoloxamine) tend to exhibit substantial anticholinergic effects.  In contrast, the newer, relatively nonsedating antihistamines (e.g., cetirizine, fexofenadine, loratadine) reportedly have low to minimal anticholinergic activity at normally recommended dosages and may be appropriate alternatives.', '2', 'Schuller DE, Turkewitz D "Adverse effects of antihistamines." Postgrad Med 79 (1986):  75-86|"Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough|"Product Information. Periactin (cyproheptadine)." Merck & Co., Inc  (2002):|"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Antivert (meclizine)." Roerig Division  (2001):|"Product Information. Marezine (cyclizine)." Glaxo Wellcome  (2001):|"Product Information. Optimine (azatadine)." Schering Corporation  (2001):|"Product Information. Semprex-D (acrivastine-pseudoephedrine)." Endo Laboratories LLC  (2001):|"Product Information. Zyrtec (cetirizine)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Drixoral (dextromethorphan)." Schering-Plough  (2001):|"Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company  (2001):|Watemberg NM, Roth KS, Alehan FK, Epstein CE "Central anticholinergic syndrome on therapeutic doses of cyproheptadine." Pediatrics 103 (1999):  158-60|"Product Information. Vistaril (hydroxyzine)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dramamine (dimenhydrinate)." Pharmacia and Upjohn  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34169, 1168, 'Brompheniramine', 'Asthma', 'It has been suggested that the anticholinergic effect of antihistamines may reduce the volume and cause thickening of bronchial secretions, resulting in obstruction of respiratory tract.  Some manufacturers and clinicians recommend that therapy with antihistamines be administered cautiously in patients with asthma or chronic obstructive pulmonary disease.', '2', '"Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough|"Product Information. Periactin (cyproheptadine)." Merck & Co., Inc  (2002):|"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Maddox DE, Reed CE "Clinical pharmacodynamics of antihistamines." Ann Allergy 59 (1987):  43-8|"Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Antivert (meclizine)." Roerig Division  (2001):|"Product Information. Marezine (cyclizine)." Glaxo Wellcome  (2001):|"Product Information. Optimine (azatadine)." Schering Corporation  (2001):|"Product Information. Semprex-D (acrivastine-pseudoephedrine)." Endo Laboratories LLC  (2001):|"Product Information. Drixoral (dextromethorphan)." Schering-Plough  (2001):|"Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company  (2001):|"Product Information. Vistaril (hydroxyzine)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dramamine (dimenhydrinate)." Pharmacia and Upjohn  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34170, 1168, 'Brompheniramine', 'Cardiovascular Diseases', 'Antihistamines may infrequently cause cardiovascular adverse effects related to their anticholinergic and local anesthetic (quinidine-like) activities.  Tachycardia, palpitation, ECG changes, arrhythmias, hypotension, and hypertension have been reported.  Although these effects are uncommon and usually limited to overdosage situations, the manufacturers and some clinicians recommend that therapy with antihistamines be administered cautiously in patients with cardiovascular disease, hypertension, and/or hyperthyroidism.', '2', 'Schuller DE, Turkewitz D "Adverse effects of antihistamines." Postgrad Med 79 (1986):  75-86|"Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough|"Product Information. Periactin (cyproheptadine)." Merck & Co., Inc  (2002):|"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Antivert (meclizine)." Roerig Division  (2001):|"Product Information. Optimine (azatadine)." Schering Corporation  (2001):|Smith SJ "Cardiovascular toxicity of antihistamines." Otolaryngol Head Neck Surg 111 Suppl (1994):  348-54|"Product Information. Zyrtec (cetirizine)." Pfizer U.S. Pharmaceuticals  (2001):|Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996):  233-52|"Product Information. Drixoral (dextromethorphan)." Schering-Plough  (2001):|"Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company  (2001):|"Product Information. Vistaril (hydroxyzine)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dramamine (dimenhydrinate)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34171, 1168, 'Brompheniramine', 'Liver Diseases', 'Limited pharmacokinetic data are available for the older, first-generation antihistamines.  Many appear to be primarily metabolized by the liver, and both parent drugs and metabolites are excreted in the urine.  Patients with renal and/or liver disease may be at greater risk for adverse effects from antihistamines due to drug and metabolite accumulation.  Therapy with antihistamines should be administered cautiously in such patients.  Lower initial dosages may be appropriate.', '2', 'Glazko AJ, Dill WA, Young RM, Smith TC, Ogilvie RI "Metabolic disposition of diphenhydramine." Clin Pharmacol Ther 16 (1974):  1066-76|Paton DM, Webster DR "Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines)." Clin Pharmacokinet 10 (1985):  477-97|Rumore MM "Clinical pharmacokinetics of chlorpheniramine." Drug Intell Clin Pharm 18 (1984):  701-7|Huang SM, Athanikar NK, Sridhar K, Huang YC, Chiou WL "Pharmacokinetics of chlorpheniramine after intravenous and oral administration in normal adults." Eur J Clin Pharmacol 22 (1982):  359-65|Simons KJ, Simons FE, Luciuk GH, Frith EM "Urinary excretion of chlorpheniramine and its metabolites in children." J Pharm Sci 73 (1984):  595-9|Meredith CG, Christian CD Jr, Johnson RF, Madhavan SV, Schenker S "Diphenhydramine disposition in chronic liver disease." Clin Pharmacol Ther 35 (1984):  474-9|Blyden GT, Greenblatt DJ, Scavone JM, Shader RI "Pharmacokinetics of diphenhydramine and a demethylated metabolite following intravenous and oral administration." J Clin Pharmacol 26 (1986):  529-33|Albert KS, Hallmark MR, Sakmar E, Weidler DJ, Wagner JG "Pharmacokinetics of diphenhydramine in man." J Pharmacokinet Biopharm 3 (1975):  159-70|Simons FE, Frith EM, Simons KJ "The pharmacokinetics and antihistaminic effects of brompheniramine." J Allergy Clin Immunol 70 (1982):  458-64|Bruce RB, Turnbull LB, Newman JH, Pitts JE "Metabolism of brompheniramine." J Med Chem 11 (1968):  1031-4|Porter CC, Arison BH, Gruber VF, Titus DC, Vandenheuvel WJ "Human metabolism of cyproheptadine." Drug Metab Dispos 3 (1975):  189-97|Hintze KL, Wold JS, Fischer LJ "Disposition of cyproheptadine in rats, mice, and humans and identification of a stable epoxide metabolite." Drug Metab Dispos 3 (1975):  1-9|Maddox DE, Reed CE "Clinical pharmacodynamics of antihistamines." Ann Allergy 59 (1987):  43-8|Simons FE, Simons KJ, Frith EM "The pharmacokinetics and antihistaminic of the H1 receptor antagonist hydroxyzine." J Allergy Clin Immunol 73 (1984):  69-75|Simons FE, Watson WT, Chen XY, Minuk GY, Simons KJ "The pharmacokinetics and pharmacodynamics of hydroxyzine in patients with primary biliary cirrhosis." J Clin Pharmacol 29 (1989):  809-15', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34172, 0, 'Burosumab', 'Hyperphosphatemia', 'Do not initiate burosumab-twza treatment if serum phosphorus is within or above the normal range for age.  Increases in serum phosphorus to above the upper limit of normal may be associated with an increased risk of nephrocalcinosis.  It is recommended to obtain baseline fasting serum phosphorus levels and to monitor fasting serum phosphorus levels.  Dose interruption and/or dose reduction may be required based on a patient''s serum phosphorus levels.', '3', '"Product Information. Crysvita (burosumab)." Ultragenyx Pharmaceutical  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34173, 0, 'Burosumab', 'Kidney Diseases', 'Burosumab-twza is contraindicated in patients with severe renal impairment or end stage renal disease because these conditions are associated with abnormal mineral metabolism.  The effect of renal impairment on the pharmacokinetics of burosumab-twza is unknown.', '3', '"Product Information. Crysvita (burosumab)." Ultragenyx Pharmaceutical  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34174, 0, 'Burosumab', 'Restless Legs Syndrome', 'The use of burosumab-twza may cause new onset of restless leg syndrome (RLS) or worsen RLS severity.  Care should be exercised when using this agent in patients with existing RLS diagnosis.', '2', '"Product Information. Crysvita (burosumab)." Ultragenyx Pharmaceutical  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34175, 2409, 'Bumetanide', 'Anuria', 'The use of loop diuretics is contraindicated in patients with anuria.', '3', '"Product Information. Bumex (bumetanide)." Roche Laboratories  (2002):|"Product Information. Lasix (furosemide)." sanofi-aventis  (2007):|"Product Information. Demadex (torsemide)." Boehringer Mannheim|"Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34176, 3997, 'Bumetanide', 'Anuria', 'The use of loop diuretics is contraindicated in patients with anuria.', '3', '"Product Information. Bumex (bumetanide)." Roche Laboratories  (2002):|"Product Information. Lasix (furosemide)." sanofi-aventis  (2007):|"Product Information. Demadex (torsemide)." Boehringer Mannheim|"Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34177, 15562, 'Bumetanide', 'Anuria', 'The use of loop diuretics is contraindicated in patients with anuria.', '3', '"Product Information. Bumex (bumetanide)." Roche Laboratories  (2002):|"Product Information. Lasix (furosemide)." sanofi-aventis  (2007):|"Product Information. Demadex (torsemide)." Boehringer Mannheim|"Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34178, 18075, 'Bumetanide', 'Anuria', 'The use of loop diuretics is contraindicated in patients with anuria.', '3', '"Product Information. Bumex (bumetanide)." Roche Laboratories  (2002):|"Product Information. Lasix (furosemide)." sanofi-aventis  (2007):|"Product Information. Demadex (torsemide)." Boehringer Mannheim|"Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34179, 2409, 'Bumetanide', 'Fibrosis', 'Loop diuretic therapy should be initiated in the hospital under strict observation in patients with liver cirrhosis and ascites.  Sudden alteration of fluid and electrolyte balance may precipitate hepatic encephalopathy and coma in such patients, who are also at increased risk for the development of hypokalemia.  Supplemental potassium and/or concomitant use of an aldosterone antagonist or potassium-sparing agent may help prevent hypokalemia and metabolic alkalosis.  Loop diuretics should be withheld in patients with hepatic coma until the condition improves.', '3', 'Ring-Larsen H "Bumetanide in the treatment of hepatic ascites. A short and long-term study." Acta Med Scand 195 (1974):  411-4|"Product Information. Bumex (bumetanide)." Roche Laboratories  (2002):|"Product Information. Lasix (furosemide)." sanofi-aventis  (2007):|"Product Information. Demadex (torsemide)." Boehringer Mannheim|Schwartz FD, Pillay VK, Kark RM "Ethacrynic acid: its usefulness and untoward effects." Am Heart J 79 (1970):  427-8|Lieberman FL, Reynolds TB "The use of ethacrynic acid in patients with cirrhosis and ascites." Gastroenterology 49 (1965):  531-8|"Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc  (2001):|Knauf H, Mutschler E "Liver cirrhosis with ascites: pathogenesis of resistance to diuretics and long-term efficacy and safety of torasemide." Cardiology 84 (1994):  87-98', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34180, 3997, 'Bumetanide', 'Fibrosis', 'Loop diuretic therapy should be initiated in the hospital under strict observation in patients with liver cirrhosis and ascites.  Sudden alteration of fluid and electrolyte balance may precipitate hepatic encephalopathy and coma in such patients, who are also at increased risk for the development of hypokalemia.  Supplemental potassium and/or concomitant use of an aldosterone antagonist or potassium-sparing agent may help prevent hypokalemia and metabolic alkalosis.  Loop diuretics should be withheld in patients with hepatic coma until the condition improves.', '3', 'Ring-Larsen H "Bumetanide in the treatment of hepatic ascites. A short and long-term study." Acta Med Scand 195 (1974):  411-4|"Product Information. Bumex (bumetanide)." Roche Laboratories  (2002):|"Product Information. Lasix (furosemide)." sanofi-aventis  (2007):|"Product Information. Demadex (torsemide)." Boehringer Mannheim|Schwartz FD, Pillay VK, Kark RM "Ethacrynic acid: its usefulness and untoward effects." Am Heart J 79 (1970):  427-8|Lieberman FL, Reynolds TB "The use of ethacrynic acid in patients with cirrhosis and ascites." Gastroenterology 49 (1965):  531-8|"Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc  (2001):|Knauf H, Mutschler E "Liver cirrhosis with ascites: pathogenesis of resistance to diuretics and long-term efficacy and safety of torasemide." Cardiology 84 (1994):  87-98', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34181, 15562, 'Bumetanide', 'Fibrosis', 'Loop diuretic therapy should be initiated in the hospital under strict observation in patients with liver cirrhosis and ascites.  Sudden alteration of fluid and electrolyte balance may precipitate hepatic encephalopathy and coma in such patients, who are also at increased risk for the development of hypokalemia.  Supplemental potassium and/or concomitant use of an aldosterone antagonist or potassium-sparing agent may help prevent hypokalemia and metabolic alkalosis.  Loop diuretics should be withheld in patients with hepatic coma until the condition improves.', '3', 'Ring-Larsen H "Bumetanide in the treatment of hepatic ascites. A short and long-term study." Acta Med Scand 195 (1974):  411-4|"Product Information. Bumex (bumetanide)." Roche Laboratories  (2002):|"Product Information. Lasix (furosemide)." sanofi-aventis  (2007):|"Product Information. Demadex (torsemide)." Boehringer Mannheim|Schwartz FD, Pillay VK, Kark RM "Ethacrynic acid: its usefulness and untoward effects." Am Heart J 79 (1970):  427-8|Lieberman FL, Reynolds TB "The use of ethacrynic acid in patients with cirrhosis and ascites." Gastroenterology 49 (1965):  531-8|"Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc  (2001):|Knauf H, Mutschler E "Liver cirrhosis with ascites: pathogenesis of resistance to diuretics and long-term efficacy and safety of torasemide." Cardiology 84 (1994):  87-98', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34182, 18075, 'Bumetanide', 'Fibrosis', 'Loop diuretic therapy should be initiated in the hospital under strict observation in patients with liver cirrhosis and ascites.  Sudden alteration of fluid and electrolyte balance may precipitate hepatic encephalopathy and coma in such patients, who are also at increased risk for the development of hypokalemia.  Supplemental potassium and/or concomitant use of an aldosterone antagonist or potassium-sparing agent may help prevent hypokalemia and metabolic alkalosis.  Loop diuretics should be withheld in patients with hepatic coma until the condition improves.', '3', 'Ring-Larsen H "Bumetanide in the treatment of hepatic ascites. A short and long-term study." Acta Med Scand 195 (1974):  411-4|"Product Information. Bumex (bumetanide)." Roche Laboratories  (2002):|"Product Information. Lasix (furosemide)." sanofi-aventis  (2007):|"Product Information. Demadex (torsemide)." Boehringer Mannheim|Schwartz FD, Pillay VK, Kark RM "Ethacrynic acid: its usefulness and untoward effects." Am Heart J 79 (1970):  427-8|Lieberman FL, Reynolds TB "The use of ethacrynic acid in patients with cirrhosis and ascites." Gastroenterology 49 (1965):  531-8|"Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc  (2001):|Knauf H, Mutschler E "Liver cirrhosis with ascites: pathogenesis of resistance to diuretics and long-term efficacy and safety of torasemide." Cardiology 84 (1994):  87-98', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34183, 2409, 'Bumetanide', 'Water-Electrolyte Imbalance', 'The use of loop diuretics, particularly at high dosages or during chronic therapy, is commonly associated with loss of electrolytes, including potassium, sodium, chloride, magnesium, and calcium.  Potassium and magnesium depletion may lead to cardiac arrhythmias and cardiac arrest.  Other electrolyte-related complications include metabolic alkalosis and hyponatremia, which are rarely life-threatening.  Excessive diuresis, as indicated by rapid weight loss, may induce dehydration and hypovolemia, which can result in acute hypotension, orthostasis, circulatory collapse, vascular thrombosis and embolism, and abrupt reduction in glomerular filtration and renal blood flow.  Severe dehydration is most likely to occur in the elderly and patients under prolonged sodium restriction.  Therapy with loop diuretics should be administered cautiously in patients with or predisposed to fluid and electrolyte depletion, including patients with primary or secondary aldosteronism (may have low potassium levels); those with severe or prolonged diarrhea or vomiting; and those with poor nutritional status.  Fluid and electrolyte abnormalities should be corrected before initiating therapy, and blood pressure as well as serum electrolyte concentrations monitored periodically and maintained at normal ranges during therapy.  Patients should be advised to immediately report signs and symptoms of fluid or electrolyte imbalance, including dry mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, arrhythmia, or gastrointestinal disturbances such as nausea and vomiting.  Digitalized patients and patients with a history of ventricular arrhythmias should be monitored carefully, since the development of hypokalemia may be particularly dangerous in these patients.  The risk of hypokalemia may be minimized by slow diuresis, a lower diuretic dosage, potassium supplementation, or combined use with a potassium-sparing diuretic.  Similarly, to prevent excessive dehydration and hyponatremia, sodium intake should be liberalized if clinically feasible.', '3', 'Tambyah JA, Lim MK "Effect of furesomide on calcium excretion." Br Med J 03/22/69 (1969):  751-2|Roesner M "The loop diuretics: focus on furosemide and ethacrynic acid." N C Med J 47 (1986):  93-6|Ponto LL, Schoenwald RD "Furosemide (frusemide): a pharmacokinetic/pharmacodynamic review." Clin Pharmacokinet 18 (1990):  381-408|Ward A, Heel RC "Bumetanide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use." Drugs 28 (1984):  426-64|Menday AP, Adnitt PI, Underwood PN "Effect of long-term treatment with bumetanide/amiloride on electrolytes and renal function in elderly patients with heart failure." Curr Ther Res Clin Exp 50 (1991):  57-64|Kubik MM, Bowers E, Underwood PN "Longterm experience of the routine use of bumetanide." Br J Clin Pract 30 (1976):  11-4|"Product Information. Bumex (bumetanide)." Roche Laboratories  (2002):|"Product Information. Lasix (furosemide)." sanofi-aventis  (2007):|"Product Information. Demadex (torsemide)." Boehringer Mannheim|Schwartz AB "Diuretic-induced hypokalemia." Am Fam Physician 11 (1975):  101-4|Cooperman LB, Rubin IL "Toxicity of ethacrynic acid and furosemide." Am Heart J 85 (1973):  831-4|Schwartz FD, Pillay VK, Kark RM "Ethacrynic acid: its usefulness and untoward effects." Am Heart J 79 (1970):  427-8|DeRubertis FR, Michelis MF, Beck N, Davis BB "Complications of diuretic therapy: severe alkalosis and syndrome resembling inappropriate secretion of antidiuretic hormone." Metabolism 19 (1970):  709-19|Sullivan RC, Freemon FR, Caranasos GJ "Complications from diuretic therapy with ethacrynic acid and furosemide." South Med J 64 (1971):  869-72|Plumb VJ, James TN "Clinical hazards of powerful diuretics. Furosemide and ethacrynic acid." Mod Concepts Cardiovasc Dis 47 (1978):  91-4|Schmidt P, Friedman IS "Adverse effects of ethacrynic acid." N Y State J Med 67 (1967):  1438-42|Martinez-Maldonado M "Electrolyte disturbances resulting from diuretic therapy." Tex Med 69 (1973):  83-7|Gaillard R, Vallotton B, Muller F "Letter: Hypotension after angiotensin-II infusion and hypovolaemia induced by diuretic." Lancet 1 (1974):  1349|White SJ, Williamson K "What to watch for when you give loop diuretics." RN 42 (1979):  25-7|"Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc  (2001):|Patterson JH, Adams KF, Applefeld MM, Corder CN, Masse BR "Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion." Pharmacotherapy 14 (1994):  514-21|Oberbauer R, Krivanek P, Turnheim K "Pharmacokinetics and pharmacodynamics of the diuretic bumetanide in the elderly." Clin Pharmacol Ther 57 (1995):  42-51|Dunn CJ, Fitton A, Brogden RN "Torasemide: an update of its pharmacological properties and therapeutic efficacy." Drugs 49 (1995):  121-42|Blose JS, Adams KF, Patterson JH "Torsemide: a pyridine-sulfonylurea loop diuretic." Ann Pharmacother 29 (1995):  396-402|Fowler SF, Murray KM "Torsemide: a new loop diuretic." Am J Health Syst Pharm 52 (1995):  1771-80|Fowler SF, Murray KM "Torsemide: a new loop diuretic." Am J Health Syst Pharm 52 (1995):  1771-80|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34184, 3997, 'Bumetanide', 'Water-Electrolyte Imbalance', 'The use of loop diuretics, particularly at high dosages or during chronic therapy, is commonly associated with loss of electrolytes, including potassium, sodium, chloride, magnesium, and calcium.  Potassium and magnesium depletion may lead to cardiac arrhythmias and cardiac arrest.  Other electrolyte-related complications include metabolic alkalosis and hyponatremia, which are rarely life-threatening.  Excessive diuresis, as indicated by rapid weight loss, may induce dehydration and hypovolemia, which can result in acute hypotension, orthostasis, circulatory collapse, vascular thrombosis and embolism, and abrupt reduction in glomerular filtration and renal blood flow.  Severe dehydration is most likely to occur in the elderly and patients under prolonged sodium restriction.  Therapy with loop diuretics should be administered cautiously in patients with or predisposed to fluid and electrolyte depletion, including patients with primary or secondary aldosteronism (may have low potassium levels); those with severe or prolonged diarrhea or vomiting; and those with poor nutritional status.  Fluid and electrolyte abnormalities should be corrected before initiating therapy, and blood pressure as well as serum electrolyte concentrations monitored periodically and maintained at normal ranges during therapy.  Patients should be advised to immediately report signs and symptoms of fluid or electrolyte imbalance, including dry mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, arrhythmia, or gastrointestinal disturbances such as nausea and vomiting.  Digitalized patients and patients with a history of ventricular arrhythmias should be monitored carefully, since the development of hypokalemia may be particularly dangerous in these patients.  The risk of hypokalemia may be minimized by slow diuresis, a lower diuretic dosage, potassium supplementation, or combined use with a potassium-sparing diuretic.  Similarly, to prevent excessive dehydration and hyponatremia, sodium intake should be liberalized if clinically feasible.', '3', 'Tambyah JA, Lim MK "Effect of furesomide on calcium excretion." Br Med J 03/22/69 (1969):  751-2|Roesner M "The loop diuretics: focus on furosemide and ethacrynic acid." N C Med J 47 (1986):  93-6|Ponto LL, Schoenwald RD "Furosemide (frusemide): a pharmacokinetic/pharmacodynamic review." Clin Pharmacokinet 18 (1990):  381-408|Ward A, Heel RC "Bumetanide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use." Drugs 28 (1984):  426-64|Menday AP, Adnitt PI, Underwood PN "Effect of long-term treatment with bumetanide/amiloride on electrolytes and renal function in elderly patients with heart failure." Curr Ther Res Clin Exp 50 (1991):  57-64|Kubik MM, Bowers E, Underwood PN "Longterm experience of the routine use of bumetanide." Br J Clin Pract 30 (1976):  11-4|"Product Information. Bumex (bumetanide)." Roche Laboratories  (2002):|"Product Information. Lasix (furosemide)." sanofi-aventis  (2007):|"Product Information. Demadex (torsemide)." Boehringer Mannheim|Schwartz AB "Diuretic-induced hypokalemia." Am Fam Physician 11 (1975):  101-4|Cooperman LB, Rubin IL "Toxicity of ethacrynic acid and furosemide." Am Heart J 85 (1973):  831-4|Schwartz FD, Pillay VK, Kark RM "Ethacrynic acid: its usefulness and untoward effects." Am Heart J 79 (1970):  427-8|DeRubertis FR, Michelis MF, Beck N, Davis BB "Complications of diuretic therapy: severe alkalosis and syndrome resembling inappropriate secretion of antidiuretic hormone." Metabolism 19 (1970):  709-19|Sullivan RC, Freemon FR, Caranasos GJ "Complications from diuretic therapy with ethacrynic acid and furosemide." South Med J 64 (1971):  869-72|Plumb VJ, James TN "Clinical hazards of powerful diuretics. Furosemide and ethacrynic acid." Mod Concepts Cardiovasc Dis 47 (1978):  91-4|Schmidt P, Friedman IS "Adverse effects of ethacrynic acid." N Y State J Med 67 (1967):  1438-42|Martinez-Maldonado M "Electrolyte disturbances resulting from diuretic therapy." Tex Med 69 (1973):  83-7|Gaillard R, Vallotton B, Muller F "Letter: Hypotension after angiotensin-II infusion and hypovolaemia induced by diuretic." Lancet 1 (1974):  1349|White SJ, Williamson K "What to watch for when you give loop diuretics." RN 42 (1979):  25-7|"Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc  (2001):|Patterson JH, Adams KF, Applefeld MM, Corder CN, Masse BR "Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion." Pharmacotherapy 14 (1994):  514-21|Oberbauer R, Krivanek P, Turnheim K "Pharmacokinetics and pharmacodynamics of the diuretic bumetanide in the elderly." Clin Pharmacol Ther 57 (1995):  42-51|Dunn CJ, Fitton A, Brogden RN "Torasemide: an update of its pharmacological properties and therapeutic efficacy." Drugs 49 (1995):  121-42|Blose JS, Adams KF, Patterson JH "Torsemide: a pyridine-sulfonylurea loop diuretic." Ann Pharmacother 29 (1995):  396-402|Fowler SF, Murray KM "Torsemide: a new loop diuretic." Am J Health Syst Pharm 52 (1995):  1771-80|Fowler SF, Murray KM "Torsemide: a new loop diuretic." Am J Health Syst Pharm 52 (1995):  1771-80|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34185, 15562, 'Bumetanide', 'Water-Electrolyte Imbalance', 'The use of loop diuretics, particularly at high dosages or during chronic therapy, is commonly associated with loss of electrolytes, including potassium, sodium, chloride, magnesium, and calcium.  Potassium and magnesium depletion may lead to cardiac arrhythmias and cardiac arrest.  Other electrolyte-related complications include metabolic alkalosis and hyponatremia, which are rarely life-threatening.  Excessive diuresis, as indicated by rapid weight loss, may induce dehydration and hypovolemia, which can result in acute hypotension, orthostasis, circulatory collapse, vascular thrombosis and embolism, and abrupt reduction in glomerular filtration and renal blood flow.  Severe dehydration is most likely to occur in the elderly and patients under prolonged sodium restriction.  Therapy with loop diuretics should be administered cautiously in patients with or predisposed to fluid and electrolyte depletion, including patients with primary or secondary aldosteronism (may have low potassium levels); those with severe or prolonged diarrhea or vomiting; and those with poor nutritional status.  Fluid and electrolyte abnormalities should be corrected before initiating therapy, and blood pressure as well as serum electrolyte concentrations monitored periodically and maintained at normal ranges during therapy.  Patients should be advised to immediately report signs and symptoms of fluid or electrolyte imbalance, including dry mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, arrhythmia, or gastrointestinal disturbances such as nausea and vomiting.  Digitalized patients and patients with a history of ventricular arrhythmias should be monitored carefully, since the development of hypokalemia may be particularly dangerous in these patients.  The risk of hypokalemia may be minimized by slow diuresis, a lower diuretic dosage, potassium supplementation, or combined use with a potassium-sparing diuretic.  Similarly, to prevent excessive dehydration and hyponatremia, sodium intake should be liberalized if clinically feasible.', '3', 'Tambyah JA, Lim MK "Effect of furesomide on calcium excretion." Br Med J 03/22/69 (1969):  751-2|Roesner M "The loop diuretics: focus on furosemide and ethacrynic acid." N C Med J 47 (1986):  93-6|Ponto LL, Schoenwald RD "Furosemide (frusemide): a pharmacokinetic/pharmacodynamic review." Clin Pharmacokinet 18 (1990):  381-408|Ward A, Heel RC "Bumetanide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use." Drugs 28 (1984):  426-64|Menday AP, Adnitt PI, Underwood PN "Effect of long-term treatment with bumetanide/amiloride on electrolytes and renal function in elderly patients with heart failure." Curr Ther Res Clin Exp 50 (1991):  57-64|Kubik MM, Bowers E, Underwood PN "Longterm experience of the routine use of bumetanide." Br J Clin Pract 30 (1976):  11-4|"Product Information. Bumex (bumetanide)." Roche Laboratories  (2002):|"Product Information. Lasix (furosemide)." sanofi-aventis  (2007):|"Product Information. Demadex (torsemide)." Boehringer Mannheim|Schwartz AB "Diuretic-induced hypokalemia." Am Fam Physician 11 (1975):  101-4|Cooperman LB, Rubin IL "Toxicity of ethacrynic acid and furosemide." Am Heart J 85 (1973):  831-4|Schwartz FD, Pillay VK, Kark RM "Ethacrynic acid: its usefulness and untoward effects." Am Heart J 79 (1970):  427-8|DeRubertis FR, Michelis MF, Beck N, Davis BB "Complications of diuretic therapy: severe alkalosis and syndrome resembling inappropriate secretion of antidiuretic hormone." Metabolism 19 (1970):  709-19|Sullivan RC, Freemon FR, Caranasos GJ "Complications from diuretic therapy with ethacrynic acid and furosemide." South Med J 64 (1971):  869-72|Plumb VJ, James TN "Clinical hazards of powerful diuretics. Furosemide and ethacrynic acid." Mod Concepts Cardiovasc Dis 47 (1978):  91-4|Schmidt P, Friedman IS "Adverse effects of ethacrynic acid." N Y State J Med 67 (1967):  1438-42|Martinez-Maldonado M "Electrolyte disturbances resulting from diuretic therapy." Tex Med 69 (1973):  83-7|Gaillard R, Vallotton B, Muller F "Letter: Hypotension after angiotensin-II infusion and hypovolaemia induced by diuretic." Lancet 1 (1974):  1349|White SJ, Williamson K "What to watch for when you give loop diuretics." RN 42 (1979):  25-7|"Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc  (2001):|Patterson JH, Adams KF, Applefeld MM, Corder CN, Masse BR "Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion." Pharmacotherapy 14 (1994):  514-21|Oberbauer R, Krivanek P, Turnheim K "Pharmacokinetics and pharmacodynamics of the diuretic bumetanide in the elderly." Clin Pharmacol Ther 57 (1995):  42-51|Dunn CJ, Fitton A, Brogden RN "Torasemide: an update of its pharmacological properties and therapeutic efficacy." Drugs 49 (1995):  121-42|Blose JS, Adams KF, Patterson JH "Torsemide: a pyridine-sulfonylurea loop diuretic." Ann Pharmacother 29 (1995):  396-402|Fowler SF, Murray KM "Torsemide: a new loop diuretic." Am J Health Syst Pharm 52 (1995):  1771-80|Fowler SF, Murray KM "Torsemide: a new loop diuretic." Am J Health Syst Pharm 52 (1995):  1771-80|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34186, 18075, 'Bumetanide', 'Water-Electrolyte Imbalance', 'The use of loop diuretics, particularly at high dosages or during chronic therapy, is commonly associated with loss of electrolytes, including potassium, sodium, chloride, magnesium, and calcium.  Potassium and magnesium depletion may lead to cardiac arrhythmias and cardiac arrest.  Other electrolyte-related complications include metabolic alkalosis and hyponatremia, which are rarely life-threatening.  Excessive diuresis, as indicated by rapid weight loss, may induce dehydration and hypovolemia, which can result in acute hypotension, orthostasis, circulatory collapse, vascular thrombosis and embolism, and abrupt reduction in glomerular filtration and renal blood flow.  Severe dehydration is most likely to occur in the elderly and patients under prolonged sodium restriction.  Therapy with loop diuretics should be administered cautiously in patients with or predisposed to fluid and electrolyte depletion, including patients with primary or secondary aldosteronism (may have low potassium levels); those with severe or prolonged diarrhea or vomiting; and those with poor nutritional status.  Fluid and electrolyte abnormalities should be corrected before initiating therapy, and blood pressure as well as serum electrolyte concentrations monitored periodically and maintained at normal ranges during therapy.  Patients should be advised to immediately report signs and symptoms of fluid or electrolyte imbalance, including dry mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, arrhythmia, or gastrointestinal disturbances such as nausea and vomiting.  Digitalized patients and patients with a history of ventricular arrhythmias should be monitored carefully, since the development of hypokalemia may be particularly dangerous in these patients.  The risk of hypokalemia may be minimized by slow diuresis, a lower diuretic dosage, potassium supplementation, or combined use with a potassium-sparing diuretic.  Similarly, to prevent excessive dehydration and hyponatremia, sodium intake should be liberalized if clinically feasible.', '3', 'Tambyah JA, Lim MK "Effect of furesomide on calcium excretion." Br Med J 03/22/69 (1969):  751-2|Roesner M "The loop diuretics: focus on furosemide and ethacrynic acid." N C Med J 47 (1986):  93-6|Ponto LL, Schoenwald RD "Furosemide (frusemide): a pharmacokinetic/pharmacodynamic review." Clin Pharmacokinet 18 (1990):  381-408|Ward A, Heel RC "Bumetanide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use." Drugs 28 (1984):  426-64|Menday AP, Adnitt PI, Underwood PN "Effect of long-term treatment with bumetanide/amiloride on electrolytes and renal function in elderly patients with heart failure." Curr Ther Res Clin Exp 50 (1991):  57-64|Kubik MM, Bowers E, Underwood PN "Longterm experience of the routine use of bumetanide." Br J Clin Pract 30 (1976):  11-4|"Product Information. Bumex (bumetanide)." Roche Laboratories  (2002):|"Product Information. Lasix (furosemide)." sanofi-aventis  (2007):|"Product Information. Demadex (torsemide)." Boehringer Mannheim|Schwartz AB "Diuretic-induced hypokalemia." Am Fam Physician 11 (1975):  101-4|Cooperman LB, Rubin IL "Toxicity of ethacrynic acid and furosemide." Am Heart J 85 (1973):  831-4|Schwartz FD, Pillay VK, Kark RM "Ethacrynic acid: its usefulness and untoward effects." Am Heart J 79 (1970):  427-8|DeRubertis FR, Michelis MF, Beck N, Davis BB "Complications of diuretic therapy: severe alkalosis and syndrome resembling inappropriate secretion of antidiuretic hormone." Metabolism 19 (1970):  709-19|Sullivan RC, Freemon FR, Caranasos GJ "Complications from diuretic therapy with ethacrynic acid and furosemide." South Med J 64 (1971):  869-72|Plumb VJ, James TN "Clinical hazards of powerful diuretics. Furosemide and ethacrynic acid." Mod Concepts Cardiovasc Dis 47 (1978):  91-4|Schmidt P, Friedman IS "Adverse effects of ethacrynic acid." N Y State J Med 67 (1967):  1438-42|Martinez-Maldonado M "Electrolyte disturbances resulting from diuretic therapy." Tex Med 69 (1973):  83-7|Gaillard R, Vallotton B, Muller F "Letter: Hypotension after angiotensin-II infusion and hypovolaemia induced by diuretic." Lancet 1 (1974):  1349|White SJ, Williamson K "What to watch for when you give loop diuretics." RN 42 (1979):  25-7|"Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc  (2001):|Patterson JH, Adams KF, Applefeld MM, Corder CN, Masse BR "Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion." Pharmacotherapy 14 (1994):  514-21|Oberbauer R, Krivanek P, Turnheim K "Pharmacokinetics and pharmacodynamics of the diuretic bumetanide in the elderly." Clin Pharmacol Ther 57 (1995):  42-51|Dunn CJ, Fitton A, Brogden RN "Torasemide: an update of its pharmacological properties and therapeutic efficacy." Drugs 49 (1995):  121-42|Blose JS, Adams KF, Patterson JH "Torsemide: a pyridine-sulfonylurea loop diuretic." Ann Pharmacother 29 (1995):  396-402|Fowler SF, Murray KM "Torsemide: a new loop diuretic." Am J Health Syst Pharm 52 (1995):  1771-80|Fowler SF, Murray KM "Torsemide: a new loop diuretic." Am J Health Syst Pharm 52 (1995):  1771-80|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34187, 2409, 'Bumetanide', 'Ototoxicity', 'Tinnitus and hearing loss, both reversible and permanent, have been reported with the use of loop diuretics.  Ototoxic effects have generally been associated with rapid intravenous or intramuscular injection, severe renal impairment, unusually high dosages (i.e. several times the usual recommended dosages), and/or concomitant use of other ototoxic agents.  Therapy with loop diuretics should be administered cautiously in patients with preexisting vestibular and/or auditory impairment, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  High-dose parenteral therapy should be administered as controlled infusion.', '3', '"Product Information. Bumex (bumetanide)." Roche Laboratories  (2002):|"Product Information. Lasix (furosemide)." sanofi-aventis  (2007):|Vargish T, Benjamin R, Shenkman L "Deafness from furosemide." Ann Intern Med 72 (1970):  761|Quick CA, Hoppe W "Permanent deafness associated with furosemide administration." Ann Otol Rhinol Laryngol 84 (1975):  94-101|David D, Hitzig P "Diuretics and ototoxicity." N Engl J Med 284 (1971):  1328|Heidland A, Wigand N "Influence of high doses of furosemide on hearing of uremic patients." Klin Wochenschr 48 (1970):  1052|Lloyd-Mostyn R, Lord I "Ototoxicity of intravenous furosemide." Lancet 2 (1971):  1156|Schwartz G "Ototoxicity induced by furosemide." N Engl J Med 282 (1970):  1413|Venkateswaran P "Transient deafness from high doses of furosemide." Br Med J 4 (1971):  113|"Product Information. Demadex (torsemide)." Boehringer Mannheim|Cooperman LB, Rubin IL "Toxicity of ethacrynic acid and furosemide." Am Heart J 85 (1973):  831-4|Schwartz FD, Pillay VK, Kark RM "Ethacrynic acid: its usefulness and untoward effects." Am Heart J 79 (1970):  427-8|Schneider WJ, Becker EL "Acute transient hearing loss after ethacrynic acid therapy." Arch Intern Med 117 (1966):  715-7|Matz GJ, Beal DD, Krames L "Ototoxicity of ethacrynic acid. Demonstrated in a human temporal bone." Arch Otolaryngol 90 (1969):  152-5|Rybak LP "Ototoxicity of ethacrynic acid (a persistent clinical problem)." J Laryngol Otol 102 (1988):  518-20|Meriwether WD, Mangi RJ, Serpick AA "Deafness following standard intravenous dose of ethacrynic acid." JAMA 216 (1971):  795-8|Merrill JP "Hazards of ethacrynic acid." JAMA 212 (1970):  159|Chaffee WG Jr "Hazards of ethacrynic acid." JAMA 212 (1970):  159|Matz GJ, Naunton RF "Ototoxic drugs and poor renal function." JAMA 206 (1968):  2119|Pillay VK, Schwartz FD, Aimi K, Kark RM "Transient and permanent deafness following treatment with ethacrynic acid in renal failure." Lancet 1 (1969):  77-9|Ng PS, Conley CE, Ing TS "Deafness after ethacrynic acid." Lancet 1 (1969):  673-4|Matz GJ "The ototoxic effects of ethacrynic acid in man and animals." Laryngoscope 86 (1976):  1065-86|Quick CA, Duvall AJ 3d "Early changes in the cochlear duct from ethacrynic acid: an electronmicroscopie evaluation." Laryngoscope 80 (1970):  954-65|Hybels RL "Drug toxicity of the inner ear." Med Clin North Am 63 (1979):  309-19|Gomolin IH, Garschick E "Ethacrynic acid-induced deafness accompanied by nystagmus." N Engl J Med 303 (1980):  702|Homer MJ "Deafness after ethacrynic acid." N Engl J Med 285 (1971):  1152|David DS, Hitzig P "Diuretics and ototoxicity." N Engl J Med 284 (1971):  1328-9|Marlowe FI "Ototoxic agents." Otolaryngol Clin North Am 11 (1978):  791-800|Rybak LP "Ototoxicity of loop diuretics." Otolaryngol Clin North Am 26 (1993):  829-44|Sheffield PA, Turner JS Jr "Ototoxic drugs: a review of clinical aspects, histopathologic changes and mechanisms of action." South Med J 64 (1971):  359-63|Arnold W, Nadol JB Jr, Weidauer H "Ultrastructural histopathology in a case of human ototoxicity due to loop diuretics." Acta Otolaryngol (Stockh) 91 (1981):  399-414|Ballantyne J "Ototoxicity: a clinical review." Audiology 12 (1973):  325-36|Beauchamp GD, Crouch TC "Deafness. Review of intravenous ethacrynic acid." J Kans Med Soc 76 (1975):  166-8,180|Ajodhia JM, Dix MR "Drug-induced deafness and its treatment." Practitioner 216 (1976):  561-70|Boston Collaborative Drug Surveillance Program "Drug-induced deafness." JAMA 224 (1973):  515-6|"Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc  (2001):|Dunn CJ, Fitton A, Brogden RN "Torasemide: an update of its pharmacological properties and therapeutic efficacy." Drugs 49 (1995):  121-42|Blose JS, Adams KF, Patterson JH "Torsemide: a pyridine-sulfonylurea loop diuretic." Ann Pharmacother 29 (1995):  396-402|Fowler SF, Murray KM "Torsemide: a new loop diuretic." Am J Health Syst Pharm 52 (1995):  1771-80|Fowler SF, Murray KM "Torsemide: a new loop diuretic." Am J Health Syst Pharm 52 (1995):  1771-80', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34188, 3997, 'Bumetanide', 'Ototoxicity', 'Tinnitus and hearing loss, both reversible and permanent, have been reported with the use of loop diuretics.  Ototoxic effects have generally been associated with rapid intravenous or intramuscular injection, severe renal impairment, unusually high dosages (i.e. several times the usual recommended dosages), and/or concomitant use of other ototoxic agents.  Therapy with loop diuretics should be administered cautiously in patients with preexisting vestibular and/or auditory impairment, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  High-dose parenteral therapy should be administered as controlled infusion.', '3', '"Product Information. Bumex (bumetanide)." Roche Laboratories  (2002):|"Product Information. Lasix (furosemide)." sanofi-aventis  (2007):|Vargish T, Benjamin R, Shenkman L "Deafness from furosemide." Ann Intern Med 72 (1970):  761|Quick CA, Hoppe W "Permanent deafness associated with furosemide administration." Ann Otol Rhinol Laryngol 84 (1975):  94-101|David D, Hitzig P "Diuretics and ototoxicity." N Engl J Med 284 (1971):  1328|Heidland A, Wigand N "Influence of high doses of furosemide on hearing of uremic patients." Klin Wochenschr 48 (1970):  1052|Lloyd-Mostyn R, Lord I "Ototoxicity of intravenous furosemide." Lancet 2 (1971):  1156|Schwartz G "Ototoxicity induced by furosemide." N Engl J Med 282 (1970):  1413|Venkateswaran P "Transient deafness from high doses of furosemide." Br Med J 4 (1971):  113|"Product Information. Demadex (torsemide)." Boehringer Mannheim|Cooperman LB, Rubin IL "Toxicity of ethacrynic acid and furosemide." Am Heart J 85 (1973):  831-4|Schwartz FD, Pillay VK, Kark RM "Ethacrynic acid: its usefulness and untoward effects." Am Heart J 79 (1970):  427-8|Schneider WJ, Becker EL "Acute transient hearing loss after ethacrynic acid therapy." Arch Intern Med 117 (1966):  715-7|Matz GJ, Beal DD, Krames L "Ototoxicity of ethacrynic acid. Demonstrated in a human temporal bone." Arch Otolaryngol 90 (1969):  152-5|Rybak LP "Ototoxicity of ethacrynic acid (a persistent clinical problem)." J Laryngol Otol 102 (1988):  518-20|Meriwether WD, Mangi RJ, Serpick AA "Deafness following standard intravenous dose of ethacrynic acid." JAMA 216 (1971):  795-8|Merrill JP "Hazards of ethacrynic acid." JAMA 212 (1970):  159|Chaffee WG Jr "Hazards of ethacrynic acid." JAMA 212 (1970):  159|Matz GJ, Naunton RF "Ototoxic drugs and poor renal function." JAMA 206 (1968):  2119|Pillay VK, Schwartz FD, Aimi K, Kark RM "Transient and permanent deafness following treatment with ethacrynic acid in renal failure." Lancet 1 (1969):  77-9|Ng PS, Conley CE, Ing TS "Deafness after ethacrynic acid." Lancet 1 (1969):  673-4|Matz GJ "The ototoxic effects of ethacrynic acid in man and animals." Laryngoscope 86 (1976):  1065-86|Quick CA, Duvall AJ 3d "Early changes in the cochlear duct from ethacrynic acid: an electronmicroscopie evaluation." Laryngoscope 80 (1970):  954-65|Hybels RL "Drug toxicity of the inner ear." Med Clin North Am 63 (1979):  309-19|Gomolin IH, Garschick E "Ethacrynic acid-induced deafness accompanied by nystagmus." N Engl J Med 303 (1980):  702|Homer MJ "Deafness after ethacrynic acid." N Engl J Med 285 (1971):  1152|David DS, Hitzig P "Diuretics and ototoxicity." N Engl J Med 284 (1971):  1328-9|Marlowe FI "Ototoxic agents." Otolaryngol Clin North Am 11 (1978):  791-800|Rybak LP "Ototoxicity of loop diuretics." Otolaryngol Clin North Am 26 (1993):  829-44|Sheffield PA, Turner JS Jr "Ototoxic drugs: a review of clinical aspects, histopathologic changes and mechanisms of action." South Med J 64 (1971):  359-63|Arnold W, Nadol JB Jr, Weidauer H "Ultrastructural histopathology in a case of human ototoxicity due to loop diuretics." Acta Otolaryngol (Stockh) 91 (1981):  399-414|Ballantyne J "Ototoxicity: a clinical review." Audiology 12 (1973):  325-36|Beauchamp GD, Crouch TC "Deafness. Review of intravenous ethacrynic acid." J Kans Med Soc 76 (1975):  166-8,180|Ajodhia JM, Dix MR "Drug-induced deafness and its treatment." Practitioner 216 (1976):  561-70|Boston Collaborative Drug Surveillance Program "Drug-induced deafness." JAMA 224 (1973):  515-6|"Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc  (2001):|Dunn CJ, Fitton A, Brogden RN "Torasemide: an update of its pharmacological properties and therapeutic efficacy." Drugs 49 (1995):  121-42|Blose JS, Adams KF, Patterson JH "Torsemide: a pyridine-sulfonylurea loop diuretic." Ann Pharmacother 29 (1995):  396-402|Fowler SF, Murray KM "Torsemide: a new loop diuretic." Am J Health Syst Pharm 52 (1995):  1771-80|Fowler SF, Murray KM "Torsemide: a new loop diuretic." Am J Health Syst Pharm 52 (1995):  1771-80', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34189, 15562, 'Bumetanide', 'Ototoxicity', 'Tinnitus and hearing loss, both reversible and permanent, have been reported with the use of loop diuretics.  Ototoxic effects have generally been associated with rapid intravenous or intramuscular injection, severe renal impairment, unusually high dosages (i.e. several times the usual recommended dosages), and/or concomitant use of other ototoxic agents.  Therapy with loop diuretics should be administered cautiously in patients with preexisting vestibular and/or auditory impairment, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  High-dose parenteral therapy should be administered as controlled infusion.', '3', '"Product Information. Bumex (bumetanide)." Roche Laboratories  (2002):|"Product Information. Lasix (furosemide)." sanofi-aventis  (2007):|Vargish T, Benjamin R, Shenkman L "Deafness from furosemide." Ann Intern Med 72 (1970):  761|Quick CA, Hoppe W "Permanent deafness associated with furosemide administration." Ann Otol Rhinol Laryngol 84 (1975):  94-101|David D, Hitzig P "Diuretics and ototoxicity." N Engl J Med 284 (1971):  1328|Heidland A, Wigand N "Influence of high doses of furosemide on hearing of uremic patients." Klin Wochenschr 48 (1970):  1052|Lloyd-Mostyn R, Lord I "Ototoxicity of intravenous furosemide." Lancet 2 (1971):  1156|Schwartz G "Ototoxicity induced by furosemide." N Engl J Med 282 (1970):  1413|Venkateswaran P "Transient deafness from high doses of furosemide." Br Med J 4 (1971):  113|"Product Information. Demadex (torsemide)." Boehringer Mannheim|Cooperman LB, Rubin IL "Toxicity of ethacrynic acid and furosemide." Am Heart J 85 (1973):  831-4|Schwartz FD, Pillay VK, Kark RM "Ethacrynic acid: its usefulness and untoward effects." Am Heart J 79 (1970):  427-8|Schneider WJ, Becker EL "Acute transient hearing loss after ethacrynic acid therapy." Arch Intern Med 117 (1966):  715-7|Matz GJ, Beal DD, Krames L "Ototoxicity of ethacrynic acid. Demonstrated in a human temporal bone." Arch Otolaryngol 90 (1969):  152-5|Rybak LP "Ototoxicity of ethacrynic acid (a persistent clinical problem)." J Laryngol Otol 102 (1988):  518-20|Meriwether WD, Mangi RJ, Serpick AA "Deafness following standard intravenous dose of ethacrynic acid." JAMA 216 (1971):  795-8|Merrill JP "Hazards of ethacrynic acid." JAMA 212 (1970):  159|Chaffee WG Jr "Hazards of ethacrynic acid." JAMA 212 (1970):  159|Matz GJ, Naunton RF "Ototoxic drugs and poor renal function." JAMA 206 (1968):  2119|Pillay VK, Schwartz FD, Aimi K, Kark RM "Transient and permanent deafness following treatment with ethacrynic acid in renal failure." Lancet 1 (1969):  77-9|Ng PS, Conley CE, Ing TS "Deafness after ethacrynic acid." Lancet 1 (1969):  673-4|Matz GJ "The ototoxic effects of ethacrynic acid in man and animals." Laryngoscope 86 (1976):  1065-86|Quick CA, Duvall AJ 3d "Early changes in the cochlear duct from ethacrynic acid: an electronmicroscopie evaluation." Laryngoscope 80 (1970):  954-65|Hybels RL "Drug toxicity of the inner ear." Med Clin North Am 63 (1979):  309-19|Gomolin IH, Garschick E "Ethacrynic acid-induced deafness accompanied by nystagmus." N Engl J Med 303 (1980):  702|Homer MJ "Deafness after ethacrynic acid." N Engl J Med 285 (1971):  1152|David DS, Hitzig P "Diuretics and ototoxicity." N Engl J Med 284 (1971):  1328-9|Marlowe FI "Ototoxic agents." Otolaryngol Clin North Am 11 (1978):  791-800|Rybak LP "Ototoxicity of loop diuretics." Otolaryngol Clin North Am 26 (1993):  829-44|Sheffield PA, Turner JS Jr "Ototoxic drugs: a review of clinical aspects, histopathologic changes and mechanisms of action." South Med J 64 (1971):  359-63|Arnold W, Nadol JB Jr, Weidauer H "Ultrastructural histopathology in a case of human ototoxicity due to loop diuretics." Acta Otolaryngol (Stockh) 91 (1981):  399-414|Ballantyne J "Ototoxicity: a clinical review." Audiology 12 (1973):  325-36|Beauchamp GD, Crouch TC "Deafness. Review of intravenous ethacrynic acid." J Kans Med Soc 76 (1975):  166-8,180|Ajodhia JM, Dix MR "Drug-induced deafness and its treatment." Practitioner 216 (1976):  561-70|Boston Collaborative Drug Surveillance Program "Drug-induced deafness." JAMA 224 (1973):  515-6|"Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc  (2001):|Dunn CJ, Fitton A, Brogden RN "Torasemide: an update of its pharmacological properties and therapeutic efficacy." Drugs 49 (1995):  121-42|Blose JS, Adams KF, Patterson JH "Torsemide: a pyridine-sulfonylurea loop diuretic." Ann Pharmacother 29 (1995):  396-402|Fowler SF, Murray KM "Torsemide: a new loop diuretic." Am J Health Syst Pharm 52 (1995):  1771-80|Fowler SF, Murray KM "Torsemide: a new loop diuretic." Am J Health Syst Pharm 52 (1995):  1771-80', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34190, 18075, 'Bumetanide', 'Ototoxicity', 'Tinnitus and hearing loss, both reversible and permanent, have been reported with the use of loop diuretics.  Ototoxic effects have generally been associated with rapid intravenous or intramuscular injection, severe renal impairment, unusually high dosages (i.e. several times the usual recommended dosages), and/or concomitant use of other ototoxic agents.  Therapy with loop diuretics should be administered cautiously in patients with preexisting vestibular and/or auditory impairment, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  High-dose parenteral therapy should be administered as controlled infusion.', '3', '"Product Information. Bumex (bumetanide)." Roche Laboratories  (2002):|"Product Information. Lasix (furosemide)." sanofi-aventis  (2007):|Vargish T, Benjamin R, Shenkman L "Deafness from furosemide." Ann Intern Med 72 (1970):  761|Quick CA, Hoppe W "Permanent deafness associated with furosemide administration." Ann Otol Rhinol Laryngol 84 (1975):  94-101|David D, Hitzig P "Diuretics and ototoxicity." N Engl J Med 284 (1971):  1328|Heidland A, Wigand N "Influence of high doses of furosemide on hearing of uremic patients." Klin Wochenschr 48 (1970):  1052|Lloyd-Mostyn R, Lord I "Ototoxicity of intravenous furosemide." Lancet 2 (1971):  1156|Schwartz G "Ototoxicity induced by furosemide." N Engl J Med 282 (1970):  1413|Venkateswaran P "Transient deafness from high doses of furosemide." Br Med J 4 (1971):  113|"Product Information. Demadex (torsemide)." Boehringer Mannheim|Cooperman LB, Rubin IL "Toxicity of ethacrynic acid and furosemide." Am Heart J 85 (1973):  831-4|Schwartz FD, Pillay VK, Kark RM "Ethacrynic acid: its usefulness and untoward effects." Am Heart J 79 (1970):  427-8|Schneider WJ, Becker EL "Acute transient hearing loss after ethacrynic acid therapy." Arch Intern Med 117 (1966):  715-7|Matz GJ, Beal DD, Krames L "Ototoxicity of ethacrynic acid. Demonstrated in a human temporal bone." Arch Otolaryngol 90 (1969):  152-5|Rybak LP "Ototoxicity of ethacrynic acid (a persistent clinical problem)." J Laryngol Otol 102 (1988):  518-20|Meriwether WD, Mangi RJ, Serpick AA "Deafness following standard intravenous dose of ethacrynic acid." JAMA 216 (1971):  795-8|Merrill JP "Hazards of ethacrynic acid." JAMA 212 (1970):  159|Chaffee WG Jr "Hazards of ethacrynic acid." JAMA 212 (1970):  159|Matz GJ, Naunton RF "Ototoxic drugs and poor renal function." JAMA 206 (1968):  2119|Pillay VK, Schwartz FD, Aimi K, Kark RM "Transient and permanent deafness following treatment with ethacrynic acid in renal failure." Lancet 1 (1969):  77-9|Ng PS, Conley CE, Ing TS "Deafness after ethacrynic acid." Lancet 1 (1969):  673-4|Matz GJ "The ototoxic effects of ethacrynic acid in man and animals." Laryngoscope 86 (1976):  1065-86|Quick CA, Duvall AJ 3d "Early changes in the cochlear duct from ethacrynic acid: an electronmicroscopie evaluation." Laryngoscope 80 (1970):  954-65|Hybels RL "Drug toxicity of the inner ear." Med Clin North Am 63 (1979):  309-19|Gomolin IH, Garschick E "Ethacrynic acid-induced deafness accompanied by nystagmus." N Engl J Med 303 (1980):  702|Homer MJ "Deafness after ethacrynic acid." N Engl J Med 285 (1971):  1152|David DS, Hitzig P "Diuretics and ototoxicity." N Engl J Med 284 (1971):  1328-9|Marlowe FI "Ototoxic agents." Otolaryngol Clin North Am 11 (1978):  791-800|Rybak LP "Ototoxicity of loop diuretics." Otolaryngol Clin North Am 26 (1993):  829-44|Sheffield PA, Turner JS Jr "Ototoxic drugs: a review of clinical aspects, histopathologic changes and mechanisms of action." South Med J 64 (1971):  359-63|Arnold W, Nadol JB Jr, Weidauer H "Ultrastructural histopathology in a case of human ototoxicity due to loop diuretics." Acta Otolaryngol (Stockh) 91 (1981):  399-414|Ballantyne J "Ototoxicity: a clinical review." Audiology 12 (1973):  325-36|Beauchamp GD, Crouch TC "Deafness. Review of intravenous ethacrynic acid." J Kans Med Soc 76 (1975):  166-8,180|Ajodhia JM, Dix MR "Drug-induced deafness and its treatment." Practitioner 216 (1976):  561-70|Boston Collaborative Drug Surveillance Program "Drug-induced deafness." JAMA 224 (1973):  515-6|"Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc  (2001):|Dunn CJ, Fitton A, Brogden RN "Torasemide: an update of its pharmacological properties and therapeutic efficacy." Drugs 49 (1995):  121-42|Blose JS, Adams KF, Patterson JH "Torsemide: a pyridine-sulfonylurea loop diuretic." Ann Pharmacother 29 (1995):  396-402|Fowler SF, Murray KM "Torsemide: a new loop diuretic." Am J Health Syst Pharm 52 (1995):  1771-80|Fowler SF, Murray KM "Torsemide: a new loop diuretic." Am J Health Syst Pharm 52 (1995):  1771-80', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34191, 2409, 'Bumetanide', 'Kidney Diseases', 'Impaired effectiveness and possible delayed excretion of loop diuretics may occur in patients with severe renal dysfunction.  These individuals may require high dosages that are associated with an increased risk of electrolyte abnormalities (hyponatremia, hypochloremic alkalosis, hypokalemia, hypomagnesemia, hypocalcemia) and ototoxicity (tinnitus, hearing loss).  Therapy with loop diuretics should be administered cautiously in patients with significantly impaired renal function.  Prolongation of the dosing intervals may be appropriate to prevent drug accumulation.  The patient should be monitored closely for the signs and symptoms of fluid or electrolyte imbalance, including dry mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, arrhythmia, or gastrointestinal disturbances such as nausea and vomiting.  Excessive diuresis should be avoided as it may induce dehydration and hypovolemia, which can result in an abrupt reduction in glomerular filtration and renal blood flow.  If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, or if renal function becomes progressively worse as indicated by rising BUN or serum creatinine levels, an interruption or discontinuation of therapy should be considered.', '3', 'Huang CM, Atkinson AJ, Levin M, et al. "Pharmacokinetics of furosemide in advanced renal failure." Clin Pharmacol Ther 16 (1974):  659-66|Cutler RE, Forrey AW, Christopher TG, Kimpel BM "Pharmacokinetics of furosemide in normal subjects and functionally anephric patients." Clin Pharmacol Ther 15 (1974):  588-96|Rose HJ, O''Malley K, Pruitt AW "Depression of renal clearance of furosemide in man by azotemia." Clin Pharmacol Ther 21 (1976):  141-6|Beermann B, Dalen E, Lindstrom B "Elimination of furosemide in healthy subjects and in those with renal failure." Clin Pharmacol Ther 22 (1977):  70-8|Tilstone WJ, Fine A "Furosemide kinetics in renal failure." Clin Pharmacol Ther 23 (1978):  644-50|Rane A, Villeneuve JP, Stone WJ, et al. "Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia." Clin Pharmacol Ther 24 (1978):  199-207|Andreasen F, Hansen HE, Mikkelsen E "Pharmacokinetics of furosemide in anephric patients and in normal subjects." Eur J Clin Pharmacol 13 (1978):  41-8|Keller E, Hoppe-Seyler G, Mumm R, Schollmeyer P "Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide." Eur J Clin Pharmacol 20 (1981):  27-33|Donatucci CF, Deshon GE, Wade CE, Hunt M "Furosemide-induced disturbances of renal function in patients undergoing TURP." Urology 35 (1990):  295-300|Keller E, Hoppe-Seyler G, Schollmeyer P "Disposition and diuretic effect of furosemide in the nephrotic syndrome." Clin Pharmacol Ther 32 (1982):  442-9|Ward A, Heel RC "Bumetanide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use." Drugs 28 (1984):  426-64|Menday AP, Adnitt PI, Underwood PN "Effect of long-term treatment with bumetanide/amiloride on electrolytes and renal function in elderly patients with heart failure." Curr Ther Res Clin Exp 50 (1991):  57-64|Pentikainen PJ, Pasternack A, Lampainen E, Neuvonen PJ, Penttila A "Bumetanide kinetics in renal failure." Clin Pharmacol Ther 37 (1985):  582-8|Marcantonio LA, Auld WH, Murdoch WR, Purohit R, Skellern GG, Howes CA "The pharmacokinetics and pharmacodynamics of the diuretic bumetanide in hepatic and renal disease." Br J Clin Pharmacol 15 (1983):  245-52|Berg KJ, Tromsdal A, Wideroe TE "Diuretic action of bumetanide in advanced chronic renal insufficiency." Eur J Clin Pharmacol 9 (1976):  265-75|Lowenthal DT, Dickerman D "The use of diuretics in varying degrees of renal impairment: an overview." Clin Exp Hypertens A 5 (1983):  297-307|"Product Information. Bumex (bumetanide)." Roche Laboratories  (2002):|"Product Information. Lasix (furosemide)." sanofi-aventis  (2007):|"Product Information. Demadex (torsemide)." Boehringer Mannheim|Matz GJ, Naunton RF "Ototoxic drugs and poor renal function." JAMA 206 (1968):  2119|Pillay VK, Schwartz FD, Aimi K, Kark RM "Transient and permanent deafness following treatment with ethacrynic acid in renal failure." Lancet 1 (1969):  77-9|Kaye M, Dufresne L, McDade D "Ethacrynic acid in acute renal failure." Lancet 1 (1968):  1255|Sullivan RC, Freemon FR, Caranasos GJ "Complications from diuretic therapy with ethacrynic acid and furosemide." South Med J 64 (1971):  869-72|Plumb VJ, James TN "Clinical hazards of powerful diuretics. Furosemide and ethacrynic acid." Mod Concepts Cardiovasc Dis 47 (1978):  91-4|White SJ, Williamson K "What to watch for when you give loop diuretics." RN 42 (1979):  25-7|"Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc  (2001):|Risler T, Schwab A, Kramer B, Braun N, Erley C "Comparative pharmacokinetics and pharmacodynamics of loop diuretics in renal failure." Cardiology 84 (1994):  155-61|Russo D, Minutolo R, Andreucci VE "Role of loop diuretics in chronic renal failure." Cardiology 84 (1994):  162-70', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34192, 3997, 'Bumetanide', 'Kidney Diseases', 'Impaired effectiveness and possible delayed excretion of loop diuretics may occur in patients with severe renal dysfunction.  These individuals may require high dosages that are associated with an increased risk of electrolyte abnormalities (hyponatremia, hypochloremic alkalosis, hypokalemia, hypomagnesemia, hypocalcemia) and ototoxicity (tinnitus, hearing loss).  Therapy with loop diuretics should be administered cautiously in patients with significantly impaired renal function.  Prolongation of the dosing intervals may be appropriate to prevent drug accumulation.  The patient should be monitored closely for the signs and symptoms of fluid or electrolyte imbalance, including dry mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, arrhythmia, or gastrointestinal disturbances such as nausea and vomiting.  Excessive diuresis should be avoided as it may induce dehydration and hypovolemia, which can result in an abrupt reduction in glomerular filtration and renal blood flow.  If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, or if renal function becomes progressively worse as indicated by rising BUN or serum creatinine levels, an interruption or discontinuation of therapy should be considered.', '3', 'Huang CM, Atkinson AJ, Levin M, et al. "Pharmacokinetics of furosemide in advanced renal failure." Clin Pharmacol Ther 16 (1974):  659-66|Cutler RE, Forrey AW, Christopher TG, Kimpel BM "Pharmacokinetics of furosemide in normal subjects and functionally anephric patients." Clin Pharmacol Ther 15 (1974):  588-96|Rose HJ, O''Malley K, Pruitt AW "Depression of renal clearance of furosemide in man by azotemia." Clin Pharmacol Ther 21 (1976):  141-6|Beermann B, Dalen E, Lindstrom B "Elimination of furosemide in healthy subjects and in those with renal failure." Clin Pharmacol Ther 22 (1977):  70-8|Tilstone WJ, Fine A "Furosemide kinetics in renal failure." Clin Pharmacol Ther 23 (1978):  644-50|Rane A, Villeneuve JP, Stone WJ, et al. "Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia." Clin Pharmacol Ther 24 (1978):  199-207|Andreasen F, Hansen HE, Mikkelsen E "Pharmacokinetics of furosemide in anephric patients and in normal subjects." Eur J Clin Pharmacol 13 (1978):  41-8|Keller E, Hoppe-Seyler G, Mumm R, Schollmeyer P "Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide." Eur J Clin Pharmacol 20 (1981):  27-33|Donatucci CF, Deshon GE, Wade CE, Hunt M "Furosemide-induced disturbances of renal function in patients undergoing TURP." Urology 35 (1990):  295-300|Keller E, Hoppe-Seyler G, Schollmeyer P "Disposition and diuretic effect of furosemide in the nephrotic syndrome." Clin Pharmacol Ther 32 (1982):  442-9|Ward A, Heel RC "Bumetanide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use." Drugs 28 (1984):  426-64|Menday AP, Adnitt PI, Underwood PN "Effect of long-term treatment with bumetanide/amiloride on electrolytes and renal function in elderly patients with heart failure." Curr Ther Res Clin Exp 50 (1991):  57-64|Pentikainen PJ, Pasternack A, Lampainen E, Neuvonen PJ, Penttila A "Bumetanide kinetics in renal failure." Clin Pharmacol Ther 37 (1985):  582-8|Marcantonio LA, Auld WH, Murdoch WR, Purohit R, Skellern GG, Howes CA "The pharmacokinetics and pharmacodynamics of the diuretic bumetanide in hepatic and renal disease." Br J Clin Pharmacol 15 (1983):  245-52|Berg KJ, Tromsdal A, Wideroe TE "Diuretic action of bumetanide in advanced chronic renal insufficiency." Eur J Clin Pharmacol 9 (1976):  265-75|Lowenthal DT, Dickerman D "The use of diuretics in varying degrees of renal impairment: an overview." Clin Exp Hypertens A 5 (1983):  297-307|"Product Information. Bumex (bumetanide)." Roche Laboratories  (2002):|"Product Information. Lasix (furosemide)." sanofi-aventis  (2007):|"Product Information. Demadex (torsemide)." Boehringer Mannheim|Matz GJ, Naunton RF "Ototoxic drugs and poor renal function." JAMA 206 (1968):  2119|Pillay VK, Schwartz FD, Aimi K, Kark RM "Transient and permanent deafness following treatment with ethacrynic acid in renal failure." Lancet 1 (1969):  77-9|Kaye M, Dufresne L, McDade D "Ethacrynic acid in acute renal failure." Lancet 1 (1968):  1255|Sullivan RC, Freemon FR, Caranasos GJ "Complications from diuretic therapy with ethacrynic acid and furosemide." South Med J 64 (1971):  869-72|Plumb VJ, James TN "Clinical hazards of powerful diuretics. Furosemide and ethacrynic acid." Mod Concepts Cardiovasc Dis 47 (1978):  91-4|White SJ, Williamson K "What to watch for when you give loop diuretics." RN 42 (1979):  25-7|"Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc  (2001):|Risler T, Schwab A, Kramer B, Braun N, Erley C "Comparative pharmacokinetics and pharmacodynamics of loop diuretics in renal failure." Cardiology 84 (1994):  155-61|Russo D, Minutolo R, Andreucci VE "Role of loop diuretics in chronic renal failure." Cardiology 84 (1994):  162-70', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34193, 15562, 'Bumetanide', 'Kidney Diseases', 'Impaired effectiveness and possible delayed excretion of loop diuretics may occur in patients with severe renal dysfunction.  These individuals may require high dosages that are associated with an increased risk of electrolyte abnormalities (hyponatremia, hypochloremic alkalosis, hypokalemia, hypomagnesemia, hypocalcemia) and ototoxicity (tinnitus, hearing loss).  Therapy with loop diuretics should be administered cautiously in patients with significantly impaired renal function.  Prolongation of the dosing intervals may be appropriate to prevent drug accumulation.  The patient should be monitored closely for the signs and symptoms of fluid or electrolyte imbalance, including dry mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, arrhythmia, or gastrointestinal disturbances such as nausea and vomiting.  Excessive diuresis should be avoided as it may induce dehydration and hypovolemia, which can result in an abrupt reduction in glomerular filtration and renal blood flow.  If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, or if renal function becomes progressively worse as indicated by rising BUN or serum creatinine levels, an interruption or discontinuation of therapy should be considered.', '3', 'Huang CM, Atkinson AJ, Levin M, et al. "Pharmacokinetics of furosemide in advanced renal failure." Clin Pharmacol Ther 16 (1974):  659-66|Cutler RE, Forrey AW, Christopher TG, Kimpel BM "Pharmacokinetics of furosemide in normal subjects and functionally anephric patients." Clin Pharmacol Ther 15 (1974):  588-96|Rose HJ, O''Malley K, Pruitt AW "Depression of renal clearance of furosemide in man by azotemia." Clin Pharmacol Ther 21 (1976):  141-6|Beermann B, Dalen E, Lindstrom B "Elimination of furosemide in healthy subjects and in those with renal failure." Clin Pharmacol Ther 22 (1977):  70-8|Tilstone WJ, Fine A "Furosemide kinetics in renal failure." Clin Pharmacol Ther 23 (1978):  644-50|Rane A, Villeneuve JP, Stone WJ, et al. "Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia." Clin Pharmacol Ther 24 (1978):  199-207|Andreasen F, Hansen HE, Mikkelsen E "Pharmacokinetics of furosemide in anephric patients and in normal subjects." Eur J Clin Pharmacol 13 (1978):  41-8|Keller E, Hoppe-Seyler G, Mumm R, Schollmeyer P "Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide." Eur J Clin Pharmacol 20 (1981):  27-33|Donatucci CF, Deshon GE, Wade CE, Hunt M "Furosemide-induced disturbances of renal function in patients undergoing TURP." Urology 35 (1990):  295-300|Keller E, Hoppe-Seyler G, Schollmeyer P "Disposition and diuretic effect of furosemide in the nephrotic syndrome." Clin Pharmacol Ther 32 (1982):  442-9|Ward A, Heel RC "Bumetanide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use." Drugs 28 (1984):  426-64|Menday AP, Adnitt PI, Underwood PN "Effect of long-term treatment with bumetanide/amiloride on electrolytes and renal function in elderly patients with heart failure." Curr Ther Res Clin Exp 50 (1991):  57-64|Pentikainen PJ, Pasternack A, Lampainen E, Neuvonen PJ, Penttila A "Bumetanide kinetics in renal failure." Clin Pharmacol Ther 37 (1985):  582-8|Marcantonio LA, Auld WH, Murdoch WR, Purohit R, Skellern GG, Howes CA "The pharmacokinetics and pharmacodynamics of the diuretic bumetanide in hepatic and renal disease." Br J Clin Pharmacol 15 (1983):  245-52|Berg KJ, Tromsdal A, Wideroe TE "Diuretic action of bumetanide in advanced chronic renal insufficiency." Eur J Clin Pharmacol 9 (1976):  265-75|Lowenthal DT, Dickerman D "The use of diuretics in varying degrees of renal impairment: an overview." Clin Exp Hypertens A 5 (1983):  297-307|"Product Information. Bumex (bumetanide)." Roche Laboratories  (2002):|"Product Information. Lasix (furosemide)." sanofi-aventis  (2007):|"Product Information. Demadex (torsemide)." Boehringer Mannheim|Matz GJ, Naunton RF "Ototoxic drugs and poor renal function." JAMA 206 (1968):  2119|Pillay VK, Schwartz FD, Aimi K, Kark RM "Transient and permanent deafness following treatment with ethacrynic acid in renal failure." Lancet 1 (1969):  77-9|Kaye M, Dufresne L, McDade D "Ethacrynic acid in acute renal failure." Lancet 1 (1968):  1255|Sullivan RC, Freemon FR, Caranasos GJ "Complications from diuretic therapy with ethacrynic acid and furosemide." South Med J 64 (1971):  869-72|Plumb VJ, James TN "Clinical hazards of powerful diuretics. Furosemide and ethacrynic acid." Mod Concepts Cardiovasc Dis 47 (1978):  91-4|White SJ, Williamson K "What to watch for when you give loop diuretics." RN 42 (1979):  25-7|"Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc  (2001):|Risler T, Schwab A, Kramer B, Braun N, Erley C "Comparative pharmacokinetics and pharmacodynamics of loop diuretics in renal failure." Cardiology 84 (1994):  155-61|Russo D, Minutolo R, Andreucci VE "Role of loop diuretics in chronic renal failure." Cardiology 84 (1994):  162-70', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34194, 18075, 'Bumetanide', 'Kidney Diseases', 'Impaired effectiveness and possible delayed excretion of loop diuretics may occur in patients with severe renal dysfunction.  These individuals may require high dosages that are associated with an increased risk of electrolyte abnormalities (hyponatremia, hypochloremic alkalosis, hypokalemia, hypomagnesemia, hypocalcemia) and ototoxicity (tinnitus, hearing loss).  Therapy with loop diuretics should be administered cautiously in patients with significantly impaired renal function.  Prolongation of the dosing intervals may be appropriate to prevent drug accumulation.  The patient should be monitored closely for the signs and symptoms of fluid or electrolyte imbalance, including dry mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, arrhythmia, or gastrointestinal disturbances such as nausea and vomiting.  Excessive diuresis should be avoided as it may induce dehydration and hypovolemia, which can result in an abrupt reduction in glomerular filtration and renal blood flow.  If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, or if renal function becomes progressively worse as indicated by rising BUN or serum creatinine levels, an interruption or discontinuation of therapy should be considered.', '3', 'Huang CM, Atkinson AJ, Levin M, et al. "Pharmacokinetics of furosemide in advanced renal failure." Clin Pharmacol Ther 16 (1974):  659-66|Cutler RE, Forrey AW, Christopher TG, Kimpel BM "Pharmacokinetics of furosemide in normal subjects and functionally anephric patients." Clin Pharmacol Ther 15 (1974):  588-96|Rose HJ, O''Malley K, Pruitt AW "Depression of renal clearance of furosemide in man by azotemia." Clin Pharmacol Ther 21 (1976):  141-6|Beermann B, Dalen E, Lindstrom B "Elimination of furosemide in healthy subjects and in those with renal failure." Clin Pharmacol Ther 22 (1977):  70-8|Tilstone WJ, Fine A "Furosemide kinetics in renal failure." Clin Pharmacol Ther 23 (1978):  644-50|Rane A, Villeneuve JP, Stone WJ, et al. "Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia." Clin Pharmacol Ther 24 (1978):  199-207|Andreasen F, Hansen HE, Mikkelsen E "Pharmacokinetics of furosemide in anephric patients and in normal subjects." Eur J Clin Pharmacol 13 (1978):  41-8|Keller E, Hoppe-Seyler G, Mumm R, Schollmeyer P "Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide." Eur J Clin Pharmacol 20 (1981):  27-33|Donatucci CF, Deshon GE, Wade CE, Hunt M "Furosemide-induced disturbances of renal function in patients undergoing TURP." Urology 35 (1990):  295-300|Keller E, Hoppe-Seyler G, Schollmeyer P "Disposition and diuretic effect of furosemide in the nephrotic syndrome." Clin Pharmacol Ther 32 (1982):  442-9|Ward A, Heel RC "Bumetanide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use." Drugs 28 (1984):  426-64|Menday AP, Adnitt PI, Underwood PN "Effect of long-term treatment with bumetanide/amiloride on electrolytes and renal function in elderly patients with heart failure." Curr Ther Res Clin Exp 50 (1991):  57-64|Pentikainen PJ, Pasternack A, Lampainen E, Neuvonen PJ, Penttila A "Bumetanide kinetics in renal failure." Clin Pharmacol Ther 37 (1985):  582-8|Marcantonio LA, Auld WH, Murdoch WR, Purohit R, Skellern GG, Howes CA "The pharmacokinetics and pharmacodynamics of the diuretic bumetanide in hepatic and renal disease." Br J Clin Pharmacol 15 (1983):  245-52|Berg KJ, Tromsdal A, Wideroe TE "Diuretic action of bumetanide in advanced chronic renal insufficiency." Eur J Clin Pharmacol 9 (1976):  265-75|Lowenthal DT, Dickerman D "The use of diuretics in varying degrees of renal impairment: an overview." Clin Exp Hypertens A 5 (1983):  297-307|"Product Information. Bumex (bumetanide)." Roche Laboratories  (2002):|"Product Information. Lasix (furosemide)." sanofi-aventis  (2007):|"Product Information. Demadex (torsemide)." Boehringer Mannheim|Matz GJ, Naunton RF "Ototoxic drugs and poor renal function." JAMA 206 (1968):  2119|Pillay VK, Schwartz FD, Aimi K, Kark RM "Transient and permanent deafness following treatment with ethacrynic acid in renal failure." Lancet 1 (1969):  77-9|Kaye M, Dufresne L, McDade D "Ethacrynic acid in acute renal failure." Lancet 1 (1968):  1255|Sullivan RC, Freemon FR, Caranasos GJ "Complications from diuretic therapy with ethacrynic acid and furosemide." South Med J 64 (1971):  869-72|Plumb VJ, James TN "Clinical hazards of powerful diuretics. Furosemide and ethacrynic acid." Mod Concepts Cardiovasc Dis 47 (1978):  91-4|White SJ, Williamson K "What to watch for when you give loop diuretics." RN 42 (1979):  25-7|"Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc  (2001):|Risler T, Schwab A, Kramer B, Braun N, Erley C "Comparative pharmacokinetics and pharmacodynamics of loop diuretics in renal failure." Cardiology 84 (1994):  155-61|Russo D, Minutolo R, Andreucci VE "Role of loop diuretics in chronic renal failure." Cardiology 84 (1994):  162-70', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34195, 2409, 'Bumetanide', 'Diabetes Mellitus', 'Loop diuretics may cause hyperglycemia, glycosuria, and alterations in glucose tolerance tests.  Rarely, precipitation of diabetes mellitus has been reported.  Therapy with loop diuretics should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during therapy, and their antidiabetic regimen adjusted accordingly.', '2', 'Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988):  427-9|Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968):  798-801|Gray GM "Drugs, malnutrition, and carbohydrate absorption." Am J Clin Nutr 26 (1973):  121-4|"Product Information. Bumex (bumetanide)." Roche Laboratories  (2002):|"Product Information. Lasix (furosemide)." sanofi-aventis  (2007):|Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993):  557-9|"Product Information. Demadex (torsemide)." Boehringer Mannheim|Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968):  188|Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974):  85-90|"Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34196, 3997, 'Bumetanide', 'Diabetes Mellitus', 'Loop diuretics may cause hyperglycemia, glycosuria, and alterations in glucose tolerance tests.  Rarely, precipitation of diabetes mellitus has been reported.  Therapy with loop diuretics should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during therapy, and their antidiabetic regimen adjusted accordingly.', '2', 'Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988):  427-9|Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968):  798-801|Gray GM "Drugs, malnutrition, and carbohydrate absorption." Am J Clin Nutr 26 (1973):  121-4|"Product Information. Bumex (bumetanide)." Roche Laboratories  (2002):|"Product Information. Lasix (furosemide)." sanofi-aventis  (2007):|Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993):  557-9|"Product Information. Demadex (torsemide)." Boehringer Mannheim|Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968):  188|Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974):  85-90|"Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34197, 15562, 'Bumetanide', 'Diabetes Mellitus', 'Loop diuretics may cause hyperglycemia, glycosuria, and alterations in glucose tolerance tests.  Rarely, precipitation of diabetes mellitus has been reported.  Therapy with loop diuretics should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during therapy, and their antidiabetic regimen adjusted accordingly.', '2', 'Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988):  427-9|Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968):  798-801|Gray GM "Drugs, malnutrition, and carbohydrate absorption." Am J Clin Nutr 26 (1973):  121-4|"Product Information. Bumex (bumetanide)." Roche Laboratories  (2002):|"Product Information. Lasix (furosemide)." sanofi-aventis  (2007):|Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993):  557-9|"Product Information. Demadex (torsemide)." Boehringer Mannheim|Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968):  188|Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974):  85-90|"Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34198, 18075, 'Bumetanide', 'Diabetes Mellitus', 'Loop diuretics may cause hyperglycemia, glycosuria, and alterations in glucose tolerance tests.  Rarely, precipitation of diabetes mellitus has been reported.  Therapy with loop diuretics should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during therapy, and their antidiabetic regimen adjusted accordingly.', '2', 'Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988):  427-9|Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968):  798-801|Gray GM "Drugs, malnutrition, and carbohydrate absorption." Am J Clin Nutr 26 (1973):  121-4|"Product Information. Bumex (bumetanide)." Roche Laboratories  (2002):|"Product Information. Lasix (furosemide)." sanofi-aventis  (2007):|Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993):  557-9|"Product Information. Demadex (torsemide)." Boehringer Mannheim|Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968):  188|Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974):  85-90|"Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34199, 2409, 'Bumetanide', 'Hyperuricemia', 'Loop diuretics may decrease the rate of uric acid excretion.  Hyperuricemia can occur but is usually asymptomatic and rarely leads to clinical gout except in patients with a history of gout or chronic renal failure.  Therapy with loop diuretics should be administered cautiously in such patients.', '2', '"Product Information. Bumex (bumetanide)." Roche Laboratories  (2002):|"Product Information. Lasix (furosemide)." sanofi-aventis  (2007):|"Product Information. Demadex (torsemide)." Boehringer Mannheim|"Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34200, 3997, 'Bumetanide', 'Hyperuricemia', 'Loop diuretics may decrease the rate of uric acid excretion.  Hyperuricemia can occur but is usually asymptomatic and rarely leads to clinical gout except in patients with a history of gout or chronic renal failure.  Therapy with loop diuretics should be administered cautiously in such patients.', '2', '"Product Information. Bumex (bumetanide)." Roche Laboratories  (2002):|"Product Information. Lasix (furosemide)." sanofi-aventis  (2007):|"Product Information. Demadex (torsemide)." Boehringer Mannheim|"Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34201, 15562, 'Bumetanide', 'Hyperuricemia', 'Loop diuretics may decrease the rate of uric acid excretion.  Hyperuricemia can occur but is usually asymptomatic and rarely leads to clinical gout except in patients with a history of gout or chronic renal failure.  Therapy with loop diuretics should be administered cautiously in such patients.', '2', '"Product Information. Bumex (bumetanide)." Roche Laboratories  (2002):|"Product Information. Lasix (furosemide)." sanofi-aventis  (2007):|"Product Information. Demadex (torsemide)." Boehringer Mannheim|"Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34202, 18075, 'Bumetanide', 'Hyperuricemia', 'Loop diuretics may decrease the rate of uric acid excretion.  Hyperuricemia can occur but is usually asymptomatic and rarely leads to clinical gout except in patients with a history of gout or chronic renal failure.  Therapy with loop diuretics should be administered cautiously in such patients.', '2', '"Product Information. Bumex (bumetanide)." Roche Laboratories  (2002):|"Product Information. Lasix (furosemide)." sanofi-aventis  (2007):|"Product Information. Demadex (torsemide)." Boehringer Mannheim|"Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34203, 1777, 'Bupivacaine (liposome)', 'Cardiovascular Diseases', 'Bupivacaine and other amide- containing products should be used with caution in patients with impaired cardiovascular function, as they may be less able to compensate for functional changes associated with the prolongation of AV conduction produced by these drugs.  Toxic blood concentrations can depress cardiac conductivity and excitability, which can lead to atrioventricular block, ventricular arrhythmias, and cardiac arrest.  In addition, myocardial contractility is depressed and peripheral vasodilation occurs, leading to decreased cardiac output and arterial blood pressure.', '2', '"Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):|"Product Information. Exparel (BUPivacaine liposome)." Pacira Pharmaceuticals Inc  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34204, 1787, 'Bupivacaine (liposome)', 'Cardiovascular Diseases', 'Bupivacaine and other amide- containing products should be used with caution in patients with impaired cardiovascular function, as they may be less able to compensate for functional changes associated with the prolongation of AV conduction produced by these drugs.  Toxic blood concentrations can depress cardiac conductivity and excitability, which can lead to atrioventricular block, ventricular arrhythmias, and cardiac arrest.  In addition, myocardial contractility is depressed and peripheral vasodilation occurs, leading to decreased cardiac output and arterial blood pressure.', '2', '"Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):|"Product Information. Exparel (BUPivacaine liposome)." Pacira Pharmaceuticals Inc  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34205, 7722, 'Bupivacaine (liposome)', 'Cardiovascular Diseases', 'Bupivacaine and other amide- containing products should be used with caution in patients with impaired cardiovascular function, as they may be less able to compensate for functional changes associated with the prolongation of AV conduction produced by these drugs.  Toxic blood concentrations can depress cardiac conductivity and excitability, which can lead to atrioventricular block, ventricular arrhythmias, and cardiac arrest.  In addition, myocardial contractility is depressed and peripheral vasodilation occurs, leading to decreased cardiac output and arterial blood pressure.', '2', '"Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):|"Product Information. Exparel (BUPivacaine liposome)." Pacira Pharmaceuticals Inc  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34206, 22306, 'Bupivacaine (liposome)', 'Cardiovascular Diseases', 'Bupivacaine and other amide- containing products should be used with caution in patients with impaired cardiovascular function, as they may be less able to compensate for functional changes associated with the prolongation of AV conduction produced by these drugs.  Toxic blood concentrations can depress cardiac conductivity and excitability, which can lead to atrioventricular block, ventricular arrhythmias, and cardiac arrest.  In addition, myocardial contractility is depressed and peripheral vasodilation occurs, leading to decreased cardiac output and arterial blood pressure.', '2', '"Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):|"Product Information. Exparel (BUPivacaine liposome)." Pacira Pharmaceuticals Inc  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34207, 27681, 'Bupivacaine (liposome)', 'Cardiovascular Diseases', 'Bupivacaine and other amide- containing products should be used with caution in patients with impaired cardiovascular function, as they may be less able to compensate for functional changes associated with the prolongation of AV conduction produced by these drugs.  Toxic blood concentrations can depress cardiac conductivity and excitability, which can lead to atrioventricular block, ventricular arrhythmias, and cardiac arrest.  In addition, myocardial contractility is depressed and peripheral vasodilation occurs, leading to decreased cardiac output and arterial blood pressure.', '2', '"Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):|"Product Information. Exparel (BUPivacaine liposome)." Pacira Pharmaceuticals Inc  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34208, 27682, 'Bupivacaine (liposome)', 'Cardiovascular Diseases', 'Bupivacaine and other amide- containing products should be used with caution in patients with impaired cardiovascular function, as they may be less able to compensate for functional changes associated with the prolongation of AV conduction produced by these drugs.  Toxic blood concentrations can depress cardiac conductivity and excitability, which can lead to atrioventricular block, ventricular arrhythmias, and cardiac arrest.  In addition, myocardial contractility is depressed and peripheral vasodilation occurs, leading to decreased cardiac output and arterial blood pressure.', '2', '"Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):|"Product Information. Exparel (BUPivacaine liposome)." Pacira Pharmaceuticals Inc  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34209, 29629, 'Bupivacaine (liposome)', 'Cardiovascular Diseases', 'Bupivacaine and other amide- containing products should be used with caution in patients with impaired cardiovascular function, as they may be less able to compensate for functional changes associated with the prolongation of AV conduction produced by these drugs.  Toxic blood concentrations can depress cardiac conductivity and excitability, which can lead to atrioventricular block, ventricular arrhythmias, and cardiac arrest.  In addition, myocardial contractility is depressed and peripheral vasodilation occurs, leading to decreased cardiac output and arterial blood pressure.', '2', '"Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):|"Product Information. Exparel (BUPivacaine liposome)." Pacira Pharmaceuticals Inc  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34210, 1777, 'Bupivacaine (liposome)', 'Liver Diseases', 'Amide-type local anesthetics, such as bupivacaine, are metabolized by the liver.  Bupivacaine should be used cautiously in patients with hepatic disease.  Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations.', '2', '"Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):|"Product Information. Exparel (BUPivacaine liposome)." Pacira Pharmaceuticals Inc  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34211, 1787, 'Bupivacaine (liposome)', 'Liver Diseases', 'Amide-type local anesthetics, such as bupivacaine, are metabolized by the liver.  Bupivacaine should be used cautiously in patients with hepatic disease.  Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations.', '2', '"Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):|"Product Information. Exparel (BUPivacaine liposome)." Pacira Pharmaceuticals Inc  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34212, 7722, 'Bupivacaine (liposome)', 'Liver Diseases', 'Amide-type local anesthetics, such as bupivacaine, are metabolized by the liver.  Bupivacaine should be used cautiously in patients with hepatic disease.  Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations.', '2', '"Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):|"Product Information. Exparel (BUPivacaine liposome)." Pacira Pharmaceuticals Inc  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34213, 22306, 'Bupivacaine (liposome)', 'Liver Diseases', 'Amide-type local anesthetics, such as bupivacaine, are metabolized by the liver.  Bupivacaine should be used cautiously in patients with hepatic disease.  Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations.', '2', '"Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):|"Product Information. Exparel (BUPivacaine liposome)." Pacira Pharmaceuticals Inc  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34214, 27681, 'Bupivacaine (liposome)', 'Liver Diseases', 'Amide-type local anesthetics, such as bupivacaine, are metabolized by the liver.  Bupivacaine should be used cautiously in patients with hepatic disease.  Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations.', '2', '"Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):|"Product Information. Exparel (BUPivacaine liposome)." Pacira Pharmaceuticals Inc  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34215, 27682, 'Bupivacaine (liposome)', 'Liver Diseases', 'Amide-type local anesthetics, such as bupivacaine, are metabolized by the liver.  Bupivacaine should be used cautiously in patients with hepatic disease.  Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations.', '2', '"Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):|"Product Information. Exparel (BUPivacaine liposome)." Pacira Pharmaceuticals Inc  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34216, 29629, 'Bupivacaine (liposome)', 'Liver Diseases', 'Amide-type local anesthetics, such as bupivacaine, are metabolized by the liver.  Bupivacaine should be used cautiously in patients with hepatic disease.  Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations.', '2', '"Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):|"Product Information. Exparel (BUPivacaine liposome)." Pacira Pharmaceuticals Inc  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34217, 1777, 'Bupivacaine (liposome)', 'Kidney Diseases', 'Bupivacaine is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment.', '2', '"Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):|"Product Information. Exparel (BUPivacaine liposome)." Pacira Pharmaceuticals Inc  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34218, 1787, 'Bupivacaine (liposome)', 'Kidney Diseases', 'Bupivacaine is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment.', '2', '"Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):|"Product Information. Exparel (BUPivacaine liposome)." Pacira Pharmaceuticals Inc  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34219, 7722, 'Bupivacaine (liposome)', 'Kidney Diseases', 'Bupivacaine is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment.', '2', '"Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):|"Product Information. Exparel (BUPivacaine liposome)." Pacira Pharmaceuticals Inc  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34220, 22306, 'Bupivacaine (liposome)', 'Kidney Diseases', 'Bupivacaine is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment.', '2', '"Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):|"Product Information. Exparel (BUPivacaine liposome)." Pacira Pharmaceuticals Inc  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34221, 27681, 'Bupivacaine (liposome)', 'Kidney Diseases', 'Bupivacaine is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment.', '2', '"Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):|"Product Information. Exparel (BUPivacaine liposome)." Pacira Pharmaceuticals Inc  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34222, 27682, 'Bupivacaine (liposome)', 'Kidney Diseases', 'Bupivacaine is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment.', '2', '"Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):|"Product Information. Exparel (BUPivacaine liposome)." Pacira Pharmaceuticals Inc  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34223, 29629, 'Bupivacaine (liposome)', 'Kidney Diseases', 'Bupivacaine is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment.', '2', '"Product Information. Marcaine HCl (bupivacaine)." Hospira Inc  (2008):|"Product Information. Exparel (BUPivacaine liposome)." Pacira Pharmaceuticals Inc  (2011):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34224, 0, 'Cabazitaxel', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34225, 0, 'Cabazitaxel', 'Hepatic Insufficiency', 'Cabazitaxel is extensively metabolized in the liver and is contraindicated in patients with severe hepatic impairment.  Caution and close monitoring is recommended when prescribing this agent to patients with mild or moderate hepatic impairment and dosage reduction should be considered for these patients.', '3', '"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34226, 0, 'Cabazitaxel', 'Bone Marrow Failure Disorders', 'The use of cabazitaxel is contraindicated in patients with neutrophils count less than or equal to 1,500/mm3.  The use of cabazitaxel may cause bone marrow suppression manifested as neutropenia, anemia, thrombocytopenia and/or pancytopenia.  Prophylaxis therapy should be considered in patients with high-risk clinical features (age >65 years, poor performance status, previous episodes of febrile neutropenia, extensive prior radiation ports, poor nutritional status, or other serious comorbidities) that predispose them to increased complications from prolonged neutropenia.  Cautions should be exercised in patients using cabazitaxel with hemoglobin counts of less than 10 g/dL.  It is recommended to monitor complete blood counts on a weekly basis during cycle 1 and before each treatment cycle thereafter so that the dose can be adjusted, if needed.', '3', '"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34227, 0, 'Cabazitaxel', 'Renal Insufficiency', 'Renal failure, sometimes with fatal outcomes has been documented with the use of cabazitaxel in clinical studies and most cases have occurred in association with sepsis, dehydration, or obstructive uropathy.  Care and appropriate measures should be taken when prescribing this agent to these patients.', '3', '"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34228, 0, 'Cabazitaxel', 'Gastrointestinal Diseases', 'Gastrointestinal hemorrhage and perforation, ileus, enterocolitis, neutropenic enterocolitis, including fatal outcome, have been reported in patients treated with cabazitaxel.  Risk may be increased with neutropenia, age, steroid use, concomitant use of NSAIDs, anti-platelet therapy or anti-coagulants, and patients with a prior history of pelvic radiotherapy, adhesions, ulceration and GI bleeding.  It is recommended to monitor closely for early manifestations of serious gastrointestinal toxicity and to delay or discontinue treatment if necessary, in particular if patients experience Grade >=3 diarrhea.', '2', '"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34229, 0, 'Cabazitaxel', 'Diseases requiring hemodialysis', 'Cabazitaxel is minimally excreted via the kidney and its use does not require dosage adjustment in patients with renal impairment not requiring hemodialysis.  Patients presenting with end-stage renal disease should be monitored carefully during treatment with cabazitaxel.', '2', '"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34230, 0, 'Cabazitaxel', 'Lung Diseases', 'Interstitial lung disease/pneumonitis and acute respiratory distress syndrome have been reported with the use of cabazitaxel.  Patients with underlying lung disease may be at higher risk for these events.  Acute respiratory distress syndrome may occur in the setting of infection.  Treatment interruption or discontinuation may be necessary if new or worsening of pulmonary symptoms develop.  Close monitoring is recommended.  The benefits of resuming therapy should be carefully evaluated.', '2', '"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34231, 1801, 'Buspirone', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34232, 1804, 'Buspirone', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34233, 1806, 'Buspirone', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34234, 4569, 'Buspirone', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34235, 8750, 'Buspirone', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34236, 14272, 'Buspirone', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34237, 23459, 'Buspirone', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34238, 26849, 'Buspirone', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):|"Product Information. Ambien (zolpidem)." sanofi-aventis  (2001):|"Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical  (2001):|"Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc  (2001):|"Product Information. Equanil (meprobamate)." Wallace Laboratories  (2001):|"Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical  (2001):|"Product Information. Xyrem (sodium oxybate)." Orphan Medical  (2002):|"Product Information. Lunesta (eszopiclone)." Sepracor Inc  (2004):|"Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America  (2005):|"Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals  (2010):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):|"Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc  (2014):|"Product Information. Belsomra (suvorexant)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34239, 1801, 'Buspirone', 'Liver Diseases', 'Buspirone is primarily metabolized by the liver and subsequently eliminated by the kidney.  In one study, steady-state area under the plasma concentration-time curve (AUC) of buspirone increased 13-fold in subjects with hepatic impairment and 4-fold in those with renal impairment compared to healthy subjects.  Therapy with buspirone is not recommended in the presence of significantly impaired hepatic or renal function.', '3', 'Gammans RE, Mayol RF, Labudde JA "Metabolism and disposition of buspirone." Am J Med 80 (1986):  41-51|Dalhoff K, Poulsen HE, Garred P, et al. "Buspirone pharmacokinetics in patients with cirrhosis." Br J Clin Pharmacol 24 (1987):  547-50|Caccia S, Vigano GL, Mingardi G, et al. "Clinical pharmacokinetics of oral buspirone in patients with impaired renal function." Clin Pharmacokinet 14 (1988):  171-7|"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34240, 1804, 'Buspirone', 'Liver Diseases', 'Buspirone is primarily metabolized by the liver and subsequently eliminated by the kidney.  In one study, steady-state area under the plasma concentration-time curve (AUC) of buspirone increased 13-fold in subjects with hepatic impairment and 4-fold in those with renal impairment compared to healthy subjects.  Therapy with buspirone is not recommended in the presence of significantly impaired hepatic or renal function.', '3', 'Gammans RE, Mayol RF, Labudde JA "Metabolism and disposition of buspirone." Am J Med 80 (1986):  41-51|Dalhoff K, Poulsen HE, Garred P, et al. "Buspirone pharmacokinetics in patients with cirrhosis." Br J Clin Pharmacol 24 (1987):  547-50|Caccia S, Vigano GL, Mingardi G, et al. "Clinical pharmacokinetics of oral buspirone in patients with impaired renal function." Clin Pharmacokinet 14 (1988):  171-7|"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34241, 1806, 'Buspirone', 'Liver Diseases', 'Buspirone is primarily metabolized by the liver and subsequently eliminated by the kidney.  In one study, steady-state area under the plasma concentration-time curve (AUC) of buspirone increased 13-fold in subjects with hepatic impairment and 4-fold in those with renal impairment compared to healthy subjects.  Therapy with buspirone is not recommended in the presence of significantly impaired hepatic or renal function.', '3', 'Gammans RE, Mayol RF, Labudde JA "Metabolism and disposition of buspirone." Am J Med 80 (1986):  41-51|Dalhoff K, Poulsen HE, Garred P, et al. "Buspirone pharmacokinetics in patients with cirrhosis." Br J Clin Pharmacol 24 (1987):  547-50|Caccia S, Vigano GL, Mingardi G, et al. "Clinical pharmacokinetics of oral buspirone in patients with impaired renal function." Clin Pharmacokinet 14 (1988):  171-7|"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34242, 4569, 'Buspirone', 'Liver Diseases', 'Buspirone is primarily metabolized by the liver and subsequently eliminated by the kidney.  In one study, steady-state area under the plasma concentration-time curve (AUC) of buspirone increased 13-fold in subjects with hepatic impairment and 4-fold in those with renal impairment compared to healthy subjects.  Therapy with buspirone is not recommended in the presence of significantly impaired hepatic or renal function.', '3', 'Gammans RE, Mayol RF, Labudde JA "Metabolism and disposition of buspirone." Am J Med 80 (1986):  41-51|Dalhoff K, Poulsen HE, Garred P, et al. "Buspirone pharmacokinetics in patients with cirrhosis." Br J Clin Pharmacol 24 (1987):  547-50|Caccia S, Vigano GL, Mingardi G, et al. "Clinical pharmacokinetics of oral buspirone in patients with impaired renal function." Clin Pharmacokinet 14 (1988):  171-7|"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34243, 8750, 'Buspirone', 'Liver Diseases', 'Buspirone is primarily metabolized by the liver and subsequently eliminated by the kidney.  In one study, steady-state area under the plasma concentration-time curve (AUC) of buspirone increased 13-fold in subjects with hepatic impairment and 4-fold in those with renal impairment compared to healthy subjects.  Therapy with buspirone is not recommended in the presence of significantly impaired hepatic or renal function.', '3', 'Gammans RE, Mayol RF, Labudde JA "Metabolism and disposition of buspirone." Am J Med 80 (1986):  41-51|Dalhoff K, Poulsen HE, Garred P, et al. "Buspirone pharmacokinetics in patients with cirrhosis." Br J Clin Pharmacol 24 (1987):  547-50|Caccia S, Vigano GL, Mingardi G, et al. "Clinical pharmacokinetics of oral buspirone in patients with impaired renal function." Clin Pharmacokinet 14 (1988):  171-7|"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34244, 14272, 'Buspirone', 'Liver Diseases', 'Buspirone is primarily metabolized by the liver and subsequently eliminated by the kidney.  In one study, steady-state area under the plasma concentration-time curve (AUC) of buspirone increased 13-fold in subjects with hepatic impairment and 4-fold in those with renal impairment compared to healthy subjects.  Therapy with buspirone is not recommended in the presence of significantly impaired hepatic or renal function.', '3', 'Gammans RE, Mayol RF, Labudde JA "Metabolism and disposition of buspirone." Am J Med 80 (1986):  41-51|Dalhoff K, Poulsen HE, Garred P, et al. "Buspirone pharmacokinetics in patients with cirrhosis." Br J Clin Pharmacol 24 (1987):  547-50|Caccia S, Vigano GL, Mingardi G, et al. "Clinical pharmacokinetics of oral buspirone in patients with impaired renal function." Clin Pharmacokinet 14 (1988):  171-7|"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34245, 23459, 'Buspirone', 'Liver Diseases', 'Buspirone is primarily metabolized by the liver and subsequently eliminated by the kidney.  In one study, steady-state area under the plasma concentration-time curve (AUC) of buspirone increased 13-fold in subjects with hepatic impairment and 4-fold in those with renal impairment compared to healthy subjects.  Therapy with buspirone is not recommended in the presence of significantly impaired hepatic or renal function.', '3', 'Gammans RE, Mayol RF, Labudde JA "Metabolism and disposition of buspirone." Am J Med 80 (1986):  41-51|Dalhoff K, Poulsen HE, Garred P, et al. "Buspirone pharmacokinetics in patients with cirrhosis." Br J Clin Pharmacol 24 (1987):  547-50|Caccia S, Vigano GL, Mingardi G, et al. "Clinical pharmacokinetics of oral buspirone in patients with impaired renal function." Clin Pharmacokinet 14 (1988):  171-7|"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34246, 26849, 'Buspirone', 'Liver Diseases', 'Buspirone is primarily metabolized by the liver and subsequently eliminated by the kidney.  In one study, steady-state area under the plasma concentration-time curve (AUC) of buspirone increased 13-fold in subjects with hepatic impairment and 4-fold in those with renal impairment compared to healthy subjects.  Therapy with buspirone is not recommended in the presence of significantly impaired hepatic or renal function.', '3', 'Gammans RE, Mayol RF, Labudde JA "Metabolism and disposition of buspirone." Am J Med 80 (1986):  41-51|Dalhoff K, Poulsen HE, Garred P, et al. "Buspirone pharmacokinetics in patients with cirrhosis." Br J Clin Pharmacol 24 (1987):  547-50|Caccia S, Vigano GL, Mingardi G, et al. "Clinical pharmacokinetics of oral buspirone in patients with impaired renal function." Clin Pharmacokinet 14 (1988):  171-7|"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34247, 1801, 'Buspirone', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34248, 1804, 'Buspirone', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34249, 1806, 'Buspirone', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34250, 4569, 'Buspirone', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34251, 8750, 'Buspirone', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34252, 14272, 'Buspirone', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34253, 23459, 'Buspirone', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34254, 26849, 'Buspirone', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', '"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34255, 1801, 'Buspirone', 'Substance-Related Disorders', 'In human and animal studies, buspirone has not shown potential for abuse or diversion, and there is no evidence that it causes tolerance or physical and psychological dependence.  However, since it is a CNS-active drug, the manufacturers recommend that therapy with buspirone be administered cautiously in addiction-prone individuals, such as those with a history of alcohol or substance abuse.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '2', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34256, 1804, 'Buspirone', 'Substance-Related Disorders', 'In human and animal studies, buspirone has not shown potential for abuse or diversion, and there is no evidence that it causes tolerance or physical and psychological dependence.  However, since it is a CNS-active drug, the manufacturers recommend that therapy with buspirone be administered cautiously in addiction-prone individuals, such as those with a history of alcohol or substance abuse.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '2', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34257, 1806, 'Buspirone', 'Substance-Related Disorders', 'In human and animal studies, buspirone has not shown potential for abuse or diversion, and there is no evidence that it causes tolerance or physical and psychological dependence.  However, since it is a CNS-active drug, the manufacturers recommend that therapy with buspirone be administered cautiously in addiction-prone individuals, such as those with a history of alcohol or substance abuse.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '2', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34258, 4569, 'Buspirone', 'Substance-Related Disorders', 'In human and animal studies, buspirone has not shown potential for abuse or diversion, and there is no evidence that it causes tolerance or physical and psychological dependence.  However, since it is a CNS-active drug, the manufacturers recommend that therapy with buspirone be administered cautiously in addiction-prone individuals, such as those with a history of alcohol or substance abuse.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '2', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34259, 8750, 'Buspirone', 'Substance-Related Disorders', 'In human and animal studies, buspirone has not shown potential for abuse or diversion, and there is no evidence that it causes tolerance or physical and psychological dependence.  However, since it is a CNS-active drug, the manufacturers recommend that therapy with buspirone be administered cautiously in addiction-prone individuals, such as those with a history of alcohol or substance abuse.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '2', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34260, 14272, 'Buspirone', 'Substance-Related Disorders', 'In human and animal studies, buspirone has not shown potential for abuse or diversion, and there is no evidence that it causes tolerance or physical and psychological dependence.  However, since it is a CNS-active drug, the manufacturers recommend that therapy with buspirone be administered cautiously in addiction-prone individuals, such as those with a history of alcohol or substance abuse.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '2', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34261, 23459, 'Buspirone', 'Substance-Related Disorders', 'In human and animal studies, buspirone has not shown potential for abuse or diversion, and there is no evidence that it causes tolerance or physical and psychological dependence.  However, since it is a CNS-active drug, the manufacturers recommend that therapy with buspirone be administered cautiously in addiction-prone individuals, such as those with a history of alcohol or substance abuse.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '2', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34262, 26849, 'Buspirone', 'Substance-Related Disorders', 'In human and animal studies, buspirone has not shown potential for abuse or diversion, and there is no evidence that it causes tolerance or physical and psychological dependence.  However, since it is a CNS-active drug, the manufacturers recommend that therapy with buspirone be administered cautiously in addiction-prone individuals, such as those with a history of alcohol or substance abuse.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '2', '"Product Information. Buspar (buspirone)." Bristol-Myers Squibb  (2002):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34263, 0, 'Cabozantinib', 'Hemorrhage', 'Fatal hemorrhagic events have been reported with the use of cabozantinib.  Therapy with cabozantinib is not recommended in patients that have or are at risk for severe hemorrhage.', '3', '"Product Information. Cometriq (cabozantinib)." Exelixis Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34264, 0, 'Cabozantinib', 'Peptic Ulcer Perforation', 'Therapy with cabozantinib should be used with caution in patients who may be at increased risk for gastrointestinal perforation, such as those with a history of diverticulitis.  Patients presenting with new onset of abdominal symptoms should be evaluated promptly for early identification of gastrointestinal perforation.  It is recommended to monitor for symptoms of gastrointestinal perforation or fistula periodically throughout the treatment.  Discontinue cabozantinib in patients who experience a fistula which cannot be appropriately managed or a GI perforation.', '2', '"Product Information. Cometriq (cabozantinib)." Exelixis Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34265, 0, 'Cabozantinib', 'Hepatic Insufficiency', 'Increased exposure to cabozantinib has been observed in patients with mild to moderate hepatic impairment.  It is recommended to reduce the cabozantinib dose in patients with mild or moderate hepatic impairment.  The use of cabozantinib is not recommended in patients with severe hepatic impairment.  It is recommended to monitor liver function and urine bilirubin tests periodically during therapy.', '2', '"Product Information. Cometriq (cabozantinib)." Exelixis Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34266, 0, 'Cabozantinib', 'Hypertension', 'The use of cabozantinib causes hypertension.  Blood pressure should be well-controlled prior to initiating cabozantinib and monitored and treated as needed with standard anti-hypertensive therapy.  It is recommended to reduce the dose in case of persistent hypertension despite use of anti-hypertensive medications and to discontinue therapy if hypertension is severe and persistent despite these measures.  Discontinue cabozantinib therapy for severe hypertension that cannot be controlled with anti-hypertensive therapy and if there is evidence of hypertensive crisis or severe hypertension despite optimal medical management.  Close monitoring is recommended.', '2', '"Product Information. Cometriq (cabozantinib)." Exelixis Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34267, 0, 'Cabozantinib', 'Kidney Diseases', 'No dose adjustment is required in patients with mild or moderate renal impairment.  There is no experience with cabozantinib in patients with severe renal impairment.  Care should be exercised in these patients.', '2', '"Product Information. Cometriq (cabozantinib)." Exelixis Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34268, 0, 'Cabozantinib', 'Posterior Leukoencephalopathy Syndrome', 'Reversible posterior leukoencephalopathy syndrome (RPLS) has been reported in patients receiving cabozantinib.  It is recommended to discontinue therapy in patients developing RPLS.  The safety of reinitiating therapy in patients previously experiencing RPLS is not known.  Care and close monitoring should be considered in these patients.', '2', '"Product Information. Cometriq (cabozantinib)." Exelixis Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34269, 0, 'Cabozantinib', 'Thromboembolism', 'Arterial and venous thromboembolic events have been reported with the use of cabozantinib.  Use with caution in patients who are at risk, or have a history of these events.  It is recommended to monitor closely for signs and symptoms of thromboembolism.  Discontinue cabozantinib in patients who develop an acute myocardial infarction or any other arterial thromboembolic complication.', '2', '"Product Information. Cometriq (cabozantinib)." Exelixis Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34270, 0, 'Cabozantinib', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', '"Product Information. Vandetanib (vandetanib)." Astra-Zeneca Pharmaceuticals  (2011):|"Product Information. Zelboraf (vemurafenib)." Genentech  (2011):|"Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group  (2011):|"Product Information. Mekinist (trametinib)." GlaxoSmithKline  (2013):|"Product Information. Zykadia (ceritinib)." Novartis Pharmaceuticals  (2014):|"Product Information. Zydelig (idelalisib)." Gilead Sciences  (2014):|"Product Information. Alecensa (alectinib)." Genentech  (2015):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34271, 0, 'Butabarbital', 'Alcoholic Intoxication', 'The use of barbiturates is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of barbiturates may be additive with those of alcohol.  Severe respiratory depression and death may occur.  Therapy with barbiturates should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', 'Plaa GL "Acute toxicity of antiepileptic drugs." Epilepsia 16 (1975):  183-91|"Product Information. Phenobarbital (phenobarbital)." Lilly, Eli and Company  (2001):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Amytal Sodium (amobarbital)." Lilly, Eli and Company  (2001):|"Product Information. Nembutal Sodium (pentobarbital)." Abbott Pharmaceutical  (2001):|"Product Information. Seconal Sodium (secobarbital)." Lilly, Eli and Company  (2001):|"Product Information. Mebaral (mephobarbital)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Butisol Sodium (butabarbital)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34272, 0, 'Butabarbital', 'Substance-Related Disorders', 'Barbiturates have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages.  Abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms.  In patients who have developed tolerance to a barbiturate, overdosage can still produce respiratory depression and death, and cross-tolerance usually will occur with other agents in the class.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with barbiturates.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of barbiturates should be undertaken gradually using a dosage-tapering schedule.', '3', 'Boisse NR, Okamoto M "Physical dependence to barbital compared to pentobarbital. II. Tolerance characteristics." J Pharmacol Exp Ther 204 (1978):  507-13|Gersema LM, Alexander B, Kunze KE "Major withdrawal symptoms after abrupt discontinuation of phenobarbital." Clin Pharm 6 (1987):  420-2|"Product Information. Phenobarbital (phenobarbital)." Lilly, Eli and Company  (2001):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Amytal Sodium (amobarbital)." Lilly, Eli and Company  (2001):|"Product Information. Nembutal Sodium (pentobarbital)." Abbott Pharmaceutical  (2001):|"Product Information. Seconal Sodium (secobarbital)." Lilly, Eli and Company  (2001):|"Product Information. Mebaral (mephobarbital)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Butisol Sodium (butabarbital)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34273, 0, 'Butabarbital', 'Liver Diseases', 'Barbiturates are extensively metabolized by the liver.  The plasma clearance of barbiturates may be decreased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with barbiturates should be administered cautiously and initiated at reduced dosages in patients with liver disease.  Barbiturates are not recommended for use in patients with cirrhosis, hepatic failure, hepatic coma, or other severe hepatic impairment.', '3', 'Alvin J, McHorse T, Hoyumpa A, et al. "The effect of liver disease in man on the disposition of phenobarbital." J Pharmacol Exp Ther 192 (1975):  224-35|Kallberg N, Agurell S, Ericsson O, et al. "Quantitation of phenobarbital and its main metabolites in human urine." Eur J Clin Pharmacol 9 (1975):  161-8|Whyte MP, Dekaban "Metabolic fate of phenobarbital: a quantitative study of p-hydroxyphenobarbital elimination in man." Drug Metab Dispos 5 (1977):  63-9|"Product Information. Phenobarbital (phenobarbital)." Lilly, Eli and Company  (2001):|"Product Information. Amytal Sodium (amobarbital)." Lilly, Eli and Company  (2001):|"Product Information. Nembutal Sodium (pentobarbital)." Abbott Pharmaceutical  (2001):|"Product Information. Seconal Sodium (secobarbital)." Lilly, Eli and Company  (2001):|"Product Information. Mebaral (mephobarbital)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Butisol Sodium (butabarbital)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34274, 0, 'Butabarbital', 'Porphyrias', 'The use of barbiturates is contraindicated in patients with a history of porphyria.  Barbiturates may exacerbate acute intermittent porphyria or porphyria variegata by inducing the enzymes responsible for porphyrin synthesis.', '3', '"Product Information. Phenobarbital (phenobarbital)." Lilly, Eli and Company  (2001):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Amytal Sodium (amobarbital)." Lilly, Eli and Company  (2001):|"Product Information. Nembutal Sodium (pentobarbital)." Abbott Pharmaceutical  (2001):|"Product Information. Seconal Sodium (secobarbital)." Lilly, Eli and Company  (2001):|"Product Information. Mebaral (mephobarbital)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Butisol Sodium (butabarbital)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34275, 0, 'Butabarbital', 'Exanthema', 'Skin eruptions may precede rare but potentially fatal barbiturate-induced reactions such as systemic lupus erythematosus and exfoliative dermatitis, the latter of which may be accompanied by hepatitis and jaundice.  Therapy with barbiturates should be administered cautiously in patients with preexisting drug-induced dermatitis, since it may delay the recognition of a potential reaction to barbiturates.  Barbiturate therapy should be withdrawn promptly at the first sign of a dermatologic adverse effect.  However, cutaneous reactions may proceed to an irreversible stage even after cessation of medication due to the slow rate of metabolism and excretion of barbiturates.  Patients should be advised to promptly report signs that may indicate impending development of barbiturate-related cutaneous lesions, including high fever, severe headache, stomatitis, conjunctivitis, rhinitis, urethritis, and balanitis.  Rashes may be more likely to occur with phenobarbital and mephobarbital.', '3', 'Pelekanos J, Camfield P, Camfield C, Gordon K "Allergic rash due to antiepileptic drugs: clinical features and management." Epilepsia 32 (1991):  554-9|Pagliaro L, Campesi G, Aguglia F "Barbiturate jaundice. Report of a case due to a barbital-containing drug, with positive rechallenge to phenobarbital." Gastroenterology 56 (1969):  938-43|Shear NH, Spielberg SP "Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk." J Clin Invest 82 (1988):  1826-32|Stuttgen G "Toxic epidermal necrolysis provoked by barbiturates." Br J Dermatol 88 (1973):  291-3|Fernandez de Corres L, Leanizbarrutia I, Munoz D "Eczematous drug reaction from phenobarbitone." Contact Dermatitis 11 (1984):  319|Dourmishev AL, Rahman MA "Phenobarbital-induced pemphigus vulgaris." Dermatologica 173 (1986):  256-8|"Product Information. Phenobarbital (phenobarbital)." Lilly, Eli and Company  (2001):|"Product Information. Amytal Sodium (amobarbital)." Lilly, Eli and Company  (2001):|"Product Information. Nembutal Sodium (pentobarbital)." Abbott Pharmaceutical  (2001):|"Product Information. Seconal Sodium (secobarbital)." Lilly, Eli and Company  (2001):|"Product Information. Mebaral (mephobarbital)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Butisol Sodium (butabarbital)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34276, 0, 'Butabarbital', 'Respiratory Insufficiency', 'Barbiturates may produce severe respiratory depression, apnea, laryngospasm, bronchospasm and cough, particularly during rapid intravenous administration.  In usual hypnotic dosages, the degree of respiratory depression produced is similar to that which occurs during physiologic sleep, while at higher dosages, the rate, depth and volume of respiration may be markedly decreased.  However, some patients may be susceptible at commonly used dosages, including the elderly, debilitated or severely ill patients, those receiving other CNS depressants, and those with limited ventilatory reserve, chronic pulmonary insufficiency or other respiratory disorders.  Therapy with barbiturates should be administered cautiously in these patients.  Appropriate monitoring and individualization of dosage are particularly important, and equipment for resuscitation should be immediately available if the parenteral route is used.  Barbiturates, especially injectable formulations, should generally be avoided in patients with sleep apnea, hypoxia, or severe pulmonary diseases in which dyspnea or obstruction is evident.', '3', 'Plaa GL "Acute toxicity of antiepileptic drugs." Epilepsia 16 (1975):  183-91|Lund A, Gormsen H "The role of antiepileptics in sudden death in epilepsy." Acta Neurol Scand 72 (1985):  444-6|"Product Information. Phenobarbital (phenobarbital)." Lilly, Eli and Company  (2001):|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Amytal Sodium (amobarbital)." Lilly, Eli and Company  (2001):|"Product Information. Nembutal Sodium (pentobarbital)." Abbott Pharmaceutical  (2001):|"Product Information. Seconal Sodium (secobarbital)." Lilly, Eli and Company  (2001):|"Product Information. Mebaral (mephobarbital)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Butisol Sodium (butabarbital)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34277, 0, 'Butabarbital', 'Adrenal Insufficiency', 'Barbiturates, especially phenobarbital, secobarbital and butabarbital, may diminish the systemic effects of exogenous and endogenous corticosteroids via induction of hepatic microsomal enzymes, thereby accelerating the metabolism of corticosteroids.  In addition, barbiturates may interfere with pituitary corticotropin production.  Therapy with barbiturates should be administered cautiously in patients with adrenal insufficiency.  Patients with borderline hypoadrenalism should be monitored closely, and patients receiving steroid supplementation may require an adjustment in dosage when barbiturates are added to or withdrawn from their medication regimen.', '2', '"Product Information. Phenobarbital (phenobarbital)." Lilly, Eli and Company  (2001):|"Product Information. Amytal Sodium (amobarbital)." Lilly, Eli and Company  (2001):|"Product Information. Nembutal Sodium (pentobarbital)." Abbott Pharmaceutical  (2001):|"Product Information. Seconal Sodium (secobarbital)." Lilly, Eli and Company  (2001):|"Product Information. Mebaral (mephobarbital)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Butisol Sodium (butabarbital)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34278, 0, 'Butabarbital', 'Depressive Disorder', 'Barbiturates depress the central nervous system and may cause or exacerbate mental depression.  Therapy with barbiturates should be administered cautiously in patients with a history of depression or suicidal tendencies.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '2', '"Product Information. Phenobarbital (phenobarbital)." Lilly, Eli and Company  (2001):|"Multum Information Services, Inc. Expert Review Panel"|"Product Information. Amytal Sodium (amobarbital)." Lilly, Eli and Company  (2001):|"Product Information. Nembutal Sodium (pentobarbital)." Abbott Pharmaceutical  (2001):|"Product Information. Seconal Sodium (secobarbital)." Lilly, Eli and Company  (2001):|"Product Information. Mebaral (mephobarbital)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Butisol Sodium (butabarbital)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34279, 0, 'Butabarbital', 'Hematologic Diseases', 'Hematologic toxicity, including agranulocytosis, thrombocytopenic purpura and megaloblastic anemia, has been reported rarely during use of barbiturates.  Therapy with barbiturates should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression.  Blood counts are recommended prior to and periodically during long-term therapy, and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, easy bruising, petechiae, bleeding, pallor, dizziness, or jaundice.  Barbiturate therapy should be discontinued if blood dyscrasias occur.', '2', 'Van Hoof A, Chamone DA, Vermylen J "Platelet aggregation and anaesthesia." Lancet 2 (1980):  373|Kiorboe E, Plum CM "Megaloblastic anaemia developing during treatment of epilepsy." Acta Med Scand Suppl 445 (1966):  349-57|Iivanainen M, Savolainen H "Side effects of phenobarbital and phenytoin during long-term treatment of epilepsy." Acta Neurol Scand Suppl 97 (1983):  49-67|"Product Information. Phenobarbital (phenobarbital)." Lilly, Eli and Company  (2001):|"Product Information. Amytal Sodium (amobarbital)." Lilly, Eli and Company  (2001):|"Product Information. Nembutal Sodium (pentobarbital)." Abbott Pharmaceutical  (2001):|"Product Information. Seconal Sodium (secobarbital)." Lilly, Eli and Company  (2001):|"Product Information. Mebaral (mephobarbital)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Butisol Sodium (butabarbital)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34280, 0, 'Butabarbital', 'Osteomalacia', 'Rickets and osteomalacia have rarely been reported following prolonged use of barbiturates, possibly due to increased metabolism of vitamin D as a result of enzyme induction by barbiturates.  Long-term therapy with barbiturates should be administered cautiously in patients with vitamin D deficiency.', '2', 'Sotaniemi EA, Hakkarainen HK, Puranen JA, Lahti RO "Radiologic bone changes and hypocalcemia with anticonvulsant therapy in epilepsy." Ann Intern Med 77 (1972):  389-94|Zerwekh JE, Homan R, Tindall R, Pak CY "Decreased serum 24,25-dihydroxyvitamin D concentration during long- term anticonvulsant therapy in adult epileptics." Ann Neurol 12 (1982):  184-6|Marsden CD, Reynolds EH, Parsons V, Harris R, Duchen L "Myopathy associated with anticonvulsant osteomalacia." Br Med J 4 (1973):  526-7|Iivanainen M, Savolainen H "Side effects of phenobarbital and phenytoin during long-term treatment of epilepsy." Acta Neurol Scand Suppl 97 (1983):  49-67|Doriguzzi C, Mongini T, Jeantet A, Monga G "Tubular aggregates in a case of osteomalacic myopathy due to anticonvulsant drugs." Clin Neuropathol 3 (1984):  42-5|"Product Information. Phenobarbital (phenobarbital)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34281, 0, 'Butabarbital', 'Psychotic Disorders', 'Paradoxical reactions characterized by excitability and restlessness may occur in pediatric patients with hyperactive aggressive disorders.  Such patients should be monitored for signs of paradoxical stimulation during therapy with barbiturates.', '2', 'Mayhew LA, Hanzel TE, Ferron FR, Kalachnik JE, Harder SR "Phenobarbital exacerbation of self-injurious behavior." J Nerv Ment Dis 180 (1992):  732-3|"Product Information. Phenobarbital (phenobarbital)." Lilly, Eli and Company  (2001):|Sylvester CE, Marchlewski A, Manaligod JM "Primidone or phenobarbital use complicating disruptive behavior disorders." Clin Pediatr (Phila) 33 (1994):  252-3|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Amytal Sodium (amobarbital)." Lilly, Eli and Company  (2001):|"Product Information. Nembutal Sodium (pentobarbital)." Abbott Pharmaceutical  (2001):|"Product Information. Seconal Sodium (secobarbital)." Lilly, Eli and Company  (2001):|"Product Information. Mebaral (mephobarbital)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Butisol Sodium (butabarbital)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34282, 12548, 'Bupropion', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34283, 13290, 'Bupropion', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34284, 19459, 'Bupropion', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34285, 29640, 'Bupropion', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34286, 29641, 'Bupropion', 'Depressive Disorder', 'Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials; these trials did not show increased risk in patients older than 24 years and risk was reduced in patients 65 years and older.  Adult and pediatric patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressants; this risk may persist until significant remission occurs.  Suicide is a known risk of depression and certain other psychiatric disorders; such disorders are the strongest predictors of suicide.  Patients of all ages treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of drug therapy, and at times of dose changes.  Family members/caregivers should be advised to monitor for changes in behavior and to notify the health care provider.  Changing the therapeutic regimen (including discontinuing the medication) should be considered in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Abilify (ARIPiprazole)." Otsuka American Pharmaceuticals Inc  (2020):|"Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc  (2021):|"Product Information. Vraylar (cariprazine)." Allergan Inc  (2019):|"Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc  (2019):|"Product Information. Seroquel (QUEtiapine)." Astra-Zeneca Pharmaceuticals  (2022):|"Product Information. Viibryd (vilazodone)." Allergan, Inc. USA  (2021):|"Product Information. Trintellix (vortioxetine)." Takeda Pharmaceuticals America  (2021):|"Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc.  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34287, 12548, 'Bupropion', 'Epilepsy', 'Bupropion is contraindicated in patients with a seizure disorder.  Bupropion can cause seizure; the risk is dose-related.  In 1 study, the seizure incidence was about 0.4% with immediate-release bupropion hydrochloride (HCl) in the range of 300 to 450 mg/day (equal to 348 to 522 mg/day of extended-release bupropion hydrobromide [HBr]); the incidence of seizures increases dramatically at higher dosages (almost 10-fold between 450 and 600 mg/day as bupropion HCl [equal to 522 and 696 mg/day as bupropion HBr]).  The risk of seizures (related to patient factors, clinical situations, and concomitant medications that lower the seizure threshold) should be considered before starting bupropion.  Bupropion is also contraindicated in patients with current/prior diagnosis of bulimia or anorexia nervosa (a higher incidence of seizures was observed in such patients treated with immediate-release bupropion) and in patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs.  Bupropion should be administered with caution in patients with conditions that increase the risk of seizure or who have other predisposing conditions including severe head injury; arteriovenous malformation; CNS infection or CNS tumor; severe stroke; metabolic disorders (e.g., hypoglycemia, hyponatremia, severe hepatic impairment, hypoxia); excessive use of alcohol, benzodiazepines, sedative/hypnotics, or opiates; use of illicit drugs (e.g., cocaine); abuse/misuse of prescription drugs (e.g., CNS stimulants); diabetes mellitus treated with oral hypoglycemic agents or insulin; use of anorectic agents; and concomitant use of medications that lower the seizure threshold.  The risk of seizure can be reduced if the maximum recommended dosage is not exceeded (e.g., 450 mg/day [as 150 mg 3 times a day] for immediate-release bupropion HCl; 400 mg/day [as 200 mg twice a day] for sustained-release bupropion HCl; 450 mg once a day for extended-release bupropion HCl; 522 mg once a day for extended-release bupropion HBr), and the titration rate is gradual.  Bupropion should be discontinued and should not be restarted if the patient has a seizure.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34288, 13290, 'Bupropion', 'Epilepsy', 'Bupropion is contraindicated in patients with a seizure disorder.  Bupropion can cause seizure; the risk is dose-related.  In 1 study, the seizure incidence was about 0.4% with immediate-release bupropion hydrochloride (HCl) in the range of 300 to 450 mg/day (equal to 348 to 522 mg/day of extended-release bupropion hydrobromide [HBr]); the incidence of seizures increases dramatically at higher dosages (almost 10-fold between 450 and 600 mg/day as bupropion HCl [equal to 522 and 696 mg/day as bupropion HBr]).  The risk of seizures (related to patient factors, clinical situations, and concomitant medications that lower the seizure threshold) should be considered before starting bupropion.  Bupropion is also contraindicated in patients with current/prior diagnosis of bulimia or anorexia nervosa (a higher incidence of seizures was observed in such patients treated with immediate-release bupropion) and in patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs.  Bupropion should be administered with caution in patients with conditions that increase the risk of seizure or who have other predisposing conditions including severe head injury; arteriovenous malformation; CNS infection or CNS tumor; severe stroke; metabolic disorders (e.g., hypoglycemia, hyponatremia, severe hepatic impairment, hypoxia); excessive use of alcohol, benzodiazepines, sedative/hypnotics, or opiates; use of illicit drugs (e.g., cocaine); abuse/misuse of prescription drugs (e.g., CNS stimulants); diabetes mellitus treated with oral hypoglycemic agents or insulin; use of anorectic agents; and concomitant use of medications that lower the seizure threshold.  The risk of seizure can be reduced if the maximum recommended dosage is not exceeded (e.g., 450 mg/day [as 150 mg 3 times a day] for immediate-release bupropion HCl; 400 mg/day [as 200 mg twice a day] for sustained-release bupropion HCl; 450 mg once a day for extended-release bupropion HCl; 522 mg once a day for extended-release bupropion HBr), and the titration rate is gradual.  Bupropion should be discontinued and should not be restarted if the patient has a seizure.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34289, 19459, 'Bupropion', 'Epilepsy', 'Bupropion is contraindicated in patients with a seizure disorder.  Bupropion can cause seizure; the risk is dose-related.  In 1 study, the seizure incidence was about 0.4% with immediate-release bupropion hydrochloride (HCl) in the range of 300 to 450 mg/day (equal to 348 to 522 mg/day of extended-release bupropion hydrobromide [HBr]); the incidence of seizures increases dramatically at higher dosages (almost 10-fold between 450 and 600 mg/day as bupropion HCl [equal to 522 and 696 mg/day as bupropion HBr]).  The risk of seizures (related to patient factors, clinical situations, and concomitant medications that lower the seizure threshold) should be considered before starting bupropion.  Bupropion is also contraindicated in patients with current/prior diagnosis of bulimia or anorexia nervosa (a higher incidence of seizures was observed in such patients treated with immediate-release bupropion) and in patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs.  Bupropion should be administered with caution in patients with conditions that increase the risk of seizure or who have other predisposing conditions including severe head injury; arteriovenous malformation; CNS infection or CNS tumor; severe stroke; metabolic disorders (e.g., hypoglycemia, hyponatremia, severe hepatic impairment, hypoxia); excessive use of alcohol, benzodiazepines, sedative/hypnotics, or opiates; use of illicit drugs (e.g., cocaine); abuse/misuse of prescription drugs (e.g., CNS stimulants); diabetes mellitus treated with oral hypoglycemic agents or insulin; use of anorectic agents; and concomitant use of medications that lower the seizure threshold.  The risk of seizure can be reduced if the maximum recommended dosage is not exceeded (e.g., 450 mg/day [as 150 mg 3 times a day] for immediate-release bupropion HCl; 400 mg/day [as 200 mg twice a day] for sustained-release bupropion HCl; 450 mg once a day for extended-release bupropion HCl; 522 mg once a day for extended-release bupropion HBr), and the titration rate is gradual.  Bupropion should be discontinued and should not be restarted if the patient has a seizure.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34290, 29640, 'Bupropion', 'Epilepsy', 'Bupropion is contraindicated in patients with a seizure disorder.  Bupropion can cause seizure; the risk is dose-related.  In 1 study, the seizure incidence was about 0.4% with immediate-release bupropion hydrochloride (HCl) in the range of 300 to 450 mg/day (equal to 348 to 522 mg/day of extended-release bupropion hydrobromide [HBr]); the incidence of seizures increases dramatically at higher dosages (almost 10-fold between 450 and 600 mg/day as bupropion HCl [equal to 522 and 696 mg/day as bupropion HBr]).  The risk of seizures (related to patient factors, clinical situations, and concomitant medications that lower the seizure threshold) should be considered before starting bupropion.  Bupropion is also contraindicated in patients with current/prior diagnosis of bulimia or anorexia nervosa (a higher incidence of seizures was observed in such patients treated with immediate-release bupropion) and in patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs.  Bupropion should be administered with caution in patients with conditions that increase the risk of seizure or who have other predisposing conditions including severe head injury; arteriovenous malformation; CNS infection or CNS tumor; severe stroke; metabolic disorders (e.g., hypoglycemia, hyponatremia, severe hepatic impairment, hypoxia); excessive use of alcohol, benzodiazepines, sedative/hypnotics, or opiates; use of illicit drugs (e.g., cocaine); abuse/misuse of prescription drugs (e.g., CNS stimulants); diabetes mellitus treated with oral hypoglycemic agents or insulin; use of anorectic agents; and concomitant use of medications that lower the seizure threshold.  The risk of seizure can be reduced if the maximum recommended dosage is not exceeded (e.g., 450 mg/day [as 150 mg 3 times a day] for immediate-release bupropion HCl; 400 mg/day [as 200 mg twice a day] for sustained-release bupropion HCl; 450 mg once a day for extended-release bupropion HCl; 522 mg once a day for extended-release bupropion HBr), and the titration rate is gradual.  Bupropion should be discontinued and should not be restarted if the patient has a seizure.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34291, 29641, 'Bupropion', 'Epilepsy', 'Bupropion is contraindicated in patients with a seizure disorder.  Bupropion can cause seizure; the risk is dose-related.  In 1 study, the seizure incidence was about 0.4% with immediate-release bupropion hydrochloride (HCl) in the range of 300 to 450 mg/day (equal to 348 to 522 mg/day of extended-release bupropion hydrobromide [HBr]); the incidence of seizures increases dramatically at higher dosages (almost 10-fold between 450 and 600 mg/day as bupropion HCl [equal to 522 and 696 mg/day as bupropion HBr]).  The risk of seizures (related to patient factors, clinical situations, and concomitant medications that lower the seizure threshold) should be considered before starting bupropion.  Bupropion is also contraindicated in patients with current/prior diagnosis of bulimia or anorexia nervosa (a higher incidence of seizures was observed in such patients treated with immediate-release bupropion) and in patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs.  Bupropion should be administered with caution in patients with conditions that increase the risk of seizure or who have other predisposing conditions including severe head injury; arteriovenous malformation; CNS infection or CNS tumor; severe stroke; metabolic disorders (e.g., hypoglycemia, hyponatremia, severe hepatic impairment, hypoxia); excessive use of alcohol, benzodiazepines, sedative/hypnotics, or opiates; use of illicit drugs (e.g., cocaine); abuse/misuse of prescription drugs (e.g., CNS stimulants); diabetes mellitus treated with oral hypoglycemic agents or insulin; use of anorectic agents; and concomitant use of medications that lower the seizure threshold.  The risk of seizure can be reduced if the maximum recommended dosage is not exceeded (e.g., 450 mg/day [as 150 mg 3 times a day] for immediate-release bupropion HCl; 400 mg/day [as 200 mg twice a day] for sustained-release bupropion HCl; 450 mg once a day for extended-release bupropion HCl; 522 mg once a day for extended-release bupropion HBr), and the titration rate is gradual.  Bupropion should be discontinued and should not be restarted if the patient has a seizure.', '3', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34292, 12548, 'Bupropion', 'Glaucoma, Angle-Closure', 'The pupillary dilation that occurs after use of many antidepressant drugs (including bupropion) can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Patients may want to be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of antidepressants (including bupropion-dextromethorphan) should be avoided in patients with untreated anatomically narrow angles.', '2', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34293, 13290, 'Bupropion', 'Glaucoma, Angle-Closure', 'The pupillary dilation that occurs after use of many antidepressant drugs (including bupropion) can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Patients may want to be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of antidepressants (including bupropion-dextromethorphan) should be avoided in patients with untreated anatomically narrow angles.', '2', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34294, 19459, 'Bupropion', 'Glaucoma, Angle-Closure', 'The pupillary dilation that occurs after use of many antidepressant drugs (including bupropion) can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Patients may want to be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of antidepressants (including bupropion-dextromethorphan) should be avoided in patients with untreated anatomically narrow angles.', '2', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34295, 29640, 'Bupropion', 'Glaucoma, Angle-Closure', 'The pupillary dilation that occurs after use of many antidepressant drugs (including bupropion) can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Patients may want to be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of antidepressants (including bupropion-dextromethorphan) should be avoided in patients with untreated anatomically narrow angles.', '2', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34296, 29641, 'Bupropion', 'Glaucoma, Angle-Closure', 'The pupillary dilation that occurs after use of many antidepressant drugs (including bupropion) can induce increased intraocular pressure and result in angle-closure (narrow-angle) glaucoma in a patient with anatomically narrow angles who does not have a patent iridectomy.  Patients may want to be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.  The use of antidepressants (including bupropion-dextromethorphan) should be avoided in patients with untreated anatomically narrow angles.', '2', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34297, 12548, 'Bupropion', 'Liver Diseases', 'Bupropion is primarily metabolized by the liver.  The systemic exposure and half-life of bupropion and its metabolites may be increased in patients with liver dysfunction.  A reduced dose and/or dosing frequency should be considered in patients with mild liver dysfunction (Child-Pugh score:  5 to 6).  A dosage reduction is required in patients with moderate to severe liver dysfunction (Child-Pugh score:  7 to 15) who are using a single-ingredient bupropion product; the dosage should not exceed 75 mg/day with immediate-release bupropion hydrochloride (HCl), 100 mg/day or 150 mg every other day with sustained-release bupropion HCl, 150 mg every other day with extended-release bupropion HCl, and 174 mg every other day with extended-release bupropion hydrobromide.  Bupropion-dextromethorphan is not recommended for patients with severe liver dysfunction (Child-Pugh C), and no dose adjustment of bupropion-dextromethorphan is recommended in patients with mild or moderate liver dysfunction (Child-Pugh A or B).', '2', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34298, 13290, 'Bupropion', 'Liver Diseases', 'Bupropion is primarily metabolized by the liver.  The systemic exposure and half-life of bupropion and its metabolites may be increased in patients with liver dysfunction.  A reduced dose and/or dosing frequency should be considered in patients with mild liver dysfunction (Child-Pugh score:  5 to 6).  A dosage reduction is required in patients with moderate to severe liver dysfunction (Child-Pugh score:  7 to 15) who are using a single-ingredient bupropion product; the dosage should not exceed 75 mg/day with immediate-release bupropion hydrochloride (HCl), 100 mg/day or 150 mg every other day with sustained-release bupropion HCl, 150 mg every other day with extended-release bupropion HCl, and 174 mg every other day with extended-release bupropion hydrobromide.  Bupropion-dextromethorphan is not recommended for patients with severe liver dysfunction (Child-Pugh C), and no dose adjustment of bupropion-dextromethorphan is recommended in patients with mild or moderate liver dysfunction (Child-Pugh A or B).', '2', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34299, 19459, 'Bupropion', 'Liver Diseases', 'Bupropion is primarily metabolized by the liver.  The systemic exposure and half-life of bupropion and its metabolites may be increased in patients with liver dysfunction.  A reduced dose and/or dosing frequency should be considered in patients with mild liver dysfunction (Child-Pugh score:  5 to 6).  A dosage reduction is required in patients with moderate to severe liver dysfunction (Child-Pugh score:  7 to 15) who are using a single-ingredient bupropion product; the dosage should not exceed 75 mg/day with immediate-release bupropion hydrochloride (HCl), 100 mg/day or 150 mg every other day with sustained-release bupropion HCl, 150 mg every other day with extended-release bupropion HCl, and 174 mg every other day with extended-release bupropion hydrobromide.  Bupropion-dextromethorphan is not recommended for patients with severe liver dysfunction (Child-Pugh C), and no dose adjustment of bupropion-dextromethorphan is recommended in patients with mild or moderate liver dysfunction (Child-Pugh A or B).', '2', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34300, 29640, 'Bupropion', 'Liver Diseases', 'Bupropion is primarily metabolized by the liver.  The systemic exposure and half-life of bupropion and its metabolites may be increased in patients with liver dysfunction.  A reduced dose and/or dosing frequency should be considered in patients with mild liver dysfunction (Child-Pugh score:  5 to 6).  A dosage reduction is required in patients with moderate to severe liver dysfunction (Child-Pugh score:  7 to 15) who are using a single-ingredient bupropion product; the dosage should not exceed 75 mg/day with immediate-release bupropion hydrochloride (HCl), 100 mg/day or 150 mg every other day with sustained-release bupropion HCl, 150 mg every other day with extended-release bupropion HCl, and 174 mg every other day with extended-release bupropion hydrobromide.  Bupropion-dextromethorphan is not recommended for patients with severe liver dysfunction (Child-Pugh C), and no dose adjustment of bupropion-dextromethorphan is recommended in patients with mild or moderate liver dysfunction (Child-Pugh A or B).', '2', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34301, 29641, 'Bupropion', 'Liver Diseases', 'Bupropion is primarily metabolized by the liver.  The systemic exposure and half-life of bupropion and its metabolites may be increased in patients with liver dysfunction.  A reduced dose and/or dosing frequency should be considered in patients with mild liver dysfunction (Child-Pugh score:  5 to 6).  A dosage reduction is required in patients with moderate to severe liver dysfunction (Child-Pugh score:  7 to 15) who are using a single-ingredient bupropion product; the dosage should not exceed 75 mg/day with immediate-release bupropion hydrochloride (HCl), 100 mg/day or 150 mg every other day with sustained-release bupropion HCl, 150 mg every other day with extended-release bupropion HCl, and 174 mg every other day with extended-release bupropion hydrobromide.  Bupropion-dextromethorphan is not recommended for patients with severe liver dysfunction (Child-Pugh C), and no dose adjustment of bupropion-dextromethorphan is recommended in patients with mild or moderate liver dysfunction (Child-Pugh A or B).', '2', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34302, 12548, 'Bupropion', 'Bipolar Disorder', 'Bupropion is not approved for the treatment of bipolar depression.  Antidepressant therapy can trigger a manic, mixed, or hypomanic episode; the risk appears increased in patients with bipolar disorder or with risk factors for bipolar disorder.  Before starting bupropion, patients should be screened for history of bipolar disorder and risk factors for bipolar disorder (e.g., family history of bipolar disorder, suicide, or depression).', '2', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34303, 13290, 'Bupropion', 'Bipolar Disorder', 'Bupropion is not approved for the treatment of bipolar depression.  Antidepressant therapy can trigger a manic, mixed, or hypomanic episode; the risk appears increased in patients with bipolar disorder or with risk factors for bipolar disorder.  Before starting bupropion, patients should be screened for history of bipolar disorder and risk factors for bipolar disorder (e.g., family history of bipolar disorder, suicide, or depression).', '2', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34304, 19459, 'Bupropion', 'Bipolar Disorder', 'Bupropion is not approved for the treatment of bipolar depression.  Antidepressant therapy can trigger a manic, mixed, or hypomanic episode; the risk appears increased in patients with bipolar disorder or with risk factors for bipolar disorder.  Before starting bupropion, patients should be screened for history of bipolar disorder and risk factors for bipolar disorder (e.g., family history of bipolar disorder, suicide, or depression).', '2', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34305, 29640, 'Bupropion', 'Bipolar Disorder', 'Bupropion is not approved for the treatment of bipolar depression.  Antidepressant therapy can trigger a manic, mixed, or hypomanic episode; the risk appears increased in patients with bipolar disorder or with risk factors for bipolar disorder.  Before starting bupropion, patients should be screened for history of bipolar disorder and risk factors for bipolar disorder (e.g., family history of bipolar disorder, suicide, or depression).', '2', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34306, 29641, 'Bupropion', 'Bipolar Disorder', 'Bupropion is not approved for the treatment of bipolar depression.  Antidepressant therapy can trigger a manic, mixed, or hypomanic episode; the risk appears increased in patients with bipolar disorder or with risk factors for bipolar disorder.  Before starting bupropion, patients should be screened for history of bipolar disorder and risk factors for bipolar disorder (e.g., family history of bipolar disorder, suicide, or depression).', '2', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34307, 12548, 'Bupropion', 'Psychotic Disorders', 'Depressed patients treated with bupropion have had various neuropsychiatric signs/symptoms, including delusions, hallucinations, psychosis, concentration disturbance, confusion, and paranoia; some of these patients had a diagnosis of bipolar disorder.  In some cases, these symptoms abated with dose reduction and/or discontinuation of therapy.  Bupropion should be discontinued if such reactions occur.', '2', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34308, 13290, 'Bupropion', 'Psychotic Disorders', 'Depressed patients treated with bupropion have had various neuropsychiatric signs/symptoms, including delusions, hallucinations, psychosis, concentration disturbance, confusion, and paranoia; some of these patients had a diagnosis of bipolar disorder.  In some cases, these symptoms abated with dose reduction and/or discontinuation of therapy.  Bupropion should be discontinued if such reactions occur.', '2', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34309, 19459, 'Bupropion', 'Psychotic Disorders', 'Depressed patients treated with bupropion have had various neuropsychiatric signs/symptoms, including delusions, hallucinations, psychosis, concentration disturbance, confusion, and paranoia; some of these patients had a diagnosis of bipolar disorder.  In some cases, these symptoms abated with dose reduction and/or discontinuation of therapy.  Bupropion should be discontinued if such reactions occur.', '2', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34310, 29640, 'Bupropion', 'Psychotic Disorders', 'Depressed patients treated with bupropion have had various neuropsychiatric signs/symptoms, including delusions, hallucinations, psychosis, concentration disturbance, confusion, and paranoia; some of these patients had a diagnosis of bipolar disorder.  In some cases, these symptoms abated with dose reduction and/or discontinuation of therapy.  Bupropion should be discontinued if such reactions occur.', '2', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34311, 29641, 'Bupropion', 'Psychotic Disorders', 'Depressed patients treated with bupropion have had various neuropsychiatric signs/symptoms, including delusions, hallucinations, psychosis, concentration disturbance, confusion, and paranoia; some of these patients had a diagnosis of bipolar disorder.  In some cases, these symptoms abated with dose reduction and/or discontinuation of therapy.  Bupropion should be discontinued if such reactions occur.', '2', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34312, 12548, 'Bupropion', 'Kidney Diseases', 'Bupropion and its metabolites, some of which are pharmacologically active with one-fifth to one-half the potency of the parent drug, are cleared renally and may accumulate in patients with renal dysfunction (GFR less than 90 mL/min) to a greater extent than usual.  Therefore, bupropion should be used with caution in patients with renal dysfunction.  A reduced dose and/or dosing frequency should be considered, and patients should be closely monitored for adverse effects that could indicate high bupropion or metabolite exposures.  Bupropion-dextromethorphan is not recommended for patients with severe renal dysfunction (estimated GFR 15 to 29 mL/min/1.73 m2); dosage adjustment of bupropion-dextromethorphan is recommended in patients with moderate renal dysfunction (estimated GFR 30 to 59 mL/min/1.73 m2).', '2', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34313, 13290, 'Bupropion', 'Kidney Diseases', 'Bupropion and its metabolites, some of which are pharmacologically active with one-fifth to one-half the potency of the parent drug, are cleared renally and may accumulate in patients with renal dysfunction (GFR less than 90 mL/min) to a greater extent than usual.  Therefore, bupropion should be used with caution in patients with renal dysfunction.  A reduced dose and/or dosing frequency should be considered, and patients should be closely monitored for adverse effects that could indicate high bupropion or metabolite exposures.  Bupropion-dextromethorphan is not recommended for patients with severe renal dysfunction (estimated GFR 15 to 29 mL/min/1.73 m2); dosage adjustment of bupropion-dextromethorphan is recommended in patients with moderate renal dysfunction (estimated GFR 30 to 59 mL/min/1.73 m2).', '2', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34314, 19459, 'Bupropion', 'Kidney Diseases', 'Bupropion and its metabolites, some of which are pharmacologically active with one-fifth to one-half the potency of the parent drug, are cleared renally and may accumulate in patients with renal dysfunction (GFR less than 90 mL/min) to a greater extent than usual.  Therefore, bupropion should be used with caution in patients with renal dysfunction.  A reduced dose and/or dosing frequency should be considered, and patients should be closely monitored for adverse effects that could indicate high bupropion or metabolite exposures.  Bupropion-dextromethorphan is not recommended for patients with severe renal dysfunction (estimated GFR 15 to 29 mL/min/1.73 m2); dosage adjustment of bupropion-dextromethorphan is recommended in patients with moderate renal dysfunction (estimated GFR 30 to 59 mL/min/1.73 m2).', '2', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34315, 29640, 'Bupropion', 'Kidney Diseases', 'Bupropion and its metabolites, some of which are pharmacologically active with one-fifth to one-half the potency of the parent drug, are cleared renally and may accumulate in patients with renal dysfunction (GFR less than 90 mL/min) to a greater extent than usual.  Therefore, bupropion should be used with caution in patients with renal dysfunction.  A reduced dose and/or dosing frequency should be considered, and patients should be closely monitored for adverse effects that could indicate high bupropion or metabolite exposures.  Bupropion-dextromethorphan is not recommended for patients with severe renal dysfunction (estimated GFR 15 to 29 mL/min/1.73 m2); dosage adjustment of bupropion-dextromethorphan is recommended in patients with moderate renal dysfunction (estimated GFR 30 to 59 mL/min/1.73 m2).', '2', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34316, 29641, 'Bupropion', 'Kidney Diseases', 'Bupropion and its metabolites, some of which are pharmacologically active with one-fifth to one-half the potency of the parent drug, are cleared renally and may accumulate in patients with renal dysfunction (GFR less than 90 mL/min) to a greater extent than usual.  Therefore, bupropion should be used with caution in patients with renal dysfunction.  A reduced dose and/or dosing frequency should be considered, and patients should be closely monitored for adverse effects that could indicate high bupropion or metabolite exposures.  Bupropion-dextromethorphan is not recommended for patients with severe renal dysfunction (estimated GFR 15 to 29 mL/min/1.73 m2); dosage adjustment of bupropion-dextromethorphan is recommended in patients with moderate renal dysfunction (estimated GFR 30 to 59 mL/min/1.73 m2).', '2', '"Product Information. Auvelity (bupropion-dextromethorphan)." Axsome Therapeutics, Inc.  (2022):|"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Zyban (buPROPion)." GlaxoSmithKline  (2021):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34317, 12548, 'Bupropion', 'Weight Loss', 'The use of bupropion is associated with weight alterations.  Both weight gain and weight loss may occur, although the latter is much more common.  Weight loss greater than 2.27 kg was reported in up to 28% of patients, which may be undesirable in patients suffering from anorexia, malnutrition, or excessive weight loss.  Weight change should be monitored during therapy if bupropion is used in these patients.', '1', '"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34318, 13290, 'Bupropion', 'Weight Loss', 'The use of bupropion is associated with weight alterations.  Both weight gain and weight loss may occur, although the latter is much more common.  Weight loss greater than 2.27 kg was reported in up to 28% of patients, which may be undesirable in patients suffering from anorexia, malnutrition, or excessive weight loss.  Weight change should be monitored during therapy if bupropion is used in these patients.', '1', '"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34319, 19459, 'Bupropion', 'Weight Loss', 'The use of bupropion is associated with weight alterations.  Both weight gain and weight loss may occur, although the latter is much more common.  Weight loss greater than 2.27 kg was reported in up to 28% of patients, which may be undesirable in patients suffering from anorexia, malnutrition, or excessive weight loss.  Weight change should be monitored during therapy if bupropion is used in these patients.', '1', '"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34320, 29640, 'Bupropion', 'Weight Loss', 'The use of bupropion is associated with weight alterations.  Both weight gain and weight loss may occur, although the latter is much more common.  Weight loss greater than 2.27 kg was reported in up to 28% of patients, which may be undesirable in patients suffering from anorexia, malnutrition, or excessive weight loss.  Weight change should be monitored during therapy if bupropion is used in these patients.', '1', '"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34321, 29641, 'Bupropion', 'Weight Loss', 'The use of bupropion is associated with weight alterations.  Both weight gain and weight loss may occur, although the latter is much more common.  Weight loss greater than 2.27 kg was reported in up to 28% of patients, which may be undesirable in patients suffering from anorexia, malnutrition, or excessive weight loss.  Weight change should be monitored during therapy if bupropion is used in these patients.', '1', '"Product Information. Aplenzin (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):|"Product Information. Forfivo XL (buPROPion)." Almatica Pharma Inc  (2019):|"Product Information. Wellbutrin SR (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin (buPROPion)." GlaxoSmithKline  (2020):|"Product Information. Wellbutrin XL (buPROPion)." Bausch Health US (formerly Valeant Pharmaceuticals)  (2022):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34322, 55, 'Acyclovir', 'Kidney Diseases', 'Acyclovir is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for neuro- and nephrotoxicity (including further deterioration in renal function, tubular damage and acute renal failure) from acyclovir due to decreased drug clearance.  Therapy with acyclovir should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended in patients with moderate to severe renal dysfunction.', '3', 'Laskin OL, Longstreth JA, Whelton A, et al. "Effect of renal failure on the pharmacokinetics of acyclovir." Am J Med 73 (1982):  197-201|Laskin OL, Longstreth JA, Whelton A, et al. "Acyclovir kinetics in end-stage renal disease." Clin Pharmacol Ther 31 (1982):  594-600|Sawyer MH, Webb DE, Balow JE, Straus SE "Acyclovir-induced renal failure." Am J Med 84 (1988):  1067-71|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Rashed A, Asadeh B, Romeh SHA "Acyclovir-induced acute tubulo-interstitial nephritis." Nephron 56 (1990):  436-8|Peterslund NA, Larsen ML, Mygind H "Acyclovir crystalluria." Scand J Infect Dis 20 (1988):  225-8|Gnann JW, Barton NH, Whitley RJ "Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications." Pharmacotherapy 3 (1983):  275-83|Hernandez E, Praga M, Moreno F, Montoyo C "Acute renal failure induced by oral acyclovir." Clin Nephrol 36 (1991):  155-6|Bianchetti MG, Roduit C, Oetliker OH "Acyclovir-induced renal failure: course and risk factors." Pediatr Nephrol 5 (1991):  238-9|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Becker BN, Fall P, Hall C, Milam D, Leonard J, Glick A, Schulman G "Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature." Am J Kidney Dis 22 (1993):  611-5|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34323, 71, 'Acyclovir', 'Kidney Diseases', 'Acyclovir is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for neuro- and nephrotoxicity (including further deterioration in renal function, tubular damage and acute renal failure) from acyclovir due to decreased drug clearance.  Therapy with acyclovir should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended in patients with moderate to severe renal dysfunction.', '3', 'Laskin OL, Longstreth JA, Whelton A, et al. "Effect of renal failure on the pharmacokinetics of acyclovir." Am J Med 73 (1982):  197-201|Laskin OL, Longstreth JA, Whelton A, et al. "Acyclovir kinetics in end-stage renal disease." Clin Pharmacol Ther 31 (1982):  594-600|Sawyer MH, Webb DE, Balow JE, Straus SE "Acyclovir-induced renal failure." Am J Med 84 (1988):  1067-71|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Rashed A, Asadeh B, Romeh SHA "Acyclovir-induced acute tubulo-interstitial nephritis." Nephron 56 (1990):  436-8|Peterslund NA, Larsen ML, Mygind H "Acyclovir crystalluria." Scand J Infect Dis 20 (1988):  225-8|Gnann JW, Barton NH, Whitley RJ "Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications." Pharmacotherapy 3 (1983):  275-83|Hernandez E, Praga M, Moreno F, Montoyo C "Acute renal failure induced by oral acyclovir." Clin Nephrol 36 (1991):  155-6|Bianchetti MG, Roduit C, Oetliker OH "Acyclovir-induced renal failure: course and risk factors." Pediatr Nephrol 5 (1991):  238-9|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Becker BN, Fall P, Hall C, Milam D, Leonard J, Glick A, Schulman G "Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature." Am J Kidney Dis 22 (1993):  611-5|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34324, 131, 'Acyclovir', 'Kidney Diseases', 'Acyclovir is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for neuro- and nephrotoxicity (including further deterioration in renal function, tubular damage and acute renal failure) from acyclovir due to decreased drug clearance.  Therapy with acyclovir should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended in patients with moderate to severe renal dysfunction.', '3', 'Laskin OL, Longstreth JA, Whelton A, et al. "Effect of renal failure on the pharmacokinetics of acyclovir." Am J Med 73 (1982):  197-201|Laskin OL, Longstreth JA, Whelton A, et al. "Acyclovir kinetics in end-stage renal disease." Clin Pharmacol Ther 31 (1982):  594-600|Sawyer MH, Webb DE, Balow JE, Straus SE "Acyclovir-induced renal failure." Am J Med 84 (1988):  1067-71|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Rashed A, Asadeh B, Romeh SHA "Acyclovir-induced acute tubulo-interstitial nephritis." Nephron 56 (1990):  436-8|Peterslund NA, Larsen ML, Mygind H "Acyclovir crystalluria." Scand J Infect Dis 20 (1988):  225-8|Gnann JW, Barton NH, Whitley RJ "Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications." Pharmacotherapy 3 (1983):  275-83|Hernandez E, Praga M, Moreno F, Montoyo C "Acute renal failure induced by oral acyclovir." Clin Nephrol 36 (1991):  155-6|Bianchetti MG, Roduit C, Oetliker OH "Acyclovir-induced renal failure: course and risk factors." Pediatr Nephrol 5 (1991):  238-9|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Becker BN, Fall P, Hall C, Milam D, Leonard J, Glick A, Schulman G "Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature." Am J Kidney Dis 22 (1993):  611-5|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34325, 133, 'Acyclovir', 'Kidney Diseases', 'Acyclovir is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for neuro- and nephrotoxicity (including further deterioration in renal function, tubular damage and acute renal failure) from acyclovir due to decreased drug clearance.  Therapy with acyclovir should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended in patients with moderate to severe renal dysfunction.', '3', 'Laskin OL, Longstreth JA, Whelton A, et al. "Effect of renal failure on the pharmacokinetics of acyclovir." Am J Med 73 (1982):  197-201|Laskin OL, Longstreth JA, Whelton A, et al. "Acyclovir kinetics in end-stage renal disease." Clin Pharmacol Ther 31 (1982):  594-600|Sawyer MH, Webb DE, Balow JE, Straus SE "Acyclovir-induced renal failure." Am J Med 84 (1988):  1067-71|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Rashed A, Asadeh B, Romeh SHA "Acyclovir-induced acute tubulo-interstitial nephritis." Nephron 56 (1990):  436-8|Peterslund NA, Larsen ML, Mygind H "Acyclovir crystalluria." Scand J Infect Dis 20 (1988):  225-8|Gnann JW, Barton NH, Whitley RJ "Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications." Pharmacotherapy 3 (1983):  275-83|Hernandez E, Praga M, Moreno F, Montoyo C "Acute renal failure induced by oral acyclovir." Clin Nephrol 36 (1991):  155-6|Bianchetti MG, Roduit C, Oetliker OH "Acyclovir-induced renal failure: course and risk factors." Pediatr Nephrol 5 (1991):  238-9|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Becker BN, Fall P, Hall C, Milam D, Leonard J, Glick A, Schulman G "Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature." Am J Kidney Dis 22 (1993):  611-5|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34326, 135, 'Acyclovir', 'Kidney Diseases', 'Acyclovir is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for neuro- and nephrotoxicity (including further deterioration in renal function, tubular damage and acute renal failure) from acyclovir due to decreased drug clearance.  Therapy with acyclovir should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended in patients with moderate to severe renal dysfunction.', '3', 'Laskin OL, Longstreth JA, Whelton A, et al. "Effect of renal failure on the pharmacokinetics of acyclovir." Am J Med 73 (1982):  197-201|Laskin OL, Longstreth JA, Whelton A, et al. "Acyclovir kinetics in end-stage renal disease." Clin Pharmacol Ther 31 (1982):  594-600|Sawyer MH, Webb DE, Balow JE, Straus SE "Acyclovir-induced renal failure." Am J Med 84 (1988):  1067-71|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Rashed A, Asadeh B, Romeh SHA "Acyclovir-induced acute tubulo-interstitial nephritis." Nephron 56 (1990):  436-8|Peterslund NA, Larsen ML, Mygind H "Acyclovir crystalluria." Scand J Infect Dis 20 (1988):  225-8|Gnann JW, Barton NH, Whitley RJ "Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications." Pharmacotherapy 3 (1983):  275-83|Hernandez E, Praga M, Moreno F, Montoyo C "Acute renal failure induced by oral acyclovir." Clin Nephrol 36 (1991):  155-6|Bianchetti MG, Roduit C, Oetliker OH "Acyclovir-induced renal failure: course and risk factors." Pediatr Nephrol 5 (1991):  238-9|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Becker BN, Fall P, Hall C, Milam D, Leonard J, Glick A, Schulman G "Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature." Am J Kidney Dis 22 (1993):  611-5|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34327, 137, 'Acyclovir', 'Kidney Diseases', 'Acyclovir is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for neuro- and nephrotoxicity (including further deterioration in renal function, tubular damage and acute renal failure) from acyclovir due to decreased drug clearance.  Therapy with acyclovir should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended in patients with moderate to severe renal dysfunction.', '3', 'Laskin OL, Longstreth JA, Whelton A, et al. "Effect of renal failure on the pharmacokinetics of acyclovir." Am J Med 73 (1982):  197-201|Laskin OL, Longstreth JA, Whelton A, et al. "Acyclovir kinetics in end-stage renal disease." Clin Pharmacol Ther 31 (1982):  594-600|Sawyer MH, Webb DE, Balow JE, Straus SE "Acyclovir-induced renal failure." Am J Med 84 (1988):  1067-71|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Rashed A, Asadeh B, Romeh SHA "Acyclovir-induced acute tubulo-interstitial nephritis." Nephron 56 (1990):  436-8|Peterslund NA, Larsen ML, Mygind H "Acyclovir crystalluria." Scand J Infect Dis 20 (1988):  225-8|Gnann JW, Barton NH, Whitley RJ "Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications." Pharmacotherapy 3 (1983):  275-83|Hernandez E, Praga M, Moreno F, Montoyo C "Acute renal failure induced by oral acyclovir." Clin Nephrol 36 (1991):  155-6|Bianchetti MG, Roduit C, Oetliker OH "Acyclovir-induced renal failure: course and risk factors." Pediatr Nephrol 5 (1991):  238-9|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Becker BN, Fall P, Hall C, Milam D, Leonard J, Glick A, Schulman G "Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature." Am J Kidney Dis 22 (1993):  611-5|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34328, 3222, 'Acyclovir', 'Kidney Diseases', 'Acyclovir is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for neuro- and nephrotoxicity (including further deterioration in renal function, tubular damage and acute renal failure) from acyclovir due to decreased drug clearance.  Therapy with acyclovir should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended in patients with moderate to severe renal dysfunction.', '3', 'Laskin OL, Longstreth JA, Whelton A, et al. "Effect of renal failure on the pharmacokinetics of acyclovir." Am J Med 73 (1982):  197-201|Laskin OL, Longstreth JA, Whelton A, et al. "Acyclovir kinetics in end-stage renal disease." Clin Pharmacol Ther 31 (1982):  594-600|Sawyer MH, Webb DE, Balow JE, Straus SE "Acyclovir-induced renal failure." Am J Med 84 (1988):  1067-71|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Rashed A, Asadeh B, Romeh SHA "Acyclovir-induced acute tubulo-interstitial nephritis." Nephron 56 (1990):  436-8|Peterslund NA, Larsen ML, Mygind H "Acyclovir crystalluria." Scand J Infect Dis 20 (1988):  225-8|Gnann JW, Barton NH, Whitley RJ "Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications." Pharmacotherapy 3 (1983):  275-83|Hernandez E, Praga M, Moreno F, Montoyo C "Acute renal failure induced by oral acyclovir." Clin Nephrol 36 (1991):  155-6|Bianchetti MG, Roduit C, Oetliker OH "Acyclovir-induced renal failure: course and risk factors." Pediatr Nephrol 5 (1991):  238-9|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Becker BN, Fall P, Hall C, Milam D, Leonard J, Glick A, Schulman G "Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature." Am J Kidney Dis 22 (1993):  611-5|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34329, 3223, 'Acyclovir', 'Kidney Diseases', 'Acyclovir is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for neuro- and nephrotoxicity (including further deterioration in renal function, tubular damage and acute renal failure) from acyclovir due to decreased drug clearance.  Therapy with acyclovir should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended in patients with moderate to severe renal dysfunction.', '3', 'Laskin OL, Longstreth JA, Whelton A, et al. "Effect of renal failure on the pharmacokinetics of acyclovir." Am J Med 73 (1982):  197-201|Laskin OL, Longstreth JA, Whelton A, et al. "Acyclovir kinetics in end-stage renal disease." Clin Pharmacol Ther 31 (1982):  594-600|Sawyer MH, Webb DE, Balow JE, Straus SE "Acyclovir-induced renal failure." Am J Med 84 (1988):  1067-71|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Rashed A, Asadeh B, Romeh SHA "Acyclovir-induced acute tubulo-interstitial nephritis." Nephron 56 (1990):  436-8|Peterslund NA, Larsen ML, Mygind H "Acyclovir crystalluria." Scand J Infect Dis 20 (1988):  225-8|Gnann JW, Barton NH, Whitley RJ "Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications." Pharmacotherapy 3 (1983):  275-83|Hernandez E, Praga M, Moreno F, Montoyo C "Acute renal failure induced by oral acyclovir." Clin Nephrol 36 (1991):  155-6|Bianchetti MG, Roduit C, Oetliker OH "Acyclovir-induced renal failure: course and risk factors." Pediatr Nephrol 5 (1991):  238-9|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Becker BN, Fall P, Hall C, Milam D, Leonard J, Glick A, Schulman G "Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature." Am J Kidney Dis 22 (1993):  611-5|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34330, 7574, 'Acyclovir', 'Kidney Diseases', 'Acyclovir is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for neuro- and nephrotoxicity (including further deterioration in renal function, tubular damage and acute renal failure) from acyclovir due to decreased drug clearance.  Therapy with acyclovir should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended in patients with moderate to severe renal dysfunction.', '3', 'Laskin OL, Longstreth JA, Whelton A, et al. "Effect of renal failure on the pharmacokinetics of acyclovir." Am J Med 73 (1982):  197-201|Laskin OL, Longstreth JA, Whelton A, et al. "Acyclovir kinetics in end-stage renal disease." Clin Pharmacol Ther 31 (1982):  594-600|Sawyer MH, Webb DE, Balow JE, Straus SE "Acyclovir-induced renal failure." Am J Med 84 (1988):  1067-71|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Rashed A, Asadeh B, Romeh SHA "Acyclovir-induced acute tubulo-interstitial nephritis." Nephron 56 (1990):  436-8|Peterslund NA, Larsen ML, Mygind H "Acyclovir crystalluria." Scand J Infect Dis 20 (1988):  225-8|Gnann JW, Barton NH, Whitley RJ "Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications." Pharmacotherapy 3 (1983):  275-83|Hernandez E, Praga M, Moreno F, Montoyo C "Acute renal failure induced by oral acyclovir." Clin Nephrol 36 (1991):  155-6|Bianchetti MG, Roduit C, Oetliker OH "Acyclovir-induced renal failure: course and risk factors." Pediatr Nephrol 5 (1991):  238-9|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Becker BN, Fall P, Hall C, Milam D, Leonard J, Glick A, Schulman G "Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature." Am J Kidney Dis 22 (1993):  611-5|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34331, 9055, 'Acyclovir', 'Kidney Diseases', 'Acyclovir is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for neuro- and nephrotoxicity (including further deterioration in renal function, tubular damage and acute renal failure) from acyclovir due to decreased drug clearance.  Therapy with acyclovir should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended in patients with moderate to severe renal dysfunction.', '3', 'Laskin OL, Longstreth JA, Whelton A, et al. "Effect of renal failure on the pharmacokinetics of acyclovir." Am J Med 73 (1982):  197-201|Laskin OL, Longstreth JA, Whelton A, et al. "Acyclovir kinetics in end-stage renal disease." Clin Pharmacol Ther 31 (1982):  594-600|Sawyer MH, Webb DE, Balow JE, Straus SE "Acyclovir-induced renal failure." Am J Med 84 (1988):  1067-71|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Rashed A, Asadeh B, Romeh SHA "Acyclovir-induced acute tubulo-interstitial nephritis." Nephron 56 (1990):  436-8|Peterslund NA, Larsen ML, Mygind H "Acyclovir crystalluria." Scand J Infect Dis 20 (1988):  225-8|Gnann JW, Barton NH, Whitley RJ "Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications." Pharmacotherapy 3 (1983):  275-83|Hernandez E, Praga M, Moreno F, Montoyo C "Acute renal failure induced by oral acyclovir." Clin Nephrol 36 (1991):  155-6|Bianchetti MG, Roduit C, Oetliker OH "Acyclovir-induced renal failure: course and risk factors." Pediatr Nephrol 5 (1991):  238-9|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Becker BN, Fall P, Hall C, Milam D, Leonard J, Glick A, Schulman G "Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature." Am J Kidney Dis 22 (1993):  611-5|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34332, 12351, 'Acyclovir', 'Kidney Diseases', 'Acyclovir is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for neuro- and nephrotoxicity (including further deterioration in renal function, tubular damage and acute renal failure) from acyclovir due to decreased drug clearance.  Therapy with acyclovir should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended in patients with moderate to severe renal dysfunction.', '3', 'Laskin OL, Longstreth JA, Whelton A, et al. "Effect of renal failure on the pharmacokinetics of acyclovir." Am J Med 73 (1982):  197-201|Laskin OL, Longstreth JA, Whelton A, et al. "Acyclovir kinetics in end-stage renal disease." Clin Pharmacol Ther 31 (1982):  594-600|Sawyer MH, Webb DE, Balow JE, Straus SE "Acyclovir-induced renal failure." Am J Med 84 (1988):  1067-71|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Rashed A, Asadeh B, Romeh SHA "Acyclovir-induced acute tubulo-interstitial nephritis." Nephron 56 (1990):  436-8|Peterslund NA, Larsen ML, Mygind H "Acyclovir crystalluria." Scand J Infect Dis 20 (1988):  225-8|Gnann JW, Barton NH, Whitley RJ "Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications." Pharmacotherapy 3 (1983):  275-83|Hernandez E, Praga M, Moreno F, Montoyo C "Acute renal failure induced by oral acyclovir." Clin Nephrol 36 (1991):  155-6|Bianchetti MG, Roduit C, Oetliker OH "Acyclovir-induced renal failure: course and risk factors." Pediatr Nephrol 5 (1991):  238-9|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Becker BN, Fall P, Hall C, Milam D, Leonard J, Glick A, Schulman G "Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature." Am J Kidney Dis 22 (1993):  611-5|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34333, 12352, 'Acyclovir', 'Kidney Diseases', 'Acyclovir is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for neuro- and nephrotoxicity (including further deterioration in renal function, tubular damage and acute renal failure) from acyclovir due to decreased drug clearance.  Therapy with acyclovir should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended in patients with moderate to severe renal dysfunction.', '3', 'Laskin OL, Longstreth JA, Whelton A, et al. "Effect of renal failure on the pharmacokinetics of acyclovir." Am J Med 73 (1982):  197-201|Laskin OL, Longstreth JA, Whelton A, et al. "Acyclovir kinetics in end-stage renal disease." Clin Pharmacol Ther 31 (1982):  594-600|Sawyer MH, Webb DE, Balow JE, Straus SE "Acyclovir-induced renal failure." Am J Med 84 (1988):  1067-71|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Rashed A, Asadeh B, Romeh SHA "Acyclovir-induced acute tubulo-interstitial nephritis." Nephron 56 (1990):  436-8|Peterslund NA, Larsen ML, Mygind H "Acyclovir crystalluria." Scand J Infect Dis 20 (1988):  225-8|Gnann JW, Barton NH, Whitley RJ "Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications." Pharmacotherapy 3 (1983):  275-83|Hernandez E, Praga M, Moreno F, Montoyo C "Acute renal failure induced by oral acyclovir." Clin Nephrol 36 (1991):  155-6|Bianchetti MG, Roduit C, Oetliker OH "Acyclovir-induced renal failure: course and risk factors." Pediatr Nephrol 5 (1991):  238-9|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Becker BN, Fall P, Hall C, Milam D, Leonard J, Glick A, Schulman G "Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature." Am J Kidney Dis 22 (1993):  611-5|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34334, 12934, 'Acyclovir', 'Kidney Diseases', 'Acyclovir is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for neuro- and nephrotoxicity (including further deterioration in renal function, tubular damage and acute renal failure) from acyclovir due to decreased drug clearance.  Therapy with acyclovir should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended in patients with moderate to severe renal dysfunction.', '3', 'Laskin OL, Longstreth JA, Whelton A, et al. "Effect of renal failure on the pharmacokinetics of acyclovir." Am J Med 73 (1982):  197-201|Laskin OL, Longstreth JA, Whelton A, et al. "Acyclovir kinetics in end-stage renal disease." Clin Pharmacol Ther 31 (1982):  594-600|Sawyer MH, Webb DE, Balow JE, Straus SE "Acyclovir-induced renal failure." Am J Med 84 (1988):  1067-71|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Rashed A, Asadeh B, Romeh SHA "Acyclovir-induced acute tubulo-interstitial nephritis." Nephron 56 (1990):  436-8|Peterslund NA, Larsen ML, Mygind H "Acyclovir crystalluria." Scand J Infect Dis 20 (1988):  225-8|Gnann JW, Barton NH, Whitley RJ "Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications." Pharmacotherapy 3 (1983):  275-83|Hernandez E, Praga M, Moreno F, Montoyo C "Acute renal failure induced by oral acyclovir." Clin Nephrol 36 (1991):  155-6|Bianchetti MG, Roduit C, Oetliker OH "Acyclovir-induced renal failure: course and risk factors." Pediatr Nephrol 5 (1991):  238-9|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Becker BN, Fall P, Hall C, Milam D, Leonard J, Glick A, Schulman G "Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature." Am J Kidney Dis 22 (1993):  611-5|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34335, 12935, 'Acyclovir', 'Kidney Diseases', 'Acyclovir is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for neuro- and nephrotoxicity (including further deterioration in renal function, tubular damage and acute renal failure) from acyclovir due to decreased drug clearance.  Therapy with acyclovir should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended in patients with moderate to severe renal dysfunction.', '3', 'Laskin OL, Longstreth JA, Whelton A, et al. "Effect of renal failure on the pharmacokinetics of acyclovir." Am J Med 73 (1982):  197-201|Laskin OL, Longstreth JA, Whelton A, et al. "Acyclovir kinetics in end-stage renal disease." Clin Pharmacol Ther 31 (1982):  594-600|Sawyer MH, Webb DE, Balow JE, Straus SE "Acyclovir-induced renal failure." Am J Med 84 (1988):  1067-71|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Rashed A, Asadeh B, Romeh SHA "Acyclovir-induced acute tubulo-interstitial nephritis." Nephron 56 (1990):  436-8|Peterslund NA, Larsen ML, Mygind H "Acyclovir crystalluria." Scand J Infect Dis 20 (1988):  225-8|Gnann JW, Barton NH, Whitley RJ "Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications." Pharmacotherapy 3 (1983):  275-83|Hernandez E, Praga M, Moreno F, Montoyo C "Acute renal failure induced by oral acyclovir." Clin Nephrol 36 (1991):  155-6|Bianchetti MG, Roduit C, Oetliker OH "Acyclovir-induced renal failure: course and risk factors." Pediatr Nephrol 5 (1991):  238-9|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Becker BN, Fall P, Hall C, Milam D, Leonard J, Glick A, Schulman G "Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature." Am J Kidney Dis 22 (1993):  611-5|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34336, 12936, 'Acyclovir', 'Kidney Diseases', 'Acyclovir is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for neuro- and nephrotoxicity (including further deterioration in renal function, tubular damage and acute renal failure) from acyclovir due to decreased drug clearance.  Therapy with acyclovir should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended in patients with moderate to severe renal dysfunction.', '3', 'Laskin OL, Longstreth JA, Whelton A, et al. "Effect of renal failure on the pharmacokinetics of acyclovir." Am J Med 73 (1982):  197-201|Laskin OL, Longstreth JA, Whelton A, et al. "Acyclovir kinetics in end-stage renal disease." Clin Pharmacol Ther 31 (1982):  594-600|Sawyer MH, Webb DE, Balow JE, Straus SE "Acyclovir-induced renal failure." Am J Med 84 (1988):  1067-71|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Rashed A, Asadeh B, Romeh SHA "Acyclovir-induced acute tubulo-interstitial nephritis." Nephron 56 (1990):  436-8|Peterslund NA, Larsen ML, Mygind H "Acyclovir crystalluria." Scand J Infect Dis 20 (1988):  225-8|Gnann JW, Barton NH, Whitley RJ "Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications." Pharmacotherapy 3 (1983):  275-83|Hernandez E, Praga M, Moreno F, Montoyo C "Acute renal failure induced by oral acyclovir." Clin Nephrol 36 (1991):  155-6|Bianchetti MG, Roduit C, Oetliker OH "Acyclovir-induced renal failure: course and risk factors." Pediatr Nephrol 5 (1991):  238-9|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Becker BN, Fall P, Hall C, Milam D, Leonard J, Glick A, Schulman G "Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature." Am J Kidney Dis 22 (1993):  611-5|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34337, 12938, 'Acyclovir', 'Kidney Diseases', 'Acyclovir is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for neuro- and nephrotoxicity (including further deterioration in renal function, tubular damage and acute renal failure) from acyclovir due to decreased drug clearance.  Therapy with acyclovir should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended in patients with moderate to severe renal dysfunction.', '3', 'Laskin OL, Longstreth JA, Whelton A, et al. "Effect of renal failure on the pharmacokinetics of acyclovir." Am J Med 73 (1982):  197-201|Laskin OL, Longstreth JA, Whelton A, et al. "Acyclovir kinetics in end-stage renal disease." Clin Pharmacol Ther 31 (1982):  594-600|Sawyer MH, Webb DE, Balow JE, Straus SE "Acyclovir-induced renal failure." Am J Med 84 (1988):  1067-71|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Rashed A, Asadeh B, Romeh SHA "Acyclovir-induced acute tubulo-interstitial nephritis." Nephron 56 (1990):  436-8|Peterslund NA, Larsen ML, Mygind H "Acyclovir crystalluria." Scand J Infect Dis 20 (1988):  225-8|Gnann JW, Barton NH, Whitley RJ "Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications." Pharmacotherapy 3 (1983):  275-83|Hernandez E, Praga M, Moreno F, Montoyo C "Acute renal failure induced by oral acyclovir." Clin Nephrol 36 (1991):  155-6|Bianchetti MG, Roduit C, Oetliker OH "Acyclovir-induced renal failure: course and risk factors." Pediatr Nephrol 5 (1991):  238-9|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Becker BN, Fall P, Hall C, Milam D, Leonard J, Glick A, Schulman G "Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature." Am J Kidney Dis 22 (1993):  611-5|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34338, 12940, 'Acyclovir', 'Kidney Diseases', 'Acyclovir is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for neuro- and nephrotoxicity (including further deterioration in renal function, tubular damage and acute renal failure) from acyclovir due to decreased drug clearance.  Therapy with acyclovir should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended in patients with moderate to severe renal dysfunction.', '3', 'Laskin OL, Longstreth JA, Whelton A, et al. "Effect of renal failure on the pharmacokinetics of acyclovir." Am J Med 73 (1982):  197-201|Laskin OL, Longstreth JA, Whelton A, et al. "Acyclovir kinetics in end-stage renal disease." Clin Pharmacol Ther 31 (1982):  594-600|Sawyer MH, Webb DE, Balow JE, Straus SE "Acyclovir-induced renal failure." Am J Med 84 (1988):  1067-71|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Rashed A, Asadeh B, Romeh SHA "Acyclovir-induced acute tubulo-interstitial nephritis." Nephron 56 (1990):  436-8|Peterslund NA, Larsen ML, Mygind H "Acyclovir crystalluria." Scand J Infect Dis 20 (1988):  225-8|Gnann JW, Barton NH, Whitley RJ "Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications." Pharmacotherapy 3 (1983):  275-83|Hernandez E, Praga M, Moreno F, Montoyo C "Acute renal failure induced by oral acyclovir." Clin Nephrol 36 (1991):  155-6|Bianchetti MG, Roduit C, Oetliker OH "Acyclovir-induced renal failure: course and risk factors." Pediatr Nephrol 5 (1991):  238-9|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Becker BN, Fall P, Hall C, Milam D, Leonard J, Glick A, Schulman G "Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature." Am J Kidney Dis 22 (1993):  611-5|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34339, 13330, 'Acyclovir', 'Kidney Diseases', 'Acyclovir is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for neuro- and nephrotoxicity (including further deterioration in renal function, tubular damage and acute renal failure) from acyclovir due to decreased drug clearance.  Therapy with acyclovir should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended in patients with moderate to severe renal dysfunction.', '3', 'Laskin OL, Longstreth JA, Whelton A, et al. "Effect of renal failure on the pharmacokinetics of acyclovir." Am J Med 73 (1982):  197-201|Laskin OL, Longstreth JA, Whelton A, et al. "Acyclovir kinetics in end-stage renal disease." Clin Pharmacol Ther 31 (1982):  594-600|Sawyer MH, Webb DE, Balow JE, Straus SE "Acyclovir-induced renal failure." Am J Med 84 (1988):  1067-71|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Rashed A, Asadeh B, Romeh SHA "Acyclovir-induced acute tubulo-interstitial nephritis." Nephron 56 (1990):  436-8|Peterslund NA, Larsen ML, Mygind H "Acyclovir crystalluria." Scand J Infect Dis 20 (1988):  225-8|Gnann JW, Barton NH, Whitley RJ "Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications." Pharmacotherapy 3 (1983):  275-83|Hernandez E, Praga M, Moreno F, Montoyo C "Acute renal failure induced by oral acyclovir." Clin Nephrol 36 (1991):  155-6|Bianchetti MG, Roduit C, Oetliker OH "Acyclovir-induced renal failure: course and risk factors." Pediatr Nephrol 5 (1991):  238-9|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Becker BN, Fall P, Hall C, Milam D, Leonard J, Glick A, Schulman G "Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature." Am J Kidney Dis 22 (1993):  611-5|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34340, 13346, 'Acyclovir', 'Kidney Diseases', 'Acyclovir is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for neuro- and nephrotoxicity (including further deterioration in renal function, tubular damage and acute renal failure) from acyclovir due to decreased drug clearance.  Therapy with acyclovir should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended in patients with moderate to severe renal dysfunction.', '3', 'Laskin OL, Longstreth JA, Whelton A, et al. "Effect of renal failure on the pharmacokinetics of acyclovir." Am J Med 73 (1982):  197-201|Laskin OL, Longstreth JA, Whelton A, et al. "Acyclovir kinetics in end-stage renal disease." Clin Pharmacol Ther 31 (1982):  594-600|Sawyer MH, Webb DE, Balow JE, Straus SE "Acyclovir-induced renal failure." Am J Med 84 (1988):  1067-71|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Rashed A, Asadeh B, Romeh SHA "Acyclovir-induced acute tubulo-interstitial nephritis." Nephron 56 (1990):  436-8|Peterslund NA, Larsen ML, Mygind H "Acyclovir crystalluria." Scand J Infect Dis 20 (1988):  225-8|Gnann JW, Barton NH, Whitley RJ "Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications." Pharmacotherapy 3 (1983):  275-83|Hernandez E, Praga M, Moreno F, Montoyo C "Acute renal failure induced by oral acyclovir." Clin Nephrol 36 (1991):  155-6|Bianchetti MG, Roduit C, Oetliker OH "Acyclovir-induced renal failure: course and risk factors." Pediatr Nephrol 5 (1991):  238-9|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Becker BN, Fall P, Hall C, Milam D, Leonard J, Glick A, Schulman G "Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature." Am J Kidney Dis 22 (1993):  611-5|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34341, 13455, 'Acyclovir', 'Kidney Diseases', 'Acyclovir is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for neuro- and nephrotoxicity (including further deterioration in renal function, tubular damage and acute renal failure) from acyclovir due to decreased drug clearance.  Therapy with acyclovir should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended in patients with moderate to severe renal dysfunction.', '3', 'Laskin OL, Longstreth JA, Whelton A, et al. "Effect of renal failure on the pharmacokinetics of acyclovir." Am J Med 73 (1982):  197-201|Laskin OL, Longstreth JA, Whelton A, et al. "Acyclovir kinetics in end-stage renal disease." Clin Pharmacol Ther 31 (1982):  594-600|Sawyer MH, Webb DE, Balow JE, Straus SE "Acyclovir-induced renal failure." Am J Med 84 (1988):  1067-71|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Rashed A, Asadeh B, Romeh SHA "Acyclovir-induced acute tubulo-interstitial nephritis." Nephron 56 (1990):  436-8|Peterslund NA, Larsen ML, Mygind H "Acyclovir crystalluria." Scand J Infect Dis 20 (1988):  225-8|Gnann JW, Barton NH, Whitley RJ "Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications." Pharmacotherapy 3 (1983):  275-83|Hernandez E, Praga M, Moreno F, Montoyo C "Acute renal failure induced by oral acyclovir." Clin Nephrol 36 (1991):  155-6|Bianchetti MG, Roduit C, Oetliker OH "Acyclovir-induced renal failure: course and risk factors." Pediatr Nephrol 5 (1991):  238-9|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Becker BN, Fall P, Hall C, Milam D, Leonard J, Glick A, Schulman G "Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature." Am J Kidney Dis 22 (1993):  611-5|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34342, 13457, 'Acyclovir', 'Kidney Diseases', 'Acyclovir is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for neuro- and nephrotoxicity (including further deterioration in renal function, tubular damage and acute renal failure) from acyclovir due to decreased drug clearance.  Therapy with acyclovir should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended in patients with moderate to severe renal dysfunction.', '3', 'Laskin OL, Longstreth JA, Whelton A, et al. "Effect of renal failure on the pharmacokinetics of acyclovir." Am J Med 73 (1982):  197-201|Laskin OL, Longstreth JA, Whelton A, et al. "Acyclovir kinetics in end-stage renal disease." Clin Pharmacol Ther 31 (1982):  594-600|Sawyer MH, Webb DE, Balow JE, Straus SE "Acyclovir-induced renal failure." Am J Med 84 (1988):  1067-71|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Rashed A, Asadeh B, Romeh SHA "Acyclovir-induced acute tubulo-interstitial nephritis." Nephron 56 (1990):  436-8|Peterslund NA, Larsen ML, Mygind H "Acyclovir crystalluria." Scand J Infect Dis 20 (1988):  225-8|Gnann JW, Barton NH, Whitley RJ "Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications." Pharmacotherapy 3 (1983):  275-83|Hernandez E, Praga M, Moreno F, Montoyo C "Acute renal failure induced by oral acyclovir." Clin Nephrol 36 (1991):  155-6|Bianchetti MG, Roduit C, Oetliker OH "Acyclovir-induced renal failure: course and risk factors." Pediatr Nephrol 5 (1991):  238-9|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Becker BN, Fall P, Hall C, Milam D, Leonard J, Glick A, Schulman G "Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature." Am J Kidney Dis 22 (1993):  611-5|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34343, 15444, 'Acyclovir', 'Kidney Diseases', 'Acyclovir is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for neuro- and nephrotoxicity (including further deterioration in renal function, tubular damage and acute renal failure) from acyclovir due to decreased drug clearance.  Therapy with acyclovir should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended in patients with moderate to severe renal dysfunction.', '3', 'Laskin OL, Longstreth JA, Whelton A, et al. "Effect of renal failure on the pharmacokinetics of acyclovir." Am J Med 73 (1982):  197-201|Laskin OL, Longstreth JA, Whelton A, et al. "Acyclovir kinetics in end-stage renal disease." Clin Pharmacol Ther 31 (1982):  594-600|Sawyer MH, Webb DE, Balow JE, Straus SE "Acyclovir-induced renal failure." Am J Med 84 (1988):  1067-71|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Rashed A, Asadeh B, Romeh SHA "Acyclovir-induced acute tubulo-interstitial nephritis." Nephron 56 (1990):  436-8|Peterslund NA, Larsen ML, Mygind H "Acyclovir crystalluria." Scand J Infect Dis 20 (1988):  225-8|Gnann JW, Barton NH, Whitley RJ "Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications." Pharmacotherapy 3 (1983):  275-83|Hernandez E, Praga M, Moreno F, Montoyo C "Acute renal failure induced by oral acyclovir." Clin Nephrol 36 (1991):  155-6|Bianchetti MG, Roduit C, Oetliker OH "Acyclovir-induced renal failure: course and risk factors." Pediatr Nephrol 5 (1991):  238-9|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Becker BN, Fall P, Hall C, Milam D, Leonard J, Glick A, Schulman G "Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature." Am J Kidney Dis 22 (1993):  611-5|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34344, 16999, 'Acyclovir', 'Kidney Diseases', 'Acyclovir is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for neuro- and nephrotoxicity (including further deterioration in renal function, tubular damage and acute renal failure) from acyclovir due to decreased drug clearance.  Therapy with acyclovir should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended in patients with moderate to severe renal dysfunction.', '3', 'Laskin OL, Longstreth JA, Whelton A, et al. "Effect of renal failure on the pharmacokinetics of acyclovir." Am J Med 73 (1982):  197-201|Laskin OL, Longstreth JA, Whelton A, et al. "Acyclovir kinetics in end-stage renal disease." Clin Pharmacol Ther 31 (1982):  594-600|Sawyer MH, Webb DE, Balow JE, Straus SE "Acyclovir-induced renal failure." Am J Med 84 (1988):  1067-71|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Rashed A, Asadeh B, Romeh SHA "Acyclovir-induced acute tubulo-interstitial nephritis." Nephron 56 (1990):  436-8|Peterslund NA, Larsen ML, Mygind H "Acyclovir crystalluria." Scand J Infect Dis 20 (1988):  225-8|Gnann JW, Barton NH, Whitley RJ "Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications." Pharmacotherapy 3 (1983):  275-83|Hernandez E, Praga M, Moreno F, Montoyo C "Acute renal failure induced by oral acyclovir." Clin Nephrol 36 (1991):  155-6|Bianchetti MG, Roduit C, Oetliker OH "Acyclovir-induced renal failure: course and risk factors." Pediatr Nephrol 5 (1991):  238-9|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Becker BN, Fall P, Hall C, Milam D, Leonard J, Glick A, Schulman G "Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature." Am J Kidney Dis 22 (1993):  611-5|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34345, 27726, 'Acyclovir', 'Kidney Diseases', 'Acyclovir is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for neuro- and nephrotoxicity (including further deterioration in renal function, tubular damage and acute renal failure) from acyclovir due to decreased drug clearance.  Therapy with acyclovir should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended in patients with moderate to severe renal dysfunction.', '3', 'Laskin OL, Longstreth JA, Whelton A, et al. "Effect of renal failure on the pharmacokinetics of acyclovir." Am J Med 73 (1982):  197-201|Laskin OL, Longstreth JA, Whelton A, et al. "Acyclovir kinetics in end-stage renal disease." Clin Pharmacol Ther 31 (1982):  594-600|Sawyer MH, Webb DE, Balow JE, Straus SE "Acyclovir-induced renal failure." Am J Med 84 (1988):  1067-71|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Rashed A, Asadeh B, Romeh SHA "Acyclovir-induced acute tubulo-interstitial nephritis." Nephron 56 (1990):  436-8|Peterslund NA, Larsen ML, Mygind H "Acyclovir crystalluria." Scand J Infect Dis 20 (1988):  225-8|Gnann JW, Barton NH, Whitley RJ "Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications." Pharmacotherapy 3 (1983):  275-83|Hernandez E, Praga M, Moreno F, Montoyo C "Acute renal failure induced by oral acyclovir." Clin Nephrol 36 (1991):  155-6|Bianchetti MG, Roduit C, Oetliker OH "Acyclovir-induced renal failure: course and risk factors." Pediatr Nephrol 5 (1991):  238-9|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Becker BN, Fall P, Hall C, Milam D, Leonard J, Glick A, Schulman G "Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature." Am J Kidney Dis 22 (1993):  611-5|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34346, 29411, 'Acyclovir', 'Kidney Diseases', 'Acyclovir is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for neuro- and nephrotoxicity (including further deterioration in renal function, tubular damage and acute renal failure) from acyclovir due to decreased drug clearance.  Therapy with acyclovir should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended in patients with moderate to severe renal dysfunction.', '3', 'Laskin OL, Longstreth JA, Whelton A, et al. "Effect of renal failure on the pharmacokinetics of acyclovir." Am J Med 73 (1982):  197-201|Laskin OL, Longstreth JA, Whelton A, et al. "Acyclovir kinetics in end-stage renal disease." Clin Pharmacol Ther 31 (1982):  594-600|Sawyer MH, Webb DE, Balow JE, Straus SE "Acyclovir-induced renal failure." Am J Med 84 (1988):  1067-71|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Rashed A, Asadeh B, Romeh SHA "Acyclovir-induced acute tubulo-interstitial nephritis." Nephron 56 (1990):  436-8|Peterslund NA, Larsen ML, Mygind H "Acyclovir crystalluria." Scand J Infect Dis 20 (1988):  225-8|Gnann JW, Barton NH, Whitley RJ "Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications." Pharmacotherapy 3 (1983):  275-83|Hernandez E, Praga M, Moreno F, Montoyo C "Acute renal failure induced by oral acyclovir." Clin Nephrol 36 (1991):  155-6|Bianchetti MG, Roduit C, Oetliker OH "Acyclovir-induced renal failure: course and risk factors." Pediatr Nephrol 5 (1991):  238-9|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Becker BN, Fall P, Hall C, Milam D, Leonard J, Glick A, Schulman G "Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature." Am J Kidney Dis 22 (1993):  611-5|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34347, 29412, 'Acyclovir', 'Kidney Diseases', 'Acyclovir is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for neuro- and nephrotoxicity (including further deterioration in renal function, tubular damage and acute renal failure) from acyclovir due to decreased drug clearance.  Therapy with acyclovir should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended in patients with moderate to severe renal dysfunction.', '3', 'Laskin OL, Longstreth JA, Whelton A, et al. "Effect of renal failure on the pharmacokinetics of acyclovir." Am J Med 73 (1982):  197-201|Laskin OL, Longstreth JA, Whelton A, et al. "Acyclovir kinetics in end-stage renal disease." Clin Pharmacol Ther 31 (1982):  594-600|Sawyer MH, Webb DE, Balow JE, Straus SE "Acyclovir-induced renal failure." Am J Med 84 (1988):  1067-71|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Rashed A, Asadeh B, Romeh SHA "Acyclovir-induced acute tubulo-interstitial nephritis." Nephron 56 (1990):  436-8|Peterslund NA, Larsen ML, Mygind H "Acyclovir crystalluria." Scand J Infect Dis 20 (1988):  225-8|Gnann JW, Barton NH, Whitley RJ "Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications." Pharmacotherapy 3 (1983):  275-83|Hernandez E, Praga M, Moreno F, Montoyo C "Acute renal failure induced by oral acyclovir." Clin Nephrol 36 (1991):  155-6|Bianchetti MG, Roduit C, Oetliker OH "Acyclovir-induced renal failure: course and risk factors." Pediatr Nephrol 5 (1991):  238-9|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Becker BN, Fall P, Hall C, Milam D, Leonard J, Glick A, Schulman G "Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature." Am J Kidney Dis 22 (1993):  611-5|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34348, 29413, 'Acyclovir', 'Kidney Diseases', 'Acyclovir is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for neuro- and nephrotoxicity (including further deterioration in renal function, tubular damage and acute renal failure) from acyclovir due to decreased drug clearance.  Therapy with acyclovir should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended in patients with moderate to severe renal dysfunction.', '3', 'Laskin OL, Longstreth JA, Whelton A, et al. "Effect of renal failure on the pharmacokinetics of acyclovir." Am J Med 73 (1982):  197-201|Laskin OL, Longstreth JA, Whelton A, et al. "Acyclovir kinetics in end-stage renal disease." Clin Pharmacol Ther 31 (1982):  594-600|Sawyer MH, Webb DE, Balow JE, Straus SE "Acyclovir-induced renal failure." Am J Med 84 (1988):  1067-71|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Rashed A, Asadeh B, Romeh SHA "Acyclovir-induced acute tubulo-interstitial nephritis." Nephron 56 (1990):  436-8|Peterslund NA, Larsen ML, Mygind H "Acyclovir crystalluria." Scand J Infect Dis 20 (1988):  225-8|Gnann JW, Barton NH, Whitley RJ "Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications." Pharmacotherapy 3 (1983):  275-83|Hernandez E, Praga M, Moreno F, Montoyo C "Acute renal failure induced by oral acyclovir." Clin Nephrol 36 (1991):  155-6|Bianchetti MG, Roduit C, Oetliker OH "Acyclovir-induced renal failure: course and risk factors." Pediatr Nephrol 5 (1991):  238-9|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Becker BN, Fall P, Hall C, Milam D, Leonard J, Glick A, Schulman G "Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature." Am J Kidney Dis 22 (1993):  611-5|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34349, 29414, 'Acyclovir', 'Kidney Diseases', 'Acyclovir is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for neuro- and nephrotoxicity (including further deterioration in renal function, tubular damage and acute renal failure) from acyclovir due to decreased drug clearance.  Therapy with acyclovir should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended in patients with moderate to severe renal dysfunction.', '3', 'Laskin OL, Longstreth JA, Whelton A, et al. "Effect of renal failure on the pharmacokinetics of acyclovir." Am J Med 73 (1982):  197-201|Laskin OL, Longstreth JA, Whelton A, et al. "Acyclovir kinetics in end-stage renal disease." Clin Pharmacol Ther 31 (1982):  594-600|Sawyer MH, Webb DE, Balow JE, Straus SE "Acyclovir-induced renal failure." Am J Med 84 (1988):  1067-71|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Rashed A, Asadeh B, Romeh SHA "Acyclovir-induced acute tubulo-interstitial nephritis." Nephron 56 (1990):  436-8|Peterslund NA, Larsen ML, Mygind H "Acyclovir crystalluria." Scand J Infect Dis 20 (1988):  225-8|Gnann JW, Barton NH, Whitley RJ "Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications." Pharmacotherapy 3 (1983):  275-83|Hernandez E, Praga M, Moreno F, Montoyo C "Acute renal failure induced by oral acyclovir." Clin Nephrol 36 (1991):  155-6|Bianchetti MG, Roduit C, Oetliker OH "Acyclovir-induced renal failure: course and risk factors." Pediatr Nephrol 5 (1991):  238-9|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Becker BN, Fall P, Hall C, Milam D, Leonard J, Glick A, Schulman G "Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature." Am J Kidney Dis 22 (1993):  611-5|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34350, 30031, 'Acyclovir', 'Kidney Diseases', 'Acyclovir is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for neuro- and nephrotoxicity (including further deterioration in renal function, tubular damage and acute renal failure) from acyclovir due to decreased drug clearance.  Therapy with acyclovir should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended in patients with moderate to severe renal dysfunction.', '3', 'Laskin OL, Longstreth JA, Whelton A, et al. "Effect of renal failure on the pharmacokinetics of acyclovir." Am J Med 73 (1982):  197-201|Laskin OL, Longstreth JA, Whelton A, et al. "Acyclovir kinetics in end-stage renal disease." Clin Pharmacol Ther 31 (1982):  594-600|Sawyer MH, Webb DE, Balow JE, Straus SE "Acyclovir-induced renal failure." Am J Med 84 (1988):  1067-71|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Rashed A, Asadeh B, Romeh SHA "Acyclovir-induced acute tubulo-interstitial nephritis." Nephron 56 (1990):  436-8|Peterslund NA, Larsen ML, Mygind H "Acyclovir crystalluria." Scand J Infect Dis 20 (1988):  225-8|Gnann JW, Barton NH, Whitley RJ "Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications." Pharmacotherapy 3 (1983):  275-83|Hernandez E, Praga M, Moreno F, Montoyo C "Acute renal failure induced by oral acyclovir." Clin Nephrol 36 (1991):  155-6|Bianchetti MG, Roduit C, Oetliker OH "Acyclovir-induced renal failure: course and risk factors." Pediatr Nephrol 5 (1991):  238-9|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Becker BN, Fall P, Hall C, Milam D, Leonard J, Glick A, Schulman G "Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature." Am J Kidney Dis 22 (1993):  611-5|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34351, 30034, 'Acyclovir', 'Kidney Diseases', 'Acyclovir is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for neuro- and nephrotoxicity (including further deterioration in renal function, tubular damage and acute renal failure) from acyclovir due to decreased drug clearance.  Therapy with acyclovir should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended in patients with moderate to severe renal dysfunction.', '3', 'Laskin OL, Longstreth JA, Whelton A, et al. "Effect of renal failure on the pharmacokinetics of acyclovir." Am J Med 73 (1982):  197-201|Laskin OL, Longstreth JA, Whelton A, et al. "Acyclovir kinetics in end-stage renal disease." Clin Pharmacol Ther 31 (1982):  594-600|Sawyer MH, Webb DE, Balow JE, Straus SE "Acyclovir-induced renal failure." Am J Med 84 (1988):  1067-71|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Rashed A, Asadeh B, Romeh SHA "Acyclovir-induced acute tubulo-interstitial nephritis." Nephron 56 (1990):  436-8|Peterslund NA, Larsen ML, Mygind H "Acyclovir crystalluria." Scand J Infect Dis 20 (1988):  225-8|Gnann JW, Barton NH, Whitley RJ "Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications." Pharmacotherapy 3 (1983):  275-83|Hernandez E, Praga M, Moreno F, Montoyo C "Acute renal failure induced by oral acyclovir." Clin Nephrol 36 (1991):  155-6|Bianchetti MG, Roduit C, Oetliker OH "Acyclovir-induced renal failure: course and risk factors." Pediatr Nephrol 5 (1991):  238-9|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Becker BN, Fall P, Hall C, Milam D, Leonard J, Glick A, Schulman G "Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature." Am J Kidney Dis 22 (1993):  611-5|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34352, 30036, 'Acyclovir', 'Kidney Diseases', 'Acyclovir is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for neuro- and nephrotoxicity (including further deterioration in renal function, tubular damage and acute renal failure) from acyclovir due to decreased drug clearance.  Therapy with acyclovir should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended in patients with moderate to severe renal dysfunction.', '3', 'Laskin OL, Longstreth JA, Whelton A, et al. "Effect of renal failure on the pharmacokinetics of acyclovir." Am J Med 73 (1982):  197-201|Laskin OL, Longstreth JA, Whelton A, et al. "Acyclovir kinetics in end-stage renal disease." Clin Pharmacol Ther 31 (1982):  594-600|Sawyer MH, Webb DE, Balow JE, Straus SE "Acyclovir-induced renal failure." Am J Med 84 (1988):  1067-71|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Rashed A, Asadeh B, Romeh SHA "Acyclovir-induced acute tubulo-interstitial nephritis." Nephron 56 (1990):  436-8|Peterslund NA, Larsen ML, Mygind H "Acyclovir crystalluria." Scand J Infect Dis 20 (1988):  225-8|Gnann JW, Barton NH, Whitley RJ "Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications." Pharmacotherapy 3 (1983):  275-83|Hernandez E, Praga M, Moreno F, Montoyo C "Acute renal failure induced by oral acyclovir." Clin Nephrol 36 (1991):  155-6|Bianchetti MG, Roduit C, Oetliker OH "Acyclovir-induced renal failure: course and risk factors." Pediatr Nephrol 5 (1991):  238-9|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Becker BN, Fall P, Hall C, Milam D, Leonard J, Glick A, Schulman G "Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature." Am J Kidney Dis 22 (1993):  611-5|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34353, 31696, 'Acyclovir', 'Kidney Diseases', 'Acyclovir is primarily eliminated by the kidney.  Patients with renal impairment may be at greater risk for neuro- and nephrotoxicity (including further deterioration in renal function, tubular damage and acute renal failure) from acyclovir due to decreased drug clearance.  Therapy with acyclovir should be administered cautiously in patients with renal impairment.  Dosage adjustments are recommended in patients with moderate to severe renal dysfunction.', '3', 'Laskin OL, Longstreth JA, Whelton A, et al. "Effect of renal failure on the pharmacokinetics of acyclovir." Am J Med 73 (1982):  197-201|Laskin OL, Longstreth JA, Whelton A, et al. "Acyclovir kinetics in end-stage renal disease." Clin Pharmacol Ther 31 (1982):  594-600|Sawyer MH, Webb DE, Balow JE, Straus SE "Acyclovir-induced renal failure." Am J Med 84 (1988):  1067-71|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Rashed A, Asadeh B, Romeh SHA "Acyclovir-induced acute tubulo-interstitial nephritis." Nephron 56 (1990):  436-8|Peterslund NA, Larsen ML, Mygind H "Acyclovir crystalluria." Scand J Infect Dis 20 (1988):  225-8|Gnann JW, Barton NH, Whitley RJ "Acyclovir: mechanism of action, pharmacokinetics, safety and clinical applications." Pharmacotherapy 3 (1983):  275-83|Hernandez E, Praga M, Moreno F, Montoyo C "Acute renal failure induced by oral acyclovir." Clin Nephrol 36 (1991):  155-6|Bianchetti MG, Roduit C, Oetliker OH "Acyclovir-induced renal failure: course and risk factors." Pediatr Nephrol 5 (1991):  238-9|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Becker BN, Fall P, Hall C, Milam D, Leonard J, Glick A, Schulman G "Rapidly progressive acute renal failure due to acyclovir: case report and review of the literature." Am J Kidney Dis 22 (1993):  611-5|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34354, 55, 'Acyclovir', 'Dehydration', 'Acyclovir crystals may precipitate in the renal tubules, particularly when the drug is injected intravenously as a bolus.  Abnormal renal function may occur, which is usually reversible but may infrequently progress to tubular damage and acute renal failure.  Patients who are dehydrated may be at increased risk for nephrotoxicity from acyclovir administration.  Intravenous acyclovir should be administered over a one-hour period accompanied by adequate hydration.  The urine flow should be monitored, especially within the first two hours following infusion when maximum urine concentration occurs.  The recommended urine output is a minimum of 500 mL per gram of drug infused.', '2', '"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34355, 71, 'Acyclovir', 'Dehydration', 'Acyclovir crystals may precipitate in the renal tubules, particularly when the drug is injected intravenously as a bolus.  Abnormal renal function may occur, which is usually reversible but may infrequently progress to tubular damage and acute renal failure.  Patients who are dehydrated may be at increased risk for nephrotoxicity from acyclovir administration.  Intravenous acyclovir should be administered over a one-hour period accompanied by adequate hydration.  The urine flow should be monitored, especially within the first two hours following infusion when maximum urine concentration occurs.  The recommended urine output is a minimum of 500 mL per gram of drug infused.', '2', '"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34356, 131, 'Acyclovir', 'Dehydration', 'Acyclovir crystals may precipitate in the renal tubules, particularly when the drug is injected intravenously as a bolus.  Abnormal renal function may occur, which is usually reversible but may infrequently progress to tubular damage and acute renal failure.  Patients who are dehydrated may be at increased risk for nephrotoxicity from acyclovir administration.  Intravenous acyclovir should be administered over a one-hour period accompanied by adequate hydration.  The urine flow should be monitored, especially within the first two hours following infusion when maximum urine concentration occurs.  The recommended urine output is a minimum of 500 mL per gram of drug infused.', '2', '"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34357, 133, 'Acyclovir', 'Dehydration', 'Acyclovir crystals may precipitate in the renal tubules, particularly when the drug is injected intravenously as a bolus.  Abnormal renal function may occur, which is usually reversible but may infrequently progress to tubular damage and acute renal failure.  Patients who are dehydrated may be at increased risk for nephrotoxicity from acyclovir administration.  Intravenous acyclovir should be administered over a one-hour period accompanied by adequate hydration.  The urine flow should be monitored, especially within the first two hours following infusion when maximum urine concentration occurs.  The recommended urine output is a minimum of 500 mL per gram of drug infused.', '2', '"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34358, 135, 'Acyclovir', 'Dehydration', 'Acyclovir crystals may precipitate in the renal tubules, particularly when the drug is injected intravenously as a bolus.  Abnormal renal function may occur, which is usually reversible but may infrequently progress to tubular damage and acute renal failure.  Patients who are dehydrated may be at increased risk for nephrotoxicity from acyclovir administration.  Intravenous acyclovir should be administered over a one-hour period accompanied by adequate hydration.  The urine flow should be monitored, especially within the first two hours following infusion when maximum urine concentration occurs.  The recommended urine output is a minimum of 500 mL per gram of drug infused.', '2', '"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34359, 137, 'Acyclovir', 'Dehydration', 'Acyclovir crystals may precipitate in the renal tubules, particularly when the drug is injected intravenously as a bolus.  Abnormal renal function may occur, which is usually reversible but may infrequently progress to tubular damage and acute renal failure.  Patients who are dehydrated may be at increased risk for nephrotoxicity from acyclovir administration.  Intravenous acyclovir should be administered over a one-hour period accompanied by adequate hydration.  The urine flow should be monitored, especially within the first two hours following infusion when maximum urine concentration occurs.  The recommended urine output is a minimum of 500 mL per gram of drug infused.', '2', '"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34360, 3222, 'Acyclovir', 'Dehydration', 'Acyclovir crystals may precipitate in the renal tubules, particularly when the drug is injected intravenously as a bolus.  Abnormal renal function may occur, which is usually reversible but may infrequently progress to tubular damage and acute renal failure.  Patients who are dehydrated may be at increased risk for nephrotoxicity from acyclovir administration.  Intravenous acyclovir should be administered over a one-hour period accompanied by adequate hydration.  The urine flow should be monitored, especially within the first two hours following infusion when maximum urine concentration occurs.  The recommended urine output is a minimum of 500 mL per gram of drug infused.', '2', '"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34361, 3223, 'Acyclovir', 'Dehydration', 'Acyclovir crystals may precipitate in the renal tubules, particularly when the drug is injected intravenously as a bolus.  Abnormal renal function may occur, which is usually reversible but may infrequently progress to tubular damage and acute renal failure.  Patients who are dehydrated may be at increased risk for nephrotoxicity from acyclovir administration.  Intravenous acyclovir should be administered over a one-hour period accompanied by adequate hydration.  The urine flow should be monitored, especially within the first two hours following infusion when maximum urine concentration occurs.  The recommended urine output is a minimum of 500 mL per gram of drug infused.', '2', '"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34362, 7574, 'Acyclovir', 'Dehydration', 'Acyclovir crystals may precipitate in the renal tubules, particularly when the drug is injected intravenously as a bolus.  Abnormal renal function may occur, which is usually reversible but may infrequently progress to tubular damage and acute renal failure.  Patients who are dehydrated may be at increased risk for nephrotoxicity from acyclovir administration.  Intravenous acyclovir should be administered over a one-hour period accompanied by adequate hydration.  The urine flow should be monitored, especially within the first two hours following infusion when maximum urine concentration occurs.  The recommended urine output is a minimum of 500 mL per gram of drug infused.', '2', '"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34363, 9055, 'Acyclovir', 'Dehydration', 'Acyclovir crystals may precipitate in the renal tubules, particularly when the drug is injected intravenously as a bolus.  Abnormal renal function may occur, which is usually reversible but may infrequently progress to tubular damage and acute renal failure.  Patients who are dehydrated may be at increased risk for nephrotoxicity from acyclovir administration.  Intravenous acyclovir should be administered over a one-hour period accompanied by adequate hydration.  The urine flow should be monitored, especially within the first two hours following infusion when maximum urine concentration occurs.  The recommended urine output is a minimum of 500 mL per gram of drug infused.', '2', '"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34364, 12351, 'Acyclovir', 'Dehydration', 'Acyclovir crystals may precipitate in the renal tubules, particularly when the drug is injected intravenously as a bolus.  Abnormal renal function may occur, which is usually reversible but may infrequently progress to tubular damage and acute renal failure.  Patients who are dehydrated may be at increased risk for nephrotoxicity from acyclovir administration.  Intravenous acyclovir should be administered over a one-hour period accompanied by adequate hydration.  The urine flow should be monitored, especially within the first two hours following infusion when maximum urine concentration occurs.  The recommended urine output is a minimum of 500 mL per gram of drug infused.', '2', '"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34365, 12352, 'Acyclovir', 'Dehydration', 'Acyclovir crystals may precipitate in the renal tubules, particularly when the drug is injected intravenously as a bolus.  Abnormal renal function may occur, which is usually reversible but may infrequently progress to tubular damage and acute renal failure.  Patients who are dehydrated may be at increased risk for nephrotoxicity from acyclovir administration.  Intravenous acyclovir should be administered over a one-hour period accompanied by adequate hydration.  The urine flow should be monitored, especially within the first two hours following infusion when maximum urine concentration occurs.  The recommended urine output is a minimum of 500 mL per gram of drug infused.', '2', '"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34366, 12934, 'Acyclovir', 'Dehydration', 'Acyclovir crystals may precipitate in the renal tubules, particularly when the drug is injected intravenously as a bolus.  Abnormal renal function may occur, which is usually reversible but may infrequently progress to tubular damage and acute renal failure.  Patients who are dehydrated may be at increased risk for nephrotoxicity from acyclovir administration.  Intravenous acyclovir should be administered over a one-hour period accompanied by adequate hydration.  The urine flow should be monitored, especially within the first two hours following infusion when maximum urine concentration occurs.  The recommended urine output is a minimum of 500 mL per gram of drug infused.', '2', '"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34367, 12935, 'Acyclovir', 'Dehydration', 'Acyclovir crystals may precipitate in the renal tubules, particularly when the drug is injected intravenously as a bolus.  Abnormal renal function may occur, which is usually reversible but may infrequently progress to tubular damage and acute renal failure.  Patients who are dehydrated may be at increased risk for nephrotoxicity from acyclovir administration.  Intravenous acyclovir should be administered over a one-hour period accompanied by adequate hydration.  The urine flow should be monitored, especially within the first two hours following infusion when maximum urine concentration occurs.  The recommended urine output is a minimum of 500 mL per gram of drug infused.', '2', '"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34368, 12936, 'Acyclovir', 'Dehydration', 'Acyclovir crystals may precipitate in the renal tubules, particularly when the drug is injected intravenously as a bolus.  Abnormal renal function may occur, which is usually reversible but may infrequently progress to tubular damage and acute renal failure.  Patients who are dehydrated may be at increased risk for nephrotoxicity from acyclovir administration.  Intravenous acyclovir should be administered over a one-hour period accompanied by adequate hydration.  The urine flow should be monitored, especially within the first two hours following infusion when maximum urine concentration occurs.  The recommended urine output is a minimum of 500 mL per gram of drug infused.', '2', '"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34369, 12938, 'Acyclovir', 'Dehydration', 'Acyclovir crystals may precipitate in the renal tubules, particularly when the drug is injected intravenously as a bolus.  Abnormal renal function may occur, which is usually reversible but may infrequently progress to tubular damage and acute renal failure.  Patients who are dehydrated may be at increased risk for nephrotoxicity from acyclovir administration.  Intravenous acyclovir should be administered over a one-hour period accompanied by adequate hydration.  The urine flow should be monitored, especially within the first two hours following infusion when maximum urine concentration occurs.  The recommended urine output is a minimum of 500 mL per gram of drug infused.', '2', '"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34370, 12940, 'Acyclovir', 'Dehydration', 'Acyclovir crystals may precipitate in the renal tubules, particularly when the drug is injected intravenously as a bolus.  Abnormal renal function may occur, which is usually reversible but may infrequently progress to tubular damage and acute renal failure.  Patients who are dehydrated may be at increased risk for nephrotoxicity from acyclovir administration.  Intravenous acyclovir should be administered over a one-hour period accompanied by adequate hydration.  The urine flow should be monitored, especially within the first two hours following infusion when maximum urine concentration occurs.  The recommended urine output is a minimum of 500 mL per gram of drug infused.', '2', '"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34371, 13330, 'Acyclovir', 'Dehydration', 'Acyclovir crystals may precipitate in the renal tubules, particularly when the drug is injected intravenously as a bolus.  Abnormal renal function may occur, which is usually reversible but may infrequently progress to tubular damage and acute renal failure.  Patients who are dehydrated may be at increased risk for nephrotoxicity from acyclovir administration.  Intravenous acyclovir should be administered over a one-hour period accompanied by adequate hydration.  The urine flow should be monitored, especially within the first two hours following infusion when maximum urine concentration occurs.  The recommended urine output is a minimum of 500 mL per gram of drug infused.', '2', '"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34372, 13346, 'Acyclovir', 'Dehydration', 'Acyclovir crystals may precipitate in the renal tubules, particularly when the drug is injected intravenously as a bolus.  Abnormal renal function may occur, which is usually reversible but may infrequently progress to tubular damage and acute renal failure.  Patients who are dehydrated may be at increased risk for nephrotoxicity from acyclovir administration.  Intravenous acyclovir should be administered over a one-hour period accompanied by adequate hydration.  The urine flow should be monitored, especially within the first two hours following infusion when maximum urine concentration occurs.  The recommended urine output is a minimum of 500 mL per gram of drug infused.', '2', '"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34373, 13455, 'Acyclovir', 'Dehydration', 'Acyclovir crystals may precipitate in the renal tubules, particularly when the drug is injected intravenously as a bolus.  Abnormal renal function may occur, which is usually reversible but may infrequently progress to tubular damage and acute renal failure.  Patients who are dehydrated may be at increased risk for nephrotoxicity from acyclovir administration.  Intravenous acyclovir should be administered over a one-hour period accompanied by adequate hydration.  The urine flow should be monitored, especially within the first two hours following infusion when maximum urine concentration occurs.  The recommended urine output is a minimum of 500 mL per gram of drug infused.', '2', '"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34374, 13457, 'Acyclovir', 'Dehydration', 'Acyclovir crystals may precipitate in the renal tubules, particularly when the drug is injected intravenously as a bolus.  Abnormal renal function may occur, which is usually reversible but may infrequently progress to tubular damage and acute renal failure.  Patients who are dehydrated may be at increased risk for nephrotoxicity from acyclovir administration.  Intravenous acyclovir should be administered over a one-hour period accompanied by adequate hydration.  The urine flow should be monitored, especially within the first two hours following infusion when maximum urine concentration occurs.  The recommended urine output is a minimum of 500 mL per gram of drug infused.', '2', '"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34375, 15444, 'Acyclovir', 'Dehydration', 'Acyclovir crystals may precipitate in the renal tubules, particularly when the drug is injected intravenously as a bolus.  Abnormal renal function may occur, which is usually reversible but may infrequently progress to tubular damage and acute renal failure.  Patients who are dehydrated may be at increased risk for nephrotoxicity from acyclovir administration.  Intravenous acyclovir should be administered over a one-hour period accompanied by adequate hydration.  The urine flow should be monitored, especially within the first two hours following infusion when maximum urine concentration occurs.  The recommended urine output is a minimum of 500 mL per gram of drug infused.', '2', '"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34376, 16999, 'Acyclovir', 'Dehydration', 'Acyclovir crystals may precipitate in the renal tubules, particularly when the drug is injected intravenously as a bolus.  Abnormal renal function may occur, which is usually reversible but may infrequently progress to tubular damage and acute renal failure.  Patients who are dehydrated may be at increased risk for nephrotoxicity from acyclovir administration.  Intravenous acyclovir should be administered over a one-hour period accompanied by adequate hydration.  The urine flow should be monitored, especially within the first two hours following infusion when maximum urine concentration occurs.  The recommended urine output is a minimum of 500 mL per gram of drug infused.', '2', '"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34377, 27726, 'Acyclovir', 'Dehydration', 'Acyclovir crystals may precipitate in the renal tubules, particularly when the drug is injected intravenously as a bolus.  Abnormal renal function may occur, which is usually reversible but may infrequently progress to tubular damage and acute renal failure.  Patients who are dehydrated may be at increased risk for nephrotoxicity from acyclovir administration.  Intravenous acyclovir should be administered over a one-hour period accompanied by adequate hydration.  The urine flow should be monitored, especially within the first two hours following infusion when maximum urine concentration occurs.  The recommended urine output is a minimum of 500 mL per gram of drug infused.', '2', '"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34378, 29411, 'Acyclovir', 'Dehydration', 'Acyclovir crystals may precipitate in the renal tubules, particularly when the drug is injected intravenously as a bolus.  Abnormal renal function may occur, which is usually reversible but may infrequently progress to tubular damage and acute renal failure.  Patients who are dehydrated may be at increased risk for nephrotoxicity from acyclovir administration.  Intravenous acyclovir should be administered over a one-hour period accompanied by adequate hydration.  The urine flow should be monitored, especially within the first two hours following infusion when maximum urine concentration occurs.  The recommended urine output is a minimum of 500 mL per gram of drug infused.', '2', '"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34379, 29412, 'Acyclovir', 'Dehydration', 'Acyclovir crystals may precipitate in the renal tubules, particularly when the drug is injected intravenously as a bolus.  Abnormal renal function may occur, which is usually reversible but may infrequently progress to tubular damage and acute renal failure.  Patients who are dehydrated may be at increased risk for nephrotoxicity from acyclovir administration.  Intravenous acyclovir should be administered over a one-hour period accompanied by adequate hydration.  The urine flow should be monitored, especially within the first two hours following infusion when maximum urine concentration occurs.  The recommended urine output is a minimum of 500 mL per gram of drug infused.', '2', '"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34380, 29413, 'Acyclovir', 'Dehydration', 'Acyclovir crystals may precipitate in the renal tubules, particularly when the drug is injected intravenously as a bolus.  Abnormal renal function may occur, which is usually reversible but may infrequently progress to tubular damage and acute renal failure.  Patients who are dehydrated may be at increased risk for nephrotoxicity from acyclovir administration.  Intravenous acyclovir should be administered over a one-hour period accompanied by adequate hydration.  The urine flow should be monitored, especially within the first two hours following infusion when maximum urine concentration occurs.  The recommended urine output is a minimum of 500 mL per gram of drug infused.', '2', '"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34381, 29414, 'Acyclovir', 'Dehydration', 'Acyclovir crystals may precipitate in the renal tubules, particularly when the drug is injected intravenously as a bolus.  Abnormal renal function may occur, which is usually reversible but may infrequently progress to tubular damage and acute renal failure.  Patients who are dehydrated may be at increased risk for nephrotoxicity from acyclovir administration.  Intravenous acyclovir should be administered over a one-hour period accompanied by adequate hydration.  The urine flow should be monitored, especially within the first two hours following infusion when maximum urine concentration occurs.  The recommended urine output is a minimum of 500 mL per gram of drug infused.', '2', '"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34382, 30031, 'Acyclovir', 'Dehydration', 'Acyclovir crystals may precipitate in the renal tubules, particularly when the drug is injected intravenously as a bolus.  Abnormal renal function may occur, which is usually reversible but may infrequently progress to tubular damage and acute renal failure.  Patients who are dehydrated may be at increased risk for nephrotoxicity from acyclovir administration.  Intravenous acyclovir should be administered over a one-hour period accompanied by adequate hydration.  The urine flow should be monitored, especially within the first two hours following infusion when maximum urine concentration occurs.  The recommended urine output is a minimum of 500 mL per gram of drug infused.', '2', '"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34383, 30034, 'Acyclovir', 'Dehydration', 'Acyclovir crystals may precipitate in the renal tubules, particularly when the drug is injected intravenously as a bolus.  Abnormal renal function may occur, which is usually reversible but may infrequently progress to tubular damage and acute renal failure.  Patients who are dehydrated may be at increased risk for nephrotoxicity from acyclovir administration.  Intravenous acyclovir should be administered over a one-hour period accompanied by adequate hydration.  The urine flow should be monitored, especially within the first two hours following infusion when maximum urine concentration occurs.  The recommended urine output is a minimum of 500 mL per gram of drug infused.', '2', '"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34384, 30036, 'Acyclovir', 'Dehydration', 'Acyclovir crystals may precipitate in the renal tubules, particularly when the drug is injected intravenously as a bolus.  Abnormal renal function may occur, which is usually reversible but may infrequently progress to tubular damage and acute renal failure.  Patients who are dehydrated may be at increased risk for nephrotoxicity from acyclovir administration.  Intravenous acyclovir should be administered over a one-hour period accompanied by adequate hydration.  The urine flow should be monitored, especially within the first two hours following infusion when maximum urine concentration occurs.  The recommended urine output is a minimum of 500 mL per gram of drug infused.', '2', '"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34385, 31696, 'Acyclovir', 'Dehydration', 'Acyclovir crystals may precipitate in the renal tubules, particularly when the drug is injected intravenously as a bolus.  Abnormal renal function may occur, which is usually reversible but may infrequently progress to tubular damage and acute renal failure.  Patients who are dehydrated may be at increased risk for nephrotoxicity from acyclovir administration.  Intravenous acyclovir should be administered over a one-hour period accompanied by adequate hydration.  The urine flow should be monitored, especially within the first two hours following infusion when maximum urine concentration occurs.  The recommended urine output is a minimum of 500 mL per gram of drug infused.', '2', '"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34386, 55, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', 'Krasny HC, Liao SH, de Miranda P, Laskin OL, Whelton A, Lietman PS "Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure." Am J Med 73 (1982):  202-4|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34387, 71, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', 'Krasny HC, Liao SH, de Miranda P, Laskin OL, Whelton A, Lietman PS "Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure." Am J Med 73 (1982):  202-4|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34388, 131, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', 'Krasny HC, Liao SH, de Miranda P, Laskin OL, Whelton A, Lietman PS "Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure." Am J Med 73 (1982):  202-4|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34389, 133, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', 'Krasny HC, Liao SH, de Miranda P, Laskin OL, Whelton A, Lietman PS "Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure." Am J Med 73 (1982):  202-4|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34390, 135, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', 'Krasny HC, Liao SH, de Miranda P, Laskin OL, Whelton A, Lietman PS "Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure." Am J Med 73 (1982):  202-4|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34391, 137, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', 'Krasny HC, Liao SH, de Miranda P, Laskin OL, Whelton A, Lietman PS "Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure." Am J Med 73 (1982):  202-4|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34392, 3222, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', 'Krasny HC, Liao SH, de Miranda P, Laskin OL, Whelton A, Lietman PS "Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure." Am J Med 73 (1982):  202-4|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34393, 3223, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', 'Krasny HC, Liao SH, de Miranda P, Laskin OL, Whelton A, Lietman PS "Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure." Am J Med 73 (1982):  202-4|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34394, 7574, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', 'Krasny HC, Liao SH, de Miranda P, Laskin OL, Whelton A, Lietman PS "Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure." Am J Med 73 (1982):  202-4|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34395, 9055, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', 'Krasny HC, Liao SH, de Miranda P, Laskin OL, Whelton A, Lietman PS "Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure." Am J Med 73 (1982):  202-4|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34396, 12351, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', 'Krasny HC, Liao SH, de Miranda P, Laskin OL, Whelton A, Lietman PS "Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure." Am J Med 73 (1982):  202-4|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34397, 12352, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', 'Krasny HC, Liao SH, de Miranda P, Laskin OL, Whelton A, Lietman PS "Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure." Am J Med 73 (1982):  202-4|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34398, 12934, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', 'Krasny HC, Liao SH, de Miranda P, Laskin OL, Whelton A, Lietman PS "Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure." Am J Med 73 (1982):  202-4|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34399, 12935, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', 'Krasny HC, Liao SH, de Miranda P, Laskin OL, Whelton A, Lietman PS "Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure." Am J Med 73 (1982):  202-4|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34400, 12936, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', 'Krasny HC, Liao SH, de Miranda P, Laskin OL, Whelton A, Lietman PS "Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure." Am J Med 73 (1982):  202-4|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34401, 12938, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', 'Krasny HC, Liao SH, de Miranda P, Laskin OL, Whelton A, Lietman PS "Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure." Am J Med 73 (1982):  202-4|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34402, 12940, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', 'Krasny HC, Liao SH, de Miranda P, Laskin OL, Whelton A, Lietman PS "Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure." Am J Med 73 (1982):  202-4|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34403, 13330, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', 'Krasny HC, Liao SH, de Miranda P, Laskin OL, Whelton A, Lietman PS "Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure." Am J Med 73 (1982):  202-4|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34404, 13346, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', 'Krasny HC, Liao SH, de Miranda P, Laskin OL, Whelton A, Lietman PS "Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure." Am J Med 73 (1982):  202-4|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34405, 13455, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', 'Krasny HC, Liao SH, de Miranda P, Laskin OL, Whelton A, Lietman PS "Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure." Am J Med 73 (1982):  202-4|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34406, 13457, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', 'Krasny HC, Liao SH, de Miranda P, Laskin OL, Whelton A, Lietman PS "Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure." Am J Med 73 (1982):  202-4|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34407, 15444, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', 'Krasny HC, Liao SH, de Miranda P, Laskin OL, Whelton A, Lietman PS "Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure." Am J Med 73 (1982):  202-4|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34408, 16999, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', 'Krasny HC, Liao SH, de Miranda P, Laskin OL, Whelton A, Lietman PS "Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure." Am J Med 73 (1982):  202-4|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34409, 27726, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', 'Krasny HC, Liao SH, de Miranda P, Laskin OL, Whelton A, Lietman PS "Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure." Am J Med 73 (1982):  202-4|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34410, 29411, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', 'Krasny HC, Liao SH, de Miranda P, Laskin OL, Whelton A, Lietman PS "Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure." Am J Med 73 (1982):  202-4|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34411, 29412, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', 'Krasny HC, Liao SH, de Miranda P, Laskin OL, Whelton A, Lietman PS "Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure." Am J Med 73 (1982):  202-4|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34412, 29413, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', 'Krasny HC, Liao SH, de Miranda P, Laskin OL, Whelton A, Lietman PS "Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure." Am J Med 73 (1982):  202-4|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34413, 29414, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', 'Krasny HC, Liao SH, de Miranda P, Laskin OL, Whelton A, Lietman PS "Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure." Am J Med 73 (1982):  202-4|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34414, 30031, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', 'Krasny HC, Liao SH, de Miranda P, Laskin OL, Whelton A, Lietman PS "Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure." Am J Med 73 (1982):  202-4|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34415, 30034, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', 'Krasny HC, Liao SH, de Miranda P, Laskin OL, Whelton A, Lietman PS "Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure." Am J Med 73 (1982):  202-4|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34416, 30036, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', 'Krasny HC, Liao SH, de Miranda P, Laskin OL, Whelton A, Lietman PS "Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure." Am J Med 73 (1982):  202-4|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34417, 31696, 'Acyclovir', 'Diseases requiring hemodialysis', 'Acyclovir is substantially removed by hemodialysis.  Plasma levels of acyclovir have been shown to reduce by 60% following 6 hours of dialysis.  Acyclovir should be administered after hemodialysis.  Otherwise, an additional dose may be given after each hemodialysis session.', '2', 'Krasny HC, Liao SH, de Miranda P, Laskin OL, Whelton A, Lietman PS "Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure." Am J Med 73 (1982):  202-4|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34418, 55, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', 'Jones PG, Beier-Hanratty SA "Acyclovir: neurologic and renal toxicity." Ann Intern Med 104 (1986):  892|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Feldman S, Rodman J, Gregory B "Excessive serum concentrations of acyclovir and neurotoxicity." J Infect Dis 157 (1988):  385-8|Cohen SM, Minkove JA, Zebley JW, Mulholland JH "Severe but reversible neurotoxicity from acyclovir." Ann Intern Med 100 (1984):  920|Wade JC, Meyers JD "Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation." Ann Intern Med 98 (1983):  921-5|Bean B, Aeppli D "Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster." J Infect Dis 151 (1985):  362-5|Gill MJ, Burgess E "Neurotoxicity of acyclovir in end stage renal disease." J Antimicrob Chemother 25 (1990):  300-1|MacDiarmaid-Gordon AR, O''Connor M, Beaman M, Ackrill P "Neurotoxicity associated with oral acyclovir in patients undergoing dialysis." Nephron 62 (1992):  280-3|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Rashiq S, Briewa L, Mooney M, Giancarlo T, Khatib R, Wilson FM "Distinguishing acyclovir neurotoxicity from encephalomyelitis." J Intern Med 234 (1993):  507-11|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34419, 71, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', 'Jones PG, Beier-Hanratty SA "Acyclovir: neurologic and renal toxicity." Ann Intern Med 104 (1986):  892|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Feldman S, Rodman J, Gregory B "Excessive serum concentrations of acyclovir and neurotoxicity." J Infect Dis 157 (1988):  385-8|Cohen SM, Minkove JA, Zebley JW, Mulholland JH "Severe but reversible neurotoxicity from acyclovir." Ann Intern Med 100 (1984):  920|Wade JC, Meyers JD "Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation." Ann Intern Med 98 (1983):  921-5|Bean B, Aeppli D "Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster." J Infect Dis 151 (1985):  362-5|Gill MJ, Burgess E "Neurotoxicity of acyclovir in end stage renal disease." J Antimicrob Chemother 25 (1990):  300-1|MacDiarmaid-Gordon AR, O''Connor M, Beaman M, Ackrill P "Neurotoxicity associated with oral acyclovir in patients undergoing dialysis." Nephron 62 (1992):  280-3|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Rashiq S, Briewa L, Mooney M, Giancarlo T, Khatib R, Wilson FM "Distinguishing acyclovir neurotoxicity from encephalomyelitis." J Intern Med 234 (1993):  507-11|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34420, 131, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', 'Jones PG, Beier-Hanratty SA "Acyclovir: neurologic and renal toxicity." Ann Intern Med 104 (1986):  892|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Feldman S, Rodman J, Gregory B "Excessive serum concentrations of acyclovir and neurotoxicity." J Infect Dis 157 (1988):  385-8|Cohen SM, Minkove JA, Zebley JW, Mulholland JH "Severe but reversible neurotoxicity from acyclovir." Ann Intern Med 100 (1984):  920|Wade JC, Meyers JD "Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation." Ann Intern Med 98 (1983):  921-5|Bean B, Aeppli D "Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster." J Infect Dis 151 (1985):  362-5|Gill MJ, Burgess E "Neurotoxicity of acyclovir in end stage renal disease." J Antimicrob Chemother 25 (1990):  300-1|MacDiarmaid-Gordon AR, O''Connor M, Beaman M, Ackrill P "Neurotoxicity associated with oral acyclovir in patients undergoing dialysis." Nephron 62 (1992):  280-3|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Rashiq S, Briewa L, Mooney M, Giancarlo T, Khatib R, Wilson FM "Distinguishing acyclovir neurotoxicity from encephalomyelitis." J Intern Med 234 (1993):  507-11|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34421, 133, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', 'Jones PG, Beier-Hanratty SA "Acyclovir: neurologic and renal toxicity." Ann Intern Med 104 (1986):  892|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Feldman S, Rodman J, Gregory B "Excessive serum concentrations of acyclovir and neurotoxicity." J Infect Dis 157 (1988):  385-8|Cohen SM, Minkove JA, Zebley JW, Mulholland JH "Severe but reversible neurotoxicity from acyclovir." Ann Intern Med 100 (1984):  920|Wade JC, Meyers JD "Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation." Ann Intern Med 98 (1983):  921-5|Bean B, Aeppli D "Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster." J Infect Dis 151 (1985):  362-5|Gill MJ, Burgess E "Neurotoxicity of acyclovir in end stage renal disease." J Antimicrob Chemother 25 (1990):  300-1|MacDiarmaid-Gordon AR, O''Connor M, Beaman M, Ackrill P "Neurotoxicity associated with oral acyclovir in patients undergoing dialysis." Nephron 62 (1992):  280-3|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Rashiq S, Briewa L, Mooney M, Giancarlo T, Khatib R, Wilson FM "Distinguishing acyclovir neurotoxicity from encephalomyelitis." J Intern Med 234 (1993):  507-11|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34422, 135, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', 'Jones PG, Beier-Hanratty SA "Acyclovir: neurologic and renal toxicity." Ann Intern Med 104 (1986):  892|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Feldman S, Rodman J, Gregory B "Excessive serum concentrations of acyclovir and neurotoxicity." J Infect Dis 157 (1988):  385-8|Cohen SM, Minkove JA, Zebley JW, Mulholland JH "Severe but reversible neurotoxicity from acyclovir." Ann Intern Med 100 (1984):  920|Wade JC, Meyers JD "Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation." Ann Intern Med 98 (1983):  921-5|Bean B, Aeppli D "Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster." J Infect Dis 151 (1985):  362-5|Gill MJ, Burgess E "Neurotoxicity of acyclovir in end stage renal disease." J Antimicrob Chemother 25 (1990):  300-1|MacDiarmaid-Gordon AR, O''Connor M, Beaman M, Ackrill P "Neurotoxicity associated with oral acyclovir in patients undergoing dialysis." Nephron 62 (1992):  280-3|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Rashiq S, Briewa L, Mooney M, Giancarlo T, Khatib R, Wilson FM "Distinguishing acyclovir neurotoxicity from encephalomyelitis." J Intern Med 234 (1993):  507-11|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34423, 137, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', 'Jones PG, Beier-Hanratty SA "Acyclovir: neurologic and renal toxicity." Ann Intern Med 104 (1986):  892|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Feldman S, Rodman J, Gregory B "Excessive serum concentrations of acyclovir and neurotoxicity." J Infect Dis 157 (1988):  385-8|Cohen SM, Minkove JA, Zebley JW, Mulholland JH "Severe but reversible neurotoxicity from acyclovir." Ann Intern Med 100 (1984):  920|Wade JC, Meyers JD "Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation." Ann Intern Med 98 (1983):  921-5|Bean B, Aeppli D "Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster." J Infect Dis 151 (1985):  362-5|Gill MJ, Burgess E "Neurotoxicity of acyclovir in end stage renal disease." J Antimicrob Chemother 25 (1990):  300-1|MacDiarmaid-Gordon AR, O''Connor M, Beaman M, Ackrill P "Neurotoxicity associated with oral acyclovir in patients undergoing dialysis." Nephron 62 (1992):  280-3|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Rashiq S, Briewa L, Mooney M, Giancarlo T, Khatib R, Wilson FM "Distinguishing acyclovir neurotoxicity from encephalomyelitis." J Intern Med 234 (1993):  507-11|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34424, 3222, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', 'Jones PG, Beier-Hanratty SA "Acyclovir: neurologic and renal toxicity." Ann Intern Med 104 (1986):  892|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Feldman S, Rodman J, Gregory B "Excessive serum concentrations of acyclovir and neurotoxicity." J Infect Dis 157 (1988):  385-8|Cohen SM, Minkove JA, Zebley JW, Mulholland JH "Severe but reversible neurotoxicity from acyclovir." Ann Intern Med 100 (1984):  920|Wade JC, Meyers JD "Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation." Ann Intern Med 98 (1983):  921-5|Bean B, Aeppli D "Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster." J Infect Dis 151 (1985):  362-5|Gill MJ, Burgess E "Neurotoxicity of acyclovir in end stage renal disease." J Antimicrob Chemother 25 (1990):  300-1|MacDiarmaid-Gordon AR, O''Connor M, Beaman M, Ackrill P "Neurotoxicity associated with oral acyclovir in patients undergoing dialysis." Nephron 62 (1992):  280-3|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Rashiq S, Briewa L, Mooney M, Giancarlo T, Khatib R, Wilson FM "Distinguishing acyclovir neurotoxicity from encephalomyelitis." J Intern Med 234 (1993):  507-11|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34425, 3223, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', 'Jones PG, Beier-Hanratty SA "Acyclovir: neurologic and renal toxicity." Ann Intern Med 104 (1986):  892|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Feldman S, Rodman J, Gregory B "Excessive serum concentrations of acyclovir and neurotoxicity." J Infect Dis 157 (1988):  385-8|Cohen SM, Minkove JA, Zebley JW, Mulholland JH "Severe but reversible neurotoxicity from acyclovir." Ann Intern Med 100 (1984):  920|Wade JC, Meyers JD "Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation." Ann Intern Med 98 (1983):  921-5|Bean B, Aeppli D "Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster." J Infect Dis 151 (1985):  362-5|Gill MJ, Burgess E "Neurotoxicity of acyclovir in end stage renal disease." J Antimicrob Chemother 25 (1990):  300-1|MacDiarmaid-Gordon AR, O''Connor M, Beaman M, Ackrill P "Neurotoxicity associated with oral acyclovir in patients undergoing dialysis." Nephron 62 (1992):  280-3|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Rashiq S, Briewa L, Mooney M, Giancarlo T, Khatib R, Wilson FM "Distinguishing acyclovir neurotoxicity from encephalomyelitis." J Intern Med 234 (1993):  507-11|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34426, 7574, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', 'Jones PG, Beier-Hanratty SA "Acyclovir: neurologic and renal toxicity." Ann Intern Med 104 (1986):  892|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Feldman S, Rodman J, Gregory B "Excessive serum concentrations of acyclovir and neurotoxicity." J Infect Dis 157 (1988):  385-8|Cohen SM, Minkove JA, Zebley JW, Mulholland JH "Severe but reversible neurotoxicity from acyclovir." Ann Intern Med 100 (1984):  920|Wade JC, Meyers JD "Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation." Ann Intern Med 98 (1983):  921-5|Bean B, Aeppli D "Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster." J Infect Dis 151 (1985):  362-5|Gill MJ, Burgess E "Neurotoxicity of acyclovir in end stage renal disease." J Antimicrob Chemother 25 (1990):  300-1|MacDiarmaid-Gordon AR, O''Connor M, Beaman M, Ackrill P "Neurotoxicity associated with oral acyclovir in patients undergoing dialysis." Nephron 62 (1992):  280-3|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Rashiq S, Briewa L, Mooney M, Giancarlo T, Khatib R, Wilson FM "Distinguishing acyclovir neurotoxicity from encephalomyelitis." J Intern Med 234 (1993):  507-11|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34427, 9055, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', 'Jones PG, Beier-Hanratty SA "Acyclovir: neurologic and renal toxicity." Ann Intern Med 104 (1986):  892|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Feldman S, Rodman J, Gregory B "Excessive serum concentrations of acyclovir and neurotoxicity." J Infect Dis 157 (1988):  385-8|Cohen SM, Minkove JA, Zebley JW, Mulholland JH "Severe but reversible neurotoxicity from acyclovir." Ann Intern Med 100 (1984):  920|Wade JC, Meyers JD "Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation." Ann Intern Med 98 (1983):  921-5|Bean B, Aeppli D "Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster." J Infect Dis 151 (1985):  362-5|Gill MJ, Burgess E "Neurotoxicity of acyclovir in end stage renal disease." J Antimicrob Chemother 25 (1990):  300-1|MacDiarmaid-Gordon AR, O''Connor M, Beaman M, Ackrill P "Neurotoxicity associated with oral acyclovir in patients undergoing dialysis." Nephron 62 (1992):  280-3|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Rashiq S, Briewa L, Mooney M, Giancarlo T, Khatib R, Wilson FM "Distinguishing acyclovir neurotoxicity from encephalomyelitis." J Intern Med 234 (1993):  507-11|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34428, 12351, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', 'Jones PG, Beier-Hanratty SA "Acyclovir: neurologic and renal toxicity." Ann Intern Med 104 (1986):  892|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Feldman S, Rodman J, Gregory B "Excessive serum concentrations of acyclovir and neurotoxicity." J Infect Dis 157 (1988):  385-8|Cohen SM, Minkove JA, Zebley JW, Mulholland JH "Severe but reversible neurotoxicity from acyclovir." Ann Intern Med 100 (1984):  920|Wade JC, Meyers JD "Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation." Ann Intern Med 98 (1983):  921-5|Bean B, Aeppli D "Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster." J Infect Dis 151 (1985):  362-5|Gill MJ, Burgess E "Neurotoxicity of acyclovir in end stage renal disease." J Antimicrob Chemother 25 (1990):  300-1|MacDiarmaid-Gordon AR, O''Connor M, Beaman M, Ackrill P "Neurotoxicity associated with oral acyclovir in patients undergoing dialysis." Nephron 62 (1992):  280-3|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Rashiq S, Briewa L, Mooney M, Giancarlo T, Khatib R, Wilson FM "Distinguishing acyclovir neurotoxicity from encephalomyelitis." J Intern Med 234 (1993):  507-11|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34429, 12352, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', 'Jones PG, Beier-Hanratty SA "Acyclovir: neurologic and renal toxicity." Ann Intern Med 104 (1986):  892|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Feldman S, Rodman J, Gregory B "Excessive serum concentrations of acyclovir and neurotoxicity." J Infect Dis 157 (1988):  385-8|Cohen SM, Minkove JA, Zebley JW, Mulholland JH "Severe but reversible neurotoxicity from acyclovir." Ann Intern Med 100 (1984):  920|Wade JC, Meyers JD "Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation." Ann Intern Med 98 (1983):  921-5|Bean B, Aeppli D "Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster." J Infect Dis 151 (1985):  362-5|Gill MJ, Burgess E "Neurotoxicity of acyclovir in end stage renal disease." J Antimicrob Chemother 25 (1990):  300-1|MacDiarmaid-Gordon AR, O''Connor M, Beaman M, Ackrill P "Neurotoxicity associated with oral acyclovir in patients undergoing dialysis." Nephron 62 (1992):  280-3|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Rashiq S, Briewa L, Mooney M, Giancarlo T, Khatib R, Wilson FM "Distinguishing acyclovir neurotoxicity from encephalomyelitis." J Intern Med 234 (1993):  507-11|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34430, 12934, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', 'Jones PG, Beier-Hanratty SA "Acyclovir: neurologic and renal toxicity." Ann Intern Med 104 (1986):  892|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Feldman S, Rodman J, Gregory B "Excessive serum concentrations of acyclovir and neurotoxicity." J Infect Dis 157 (1988):  385-8|Cohen SM, Minkove JA, Zebley JW, Mulholland JH "Severe but reversible neurotoxicity from acyclovir." Ann Intern Med 100 (1984):  920|Wade JC, Meyers JD "Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation." Ann Intern Med 98 (1983):  921-5|Bean B, Aeppli D "Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster." J Infect Dis 151 (1985):  362-5|Gill MJ, Burgess E "Neurotoxicity of acyclovir in end stage renal disease." J Antimicrob Chemother 25 (1990):  300-1|MacDiarmaid-Gordon AR, O''Connor M, Beaman M, Ackrill P "Neurotoxicity associated with oral acyclovir in patients undergoing dialysis." Nephron 62 (1992):  280-3|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Rashiq S, Briewa L, Mooney M, Giancarlo T, Khatib R, Wilson FM "Distinguishing acyclovir neurotoxicity from encephalomyelitis." J Intern Med 234 (1993):  507-11|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34431, 12935, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', 'Jones PG, Beier-Hanratty SA "Acyclovir: neurologic and renal toxicity." Ann Intern Med 104 (1986):  892|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Feldman S, Rodman J, Gregory B "Excessive serum concentrations of acyclovir and neurotoxicity." J Infect Dis 157 (1988):  385-8|Cohen SM, Minkove JA, Zebley JW, Mulholland JH "Severe but reversible neurotoxicity from acyclovir." Ann Intern Med 100 (1984):  920|Wade JC, Meyers JD "Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation." Ann Intern Med 98 (1983):  921-5|Bean B, Aeppli D "Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster." J Infect Dis 151 (1985):  362-5|Gill MJ, Burgess E "Neurotoxicity of acyclovir in end stage renal disease." J Antimicrob Chemother 25 (1990):  300-1|MacDiarmaid-Gordon AR, O''Connor M, Beaman M, Ackrill P "Neurotoxicity associated with oral acyclovir in patients undergoing dialysis." Nephron 62 (1992):  280-3|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Rashiq S, Briewa L, Mooney M, Giancarlo T, Khatib R, Wilson FM "Distinguishing acyclovir neurotoxicity from encephalomyelitis." J Intern Med 234 (1993):  507-11|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34432, 12936, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', 'Jones PG, Beier-Hanratty SA "Acyclovir: neurologic and renal toxicity." Ann Intern Med 104 (1986):  892|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Feldman S, Rodman J, Gregory B "Excessive serum concentrations of acyclovir and neurotoxicity." J Infect Dis 157 (1988):  385-8|Cohen SM, Minkove JA, Zebley JW, Mulholland JH "Severe but reversible neurotoxicity from acyclovir." Ann Intern Med 100 (1984):  920|Wade JC, Meyers JD "Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation." Ann Intern Med 98 (1983):  921-5|Bean B, Aeppli D "Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster." J Infect Dis 151 (1985):  362-5|Gill MJ, Burgess E "Neurotoxicity of acyclovir in end stage renal disease." J Antimicrob Chemother 25 (1990):  300-1|MacDiarmaid-Gordon AR, O''Connor M, Beaman M, Ackrill P "Neurotoxicity associated with oral acyclovir in patients undergoing dialysis." Nephron 62 (1992):  280-3|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Rashiq S, Briewa L, Mooney M, Giancarlo T, Khatib R, Wilson FM "Distinguishing acyclovir neurotoxicity from encephalomyelitis." J Intern Med 234 (1993):  507-11|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34433, 12938, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', 'Jones PG, Beier-Hanratty SA "Acyclovir: neurologic and renal toxicity." Ann Intern Med 104 (1986):  892|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Feldman S, Rodman J, Gregory B "Excessive serum concentrations of acyclovir and neurotoxicity." J Infect Dis 157 (1988):  385-8|Cohen SM, Minkove JA, Zebley JW, Mulholland JH "Severe but reversible neurotoxicity from acyclovir." Ann Intern Med 100 (1984):  920|Wade JC, Meyers JD "Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation." Ann Intern Med 98 (1983):  921-5|Bean B, Aeppli D "Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster." J Infect Dis 151 (1985):  362-5|Gill MJ, Burgess E "Neurotoxicity of acyclovir in end stage renal disease." J Antimicrob Chemother 25 (1990):  300-1|MacDiarmaid-Gordon AR, O''Connor M, Beaman M, Ackrill P "Neurotoxicity associated with oral acyclovir in patients undergoing dialysis." Nephron 62 (1992):  280-3|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Rashiq S, Briewa L, Mooney M, Giancarlo T, Khatib R, Wilson FM "Distinguishing acyclovir neurotoxicity from encephalomyelitis." J Intern Med 234 (1993):  507-11|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34434, 12940, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', 'Jones PG, Beier-Hanratty SA "Acyclovir: neurologic and renal toxicity." Ann Intern Med 104 (1986):  892|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Feldman S, Rodman J, Gregory B "Excessive serum concentrations of acyclovir and neurotoxicity." J Infect Dis 157 (1988):  385-8|Cohen SM, Minkove JA, Zebley JW, Mulholland JH "Severe but reversible neurotoxicity from acyclovir." Ann Intern Med 100 (1984):  920|Wade JC, Meyers JD "Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation." Ann Intern Med 98 (1983):  921-5|Bean B, Aeppli D "Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster." J Infect Dis 151 (1985):  362-5|Gill MJ, Burgess E "Neurotoxicity of acyclovir in end stage renal disease." J Antimicrob Chemother 25 (1990):  300-1|MacDiarmaid-Gordon AR, O''Connor M, Beaman M, Ackrill P "Neurotoxicity associated with oral acyclovir in patients undergoing dialysis." Nephron 62 (1992):  280-3|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Rashiq S, Briewa L, Mooney M, Giancarlo T, Khatib R, Wilson FM "Distinguishing acyclovir neurotoxicity from encephalomyelitis." J Intern Med 234 (1993):  507-11|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34435, 13330, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', 'Jones PG, Beier-Hanratty SA "Acyclovir: neurologic and renal toxicity." Ann Intern Med 104 (1986):  892|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Feldman S, Rodman J, Gregory B "Excessive serum concentrations of acyclovir and neurotoxicity." J Infect Dis 157 (1988):  385-8|Cohen SM, Minkove JA, Zebley JW, Mulholland JH "Severe but reversible neurotoxicity from acyclovir." Ann Intern Med 100 (1984):  920|Wade JC, Meyers JD "Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation." Ann Intern Med 98 (1983):  921-5|Bean B, Aeppli D "Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster." J Infect Dis 151 (1985):  362-5|Gill MJ, Burgess E "Neurotoxicity of acyclovir in end stage renal disease." J Antimicrob Chemother 25 (1990):  300-1|MacDiarmaid-Gordon AR, O''Connor M, Beaman M, Ackrill P "Neurotoxicity associated with oral acyclovir in patients undergoing dialysis." Nephron 62 (1992):  280-3|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Rashiq S, Briewa L, Mooney M, Giancarlo T, Khatib R, Wilson FM "Distinguishing acyclovir neurotoxicity from encephalomyelitis." J Intern Med 234 (1993):  507-11|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34436, 13346, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', 'Jones PG, Beier-Hanratty SA "Acyclovir: neurologic and renal toxicity." Ann Intern Med 104 (1986):  892|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Feldman S, Rodman J, Gregory B "Excessive serum concentrations of acyclovir and neurotoxicity." J Infect Dis 157 (1988):  385-8|Cohen SM, Minkove JA, Zebley JW, Mulholland JH "Severe but reversible neurotoxicity from acyclovir." Ann Intern Med 100 (1984):  920|Wade JC, Meyers JD "Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation." Ann Intern Med 98 (1983):  921-5|Bean B, Aeppli D "Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster." J Infect Dis 151 (1985):  362-5|Gill MJ, Burgess E "Neurotoxicity of acyclovir in end stage renal disease." J Antimicrob Chemother 25 (1990):  300-1|MacDiarmaid-Gordon AR, O''Connor M, Beaman M, Ackrill P "Neurotoxicity associated with oral acyclovir in patients undergoing dialysis." Nephron 62 (1992):  280-3|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Rashiq S, Briewa L, Mooney M, Giancarlo T, Khatib R, Wilson FM "Distinguishing acyclovir neurotoxicity from encephalomyelitis." J Intern Med 234 (1993):  507-11|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34437, 13455, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', 'Jones PG, Beier-Hanratty SA "Acyclovir: neurologic and renal toxicity." Ann Intern Med 104 (1986):  892|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Feldman S, Rodman J, Gregory B "Excessive serum concentrations of acyclovir and neurotoxicity." J Infect Dis 157 (1988):  385-8|Cohen SM, Minkove JA, Zebley JW, Mulholland JH "Severe but reversible neurotoxicity from acyclovir." Ann Intern Med 100 (1984):  920|Wade JC, Meyers JD "Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation." Ann Intern Med 98 (1983):  921-5|Bean B, Aeppli D "Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster." J Infect Dis 151 (1985):  362-5|Gill MJ, Burgess E "Neurotoxicity of acyclovir in end stage renal disease." J Antimicrob Chemother 25 (1990):  300-1|MacDiarmaid-Gordon AR, O''Connor M, Beaman M, Ackrill P "Neurotoxicity associated with oral acyclovir in patients undergoing dialysis." Nephron 62 (1992):  280-3|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Rashiq S, Briewa L, Mooney M, Giancarlo T, Khatib R, Wilson FM "Distinguishing acyclovir neurotoxicity from encephalomyelitis." J Intern Med 234 (1993):  507-11|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34438, 13457, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', 'Jones PG, Beier-Hanratty SA "Acyclovir: neurologic and renal toxicity." Ann Intern Med 104 (1986):  892|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Feldman S, Rodman J, Gregory B "Excessive serum concentrations of acyclovir and neurotoxicity." J Infect Dis 157 (1988):  385-8|Cohen SM, Minkove JA, Zebley JW, Mulholland JH "Severe but reversible neurotoxicity from acyclovir." Ann Intern Med 100 (1984):  920|Wade JC, Meyers JD "Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation." Ann Intern Med 98 (1983):  921-5|Bean B, Aeppli D "Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster." J Infect Dis 151 (1985):  362-5|Gill MJ, Burgess E "Neurotoxicity of acyclovir in end stage renal disease." J Antimicrob Chemother 25 (1990):  300-1|MacDiarmaid-Gordon AR, O''Connor M, Beaman M, Ackrill P "Neurotoxicity associated with oral acyclovir in patients undergoing dialysis." Nephron 62 (1992):  280-3|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Rashiq S, Briewa L, Mooney M, Giancarlo T, Khatib R, Wilson FM "Distinguishing acyclovir neurotoxicity from encephalomyelitis." J Intern Med 234 (1993):  507-11|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34439, 15444, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', 'Jones PG, Beier-Hanratty SA "Acyclovir: neurologic and renal toxicity." Ann Intern Med 104 (1986):  892|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Feldman S, Rodman J, Gregory B "Excessive serum concentrations of acyclovir and neurotoxicity." J Infect Dis 157 (1988):  385-8|Cohen SM, Minkove JA, Zebley JW, Mulholland JH "Severe but reversible neurotoxicity from acyclovir." Ann Intern Med 100 (1984):  920|Wade JC, Meyers JD "Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation." Ann Intern Med 98 (1983):  921-5|Bean B, Aeppli D "Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster." J Infect Dis 151 (1985):  362-5|Gill MJ, Burgess E "Neurotoxicity of acyclovir in end stage renal disease." J Antimicrob Chemother 25 (1990):  300-1|MacDiarmaid-Gordon AR, O''Connor M, Beaman M, Ackrill P "Neurotoxicity associated with oral acyclovir in patients undergoing dialysis." Nephron 62 (1992):  280-3|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Rashiq S, Briewa L, Mooney M, Giancarlo T, Khatib R, Wilson FM "Distinguishing acyclovir neurotoxicity from encephalomyelitis." J Intern Med 234 (1993):  507-11|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34440, 16999, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', 'Jones PG, Beier-Hanratty SA "Acyclovir: neurologic and renal toxicity." Ann Intern Med 104 (1986):  892|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Feldman S, Rodman J, Gregory B "Excessive serum concentrations of acyclovir and neurotoxicity." J Infect Dis 157 (1988):  385-8|Cohen SM, Minkove JA, Zebley JW, Mulholland JH "Severe but reversible neurotoxicity from acyclovir." Ann Intern Med 100 (1984):  920|Wade JC, Meyers JD "Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation." Ann Intern Med 98 (1983):  921-5|Bean B, Aeppli D "Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster." J Infect Dis 151 (1985):  362-5|Gill MJ, Burgess E "Neurotoxicity of acyclovir in end stage renal disease." J Antimicrob Chemother 25 (1990):  300-1|MacDiarmaid-Gordon AR, O''Connor M, Beaman M, Ackrill P "Neurotoxicity associated with oral acyclovir in patients undergoing dialysis." Nephron 62 (1992):  280-3|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Rashiq S, Briewa L, Mooney M, Giancarlo T, Khatib R, Wilson FM "Distinguishing acyclovir neurotoxicity from encephalomyelitis." J Intern Med 234 (1993):  507-11|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34441, 27726, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', 'Jones PG, Beier-Hanratty SA "Acyclovir: neurologic and renal toxicity." Ann Intern Med 104 (1986):  892|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Feldman S, Rodman J, Gregory B "Excessive serum concentrations of acyclovir and neurotoxicity." J Infect Dis 157 (1988):  385-8|Cohen SM, Minkove JA, Zebley JW, Mulholland JH "Severe but reversible neurotoxicity from acyclovir." Ann Intern Med 100 (1984):  920|Wade JC, Meyers JD "Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation." Ann Intern Med 98 (1983):  921-5|Bean B, Aeppli D "Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster." J Infect Dis 151 (1985):  362-5|Gill MJ, Burgess E "Neurotoxicity of acyclovir in end stage renal disease." J Antimicrob Chemother 25 (1990):  300-1|MacDiarmaid-Gordon AR, O''Connor M, Beaman M, Ackrill P "Neurotoxicity associated with oral acyclovir in patients undergoing dialysis." Nephron 62 (1992):  280-3|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Rashiq S, Briewa L, Mooney M, Giancarlo T, Khatib R, Wilson FM "Distinguishing acyclovir neurotoxicity from encephalomyelitis." J Intern Med 234 (1993):  507-11|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34442, 29411, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', 'Jones PG, Beier-Hanratty SA "Acyclovir: neurologic and renal toxicity." Ann Intern Med 104 (1986):  892|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Feldman S, Rodman J, Gregory B "Excessive serum concentrations of acyclovir and neurotoxicity." J Infect Dis 157 (1988):  385-8|Cohen SM, Minkove JA, Zebley JW, Mulholland JH "Severe but reversible neurotoxicity from acyclovir." Ann Intern Med 100 (1984):  920|Wade JC, Meyers JD "Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation." Ann Intern Med 98 (1983):  921-5|Bean B, Aeppli D "Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster." J Infect Dis 151 (1985):  362-5|Gill MJ, Burgess E "Neurotoxicity of acyclovir in end stage renal disease." J Antimicrob Chemother 25 (1990):  300-1|MacDiarmaid-Gordon AR, O''Connor M, Beaman M, Ackrill P "Neurotoxicity associated with oral acyclovir in patients undergoing dialysis." Nephron 62 (1992):  280-3|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Rashiq S, Briewa L, Mooney M, Giancarlo T, Khatib R, Wilson FM "Distinguishing acyclovir neurotoxicity from encephalomyelitis." J Intern Med 234 (1993):  507-11|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34443, 29412, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', 'Jones PG, Beier-Hanratty SA "Acyclovir: neurologic and renal toxicity." Ann Intern Med 104 (1986):  892|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Feldman S, Rodman J, Gregory B "Excessive serum concentrations of acyclovir and neurotoxicity." J Infect Dis 157 (1988):  385-8|Cohen SM, Minkove JA, Zebley JW, Mulholland JH "Severe but reversible neurotoxicity from acyclovir." Ann Intern Med 100 (1984):  920|Wade JC, Meyers JD "Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation." Ann Intern Med 98 (1983):  921-5|Bean B, Aeppli D "Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster." J Infect Dis 151 (1985):  362-5|Gill MJ, Burgess E "Neurotoxicity of acyclovir in end stage renal disease." J Antimicrob Chemother 25 (1990):  300-1|MacDiarmaid-Gordon AR, O''Connor M, Beaman M, Ackrill P "Neurotoxicity associated with oral acyclovir in patients undergoing dialysis." Nephron 62 (1992):  280-3|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Rashiq S, Briewa L, Mooney M, Giancarlo T, Khatib R, Wilson FM "Distinguishing acyclovir neurotoxicity from encephalomyelitis." J Intern Med 234 (1993):  507-11|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34444, 29413, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', 'Jones PG, Beier-Hanratty SA "Acyclovir: neurologic and renal toxicity." Ann Intern Med 104 (1986):  892|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Feldman S, Rodman J, Gregory B "Excessive serum concentrations of acyclovir and neurotoxicity." J Infect Dis 157 (1988):  385-8|Cohen SM, Minkove JA, Zebley JW, Mulholland JH "Severe but reversible neurotoxicity from acyclovir." Ann Intern Med 100 (1984):  920|Wade JC, Meyers JD "Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation." Ann Intern Med 98 (1983):  921-5|Bean B, Aeppli D "Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster." J Infect Dis 151 (1985):  362-5|Gill MJ, Burgess E "Neurotoxicity of acyclovir in end stage renal disease." J Antimicrob Chemother 25 (1990):  300-1|MacDiarmaid-Gordon AR, O''Connor M, Beaman M, Ackrill P "Neurotoxicity associated with oral acyclovir in patients undergoing dialysis." Nephron 62 (1992):  280-3|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Rashiq S, Briewa L, Mooney M, Giancarlo T, Khatib R, Wilson FM "Distinguishing acyclovir neurotoxicity from encephalomyelitis." J Intern Med 234 (1993):  507-11|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34445, 29414, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', 'Jones PG, Beier-Hanratty SA "Acyclovir: neurologic and renal toxicity." Ann Intern Med 104 (1986):  892|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Feldman S, Rodman J, Gregory B "Excessive serum concentrations of acyclovir and neurotoxicity." J Infect Dis 157 (1988):  385-8|Cohen SM, Minkove JA, Zebley JW, Mulholland JH "Severe but reversible neurotoxicity from acyclovir." Ann Intern Med 100 (1984):  920|Wade JC, Meyers JD "Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation." Ann Intern Med 98 (1983):  921-5|Bean B, Aeppli D "Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster." J Infect Dis 151 (1985):  362-5|Gill MJ, Burgess E "Neurotoxicity of acyclovir in end stage renal disease." J Antimicrob Chemother 25 (1990):  300-1|MacDiarmaid-Gordon AR, O''Connor M, Beaman M, Ackrill P "Neurotoxicity associated with oral acyclovir in patients undergoing dialysis." Nephron 62 (1992):  280-3|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Rashiq S, Briewa L, Mooney M, Giancarlo T, Khatib R, Wilson FM "Distinguishing acyclovir neurotoxicity from encephalomyelitis." J Intern Med 234 (1993):  507-11|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34446, 30031, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', 'Jones PG, Beier-Hanratty SA "Acyclovir: neurologic and renal toxicity." Ann Intern Med 104 (1986):  892|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Feldman S, Rodman J, Gregory B "Excessive serum concentrations of acyclovir and neurotoxicity." J Infect Dis 157 (1988):  385-8|Cohen SM, Minkove JA, Zebley JW, Mulholland JH "Severe but reversible neurotoxicity from acyclovir." Ann Intern Med 100 (1984):  920|Wade JC, Meyers JD "Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation." Ann Intern Med 98 (1983):  921-5|Bean B, Aeppli D "Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster." J Infect Dis 151 (1985):  362-5|Gill MJ, Burgess E "Neurotoxicity of acyclovir in end stage renal disease." J Antimicrob Chemother 25 (1990):  300-1|MacDiarmaid-Gordon AR, O''Connor M, Beaman M, Ackrill P "Neurotoxicity associated with oral acyclovir in patients undergoing dialysis." Nephron 62 (1992):  280-3|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Rashiq S, Briewa L, Mooney M, Giancarlo T, Khatib R, Wilson FM "Distinguishing acyclovir neurotoxicity from encephalomyelitis." J Intern Med 234 (1993):  507-11|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34447, 30034, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', 'Jones PG, Beier-Hanratty SA "Acyclovir: neurologic and renal toxicity." Ann Intern Med 104 (1986):  892|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Feldman S, Rodman J, Gregory B "Excessive serum concentrations of acyclovir and neurotoxicity." J Infect Dis 157 (1988):  385-8|Cohen SM, Minkove JA, Zebley JW, Mulholland JH "Severe but reversible neurotoxicity from acyclovir." Ann Intern Med 100 (1984):  920|Wade JC, Meyers JD "Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation." Ann Intern Med 98 (1983):  921-5|Bean B, Aeppli D "Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster." J Infect Dis 151 (1985):  362-5|Gill MJ, Burgess E "Neurotoxicity of acyclovir in end stage renal disease." J Antimicrob Chemother 25 (1990):  300-1|MacDiarmaid-Gordon AR, O''Connor M, Beaman M, Ackrill P "Neurotoxicity associated with oral acyclovir in patients undergoing dialysis." Nephron 62 (1992):  280-3|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Rashiq S, Briewa L, Mooney M, Giancarlo T, Khatib R, Wilson FM "Distinguishing acyclovir neurotoxicity from encephalomyelitis." J Intern Med 234 (1993):  507-11|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34448, 30036, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', 'Jones PG, Beier-Hanratty SA "Acyclovir: neurologic and renal toxicity." Ann Intern Med 104 (1986):  892|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Feldman S, Rodman J, Gregory B "Excessive serum concentrations of acyclovir and neurotoxicity." J Infect Dis 157 (1988):  385-8|Cohen SM, Minkove JA, Zebley JW, Mulholland JH "Severe but reversible neurotoxicity from acyclovir." Ann Intern Med 100 (1984):  920|Wade JC, Meyers JD "Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation." Ann Intern Med 98 (1983):  921-5|Bean B, Aeppli D "Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster." J Infect Dis 151 (1985):  362-5|Gill MJ, Burgess E "Neurotoxicity of acyclovir in end stage renal disease." J Antimicrob Chemother 25 (1990):  300-1|MacDiarmaid-Gordon AR, O''Connor M, Beaman M, Ackrill P "Neurotoxicity associated with oral acyclovir in patients undergoing dialysis." Nephron 62 (1992):  280-3|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Rashiq S, Briewa L, Mooney M, Giancarlo T, Khatib R, Wilson FM "Distinguishing acyclovir neurotoxicity from encephalomyelitis." J Intern Med 234 (1993):  507-11|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34449, 31696, 'Acyclovir', 'Neurotoxicity Syndromes', 'Acyclovir, particularly when administered intravenously in higher dosages, may occasionally produce neurotoxicity characterized by lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma.  Therapy with acyclovir should be administered cautiously in the elderly and in patients with underlying neurologic abnormalities, severe renal or liver disease, or significant electrolyte abnormalities or hypoxia.', '2', 'Jones PG, Beier-Hanratty SA "Acyclovir: neurologic and renal toxicity." Ann Intern Med 104 (1986):  892|Fletcher CV, Chinnock BJ, Chace B, Balfour HH "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation." Clin Pharmacol Ther 44 (1988):  158-63|Feldman S, Rodman J, Gregory B "Excessive serum concentrations of acyclovir and neurotoxicity." J Infect Dis 157 (1988):  385-8|Cohen SM, Minkove JA, Zebley JW, Mulholland JH "Severe but reversible neurotoxicity from acyclovir." Ann Intern Med 100 (1984):  920|Wade JC, Meyers JD "Neurologic symptoms associated with parenteral acyclovir treatment after marrow transplantation." Ann Intern Med 98 (1983):  921-5|Bean B, Aeppli D "Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster." J Infect Dis 151 (1985):  362-5|Gill MJ, Burgess E "Neurotoxicity of acyclovir in end stage renal disease." J Antimicrob Chemother 25 (1990):  300-1|MacDiarmaid-Gordon AR, O''Connor M, Beaman M, Ackrill P "Neurotoxicity associated with oral acyclovir in patients undergoing dialysis." Nephron 62 (1992):  280-3|"Product Information. Zovirax (acyclovir)." Mylan Pharmaceuticals Inc  (2017):|Krieble BF, Rudy DW, Glick MR, Clayman MD "Case report: acyclovir neurotoxicity and nephrotoxicity--the role for hemodialysis." Am J Med Sci 305 (1993):  36-9|Rashiq S, Briewa L, Mooney M, Giancarlo T, Khatib R, Wilson FM "Distinguishing acyclovir neurotoxicity from encephalomyelitis." J Intern Med 234 (1993):  507-11|Johnson GL, Limon L, Trikha G, Wall H "Acute renal failure and neurotoxicity following oral acyclovir." Ann Pharmacother 28 (1994):  460-3', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34450, 0, 'Busulfan', 'Infections', 'Busulfan can induce severe and prolonged myelosuppression.  Treatment with busulfan should not be initiated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during therapy with busulfan.  Close clinical monitoring of hematopoietic function is recommended.', '3', '"Product Information. Myleran (busulfan)." Prasco Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34451, 0, 'Busulfan', 'Bone Marrow Failure Disorders', 'Busulfan induces severe and prolonged myelosuppression at the recommended dosage.  Hematopoietic progenitor cell transplantation is required to prevent potentially fatal complications of the prolonged myelosuppression.  It is recommended to closely monitor complete blood counts, including white blood cell differentials, and quantitative platelet counts daily during treatment and until engraftment is demonstrated.  Extreme caution should be exercised if busulfan is administered in patients whose bone marrow reserve may be compromised by prior irradiation or chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression, such as fever, sore throat, local infection, bleeding, or symptoms of anemia.', '3', 'Fernandez LA, Zayed E "Busulfan-induced sideroblastic anemia." Am J Hematol 28 (1988):  199-200|"Product Information. Myleran (busulfan)." Prasco Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34452, 0, 'Busulfan', 'Cardiac Tamponade', 'Cardiac tamponade during high dose busulfan therapy combined with cyclophosphamide has been reported in pediatric patients with thalassemia.  Abdominal pain and vomiting may precede the tamponade.  Cardiac tamponade can result in death and therapy with busulfan should be administered cautiously to patients with thalassemia.', '2', '"Product Information. Myleran (busulfan)." Prasco Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34453, 0, 'Busulfan', 'Epilepsy', 'Seizures have been reported in patients receiving high doses of busulfan.  Therapy with busulfan should be administered cautiously to patients with a history of a seizure disorder or head trauma or who are receiving other potentially epileptogenic drugs.', '2', '"Product Information. Myleran (busulfan)." Prasco Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34454, 1832, 'Cabergoline', 'Heart Valve Diseases', 'Postmarketing cases of cardiac valvulopathy have been reported in patients receiving cabergoline.  This drug is contraindicated in patients with history of cardiac valvular disorder.  All patients should undergo a cardiovascular evaluation including echocardiogram to assess the potential of valvular disease, and if detected, the patient should not be treated with cabergoline..', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34455, 1833, 'Cabergoline', 'Heart Valve Diseases', 'Postmarketing cases of cardiac valvulopathy have been reported in patients receiving cabergoline.  This drug is contraindicated in patients with history of cardiac valvular disorder.  All patients should undergo a cardiovascular evaluation including echocardiogram to assess the potential of valvular disease, and if detected, the patient should not be treated with cabergoline..', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34456, 3857, 'Cabergoline', 'Heart Valve Diseases', 'Postmarketing cases of cardiac valvulopathy have been reported in patients receiving cabergoline.  This drug is contraindicated in patients with history of cardiac valvular disorder.  All patients should undergo a cardiovascular evaluation including echocardiogram to assess the potential of valvular disease, and if detected, the patient should not be treated with cabergoline..', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34457, 3907, 'Cabergoline', 'Heart Valve Diseases', 'Postmarketing cases of cardiac valvulopathy have been reported in patients receiving cabergoline.  This drug is contraindicated in patients with history of cardiac valvular disorder.  All patients should undergo a cardiovascular evaluation including echocardiogram to assess the potential of valvular disease, and if detected, the patient should not be treated with cabergoline..', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34458, 4091, 'Cabergoline', 'Heart Valve Diseases', 'Postmarketing cases of cardiac valvulopathy have been reported in patients receiving cabergoline.  This drug is contraindicated in patients with history of cardiac valvular disorder.  All patients should undergo a cardiovascular evaluation including echocardiogram to assess the potential of valvular disease, and if detected, the patient should not be treated with cabergoline..', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34459, 5699, 'Cabergoline', 'Heart Valve Diseases', 'Postmarketing cases of cardiac valvulopathy have been reported in patients receiving cabergoline.  This drug is contraindicated in patients with history of cardiac valvular disorder.  All patients should undergo a cardiovascular evaluation including echocardiogram to assess the potential of valvular disease, and if detected, the patient should not be treated with cabergoline..', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34460, 7750, 'Cabergoline', 'Heart Valve Diseases', 'Postmarketing cases of cardiac valvulopathy have been reported in patients receiving cabergoline.  This drug is contraindicated in patients with history of cardiac valvular disorder.  All patients should undergo a cardiovascular evaluation including echocardiogram to assess the potential of valvular disease, and if detected, the patient should not be treated with cabergoline..', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34461, 15599, 'Cabergoline', 'Heart Valve Diseases', 'Postmarketing cases of cardiac valvulopathy have been reported in patients receiving cabergoline.  This drug is contraindicated in patients with history of cardiac valvular disorder.  All patients should undergo a cardiovascular evaluation including echocardiogram to assess the potential of valvular disease, and if detected, the patient should not be treated with cabergoline..', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34462, 17197, 'Cabergoline', 'Heart Valve Diseases', 'Postmarketing cases of cardiac valvulopathy have been reported in patients receiving cabergoline.  This drug is contraindicated in patients with history of cardiac valvular disorder.  All patients should undergo a cardiovascular evaluation including echocardiogram to assess the potential of valvular disease, and if detected, the patient should not be treated with cabergoline..', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34463, 20013, 'Cabergoline', 'Heart Valve Diseases', 'Postmarketing cases of cardiac valvulopathy have been reported in patients receiving cabergoline.  This drug is contraindicated in patients with history of cardiac valvular disorder.  All patients should undergo a cardiovascular evaluation including echocardiogram to assess the potential of valvular disease, and if detected, the patient should not be treated with cabergoline..', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34464, 20639, 'Cabergoline', 'Heart Valve Diseases', 'Postmarketing cases of cardiac valvulopathy have been reported in patients receiving cabergoline.  This drug is contraindicated in patients with history of cardiac valvular disorder.  All patients should undergo a cardiovascular evaluation including echocardiogram to assess the potential of valvular disease, and if detected, the patient should not be treated with cabergoline..', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34465, 21123, 'Cabergoline', 'Heart Valve Diseases', 'Postmarketing cases of cardiac valvulopathy have been reported in patients receiving cabergoline.  This drug is contraindicated in patients with history of cardiac valvular disorder.  All patients should undergo a cardiovascular evaluation including echocardiogram to assess the potential of valvular disease, and if detected, the patient should not be treated with cabergoline..', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34466, 23755, 'Cabergoline', 'Heart Valve Diseases', 'Postmarketing cases of cardiac valvulopathy have been reported in patients receiving cabergoline.  This drug is contraindicated in patients with history of cardiac valvular disorder.  All patients should undergo a cardiovascular evaluation including echocardiogram to assess the potential of valvular disease, and if detected, the patient should not be treated with cabergoline..', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34467, 25706, 'Cabergoline', 'Heart Valve Diseases', 'Postmarketing cases of cardiac valvulopathy have been reported in patients receiving cabergoline.  This drug is contraindicated in patients with history of cardiac valvular disorder.  All patients should undergo a cardiovascular evaluation including echocardiogram to assess the potential of valvular disease, and if detected, the patient should not be treated with cabergoline..', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34468, 25855, 'Cabergoline', 'Heart Valve Diseases', 'Postmarketing cases of cardiac valvulopathy have been reported in patients receiving cabergoline.  This drug is contraindicated in patients with history of cardiac valvular disorder.  All patients should undergo a cardiovascular evaluation including echocardiogram to assess the potential of valvular disease, and if detected, the patient should not be treated with cabergoline..', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34469, 30241, 'Cabergoline', 'Heart Valve Diseases', 'Postmarketing cases of cardiac valvulopathy have been reported in patients receiving cabergoline.  This drug is contraindicated in patients with history of cardiac valvular disorder.  All patients should undergo a cardiovascular evaluation including echocardiogram to assess the potential of valvular disease, and if detected, the patient should not be treated with cabergoline..', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34470, 30242, 'Cabergoline', 'Heart Valve Diseases', 'Postmarketing cases of cardiac valvulopathy have been reported in patients receiving cabergoline.  This drug is contraindicated in patients with history of cardiac valvular disorder.  All patients should undergo a cardiovascular evaluation including echocardiogram to assess the potential of valvular disease, and if detected, the patient should not be treated with cabergoline..', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34471, 31875, 'Cabergoline', 'Heart Valve Diseases', 'Postmarketing cases of cardiac valvulopathy have been reported in patients receiving cabergoline.  This drug is contraindicated in patients with history of cardiac valvular disorder.  All patients should undergo a cardiovascular evaluation including echocardiogram to assess the potential of valvular disease, and if detected, the patient should not be treated with cabergoline..', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34472, 1832, 'Cabergoline', 'Hypertension', 'The use of cabergoline is contraindicated in patients with uncontrolled hypertension.  Cabergoline is a dopamine agonist and effects on alpha and/or beta-adrenergic receptors may alter cardiovascular function.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34473, 1833, 'Cabergoline', 'Hypertension', 'The use of cabergoline is contraindicated in patients with uncontrolled hypertension.  Cabergoline is a dopamine agonist and effects on alpha and/or beta-adrenergic receptors may alter cardiovascular function.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34474, 3857, 'Cabergoline', 'Hypertension', 'The use of cabergoline is contraindicated in patients with uncontrolled hypertension.  Cabergoline is a dopamine agonist and effects on alpha and/or beta-adrenergic receptors may alter cardiovascular function.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34475, 3907, 'Cabergoline', 'Hypertension', 'The use of cabergoline is contraindicated in patients with uncontrolled hypertension.  Cabergoline is a dopamine agonist and effects on alpha and/or beta-adrenergic receptors may alter cardiovascular function.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34476, 4091, 'Cabergoline', 'Hypertension', 'The use of cabergoline is contraindicated in patients with uncontrolled hypertension.  Cabergoline is a dopamine agonist and effects on alpha and/or beta-adrenergic receptors may alter cardiovascular function.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34477, 5699, 'Cabergoline', 'Hypertension', 'The use of cabergoline is contraindicated in patients with uncontrolled hypertension.  Cabergoline is a dopamine agonist and effects on alpha and/or beta-adrenergic receptors may alter cardiovascular function.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34478, 7750, 'Cabergoline', 'Hypertension', 'The use of cabergoline is contraindicated in patients with uncontrolled hypertension.  Cabergoline is a dopamine agonist and effects on alpha and/or beta-adrenergic receptors may alter cardiovascular function.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34479, 15599, 'Cabergoline', 'Hypertension', 'The use of cabergoline is contraindicated in patients with uncontrolled hypertension.  Cabergoline is a dopamine agonist and effects on alpha and/or beta-adrenergic receptors may alter cardiovascular function.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34480, 17197, 'Cabergoline', 'Hypertension', 'The use of cabergoline is contraindicated in patients with uncontrolled hypertension.  Cabergoline is a dopamine agonist and effects on alpha and/or beta-adrenergic receptors may alter cardiovascular function.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34481, 20013, 'Cabergoline', 'Hypertension', 'The use of cabergoline is contraindicated in patients with uncontrolled hypertension.  Cabergoline is a dopamine agonist and effects on alpha and/or beta-adrenergic receptors may alter cardiovascular function.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34482, 20639, 'Cabergoline', 'Hypertension', 'The use of cabergoline is contraindicated in patients with uncontrolled hypertension.  Cabergoline is a dopamine agonist and effects on alpha and/or beta-adrenergic receptors may alter cardiovascular function.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34483, 21123, 'Cabergoline', 'Hypertension', 'The use of cabergoline is contraindicated in patients with uncontrolled hypertension.  Cabergoline is a dopamine agonist and effects on alpha and/or beta-adrenergic receptors may alter cardiovascular function.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34484, 23755, 'Cabergoline', 'Hypertension', 'The use of cabergoline is contraindicated in patients with uncontrolled hypertension.  Cabergoline is a dopamine agonist and effects on alpha and/or beta-adrenergic receptors may alter cardiovascular function.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34485, 25706, 'Cabergoline', 'Hypertension', 'The use of cabergoline is contraindicated in patients with uncontrolled hypertension.  Cabergoline is a dopamine agonist and effects on alpha and/or beta-adrenergic receptors may alter cardiovascular function.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34486, 25855, 'Cabergoline', 'Hypertension', 'The use of cabergoline is contraindicated in patients with uncontrolled hypertension.  Cabergoline is a dopamine agonist and effects on alpha and/or beta-adrenergic receptors may alter cardiovascular function.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34487, 30241, 'Cabergoline', 'Hypertension', 'The use of cabergoline is contraindicated in patients with uncontrolled hypertension.  Cabergoline is a dopamine agonist and effects on alpha and/or beta-adrenergic receptors may alter cardiovascular function.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34488, 30242, 'Cabergoline', 'Hypertension', 'The use of cabergoline is contraindicated in patients with uncontrolled hypertension.  Cabergoline is a dopamine agonist and effects on alpha and/or beta-adrenergic receptors may alter cardiovascular function.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34489, 31875, 'Cabergoline', 'Hypertension', 'The use of cabergoline is contraindicated in patients with uncontrolled hypertension.  Cabergoline is a dopamine agonist and effects on alpha and/or beta-adrenergic receptors may alter cardiovascular function.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34490, 1832, 'Cabergoline', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34491, 1833, 'Cabergoline', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34492, 3857, 'Cabergoline', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34493, 3907, 'Cabergoline', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34494, 4091, 'Cabergoline', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34495, 5699, 'Cabergoline', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34496, 7750, 'Cabergoline', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34497, 15599, 'Cabergoline', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34498, 17197, 'Cabergoline', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34499, 20013, 'Cabergoline', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34500, 20639, 'Cabergoline', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34501, 21123, 'Cabergoline', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34502, 23755, 'Cabergoline', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34503, 25706, 'Cabergoline', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34504, 25855, 'Cabergoline', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34505, 30241, 'Cabergoline', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34506, 30242, 'Cabergoline', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34507, 31875, 'Cabergoline', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34508, 1832, 'Cabergoline', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Lodosyn (carbidopa)." DuPont Pharma  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34509, 1833, 'Cabergoline', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Lodosyn (carbidopa)." DuPont Pharma  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34510, 3857, 'Cabergoline', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Lodosyn (carbidopa)." DuPont Pharma  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34511, 3907, 'Cabergoline', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Lodosyn (carbidopa)." DuPont Pharma  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34512, 4091, 'Cabergoline', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Lodosyn (carbidopa)." DuPont Pharma  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34513, 5699, 'Cabergoline', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Lodosyn (carbidopa)." DuPont Pharma  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34514, 7750, 'Cabergoline', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Lodosyn (carbidopa)." DuPont Pharma  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34515, 15599, 'Cabergoline', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Lodosyn (carbidopa)." DuPont Pharma  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34516, 17197, 'Cabergoline', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Lodosyn (carbidopa)." DuPont Pharma  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34517, 20013, 'Cabergoline', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Lodosyn (carbidopa)." DuPont Pharma  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34518, 20639, 'Cabergoline', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Lodosyn (carbidopa)." DuPont Pharma  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34519, 21123, 'Cabergoline', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Lodosyn (carbidopa)." DuPont Pharma  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34520, 23755, 'Cabergoline', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Lodosyn (carbidopa)." DuPont Pharma  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34521, 25706, 'Cabergoline', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Lodosyn (carbidopa)." DuPont Pharma  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34522, 25855, 'Cabergoline', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Lodosyn (carbidopa)." DuPont Pharma  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34523, 30241, 'Cabergoline', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Lodosyn (carbidopa)." DuPont Pharma  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34524, 30242, 'Cabergoline', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Lodosyn (carbidopa)." DuPont Pharma  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34525, 31875, 'Cabergoline', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Lodosyn (carbidopa)." DuPont Pharma  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34526, 1832, 'Cabergoline', 'Liver Diseases', 'Cabergoline is extensively metabolized by the liver primarily by hydrolysis.  Therapy with cabergoline should be administered cautiously in patients with hepatic dysfunction.  Careful monitoring should be exercised.', '2', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34527, 1833, 'Cabergoline', 'Liver Diseases', 'Cabergoline is extensively metabolized by the liver primarily by hydrolysis.  Therapy with cabergoline should be administered cautiously in patients with hepatic dysfunction.  Careful monitoring should be exercised.', '2', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34528, 3857, 'Cabergoline', 'Liver Diseases', 'Cabergoline is extensively metabolized by the liver primarily by hydrolysis.  Therapy with cabergoline should be administered cautiously in patients with hepatic dysfunction.  Careful monitoring should be exercised.', '2', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34529, 3907, 'Cabergoline', 'Liver Diseases', 'Cabergoline is extensively metabolized by the liver primarily by hydrolysis.  Therapy with cabergoline should be administered cautiously in patients with hepatic dysfunction.  Careful monitoring should be exercised.', '2', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34530, 4091, 'Cabergoline', 'Liver Diseases', 'Cabergoline is extensively metabolized by the liver primarily by hydrolysis.  Therapy with cabergoline should be administered cautiously in patients with hepatic dysfunction.  Careful monitoring should be exercised.', '2', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34531, 5699, 'Cabergoline', 'Liver Diseases', 'Cabergoline is extensively metabolized by the liver primarily by hydrolysis.  Therapy with cabergoline should be administered cautiously in patients with hepatic dysfunction.  Careful monitoring should be exercised.', '2', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34532, 7750, 'Cabergoline', 'Liver Diseases', 'Cabergoline is extensively metabolized by the liver primarily by hydrolysis.  Therapy with cabergoline should be administered cautiously in patients with hepatic dysfunction.  Careful monitoring should be exercised.', '2', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34533, 15599, 'Cabergoline', 'Liver Diseases', 'Cabergoline is extensively metabolized by the liver primarily by hydrolysis.  Therapy with cabergoline should be administered cautiously in patients with hepatic dysfunction.  Careful monitoring should be exercised.', '2', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34534, 17197, 'Cabergoline', 'Liver Diseases', 'Cabergoline is extensively metabolized by the liver primarily by hydrolysis.  Therapy with cabergoline should be administered cautiously in patients with hepatic dysfunction.  Careful monitoring should be exercised.', '2', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34535, 20013, 'Cabergoline', 'Liver Diseases', 'Cabergoline is extensively metabolized by the liver primarily by hydrolysis.  Therapy with cabergoline should be administered cautiously in patients with hepatic dysfunction.  Careful monitoring should be exercised.', '2', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34536, 20639, 'Cabergoline', 'Liver Diseases', 'Cabergoline is extensively metabolized by the liver primarily by hydrolysis.  Therapy with cabergoline should be administered cautiously in patients with hepatic dysfunction.  Careful monitoring should be exercised.', '2', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34537, 21123, 'Cabergoline', 'Liver Diseases', 'Cabergoline is extensively metabolized by the liver primarily by hydrolysis.  Therapy with cabergoline should be administered cautiously in patients with hepatic dysfunction.  Careful monitoring should be exercised.', '2', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34538, 23755, 'Cabergoline', 'Liver Diseases', 'Cabergoline is extensively metabolized by the liver primarily by hydrolysis.  Therapy with cabergoline should be administered cautiously in patients with hepatic dysfunction.  Careful monitoring should be exercised.', '2', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34539, 25706, 'Cabergoline', 'Liver Diseases', 'Cabergoline is extensively metabolized by the liver primarily by hydrolysis.  Therapy with cabergoline should be administered cautiously in patients with hepatic dysfunction.  Careful monitoring should be exercised.', '2', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34540, 25855, 'Cabergoline', 'Liver Diseases', 'Cabergoline is extensively metabolized by the liver primarily by hydrolysis.  Therapy with cabergoline should be administered cautiously in patients with hepatic dysfunction.  Careful monitoring should be exercised.', '2', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34541, 30241, 'Cabergoline', 'Liver Diseases', 'Cabergoline is extensively metabolized by the liver primarily by hydrolysis.  Therapy with cabergoline should be administered cautiously in patients with hepatic dysfunction.  Careful monitoring should be exercised.', '2', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34542, 30242, 'Cabergoline', 'Liver Diseases', 'Cabergoline is extensively metabolized by the liver primarily by hydrolysis.  Therapy with cabergoline should be administered cautiously in patients with hepatic dysfunction.  Careful monitoring should be exercised.', '2', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34543, 31875, 'Cabergoline', 'Liver Diseases', 'Cabergoline is extensively metabolized by the liver primarily by hydrolysis.  Therapy with cabergoline should be administered cautiously in patients with hepatic dysfunction.  Careful monitoring should be exercised.', '2', '"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34544, 1841, 'Caffeine', 'Heart Diseases', 'The use of CNS stimulants is contraindicated in patients with significant cardiovascular impairment such as uncompensated heart failure, severe coronary disease, severe hypertension (including that associated with hyperthyroidism or pheochromocytoma), cardiac structural abnormalities, serious arrhythmias, etc.  Sudden death has been reported in adults and children taking CNS stimulant treatment.  Additionally, stroke, myocardial infarction, chest pain, syncope, arrhythmias and other symptoms have been reported in adults under treatment.  A careful assessment of the cardiovascular status should be done in patients being considered for treatment.  This includes family history, physical exam and further cardiac evaluation (EKG and echocardiogram).  Patients who develop symptoms should have a detailed cardiac evaluation and if needed, treatment should be suspended.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34545, 2885, 'Caffeine', 'Heart Diseases', 'The use of CNS stimulants is contraindicated in patients with significant cardiovascular impairment such as uncompensated heart failure, severe coronary disease, severe hypertension (including that associated with hyperthyroidism or pheochromocytoma), cardiac structural abnormalities, serious arrhythmias, etc.  Sudden death has been reported in adults and children taking CNS stimulant treatment.  Additionally, stroke, myocardial infarction, chest pain, syncope, arrhythmias and other symptoms have been reported in adults under treatment.  A careful assessment of the cardiovascular status should be done in patients being considered for treatment.  This includes family history, physical exam and further cardiac evaluation (EKG and echocardiogram).  Patients who develop symptoms should have a detailed cardiac evaluation and if needed, treatment should be suspended.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34546, 14477, 'Caffeine', 'Heart Diseases', 'The use of CNS stimulants is contraindicated in patients with significant cardiovascular impairment such as uncompensated heart failure, severe coronary disease, severe hypertension (including that associated with hyperthyroidism or pheochromocytoma), cardiac structural abnormalities, serious arrhythmias, etc.  Sudden death has been reported in adults and children taking CNS stimulant treatment.  Additionally, stroke, myocardial infarction, chest pain, syncope, arrhythmias and other symptoms have been reported in adults under treatment.  A careful assessment of the cardiovascular status should be done in patients being considered for treatment.  This includes family history, physical exam and further cardiac evaluation (EKG and echocardiogram).  Patients who develop symptoms should have a detailed cardiac evaluation and if needed, treatment should be suspended.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34547, 15611, 'Caffeine', 'Heart Diseases', 'The use of CNS stimulants is contraindicated in patients with significant cardiovascular impairment such as uncompensated heart failure, severe coronary disease, severe hypertension (including that associated with hyperthyroidism or pheochromocytoma), cardiac structural abnormalities, serious arrhythmias, etc.  Sudden death has been reported in adults and children taking CNS stimulant treatment.  Additionally, stroke, myocardial infarction, chest pain, syncope, arrhythmias and other symptoms have been reported in adults under treatment.  A careful assessment of the cardiovascular status should be done in patients being considered for treatment.  This includes family history, physical exam and further cardiac evaluation (EKG and echocardiogram).  Patients who develop symptoms should have a detailed cardiac evaluation and if needed, treatment should be suspended.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34548, 15613, 'Caffeine', 'Heart Diseases', 'The use of CNS stimulants is contraindicated in patients with significant cardiovascular impairment such as uncompensated heart failure, severe coronary disease, severe hypertension (including that associated with hyperthyroidism or pheochromocytoma), cardiac structural abnormalities, serious arrhythmias, etc.  Sudden death has been reported in adults and children taking CNS stimulant treatment.  Additionally, stroke, myocardial infarction, chest pain, syncope, arrhythmias and other symptoms have been reported in adults under treatment.  A careful assessment of the cardiovascular status should be done in patients being considered for treatment.  This includes family history, physical exam and further cardiac evaluation (EKG and echocardiogram).  Patients who develop symptoms should have a detailed cardiac evaluation and if needed, treatment should be suspended.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34549, 17989, 'Caffeine', 'Heart Diseases', 'The use of CNS stimulants is contraindicated in patients with significant cardiovascular impairment such as uncompensated heart failure, severe coronary disease, severe hypertension (including that associated with hyperthyroidism or pheochromocytoma), cardiac structural abnormalities, serious arrhythmias, etc.  Sudden death has been reported in adults and children taking CNS stimulant treatment.  Additionally, stroke, myocardial infarction, chest pain, syncope, arrhythmias and other symptoms have been reported in adults under treatment.  A careful assessment of the cardiovascular status should be done in patients being considered for treatment.  This includes family history, physical exam and further cardiac evaluation (EKG and echocardiogram).  Patients who develop symptoms should have a detailed cardiac evaluation and if needed, treatment should be suspended.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34550, 20221, 'Caffeine', 'Heart Diseases', 'The use of CNS stimulants is contraindicated in patients with significant cardiovascular impairment such as uncompensated heart failure, severe coronary disease, severe hypertension (including that associated with hyperthyroidism or pheochromocytoma), cardiac structural abnormalities, serious arrhythmias, etc.  Sudden death has been reported in adults and children taking CNS stimulant treatment.  Additionally, stroke, myocardial infarction, chest pain, syncope, arrhythmias and other symptoms have been reported in adults under treatment.  A careful assessment of the cardiovascular status should be done in patients being considered for treatment.  This includes family history, physical exam and further cardiac evaluation (EKG and echocardiogram).  Patients who develop symptoms should have a detailed cardiac evaluation and if needed, treatment should be suspended.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34551, 20222, 'Caffeine', 'Heart Diseases', 'The use of CNS stimulants is contraindicated in patients with significant cardiovascular impairment such as uncompensated heart failure, severe coronary disease, severe hypertension (including that associated with hyperthyroidism or pheochromocytoma), cardiac structural abnormalities, serious arrhythmias, etc.  Sudden death has been reported in adults and children taking CNS stimulant treatment.  Additionally, stroke, myocardial infarction, chest pain, syncope, arrhythmias and other symptoms have been reported in adults under treatment.  A careful assessment of the cardiovascular status should be done in patients being considered for treatment.  This includes family history, physical exam and further cardiac evaluation (EKG and echocardiogram).  Patients who develop symptoms should have a detailed cardiac evaluation and if needed, treatment should be suspended.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34552, 20223, 'Caffeine', 'Heart Diseases', 'The use of CNS stimulants is contraindicated in patients with significant cardiovascular impairment such as uncompensated heart failure, severe coronary disease, severe hypertension (including that associated with hyperthyroidism or pheochromocytoma), cardiac structural abnormalities, serious arrhythmias, etc.  Sudden death has been reported in adults and children taking CNS stimulant treatment.  Additionally, stroke, myocardial infarction, chest pain, syncope, arrhythmias and other symptoms have been reported in adults under treatment.  A careful assessment of the cardiovascular status should be done in patients being considered for treatment.  This includes family history, physical exam and further cardiac evaluation (EKG and echocardiogram).  Patients who develop symptoms should have a detailed cardiac evaluation and if needed, treatment should be suspended.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34553, 20224, 'Caffeine', 'Heart Diseases', 'The use of CNS stimulants is contraindicated in patients with significant cardiovascular impairment such as uncompensated heart failure, severe coronary disease, severe hypertension (including that associated with hyperthyroidism or pheochromocytoma), cardiac structural abnormalities, serious arrhythmias, etc.  Sudden death has been reported in adults and children taking CNS stimulant treatment.  Additionally, stroke, myocardial infarction, chest pain, syncope, arrhythmias and other symptoms have been reported in adults under treatment.  A careful assessment of the cardiovascular status should be done in patients being considered for treatment.  This includes family history, physical exam and further cardiac evaluation (EKG and echocardiogram).  Patients who develop symptoms should have a detailed cardiac evaluation and if needed, treatment should be suspended.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34554, 33264, 'Caffeine', 'Heart Diseases', 'The use of CNS stimulants is contraindicated in patients with significant cardiovascular impairment such as uncompensated heart failure, severe coronary disease, severe hypertension (including that associated with hyperthyroidism or pheochromocytoma), cardiac structural abnormalities, serious arrhythmias, etc.  Sudden death has been reported in adults and children taking CNS stimulant treatment.  Additionally, stroke, myocardial infarction, chest pain, syncope, arrhythmias and other symptoms have been reported in adults under treatment.  A careful assessment of the cardiovascular status should be done in patients being considered for treatment.  This includes family history, physical exam and further cardiac evaluation (EKG and echocardiogram).  Patients who develop symptoms should have a detailed cardiac evaluation and if needed, treatment should be suspended.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34555, 1841, 'Caffeine', 'Hypertension', 'CNS stimulant medications have shown to increase blood pressure, and their use might be contraindicated in patients with severe hypertension.  Caution should be used when administering to patients with preexisting high blood pressure and other cardiovascular conditions.  All patients under treatment should be regularly monitored for changes in blood pressure and heart rate.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34556, 2885, 'Caffeine', 'Hypertension', 'CNS stimulant medications have shown to increase blood pressure, and their use might be contraindicated in patients with severe hypertension.  Caution should be used when administering to patients with preexisting high blood pressure and other cardiovascular conditions.  All patients under treatment should be regularly monitored for changes in blood pressure and heart rate.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34557, 14477, 'Caffeine', 'Hypertension', 'CNS stimulant medications have shown to increase blood pressure, and their use might be contraindicated in patients with severe hypertension.  Caution should be used when administering to patients with preexisting high blood pressure and other cardiovascular conditions.  All patients under treatment should be regularly monitored for changes in blood pressure and heart rate.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34558, 15611, 'Caffeine', 'Hypertension', 'CNS stimulant medications have shown to increase blood pressure, and their use might be contraindicated in patients with severe hypertension.  Caution should be used when administering to patients with preexisting high blood pressure and other cardiovascular conditions.  All patients under treatment should be regularly monitored for changes in blood pressure and heart rate.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34559, 15613, 'Caffeine', 'Hypertension', 'CNS stimulant medications have shown to increase blood pressure, and their use might be contraindicated in patients with severe hypertension.  Caution should be used when administering to patients with preexisting high blood pressure and other cardiovascular conditions.  All patients under treatment should be regularly monitored for changes in blood pressure and heart rate.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34560, 17989, 'Caffeine', 'Hypertension', 'CNS stimulant medications have shown to increase blood pressure, and their use might be contraindicated in patients with severe hypertension.  Caution should be used when administering to patients with preexisting high blood pressure and other cardiovascular conditions.  All patients under treatment should be regularly monitored for changes in blood pressure and heart rate.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34561, 20221, 'Caffeine', 'Hypertension', 'CNS stimulant medications have shown to increase blood pressure, and their use might be contraindicated in patients with severe hypertension.  Caution should be used when administering to patients with preexisting high blood pressure and other cardiovascular conditions.  All patients under treatment should be regularly monitored for changes in blood pressure and heart rate.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34562, 20222, 'Caffeine', 'Hypertension', 'CNS stimulant medications have shown to increase blood pressure, and their use might be contraindicated in patients with severe hypertension.  Caution should be used when administering to patients with preexisting high blood pressure and other cardiovascular conditions.  All patients under treatment should be regularly monitored for changes in blood pressure and heart rate.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34563, 20223, 'Caffeine', 'Hypertension', 'CNS stimulant medications have shown to increase blood pressure, and their use might be contraindicated in patients with severe hypertension.  Caution should be used when administering to patients with preexisting high blood pressure and other cardiovascular conditions.  All patients under treatment should be regularly monitored for changes in blood pressure and heart rate.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34564, 20224, 'Caffeine', 'Hypertension', 'CNS stimulant medications have shown to increase blood pressure, and their use might be contraindicated in patients with severe hypertension.  Caution should be used when administering to patients with preexisting high blood pressure and other cardiovascular conditions.  All patients under treatment should be regularly monitored for changes in blood pressure and heart rate.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34565, 33264, 'Caffeine', 'Hypertension', 'CNS stimulant medications have shown to increase blood pressure, and their use might be contraindicated in patients with severe hypertension.  Caution should be used when administering to patients with preexisting high blood pressure and other cardiovascular conditions.  All patients under treatment should be regularly monitored for changes in blood pressure and heart rate.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34566, 1841, 'Caffeine', 'Liver Diseases', 'In general, CNS stimulants are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with CNS stimulants should be administered cautiously in patients with moderate to severe liver disease, and the dosage should be adjusted accordingly.  Additionally, postmarketing reports have shown that atomoxetine can cause severe liver injury.  Laboratory testing should be done at the first sign or symptom of liver dysfunction (jaundice, dark urine, upper quadrant tenderness) and treatment should be discontinued in patients with evidence of liver injury.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34567, 2885, 'Caffeine', 'Liver Diseases', 'In general, CNS stimulants are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with CNS stimulants should be administered cautiously in patients with moderate to severe liver disease, and the dosage should be adjusted accordingly.  Additionally, postmarketing reports have shown that atomoxetine can cause severe liver injury.  Laboratory testing should be done at the first sign or symptom of liver dysfunction (jaundice, dark urine, upper quadrant tenderness) and treatment should be discontinued in patients with evidence of liver injury.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34568, 14477, 'Caffeine', 'Liver Diseases', 'In general, CNS stimulants are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with CNS stimulants should be administered cautiously in patients with moderate to severe liver disease, and the dosage should be adjusted accordingly.  Additionally, postmarketing reports have shown that atomoxetine can cause severe liver injury.  Laboratory testing should be done at the first sign or symptom of liver dysfunction (jaundice, dark urine, upper quadrant tenderness) and treatment should be discontinued in patients with evidence of liver injury.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34569, 15611, 'Caffeine', 'Liver Diseases', 'In general, CNS stimulants are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with CNS stimulants should be administered cautiously in patients with moderate to severe liver disease, and the dosage should be adjusted accordingly.  Additionally, postmarketing reports have shown that atomoxetine can cause severe liver injury.  Laboratory testing should be done at the first sign or symptom of liver dysfunction (jaundice, dark urine, upper quadrant tenderness) and treatment should be discontinued in patients with evidence of liver injury.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34570, 15613, 'Caffeine', 'Liver Diseases', 'In general, CNS stimulants are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with CNS stimulants should be administered cautiously in patients with moderate to severe liver disease, and the dosage should be adjusted accordingly.  Additionally, postmarketing reports have shown that atomoxetine can cause severe liver injury.  Laboratory testing should be done at the first sign or symptom of liver dysfunction (jaundice, dark urine, upper quadrant tenderness) and treatment should be discontinued in patients with evidence of liver injury.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34571, 17989, 'Caffeine', 'Liver Diseases', 'In general, CNS stimulants are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with CNS stimulants should be administered cautiously in patients with moderate to severe liver disease, and the dosage should be adjusted accordingly.  Additionally, postmarketing reports have shown that atomoxetine can cause severe liver injury.  Laboratory testing should be done at the first sign or symptom of liver dysfunction (jaundice, dark urine, upper quadrant tenderness) and treatment should be discontinued in patients with evidence of liver injury.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34572, 20221, 'Caffeine', 'Liver Diseases', 'In general, CNS stimulants are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with CNS stimulants should be administered cautiously in patients with moderate to severe liver disease, and the dosage should be adjusted accordingly.  Additionally, postmarketing reports have shown that atomoxetine can cause severe liver injury.  Laboratory testing should be done at the first sign or symptom of liver dysfunction (jaundice, dark urine, upper quadrant tenderness) and treatment should be discontinued in patients with evidence of liver injury.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34573, 20222, 'Caffeine', 'Liver Diseases', 'In general, CNS stimulants are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with CNS stimulants should be administered cautiously in patients with moderate to severe liver disease, and the dosage should be adjusted accordingly.  Additionally, postmarketing reports have shown that atomoxetine can cause severe liver injury.  Laboratory testing should be done at the first sign or symptom of liver dysfunction (jaundice, dark urine, upper quadrant tenderness) and treatment should be discontinued in patients with evidence of liver injury.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34574, 20223, 'Caffeine', 'Liver Diseases', 'In general, CNS stimulants are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with CNS stimulants should be administered cautiously in patients with moderate to severe liver disease, and the dosage should be adjusted accordingly.  Additionally, postmarketing reports have shown that atomoxetine can cause severe liver injury.  Laboratory testing should be done at the first sign or symptom of liver dysfunction (jaundice, dark urine, upper quadrant tenderness) and treatment should be discontinued in patients with evidence of liver injury.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34575, 20224, 'Caffeine', 'Liver Diseases', 'In general, CNS stimulants are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with CNS stimulants should be administered cautiously in patients with moderate to severe liver disease, and the dosage should be adjusted accordingly.  Additionally, postmarketing reports have shown that atomoxetine can cause severe liver injury.  Laboratory testing should be done at the first sign or symptom of liver dysfunction (jaundice, dark urine, upper quadrant tenderness) and treatment should be discontinued in patients with evidence of liver injury.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34576, 33264, 'Caffeine', 'Liver Diseases', 'In general, CNS stimulants are extensively metabolized by the liver.  Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function.  Therapy with CNS stimulants should be administered cautiously in patients with moderate to severe liver disease, and the dosage should be adjusted accordingly.  Additionally, postmarketing reports have shown that atomoxetine can cause severe liver injury.  Laboratory testing should be done at the first sign or symptom of liver dysfunction (jaundice, dark urine, upper quadrant tenderness) and treatment should be discontinued in patients with evidence of liver injury.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34577, 1841, 'Caffeine', 'Mental Disorders', 'The use of CNS stimulants can cause psychotic or maniac symptoms, suicidal ideation, aggression and can exacerbate symptoms of behavior disturbance and thought disorder.  Psychiatric symptoms have been reported in patients with and without history of psychiatric disorders, and all patients should be monitored closely, specially during treatment initiation and at times of dose changes.  Extreme caution should be exercised when CNS stimulants are given to patients with a history of psychosis, depression, mania, or bipolar disorder.  All patients receiving treatment should be screened for bipolar disease prior to initiation.  If any psychiatric symptoms emerge or are exacerbated, treatment suspension should be considered.  CNS stimulants are contraindicated in patients with marked agitation or anxiety.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34578, 2885, 'Caffeine', 'Mental Disorders', 'The use of CNS stimulants can cause psychotic or maniac symptoms, suicidal ideation, aggression and can exacerbate symptoms of behavior disturbance and thought disorder.  Psychiatric symptoms have been reported in patients with and without history of psychiatric disorders, and all patients should be monitored closely, specially during treatment initiation and at times of dose changes.  Extreme caution should be exercised when CNS stimulants are given to patients with a history of psychosis, depression, mania, or bipolar disorder.  All patients receiving treatment should be screened for bipolar disease prior to initiation.  If any psychiatric symptoms emerge or are exacerbated, treatment suspension should be considered.  CNS stimulants are contraindicated in patients with marked agitation or anxiety.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34579, 14477, 'Caffeine', 'Mental Disorders', 'The use of CNS stimulants can cause psychotic or maniac symptoms, suicidal ideation, aggression and can exacerbate symptoms of behavior disturbance and thought disorder.  Psychiatric symptoms have been reported in patients with and without history of psychiatric disorders, and all patients should be monitored closely, specially during treatment initiation and at times of dose changes.  Extreme caution should be exercised when CNS stimulants are given to patients with a history of psychosis, depression, mania, or bipolar disorder.  All patients receiving treatment should be screened for bipolar disease prior to initiation.  If any psychiatric symptoms emerge or are exacerbated, treatment suspension should be considered.  CNS stimulants are contraindicated in patients with marked agitation or anxiety.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34580, 15611, 'Caffeine', 'Mental Disorders', 'The use of CNS stimulants can cause psychotic or maniac symptoms, suicidal ideation, aggression and can exacerbate symptoms of behavior disturbance and thought disorder.  Psychiatric symptoms have been reported in patients with and without history of psychiatric disorders, and all patients should be monitored closely, specially during treatment initiation and at times of dose changes.  Extreme caution should be exercised when CNS stimulants are given to patients with a history of psychosis, depression, mania, or bipolar disorder.  All patients receiving treatment should be screened for bipolar disease prior to initiation.  If any psychiatric symptoms emerge or are exacerbated, treatment suspension should be considered.  CNS stimulants are contraindicated in patients with marked agitation or anxiety.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34581, 15613, 'Caffeine', 'Mental Disorders', 'The use of CNS stimulants can cause psychotic or maniac symptoms, suicidal ideation, aggression and can exacerbate symptoms of behavior disturbance and thought disorder.  Psychiatric symptoms have been reported in patients with and without history of psychiatric disorders, and all patients should be monitored closely, specially during treatment initiation and at times of dose changes.  Extreme caution should be exercised when CNS stimulants are given to patients with a history of psychosis, depression, mania, or bipolar disorder.  All patients receiving treatment should be screened for bipolar disease prior to initiation.  If any psychiatric symptoms emerge or are exacerbated, treatment suspension should be considered.  CNS stimulants are contraindicated in patients with marked agitation or anxiety.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34582, 17989, 'Caffeine', 'Mental Disorders', 'The use of CNS stimulants can cause psychotic or maniac symptoms, suicidal ideation, aggression and can exacerbate symptoms of behavior disturbance and thought disorder.  Psychiatric symptoms have been reported in patients with and without history of psychiatric disorders, and all patients should be monitored closely, specially during treatment initiation and at times of dose changes.  Extreme caution should be exercised when CNS stimulants are given to patients with a history of psychosis, depression, mania, or bipolar disorder.  All patients receiving treatment should be screened for bipolar disease prior to initiation.  If any psychiatric symptoms emerge or are exacerbated, treatment suspension should be considered.  CNS stimulants are contraindicated in patients with marked agitation or anxiety.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34583, 20221, 'Caffeine', 'Mental Disorders', 'The use of CNS stimulants can cause psychotic or maniac symptoms, suicidal ideation, aggression and can exacerbate symptoms of behavior disturbance and thought disorder.  Psychiatric symptoms have been reported in patients with and without history of psychiatric disorders, and all patients should be monitored closely, specially during treatment initiation and at times of dose changes.  Extreme caution should be exercised when CNS stimulants are given to patients with a history of psychosis, depression, mania, or bipolar disorder.  All patients receiving treatment should be screened for bipolar disease prior to initiation.  If any psychiatric symptoms emerge or are exacerbated, treatment suspension should be considered.  CNS stimulants are contraindicated in patients with marked agitation or anxiety.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34584, 20222, 'Caffeine', 'Mental Disorders', 'The use of CNS stimulants can cause psychotic or maniac symptoms, suicidal ideation, aggression and can exacerbate symptoms of behavior disturbance and thought disorder.  Psychiatric symptoms have been reported in patients with and without history of psychiatric disorders, and all patients should be monitored closely, specially during treatment initiation and at times of dose changes.  Extreme caution should be exercised when CNS stimulants are given to patients with a history of psychosis, depression, mania, or bipolar disorder.  All patients receiving treatment should be screened for bipolar disease prior to initiation.  If any psychiatric symptoms emerge or are exacerbated, treatment suspension should be considered.  CNS stimulants are contraindicated in patients with marked agitation or anxiety.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34585, 20223, 'Caffeine', 'Mental Disorders', 'The use of CNS stimulants can cause psychotic or maniac symptoms, suicidal ideation, aggression and can exacerbate symptoms of behavior disturbance and thought disorder.  Psychiatric symptoms have been reported in patients with and without history of psychiatric disorders, and all patients should be monitored closely, specially during treatment initiation and at times of dose changes.  Extreme caution should be exercised when CNS stimulants are given to patients with a history of psychosis, depression, mania, or bipolar disorder.  All patients receiving treatment should be screened for bipolar disease prior to initiation.  If any psychiatric symptoms emerge or are exacerbated, treatment suspension should be considered.  CNS stimulants are contraindicated in patients with marked agitation or anxiety.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34586, 20224, 'Caffeine', 'Mental Disorders', 'The use of CNS stimulants can cause psychotic or maniac symptoms, suicidal ideation, aggression and can exacerbate symptoms of behavior disturbance and thought disorder.  Psychiatric symptoms have been reported in patients with and without history of psychiatric disorders, and all patients should be monitored closely, specially during treatment initiation and at times of dose changes.  Extreme caution should be exercised when CNS stimulants are given to patients with a history of psychosis, depression, mania, or bipolar disorder.  All patients receiving treatment should be screened for bipolar disease prior to initiation.  If any psychiatric symptoms emerge or are exacerbated, treatment suspension should be considered.  CNS stimulants are contraindicated in patients with marked agitation or anxiety.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34587, 33264, 'Caffeine', 'Mental Disorders', 'The use of CNS stimulants can cause psychotic or maniac symptoms, suicidal ideation, aggression and can exacerbate symptoms of behavior disturbance and thought disorder.  Psychiatric symptoms have been reported in patients with and without history of psychiatric disorders, and all patients should be monitored closely, specially during treatment initiation and at times of dose changes.  Extreme caution should be exercised when CNS stimulants are given to patients with a history of psychosis, depression, mania, or bipolar disorder.  All patients receiving treatment should be screened for bipolar disease prior to initiation.  If any psychiatric symptoms emerge or are exacerbated, treatment suspension should be considered.  CNS stimulants are contraindicated in patients with marked agitation or anxiety.', '3', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34588, 1841, 'Caffeine', 'Peptic Ulcer', 'Methylxanthines are known to stimulate peptic acid secretion.  Therapy with products containing methylxanthines should be administered with extreme caution in patients with active peptic ulcer disease.  Some manufacturers consider their use to be contraindicated under such circumstance.', '3', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34589, 2885, 'Caffeine', 'Peptic Ulcer', 'Methylxanthines are known to stimulate peptic acid secretion.  Therapy with products containing methylxanthines should be administered with extreme caution in patients with active peptic ulcer disease.  Some manufacturers consider their use to be contraindicated under such circumstance.', '3', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34590, 14477, 'Caffeine', 'Peptic Ulcer', 'Methylxanthines are known to stimulate peptic acid secretion.  Therapy with products containing methylxanthines should be administered with extreme caution in patients with active peptic ulcer disease.  Some manufacturers consider their use to be contraindicated under such circumstance.', '3', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34591, 15611, 'Caffeine', 'Peptic Ulcer', 'Methylxanthines are known to stimulate peptic acid secretion.  Therapy with products containing methylxanthines should be administered with extreme caution in patients with active peptic ulcer disease.  Some manufacturers consider their use to be contraindicated under such circumstance.', '3', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34592, 15613, 'Caffeine', 'Peptic Ulcer', 'Methylxanthines are known to stimulate peptic acid secretion.  Therapy with products containing methylxanthines should be administered with extreme caution in patients with active peptic ulcer disease.  Some manufacturers consider their use to be contraindicated under such circumstance.', '3', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34593, 17989, 'Caffeine', 'Peptic Ulcer', 'Methylxanthines are known to stimulate peptic acid secretion.  Therapy with products containing methylxanthines should be administered with extreme caution in patients with active peptic ulcer disease.  Some manufacturers consider their use to be contraindicated under such circumstance.', '3', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34594, 20221, 'Caffeine', 'Peptic Ulcer', 'Methylxanthines are known to stimulate peptic acid secretion.  Therapy with products containing methylxanthines should be administered with extreme caution in patients with active peptic ulcer disease.  Some manufacturers consider their use to be contraindicated under such circumstance.', '3', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34595, 20222, 'Caffeine', 'Peptic Ulcer', 'Methylxanthines are known to stimulate peptic acid secretion.  Therapy with products containing methylxanthines should be administered with extreme caution in patients with active peptic ulcer disease.  Some manufacturers consider their use to be contraindicated under such circumstance.', '3', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34596, 20223, 'Caffeine', 'Peptic Ulcer', 'Methylxanthines are known to stimulate peptic acid secretion.  Therapy with products containing methylxanthines should be administered with extreme caution in patients with active peptic ulcer disease.  Some manufacturers consider their use to be contraindicated under such circumstance.', '3', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34597, 20224, 'Caffeine', 'Peptic Ulcer', 'Methylxanthines are known to stimulate peptic acid secretion.  Therapy with products containing methylxanthines should be administered with extreme caution in patients with active peptic ulcer disease.  Some manufacturers consider their use to be contraindicated under such circumstance.', '3', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34598, 33264, 'Caffeine', 'Peptic Ulcer', 'Methylxanthines are known to stimulate peptic acid secretion.  Therapy with products containing methylxanthines should be administered with extreme caution in patients with active peptic ulcer disease.  Some manufacturers consider their use to be contraindicated under such circumstance.', '3', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|"Product Information. Theo-Dur (theophylline)." Schering Corporation  (2001):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34599, 1841, 'Caffeine', 'Cardiotoxicity', 'Like other methylxanthines, caffeine at high dosages may be associated with positive inotropic and chronotropic effects on the heart.  Caffeine may also produce an increase in systemic vascular resistance, resulting in elevation of blood pressure.  Therapy with products containing caffeine should be administered cautiously in patients with severe cardiac disease, hypertension, hyperthyroidism, or acute myocardial injury.  Some clinicians recommend avoiding caffeine in patients with symptomatic cardiac arrhythmias and/or palpitations and during the first several days to weeks after an acute myocardial infarction.', '2', '"Multum Information Services, Inc. Expert Review Panel"', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34600, 2885, 'Caffeine', 'Cardiotoxicity', 'Like other methylxanthines, caffeine at high dosages may be associated with positive inotropic and chronotropic effects on the heart.  Caffeine may also produce an increase in systemic vascular resistance, resulting in elevation of blood pressure.  Therapy with products containing caffeine should be administered cautiously in patients with severe cardiac disease, hypertension, hyperthyroidism, or acute myocardial injury.  Some clinicians recommend avoiding caffeine in patients with symptomatic cardiac arrhythmias and/or palpitations and during the first several days to weeks after an acute myocardial infarction.', '2', '"Multum Information Services, Inc. Expert Review Panel"', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34601, 14477, 'Caffeine', 'Cardiotoxicity', 'Like other methylxanthines, caffeine at high dosages may be associated with positive inotropic and chronotropic effects on the heart.  Caffeine may also produce an increase in systemic vascular resistance, resulting in elevation of blood pressure.  Therapy with products containing caffeine should be administered cautiously in patients with severe cardiac disease, hypertension, hyperthyroidism, or acute myocardial injury.  Some clinicians recommend avoiding caffeine in patients with symptomatic cardiac arrhythmias and/or palpitations and during the first several days to weeks after an acute myocardial infarction.', '2', '"Multum Information Services, Inc. Expert Review Panel"', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34602, 15611, 'Caffeine', 'Cardiotoxicity', 'Like other methylxanthines, caffeine at high dosages may be associated with positive inotropic and chronotropic effects on the heart.  Caffeine may also produce an increase in systemic vascular resistance, resulting in elevation of blood pressure.  Therapy with products containing caffeine should be administered cautiously in patients with severe cardiac disease, hypertension, hyperthyroidism, or acute myocardial injury.  Some clinicians recommend avoiding caffeine in patients with symptomatic cardiac arrhythmias and/or palpitations and during the first several days to weeks after an acute myocardial infarction.', '2', '"Multum Information Services, Inc. Expert Review Panel"', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34603, 15613, 'Caffeine', 'Cardiotoxicity', 'Like other methylxanthines, caffeine at high dosages may be associated with positive inotropic and chronotropic effects on the heart.  Caffeine may also produce an increase in systemic vascular resistance, resulting in elevation of blood pressure.  Therapy with products containing caffeine should be administered cautiously in patients with severe cardiac disease, hypertension, hyperthyroidism, or acute myocardial injury.  Some clinicians recommend avoiding caffeine in patients with symptomatic cardiac arrhythmias and/or palpitations and during the first several days to weeks after an acute myocardial infarction.', '2', '"Multum Information Services, Inc. Expert Review Panel"', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34604, 17989, 'Caffeine', 'Cardiotoxicity', 'Like other methylxanthines, caffeine at high dosages may be associated with positive inotropic and chronotropic effects on the heart.  Caffeine may also produce an increase in systemic vascular resistance, resulting in elevation of blood pressure.  Therapy with products containing caffeine should be administered cautiously in patients with severe cardiac disease, hypertension, hyperthyroidism, or acute myocardial injury.  Some clinicians recommend avoiding caffeine in patients with symptomatic cardiac arrhythmias and/or palpitations and during the first several days to weeks after an acute myocardial infarction.', '2', '"Multum Information Services, Inc. Expert Review Panel"', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34605, 20221, 'Caffeine', 'Cardiotoxicity', 'Like other methylxanthines, caffeine at high dosages may be associated with positive inotropic and chronotropic effects on the heart.  Caffeine may also produce an increase in systemic vascular resistance, resulting in elevation of blood pressure.  Therapy with products containing caffeine should be administered cautiously in patients with severe cardiac disease, hypertension, hyperthyroidism, or acute myocardial injury.  Some clinicians recommend avoiding caffeine in patients with symptomatic cardiac arrhythmias and/or palpitations and during the first several days to weeks after an acute myocardial infarction.', '2', '"Multum Information Services, Inc. Expert Review Panel"', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34606, 20222, 'Caffeine', 'Cardiotoxicity', 'Like other methylxanthines, caffeine at high dosages may be associated with positive inotropic and chronotropic effects on the heart.  Caffeine may also produce an increase in systemic vascular resistance, resulting in elevation of blood pressure.  Therapy with products containing caffeine should be administered cautiously in patients with severe cardiac disease, hypertension, hyperthyroidism, or acute myocardial injury.  Some clinicians recommend avoiding caffeine in patients with symptomatic cardiac arrhythmias and/or palpitations and during the first several days to weeks after an acute myocardial infarction.', '2', '"Multum Information Services, Inc. Expert Review Panel"', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34607, 20223, 'Caffeine', 'Cardiotoxicity', 'Like other methylxanthines, caffeine at high dosages may be associated with positive inotropic and chronotropic effects on the heart.  Caffeine may also produce an increase in systemic vascular resistance, resulting in elevation of blood pressure.  Therapy with products containing caffeine should be administered cautiously in patients with severe cardiac disease, hypertension, hyperthyroidism, or acute myocardial injury.  Some clinicians recommend avoiding caffeine in patients with symptomatic cardiac arrhythmias and/or palpitations and during the first several days to weeks after an acute myocardial infarction.', '2', '"Multum Information Services, Inc. Expert Review Panel"', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34608, 20224, 'Caffeine', 'Cardiotoxicity', 'Like other methylxanthines, caffeine at high dosages may be associated with positive inotropic and chronotropic effects on the heart.  Caffeine may also produce an increase in systemic vascular resistance, resulting in elevation of blood pressure.  Therapy with products containing caffeine should be administered cautiously in patients with severe cardiac disease, hypertension, hyperthyroidism, or acute myocardial injury.  Some clinicians recommend avoiding caffeine in patients with symptomatic cardiac arrhythmias and/or palpitations and during the first several days to weeks after an acute myocardial infarction.', '2', '"Multum Information Services, Inc. Expert Review Panel"', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34609, 33264, 'Caffeine', 'Cardiotoxicity', 'Like other methylxanthines, caffeine at high dosages may be associated with positive inotropic and chronotropic effects on the heart.  Caffeine may also produce an increase in systemic vascular resistance, resulting in elevation of blood pressure.  Therapy with products containing caffeine should be administered cautiously in patients with severe cardiac disease, hypertension, hyperthyroidism, or acute myocardial injury.  Some clinicians recommend avoiding caffeine in patients with symptomatic cardiac arrhythmias and/or palpitations and during the first several days to weeks after an acute myocardial infarction.', '2', '"Multum Information Services, Inc. Expert Review Panel"', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34610, 1841, 'Caffeine', 'Bipolar Disorder', 'Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder.  Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).  Close monitoring is recommended when using these agents in patients with bipolar disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34611, 2885, 'Caffeine', 'Bipolar Disorder', 'Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder.  Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).  Close monitoring is recommended when using these agents in patients with bipolar disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34612, 14477, 'Caffeine', 'Bipolar Disorder', 'Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder.  Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).  Close monitoring is recommended when using these agents in patients with bipolar disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34613, 15611, 'Caffeine', 'Bipolar Disorder', 'Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder.  Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).  Close monitoring is recommended when using these agents in patients with bipolar disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34614, 15613, 'Caffeine', 'Bipolar Disorder', 'Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder.  Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).  Close monitoring is recommended when using these agents in patients with bipolar disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34615, 17989, 'Caffeine', 'Bipolar Disorder', 'Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder.  Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).  Close monitoring is recommended when using these agents in patients with bipolar disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34616, 20221, 'Caffeine', 'Bipolar Disorder', 'Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder.  Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).  Close monitoring is recommended when using these agents in patients with bipolar disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34617, 20222, 'Caffeine', 'Bipolar Disorder', 'Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder.  Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).  Close monitoring is recommended when using these agents in patients with bipolar disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34618, 20223, 'Caffeine', 'Bipolar Disorder', 'Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder.  Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).  Close monitoring is recommended when using these agents in patients with bipolar disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34619, 20224, 'Caffeine', 'Bipolar Disorder', 'Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder.  Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).  Close monitoring is recommended when using these agents in patients with bipolar disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34620, 33264, 'Caffeine', 'Bipolar Disorder', 'Central nervous system (CNS) stimulants may induce a mixed/manic episode in patients with bipolar disorder.  Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).  Close monitoring is recommended when using these agents in patients with bipolar disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34621, 1841, 'Caffeine', 'Psychotic Disorders', 'Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder.  Close monitoring is recommended when using these agents in patients with psychotic disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34622, 2885, 'Caffeine', 'Psychotic Disorders', 'Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder.  Close monitoring is recommended when using these agents in patients with psychotic disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34623, 14477, 'Caffeine', 'Psychotic Disorders', 'Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder.  Close monitoring is recommended when using these agents in patients with psychotic disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34624, 15611, 'Caffeine', 'Psychotic Disorders', 'Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder.  Close monitoring is recommended when using these agents in patients with psychotic disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34625, 15613, 'Caffeine', 'Psychotic Disorders', 'Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder.  Close monitoring is recommended when using these agents in patients with psychotic disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34626, 17989, 'Caffeine', 'Psychotic Disorders', 'Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder.  Close monitoring is recommended when using these agents in patients with psychotic disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34627, 20221, 'Caffeine', 'Psychotic Disorders', 'Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder.  Close monitoring is recommended when using these agents in patients with psychotic disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34628, 20222, 'Caffeine', 'Psychotic Disorders', 'Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder.  Close monitoring is recommended when using these agents in patients with psychotic disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34629, 20223, 'Caffeine', 'Psychotic Disorders', 'Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder.  Close monitoring is recommended when using these agents in patients with psychotic disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34630, 20224, 'Caffeine', 'Psychotic Disorders', 'Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder.  Close monitoring is recommended when using these agents in patients with psychotic disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34631, 33264, 'Caffeine', 'Psychotic Disorders', 'Central nervous system (CNS) stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder.  Close monitoring is recommended when using these agents in patients with psychotic disorders.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Prelu-2 (phendimetrazine)." Boehringer-Ingelheim  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34632, 1841, 'Caffeine', 'Kidney Diseases', 'Overall CNS stimulants should be administered with caution in patients with significantly impaired renal function as the reduction in the rate of elimination may alter the therapeutic response.  The dosage should be adjusted accordingly.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34633, 2885, 'Caffeine', 'Kidney Diseases', 'Overall CNS stimulants should be administered with caution in patients with significantly impaired renal function as the reduction in the rate of elimination may alter the therapeutic response.  The dosage should be adjusted accordingly.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34634, 14477, 'Caffeine', 'Kidney Diseases', 'Overall CNS stimulants should be administered with caution in patients with significantly impaired renal function as the reduction in the rate of elimination may alter the therapeutic response.  The dosage should be adjusted accordingly.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34635, 15611, 'Caffeine', 'Kidney Diseases', 'Overall CNS stimulants should be administered with caution in patients with significantly impaired renal function as the reduction in the rate of elimination may alter the therapeutic response.  The dosage should be adjusted accordingly.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34636, 15613, 'Caffeine', 'Kidney Diseases', 'Overall CNS stimulants should be administered with caution in patients with significantly impaired renal function as the reduction in the rate of elimination may alter the therapeutic response.  The dosage should be adjusted accordingly.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34637, 17989, 'Caffeine', 'Kidney Diseases', 'Overall CNS stimulants should be administered with caution in patients with significantly impaired renal function as the reduction in the rate of elimination may alter the therapeutic response.  The dosage should be adjusted accordingly.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34638, 20221, 'Caffeine', 'Kidney Diseases', 'Overall CNS stimulants should be administered with caution in patients with significantly impaired renal function as the reduction in the rate of elimination may alter the therapeutic response.  The dosage should be adjusted accordingly.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34639, 20222, 'Caffeine', 'Kidney Diseases', 'Overall CNS stimulants should be administered with caution in patients with significantly impaired renal function as the reduction in the rate of elimination may alter the therapeutic response.  The dosage should be adjusted accordingly.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34640, 20223, 'Caffeine', 'Kidney Diseases', 'Overall CNS stimulants should be administered with caution in patients with significantly impaired renal function as the reduction in the rate of elimination may alter the therapeutic response.  The dosage should be adjusted accordingly.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34641, 20224, 'Caffeine', 'Kidney Diseases', 'Overall CNS stimulants should be administered with caution in patients with significantly impaired renal function as the reduction in the rate of elimination may alter the therapeutic response.  The dosage should be adjusted accordingly.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34642, 33264, 'Caffeine', 'Kidney Diseases', 'Overall CNS stimulants should be administered with caution in patients with significantly impaired renal function as the reduction in the rate of elimination may alter the therapeutic response.  The dosage should be adjusted accordingly.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Dopram (doxapram)." West Ward Pharmaceutical Corporation  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34643, 1841, 'Caffeine', 'Epilepsy', 'Due to general central nervous system stimulation, therapy with CNS stimulant drugs may cause seizures.  These drugs may lower the convulsive threshold in patients with prior history of seizures or EEG abnormalities, and very rarely in patients with no previous history of seizures.  Therapy with CNS stimulants should be used with caution in patients with or predisposed to seizures.  If seizures appear, therapy should be discontinued.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34644, 2885, 'Caffeine', 'Epilepsy', 'Due to general central nervous system stimulation, therapy with CNS stimulant drugs may cause seizures.  These drugs may lower the convulsive threshold in patients with prior history of seizures or EEG abnormalities, and very rarely in patients with no previous history of seizures.  Therapy with CNS stimulants should be used with caution in patients with or predisposed to seizures.  If seizures appear, therapy should be discontinued.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34645, 14477, 'Caffeine', 'Epilepsy', 'Due to general central nervous system stimulation, therapy with CNS stimulant drugs may cause seizures.  These drugs may lower the convulsive threshold in patients with prior history of seizures or EEG abnormalities, and very rarely in patients with no previous history of seizures.  Therapy with CNS stimulants should be used with caution in patients with or predisposed to seizures.  If seizures appear, therapy should be discontinued.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34646, 15611, 'Caffeine', 'Epilepsy', 'Due to general central nervous system stimulation, therapy with CNS stimulant drugs may cause seizures.  These drugs may lower the convulsive threshold in patients with prior history of seizures or EEG abnormalities, and very rarely in patients with no previous history of seizures.  Therapy with CNS stimulants should be used with caution in patients with or predisposed to seizures.  If seizures appear, therapy should be discontinued.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34647, 15613, 'Caffeine', 'Epilepsy', 'Due to general central nervous system stimulation, therapy with CNS stimulant drugs may cause seizures.  These drugs may lower the convulsive threshold in patients with prior history of seizures or EEG abnormalities, and very rarely in patients with no previous history of seizures.  Therapy with CNS stimulants should be used with caution in patients with or predisposed to seizures.  If seizures appear, therapy should be discontinued.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34648, 17989, 'Caffeine', 'Epilepsy', 'Due to general central nervous system stimulation, therapy with CNS stimulant drugs may cause seizures.  These drugs may lower the convulsive threshold in patients with prior history of seizures or EEG abnormalities, and very rarely in patients with no previous history of seizures.  Therapy with CNS stimulants should be used with caution in patients with or predisposed to seizures.  If seizures appear, therapy should be discontinued.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34649, 20221, 'Caffeine', 'Epilepsy', 'Due to general central nervous system stimulation, therapy with CNS stimulant drugs may cause seizures.  These drugs may lower the convulsive threshold in patients with prior history of seizures or EEG abnormalities, and very rarely in patients with no previous history of seizures.  Therapy with CNS stimulants should be used with caution in patients with or predisposed to seizures.  If seizures appear, therapy should be discontinued.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34650, 20222, 'Caffeine', 'Epilepsy', 'Due to general central nervous system stimulation, therapy with CNS stimulant drugs may cause seizures.  These drugs may lower the convulsive threshold in patients with prior history of seizures or EEG abnormalities, and very rarely in patients with no previous history of seizures.  Therapy with CNS stimulants should be used with caution in patients with or predisposed to seizures.  If seizures appear, therapy should be discontinued.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34651, 20223, 'Caffeine', 'Epilepsy', 'Due to general central nervous system stimulation, therapy with CNS stimulant drugs may cause seizures.  These drugs may lower the convulsive threshold in patients with prior history of seizures or EEG abnormalities, and very rarely in patients with no previous history of seizures.  Therapy with CNS stimulants should be used with caution in patients with or predisposed to seizures.  If seizures appear, therapy should be discontinued.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34652, 20224, 'Caffeine', 'Epilepsy', 'Due to general central nervous system stimulation, therapy with CNS stimulant drugs may cause seizures.  These drugs may lower the convulsive threshold in patients with prior history of seizures or EEG abnormalities, and very rarely in patients with no previous history of seizures.  Therapy with CNS stimulants should be used with caution in patients with or predisposed to seizures.  If seizures appear, therapy should be discontinued.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34653, 33264, 'Caffeine', 'Epilepsy', 'Due to general central nervous system stimulation, therapy with CNS stimulant drugs may cause seizures.  These drugs may lower the convulsive threshold in patients with prior history of seizures or EEG abnormalities, and very rarely in patients with no previous history of seizures.  Therapy with CNS stimulants should be used with caution in patients with or predisposed to seizures.  If seizures appear, therapy should be discontinued.', '2', '"Product Information. Fastin (phentermine)." SmithKline Beecham  (2001):|"Product Information. Provigil (modafinil)." Cephalon, Inc  (2001):|"Product Information. Cylert (pemoline)." Abbott Pharmaceutical  (2001):|"Product Information. Desoxyn (methamphetamine)." Abbott Pharmaceutical  (2001):|"Product Information. Dexedrine (dextroamphetamine)." SmithKline Beecham  (2001):|"Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn  (2001):|"Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals  (2001):|"Product Information. Focalin (dexmethylphenidate)." Mikart Inc  (2001):|"Product Information. Concerta (methylphenidate)." Alza  (2002):|"Product Information. Strattera (atomoxetine)." Lilly, Eli and Company  (2002):|"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc  (2007):|"Product Information. Nuvigil (armodafinil)." Cephalon Inc  (2007):|"Product Information. Phendimetrazine Tartrate SR (phendimetrazine)." Sandoz Inc  (2012):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34654, 1841, 'Caffeine', 'Gastroesophageal Reflux', 'Methylxanthines increase gastric acidity and may also relax lower esophageal sphincter, which can lead to gastric reflux into the esophagus.  Therapy with products containing methylxanthines should be administered cautiously in patients with significant gastroesophageal reflux.', '2', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34655, 2885, 'Caffeine', 'Gastroesophageal Reflux', 'Methylxanthines increase gastric acidity and may also relax lower esophageal sphincter, which can lead to gastric reflux into the esophagus.  Therapy with products containing methylxanthines should be administered cautiously in patients with significant gastroesophageal reflux.', '2', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34656, 14477, 'Caffeine', 'Gastroesophageal Reflux', 'Methylxanthines increase gastric acidity and may also relax lower esophageal sphincter, which can lead to gastric reflux into the esophagus.  Therapy with products containing methylxanthines should be administered cautiously in patients with significant gastroesophageal reflux.', '2', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34657, 15611, 'Caffeine', 'Gastroesophageal Reflux', 'Methylxanthines increase gastric acidity and may also relax lower esophageal sphincter, which can lead to gastric reflux into the esophagus.  Therapy with products containing methylxanthines should be administered cautiously in patients with significant gastroesophageal reflux.', '2', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34658, 15613, 'Caffeine', 'Gastroesophageal Reflux', 'Methylxanthines increase gastric acidity and may also relax lower esophageal sphincter, which can lead to gastric reflux into the esophagus.  Therapy with products containing methylxanthines should be administered cautiously in patients with significant gastroesophageal reflux.', '2', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34659, 17989, 'Caffeine', 'Gastroesophageal Reflux', 'Methylxanthines increase gastric acidity and may also relax lower esophageal sphincter, which can lead to gastric reflux into the esophagus.  Therapy with products containing methylxanthines should be administered cautiously in patients with significant gastroesophageal reflux.', '2', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34660, 20221, 'Caffeine', 'Gastroesophageal Reflux', 'Methylxanthines increase gastric acidity and may also relax lower esophageal sphincter, which can lead to gastric reflux into the esophagus.  Therapy with products containing methylxanthines should be administered cautiously in patients with significant gastroesophageal reflux.', '2', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34661, 20222, 'Caffeine', 'Gastroesophageal Reflux', 'Methylxanthines increase gastric acidity and may also relax lower esophageal sphincter, which can lead to gastric reflux into the esophagus.  Therapy with products containing methylxanthines should be administered cautiously in patients with significant gastroesophageal reflux.', '2', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34662, 20223, 'Caffeine', 'Gastroesophageal Reflux', 'Methylxanthines increase gastric acidity and may also relax lower esophageal sphincter, which can lead to gastric reflux into the esophagus.  Therapy with products containing methylxanthines should be administered cautiously in patients with significant gastroesophageal reflux.', '2', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34663, 20224, 'Caffeine', 'Gastroesophageal Reflux', 'Methylxanthines increase gastric acidity and may also relax lower esophageal sphincter, which can lead to gastric reflux into the esophagus.  Therapy with products containing methylxanthines should be administered cautiously in patients with significant gastroesophageal reflux.', '2', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34664, 33264, 'Caffeine', 'Gastroesophageal Reflux', 'Methylxanthines increase gastric acidity and may also relax lower esophageal sphincter, which can lead to gastric reflux into the esophagus.  Therapy with products containing methylxanthines should be administered cautiously in patients with significant gastroesophageal reflux.', '2', 'Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985):  328-9|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996):  1473|"Product Information. Lufyllin (dyphylline)." Wallace Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34665, 1841, 'Caffeine', 'Water-Electrolyte Imbalance', 'Sodium chloride can induce sodium and water retention and result in hypernatremia, hypokalemia, edema and aggravation of congestive heart failure.  Therapy with sodium- containing agents should be administered with extreme caution, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states where there is edema with sodium retention.  Clinical monitoring of acid/base balance and electrolytes prior to, during, a following completion of therapy with sodium- containing agents is recommended.', '3', '"Product Information. Megace (megestrol)." Bristol-Myers Squibb  (2001):|"Product Information. Calcibind (cellulose sodium phosphate)." Mission Pharmacal Company  (2001):|"Product Information. Sodium Benzoate (sodium benzoate)." Taylor Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34666, 2885, 'Caffeine', 'Water-Electrolyte Imbalance', 'Sodium chloride can induce sodium and water retention and result in hypernatremia, hypokalemia, edema and aggravation of congestive heart failure.  Therapy with sodium- containing agents should be administered with extreme caution, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states where there is edema with sodium retention.  Clinical monitoring of acid/base balance and electrolytes prior to, during, a following completion of therapy with sodium- containing agents is recommended.', '3', '"Product Information. Megace (megestrol)." Bristol-Myers Squibb  (2001):|"Product Information. Calcibind (cellulose sodium phosphate)." Mission Pharmacal Company  (2001):|"Product Information. Sodium Benzoate (sodium benzoate)." Taylor Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34667, 14477, 'Caffeine', 'Water-Electrolyte Imbalance', 'Sodium chloride can induce sodium and water retention and result in hypernatremia, hypokalemia, edema and aggravation of congestive heart failure.  Therapy with sodium- containing agents should be administered with extreme caution, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states where there is edema with sodium retention.  Clinical monitoring of acid/base balance and electrolytes prior to, during, a following completion of therapy with sodium- containing agents is recommended.', '3', '"Product Information. Megace (megestrol)." Bristol-Myers Squibb  (2001):|"Product Information. Calcibind (cellulose sodium phosphate)." Mission Pharmacal Company  (2001):|"Product Information. Sodium Benzoate (sodium benzoate)." Taylor Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34668, 15611, 'Caffeine', 'Water-Electrolyte Imbalance', 'Sodium chloride can induce sodium and water retention and result in hypernatremia, hypokalemia, edema and aggravation of congestive heart failure.  Therapy with sodium- containing agents should be administered with extreme caution, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states where there is edema with sodium retention.  Clinical monitoring of acid/base balance and electrolytes prior to, during, a following completion of therapy with sodium- containing agents is recommended.', '3', '"Product Information. Megace (megestrol)." Bristol-Myers Squibb  (2001):|"Product Information. Calcibind (cellulose sodium phosphate)." Mission Pharmacal Company  (2001):|"Product Information. Sodium Benzoate (sodium benzoate)." Taylor Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34669, 15613, 'Caffeine', 'Water-Electrolyte Imbalance', 'Sodium chloride can induce sodium and water retention and result in hypernatremia, hypokalemia, edema and aggravation of congestive heart failure.  Therapy with sodium- containing agents should be administered with extreme caution, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states where there is edema with sodium retention.  Clinical monitoring of acid/base balance and electrolytes prior to, during, a following completion of therapy with sodium- containing agents is recommended.', '3', '"Product Information. Megace (megestrol)." Bristol-Myers Squibb  (2001):|"Product Information. Calcibind (cellulose sodium phosphate)." Mission Pharmacal Company  (2001):|"Product Information. Sodium Benzoate (sodium benzoate)." Taylor Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34670, 17989, 'Caffeine', 'Water-Electrolyte Imbalance', 'Sodium chloride can induce sodium and water retention and result in hypernatremia, hypokalemia, edema and aggravation of congestive heart failure.  Therapy with sodium- containing agents should be administered with extreme caution, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states where there is edema with sodium retention.  Clinical monitoring of acid/base balance and electrolytes prior to, during, a following completion of therapy with sodium- containing agents is recommended.', '3', '"Product Information. Megace (megestrol)." Bristol-Myers Squibb  (2001):|"Product Information. Calcibind (cellulose sodium phosphate)." Mission Pharmacal Company  (2001):|"Product Information. Sodium Benzoate (sodium benzoate)." Taylor Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34671, 20221, 'Caffeine', 'Water-Electrolyte Imbalance', 'Sodium chloride can induce sodium and water retention and result in hypernatremia, hypokalemia, edema and aggravation of congestive heart failure.  Therapy with sodium- containing agents should be administered with extreme caution, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states where there is edema with sodium retention.  Clinical monitoring of acid/base balance and electrolytes prior to, during, a following completion of therapy with sodium- containing agents is recommended.', '3', '"Product Information. Megace (megestrol)." Bristol-Myers Squibb  (2001):|"Product Information. Calcibind (cellulose sodium phosphate)." Mission Pharmacal Company  (2001):|"Product Information. Sodium Benzoate (sodium benzoate)." Taylor Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34672, 20222, 'Caffeine', 'Water-Electrolyte Imbalance', 'Sodium chloride can induce sodium and water retention and result in hypernatremia, hypokalemia, edema and aggravation of congestive heart failure.  Therapy with sodium- containing agents should be administered with extreme caution, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states where there is edema with sodium retention.  Clinical monitoring of acid/base balance and electrolytes prior to, during, a following completion of therapy with sodium- containing agents is recommended.', '3', '"Product Information. Megace (megestrol)." Bristol-Myers Squibb  (2001):|"Product Information. Calcibind (cellulose sodium phosphate)." Mission Pharmacal Company  (2001):|"Product Information. Sodium Benzoate (sodium benzoate)." Taylor Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34673, 20223, 'Caffeine', 'Water-Electrolyte Imbalance', 'Sodium chloride can induce sodium and water retention and result in hypernatremia, hypokalemia, edema and aggravation of congestive heart failure.  Therapy with sodium- containing agents should be administered with extreme caution, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states where there is edema with sodium retention.  Clinical monitoring of acid/base balance and electrolytes prior to, during, a following completion of therapy with sodium- containing agents is recommended.', '3', '"Product Information. Megace (megestrol)." Bristol-Myers Squibb  (2001):|"Product Information. Calcibind (cellulose sodium phosphate)." Mission Pharmacal Company  (2001):|"Product Information. Sodium Benzoate (sodium benzoate)." Taylor Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34674, 20224, 'Caffeine', 'Water-Electrolyte Imbalance', 'Sodium chloride can induce sodium and water retention and result in hypernatremia, hypokalemia, edema and aggravation of congestive heart failure.  Therapy with sodium- containing agents should be administered with extreme caution, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states where there is edema with sodium retention.  Clinical monitoring of acid/base balance and electrolytes prior to, during, a following completion of therapy with sodium- containing agents is recommended.', '3', '"Product Information. Megace (megestrol)." Bristol-Myers Squibb  (2001):|"Product Information. Calcibind (cellulose sodium phosphate)." Mission Pharmacal Company  (2001):|"Product Information. Sodium Benzoate (sodium benzoate)." Taylor Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34675, 33264, 'Caffeine', 'Water-Electrolyte Imbalance', 'Sodium chloride can induce sodium and water retention and result in hypernatremia, hypokalemia, edema and aggravation of congestive heart failure.  Therapy with sodium- containing agents should be administered with extreme caution, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states where there is edema with sodium retention.  Clinical monitoring of acid/base balance and electrolytes prior to, during, a following completion of therapy with sodium- containing agents is recommended.', '3', '"Product Information. Megace (megestrol)." Bristol-Myers Squibb  (2001):|"Product Information. Calcibind (cellulose sodium phosphate)." Mission Pharmacal Company  (2001):|"Product Information. Sodium Benzoate (sodium benzoate)." Taylor Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34676, 1841, 'Caffeine', 'Acid-Base Imbalance', 'Sodium benzoate is structurally similar to salicylates and  mild respiratory alkalosis may occur.  Therapy with sodium benzoate should be administered cautiously in patients with or predisposed to respiratory acidosis.', '2', '"Product Information. Sodium Benzoate (sodium benzoate)." Taylor Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34677, 2885, 'Caffeine', 'Acid-Base Imbalance', 'Sodium benzoate is structurally similar to salicylates and  mild respiratory alkalosis may occur.  Therapy with sodium benzoate should be administered cautiously in patients with or predisposed to respiratory acidosis.', '2', '"Product Information. Sodium Benzoate (sodium benzoate)." Taylor Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34678, 14477, 'Caffeine', 'Acid-Base Imbalance', 'Sodium benzoate is structurally similar to salicylates and  mild respiratory alkalosis may occur.  Therapy with sodium benzoate should be administered cautiously in patients with or predisposed to respiratory acidosis.', '2', '"Product Information. Sodium Benzoate (sodium benzoate)." Taylor Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34679, 15611, 'Caffeine', 'Acid-Base Imbalance', 'Sodium benzoate is structurally similar to salicylates and  mild respiratory alkalosis may occur.  Therapy with sodium benzoate should be administered cautiously in patients with or predisposed to respiratory acidosis.', '2', '"Product Information. Sodium Benzoate (sodium benzoate)." Taylor Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34680, 15613, 'Caffeine', 'Acid-Base Imbalance', 'Sodium benzoate is structurally similar to salicylates and  mild respiratory alkalosis may occur.  Therapy with sodium benzoate should be administered cautiously in patients with or predisposed to respiratory acidosis.', '2', '"Product Information. Sodium Benzoate (sodium benzoate)." Taylor Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34681, 17989, 'Caffeine', 'Acid-Base Imbalance', 'Sodium benzoate is structurally similar to salicylates and  mild respiratory alkalosis may occur.  Therapy with sodium benzoate should be administered cautiously in patients with or predisposed to respiratory acidosis.', '2', '"Product Information. Sodium Benzoate (sodium benzoate)." Taylor Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34682, 20221, 'Caffeine', 'Acid-Base Imbalance', 'Sodium benzoate is structurally similar to salicylates and  mild respiratory alkalosis may occur.  Therapy with sodium benzoate should be administered cautiously in patients with or predisposed to respiratory acidosis.', '2', '"Product Information. Sodium Benzoate (sodium benzoate)." Taylor Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34683, 20222, 'Caffeine', 'Acid-Base Imbalance', 'Sodium benzoate is structurally similar to salicylates and  mild respiratory alkalosis may occur.  Therapy with sodium benzoate should be administered cautiously in patients with or predisposed to respiratory acidosis.', '2', '"Product Information. Sodium Benzoate (sodium benzoate)." Taylor Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34684, 20223, 'Caffeine', 'Acid-Base Imbalance', 'Sodium benzoate is structurally similar to salicylates and  mild respiratory alkalosis may occur.  Therapy with sodium benzoate should be administered cautiously in patients with or predisposed to respiratory acidosis.', '2', '"Product Information. Sodium Benzoate (sodium benzoate)." Taylor Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34685, 20224, 'Caffeine', 'Acid-Base Imbalance', 'Sodium benzoate is structurally similar to salicylates and  mild respiratory alkalosis may occur.  Therapy with sodium benzoate should be administered cautiously in patients with or predisposed to respiratory acidosis.', '2', '"Product Information. Sodium Benzoate (sodium benzoate)." Taylor Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34686, 33264, 'Caffeine', 'Acid-Base Imbalance', 'Sodium benzoate is structurally similar to salicylates and  mild respiratory alkalosis may occur.  Therapy with sodium benzoate should be administered cautiously in patients with or predisposed to respiratory acidosis.', '2', '"Product Information. Sodium Benzoate (sodium benzoate)." Taylor Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34687, 0, 'Buprenorphine', 'Gastrointestinal Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the gastrointestinal tract and decrease peristalsis, which can lead to elevated intraluminal pressure, spasm, and constipation following prolonged use.  In patients with severe or acute inflammatory bowel disease, the decrease in colonic motility may induce toxic megacolon.  Therapy with opioids should be administered cautiously in patients with gastrointestinal obstruction, constipation, inflammatory bowel disease, or recent gastrointestinal tract surgery.  Gastrointestinal effects appear to be the most pronounced with morphine.', '3', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|White MJ, Berghausen EJ, Dumont SW, Tsueda K, Schroeder JA, Vogel RL, Heine MF, Huang KC "Side effects during continuous epidural infusion of morphine and fentanyl." Can J Anaesth 39 (1992):  576-82|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Thorn SE, Wattwil M, Kallander A "Effects of epidural morphine and epidural bupivacaine on gastroduodenal motility during the fasted state and after food intake." Acta Anaesthesiol Scand 38 (1994):  57-62|Bennett MWR, Shah MV, Bembridge JL "A comparison of the effect on gastric emptying of alfentanil or morphine given during anaesthesia for minor surgery." Anaesthesia 49 (1994):  155-6|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34688, 0, 'Buprenorphine', 'Dysentery', 'Narcotic (opioid) analgesic agents may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella, Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  These agents decrease gastrointestinal motility, which may delay the excretion of infective gastroenteric organisms and/or their toxins.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  Therapy with opioids should be avoided or administered cautiously in patients with infectious diarrhea, particularly that due to pseudomembranous enterocolitis or enterotoxin-producing bacteria or if accompanied by high fever, pus, or blood in the stool.', '3', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|White MJ, Berghausen EJ, Dumont SW, Tsueda K, Schroeder JA, Vogel RL, Heine MF, Huang KC "Side effects during continuous epidural infusion of morphine and fentanyl." Can J Anaesth 39 (1992):  576-82|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Thorn SE, Wattwil M, Kallander A "Effects of epidural morphine and epidural bupivacaine on gastroduodenal motility during the fasted state and after food intake." Acta Anaesthesiol Scand 38 (1994):  57-62|Bennett MWR, Shah MV, Bembridge JL "A comparison of the effect on gastric emptying of alfentanil or morphine given during anaesthesia for minor surgery." Anaesthesia 49 (1994):  155-6|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34689, 0, 'Buprenorphine', 'Liver Diseases', 'Narcotic (opioid) analgesic agents are extensively metabolized by the liver, and several of them (e.g., codeine, hydrocodone, meperidine, methadone, morphine, propoxyphene) have active metabolites that are further converted to inactive substances.  The serum concentrations of these agents and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with liver disease.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '3', 'Yue QY, Hasselstrom J, Svensson JO, Sawe J "Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine." Br J Clin Pharmacol 31 (1991):  635-42|Pond SM, Tong T, Benowitz NL, et al. "Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects." Clin Pharmacol Ther 30 (1981):  183-8|Neal EA, Meffin PJ, Gregory PB, Blaschke TF "Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis." Gastroenterology 77 (1979):  96-102|Bower S, Sear JW, Roy RC, Carter RF "Effects of different hepatic pathologies on disposition of alfentanil in anaesthetized patients." Br J Anaesth 68 (1992):  462-5|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Mazoit J-X, Sandouk P, Zetlaoui P, Scherrmann J-M "Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects." Anesth Analg 66 (1987):  293-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Osborne R, Joel S, Trew D, Slevin M "Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucoronide." Clin Pharmacol Ther 47 (1990):  12-9|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Yun CH, Wood M, Wood AJ, Guengerich FP "Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4: an explanation of the variable elimination clearance." Anesthesiology 77 (1992):  467-74|Cone EJ, Darwin WD, Gorodetzky CW "Comparative metabolism of codeine in man, rat, dog, guinea-pig and rabbit: identification of four new metabolites." J Pharm Pharmacol 31 (1979):  314-7|McHorse TS, Klotz U, Wilkinson G, Schenker S "Impaired elimination of meperidine in patients with liver disease." Trans Assoc Am Physicians 87 (1974):  281-7|Hasselstrom J, Eriksson S, Persson A, Rane A, Svensson JO, Sawe J "The metabolism and bioavailability of morphine in patients with severe liver cirrhosis." Br J Clin Pharmacol 29 (1990):  289-97|Novick DM, Kreek MJ, Arns PA, et al. "Effect of severe alcoholic liver disease on the disposition of methadone in maintenance patients." Alcohol Clin Exp Res 9 (1985):  349|Kreek MJ, Fanizza AM, et al. "Methadone disposition in patients with chronic liver disease." Clin Pharmacol Ther 30 (1981):  353-62|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|Goromaru T, Matsuura H, Yoshimura N, Miyawaki T, Sameshima T, Miyao J, Furuta T, Baba S "Identification and quantitative determination of fentanyl metabolites in patients by gas chromatography--mass spectrometry." Anesthesiology 61 (1984):  73-7|Haberer JP, Schoeffler P, Couderc E, Duvaldestin P "Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis." Br J Anaesth 54 (1982):  1267-70|McClain DA, Hug CC, Jr "Intravenous fentanyl kinetics." Clin Pharmacol Ther 28 (1980):  106-14|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM "CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone." Clin Pharmacol Ther 54 (1993):  463-72|Cone EJ, Darwin WD, Gorodetzky CW, Tan T "Comparative metabolism of hydrocodone in man, rat, guinea pig, rabbit, and dog." Drug Metab Dispos 6 (1978):  488-93|Hasselstrom J, Sawe J "Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations." Clin Pharmacokinet 24 (1993):  344-54|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Giacomini KM, Giacomini JC, Gibson TP, Levy G "Propoxyphene and norpropoxyphene plasma concentrations after oral propoxyphene in cirrhotic patients with and without surgically constructed portacaval shunt." Clin Pharmacol Ther 28 (1980):  417-24|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Chen ZR, Somogy AA, Reynolds G, Bochner F "Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers." Br J Clin Pharmacol 31 (1991):  381-90|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Hagen N, Thirlwell MP, Dhaliwal HS, Babul N, Harsanyi Z, Darke AC "Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone." J Clin Pharmacol 35 (1995):  37-44|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Beckett AH, Vaughan DP, Essien EE "N-Oxidation--an important route in the metabolism of methadone in man." J Pharm Pharmacol 24 (1972):  244|Beckett AH, Taylor JF, Casy AF, Hassan MM "The biotransformation of methadone in man: synthesis and identification of a major metabolite." J Pharm Pharmacol 20 (1968):  754-62|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|Dershwitz M, Randel GI, Rosow CE, Fragen RJ, Connors PM, Librojo ES, Shaw DL, Peng AW, Jamerson BD "Initial clinical experience with remifentanil, a new opioid metabolized by esterases." Anesth Analg 81 (1995):  619-23|Dershwitz M, Hoke JF, Rosow CE, Michalowski P, Connors PM, Muir KT, Dienstag JL "Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease." Anesthesiology 84 (1996):  812-20|Westmoreland CL, Hoke JF, Sebel PS, Hug CC Jr, Muir KT "Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery." Anesthesiology 79 (1993):  893-903|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34690, 0, 'Buprenorphine', 'Premature Birth', 'The use of narcotic (opioid) analgesic agents is contraindicated in premature infants.  These agents may cross the immature blood-brain barrier to a greater extent than in adults, resulting in disproportionate respiratory depression.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Multum Information Services, Inc. Expert Review Panel"', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34691, 0, 'Buprenorphine', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34692, 0, 'Buprenorphine', 'Myocardial Infarction', 'Opiate partial agonists may increase systemic and pulmonary arterial pressure and systemic vascular resistance, particularly when given by intravenous administration.  Data are available for pentazocine and butorphanol.  Therapy with opiate partial agonists should be administered cautiously and only if the benefit justifies the risk in patients with acute myocardial infarction (especially if accompanied by hypertension or left ventricular failure) or coronary insufficiency.', '3', '"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34693, 0, 'Buprenorphine', 'Substance-Related Disorders', 'Opiate partial agonists have the potential to cause dependence and abuse, particularly in patients with a history of drug abuse.  Tolerance as well as physical and psychological dependence can develop after prolonged use, and abrupt cessation or a significant reduction in dosage may precipitate withdrawal symptoms.  Because of their opiate antagonistic effect, withdrawal symptoms may also occur if opiate partial agonists are administered to patients with an opiate dependence or in whom substantial amounts of narcotics have recently been administered.  Therapy with opiate partial agonists is not recommended in patients who are physically dependent on narcotics.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with opiate partial agonists.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of opiate therapy should be undertaken gradually using a dosage-tapering schedule.', '3', 'Miser AW, Chayt KJ, Sandlund JT, Cohen PS, Dothage JA, Miser JS "Narcotic withdrawal syndrome in young adults after the therapeutic use of opiates." Am J Dis Child 140 (1986):  603-4|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34694, 0, 'Buprenorphine', 'Intracranial Hypertension', 'The hypoventilation associated with administration of opiate partial agonists can induce cerebral hypoxia and vasodilatation with resultant increase in intracranial pressure.  Unless mechanical ventilation is provided, extreme caution is advised when opiate partial agonists are given to patients head injury, intracranial lesions, or a preexisting elevated CSF pressure.  Also, clinicians treating such patients should be aware that opiate partial agonists may interfere with the evaluation of CNS function, especially with respect to consciousness levels, respiratory status, and pupillary changes.', '3', '"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34695, 0, 'Buprenorphine', 'Respiratory Insufficiency', 'Opiate partial agonists may produce respiratory depression by decreasing respiratory drive and increasing airway resistance.  A "ceiling effect" has been noted for these agents, and increasing doses do not produce proportional or further respiratory depression.  However, the duration of effect is prolonged.  At therapeutic analgesic dosages, the respiratory effects are usually not clinically important except in patients with preexisting pulmonary impairment.  Therapy with opiate partial agonists should be avoided or administered with extreme caution and initiated at reduced dosages in patients with severe CNS or respiratory depression; acute alcohol intoxication; sleep apnea; hypoxia, anoxia, or hypercapnia; upper airway obstruction; chronic pulmonary insufficiency; a limited ventilatory reserve; or other respiratory disorders.  In the presence of excessive respiratory secretions, the use of opiate partial agonists may also be problematic because they decrease ciliary activity and reduce the cough reflex.  Caution is also advised in patients who may be at increased risk for respiratory depression, such as comatose patients or those with head injury, intracranial lesions, or intracranial hypertension.  Clinical monitoring of pulmonary function is recommended, and equipment for resuscitation should be immediately available if parenteral routes are used.  Naloxone may be administered to reverse clinically significant respiratory depression.  However, in the case of buprenorphine, naloxone may not be effective due to buprenorphine''s slow rate of dissociation from mu receptors.', '3', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34696, 0, 'Buprenorphine', 'Adrenal Insufficiency', 'Patients with Addison''s disease may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  Conversely, these agents may cause or potentiate adrenal insufficiency.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with adrenocortical insufficiency.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Olinvyk (oliceridine)." Trevena Inc  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34697, 0, 'Buprenorphine', 'Gallbladder Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the biliary tract, which can lead to spasm and elevated biliary tract pressure, especially in the sphincter of Oddi.  Biliary effects appear to be the most pronounced with morphine, although they do not always occur with therapeutic doses.  Therapy with opioids should be administered cautiously in patients with biliary or gallbladder disease.', '2', 'Jones RM, Fiddian-Green R, Knight PR "Narcotic-induced choledochoduodenal sphincter spasm reversed by glucagon." Anesth Analg 59 (1980):  946-7|Hey VM, Ostick DG, Mazumder JK, Lord WD "Pethidine, metoclopramide and the gastro-oesophageal sphincter." Anaesthesia 36 (1981):  173-6|Lang DW, Pilon RN "Naloxone reversal of morphine-induced biliary colic." Anesth Analg 59 (1980):  619-20|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|McCammon RL, Viegas OJ, Stoelting RK, Dryden GE "Naloxone reversal of choledochoduodenal sphincter spasm associated with narcotic administration." Anesthesiology 48 (1978):  437|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Zsigmond EK, Vieira ZEG, Duarte B, Renigers SA, Hirota K "Double-blind placebo-controlled ultrasonographic confirmation of constriction of the common bile duct by morphine." Int J Clin Pharmacol Ther Toxicol 31 (1993):  506-9|Ford MJ, Kellett RJ, Busuttil A, Finlayson ND "Dextropropoxyphene and jaundice." Br Med J 2 (1977):  674|Daikos GK, Kosmidis JC "Propoxyphene jaundice." JAMA 232 (1975):  835|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34698, 0, 'Buprenorphine', 'Hypothyroidism', 'Patients with hypothyroidism may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  These agents may also exacerbate the effects of hypothyroidism such as lethargy, impaired mentation, depression, and constipation.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with uncontrolled hypothyroidism or myxedema.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34699, 0, 'Buprenorphine', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'Findlay JW, Butz RF, Welch RM "Codeine kinetics as determined by radioimmunoassay." Clin Pharmacol Ther 22 (1977):  439-46|Barnes JN, Williams AJ, Tomson MJ, et al. "Dihydrocodeine in renal failure: further evidence for an important role of the kidney in the handling of opioid drugs." Br Med J (Clin Res Ed) 290 (1985):  740-2|Matske GR, Chan GL, Abraham PA "Codeine dosage in renal failure." Clin Pharm 5 (1986):  15-6|Guy DR, Awni WM, Findlay JW, et al. "Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease." Clin Pharmacol Ther 43 (1988):  63-71|Charuvastra VC, Ouren J "Renal failure and treatment of a methadone maintenance patient." Med J Aust 09/24/77 (1977):  433-4|Verbeeck RK, Branch RA, Wilkinson GR "Drug metabolites in renal failure: pharmacokinetic and clinical implications." Clin Pharmacokinet 6 (1981):  329-45|Drayer DE "Active drug metabolites and renal failure." Am J Med 62 (1977):  486-9|Drayer DE "Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure." Clin Pharmacokinet 1 (1976):  426-43|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Wolff J, Bigler D, Christensen CB, et al. "Influence of renal function on the elimination of morphine and morphine glucoronides." Eur J Clin Pharmacol 34 (1988):  353-7|Covington EC, Gonsalves-Ebrahim L, Currie KO, et al. "Severe respiratory depression from patient-controlled analgesia in renal failure." Psychosomatics 30 (1989):  226-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Bechtel WD, Sinterhauf K "Plasma level and renal excretion of [3H] codeine phosphate in man and in the dog." Arzneimittelforschung 28 (1978):  308-11|Wolfert AI, Sica DA "Narcotic usage in renal failure." Int J Artif Organs 11 (1988):  411-5|Inturrisi CE "Disposition of narcotics in patients with renal disease." Am J Med 62 (1977):  528-9|Chan K, Jennings F, Orme ML "Pharmacokinetics of low-dose intravenous pethidine in patients with renal dysfunction." J Clin Pharmacol 27 (1987):  516-22|Chauvin M, Sandouk P, Scherrmann JM, Farinotti R, Strumza P, Duvaldestin P "Morphine pharmacokinetics in renal failure." Anesthesiology 66 (1987):  327-31|Aitkenhead AR, Vater M, Achola K, Cooper CM, Smith G "Pharmacokinetics of single-dose i.v. morphine in normal volunteers and patients with end-stage renal failure." Br J Anaesth 56 (1984):  813-9|Sawe J, Odar-Cederlof I "Kinetics of morphine in patients with renal failure." Eur J Clin Pharmacol 32 (1987):  377-82|Baselt RC, Casarett LJ "Urinary excretion of methadone in man." Clin Pharmacol Ther 13 (1972):  64-70|Kreek MJ, Schecter AJ, Gutjahr CL, et al. "Methadone use in patients with chronic renal failure." Drug Alcohol Depend 5 (1980):  197-205|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hanna MH, D''Costa F, Peat SJ, Fung C, Venkat N, Zilkha TR, Davies S "Morphine-6-glucuronide disposition in renal impairment." Br J Anaesth 70 (1993):  511-4|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Gibson TP, Giacomini KM, Briggs WA, Whitman W, Levy G "Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient." Clin Pharmacol Ther 27 (1980):  665-70|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Giacomini KM, Gibson TP, Levy G "Plasma protein binding of d-propoxyphene in normal subjects and anephric patients." J Clin Pharmacol 18 (1978):  106-9|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Dhonneur G, Gilton A, Sandouk P, Scherrmann JM, Duvaldestin P "Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine - the influence of renal failure." Anesthesiology 81 (1994):  87-93|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34700, 0, 'Buprenorphine', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', 'Kaiko RF, Foley KM, Grabinski PY, et al. "Central nervous system excitatory effects of meperidine in cancer patients." Ann Neurol 13 (1983):  180-5|Goetting MG, Thirman MJ "Neurotoxicity of meperidine." Ann Emerg Med 14 (1985):  1007-9|Mauro VF, Bonfiglio MF, Spunt AL "Meperidine-induced seizure in a patient without renal dysfunction or sickle cell anemia." Clin Pharm 5 (1986):  837-9|Reutens DC, Stewart-Wynne EG "Norpethidine induced myoclonus in a patient with renal failure." J Neurol Neurosurg Psychiatry 52 (1989):  1450-1|Armstrong PJ, Bersten A "Normeperidine toxicity." Anesth Analg 65 (1986):  536-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Babul N, Darke AC "Putative role of hydromorphone metabolites in myoclonus." Pain 51 (1992):  260-1|Hagmeyer KO, Mauro LS, Mauro VF "Meperidine-related seizures associated with patient-controlled analgesia pumps." Ann Pharmacother 27 (1993):  29-32|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG "Fentanyl and convulsions." Anesth Analg 62 (1983):  858-9|Rao TL, Mummaneni N, El-Etr AA "Convulsions: an unusual response to intravenous fentanyl administration." Anesth Analg 61 (1982):  1020-1|Goroszeniuk T, Albin M, Jones RM "Generalized grand mal seizure after recovery from uncomplicated fentanyl-etomidate anesthesia." Anesth Analg 65 (1986):  979-81|Hoien AO "Another case of grand mal seizure after fentanyl administration." Anesthesiology 60 (1984):  387-8|Safwat AM, Daniel D "Grand mal seizure after fentanyl administration." Anesthesiology 59 (1983):  78|Smith NT, Benthuysen JL, Bickford RG, Sanford TJ, Blasco T, Duke PC, Head N, Dec-Silver H "Seizures during opioid anesthetic induction--are they opioid-induced rigidity?" Anesthesiology 71 (1989):  852-62|Benthuysen JL, Stanley TH "Concerning the possible nature of reported fentanyl seizures." Anesthesiology 62 (1985):  205|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Stone PA, Macintyre PE, Jarvis DA "Norpethidine toxicity and patient controlled analgesia." Br J Anaesth 71 (1993):  738-40|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Strong WE, Matson M "Probable seizure after alfentanil." Anesth Analg 68 (1989):  692-3|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34701, 0, 'Buprenorphine', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Petersen TK, Husted SE, Rybro L, et al. "Urinary retention during I.M. and extradural morphine analgesia." Br J Anaesth 54 (1982):  1175-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|Petros JG, Mallen JK, Howe K, Rimm EB, Robillard RJ "Patient-controlled analgesia and postoperative urinary retention after open appendectomy." Surg Gynecol Obstet 177 (1993):  172-5|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34702, 0, 'Cabotegravir', 'Depressive Disorder', 'Depressive disorders (including depressed mood, depression, altered mood, mood swings) have been reported with oral cabotegravir.  Depressive disorders (including depressed mood, depression, major depression, altered mood, mood swings, dysphoria, negative thoughts, suicidal ideation/attempt) have been reported with IM cabotegravir-rilpivirine or the individual drug products.  Patients with severe depressive symptoms should be evaluated promptly.  Caution should be used in patients with a history of depression or other psychiatric conditions.', '2', '"Product Information. Cabenuva (cabotegravir-rilpivirine)." ViiV Healthcare ULC  (2021):|"Product Information. Vocabria (cabotegravir)." ViiV Healthcare  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34703, 0, 'Cabotegravir', 'Liver Failure', 'Hepatotoxicity has been reported in patients taking cabotegravir with or without known preexisting hepatic disease or identifiable risk factors.  Patients with underlying liver disease or marked transaminase elevations prior to therapy may be at increased risk for worsening or development of transaminase elevations.  Monitoring of liver chemistries is recommended and cabotegravir should be discontinued if hepatotoxicity is suspected.  Cabotegravir has not been studied in patients with severe liver dysfunction (Child-Pugh C); caution is recommended.', '2', '"Product Information. Cabenuva (cabotegravir-rilpivirine)." ViiV Healthcare ULC  (2021):|"Product Information. Vocabria (cabotegravir)." ViiV Healthcare  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34704, 0, 'Cabotegravir', 'Kidney Diseases', 'No dose adjustment of IM or oral cabotegravir is required in patients with mild to moderate or mild to severe renal dysfunction, respectively.  Cabotegravir has not been studied in patients with ESRD not on dialysis; caution is recommended.  IM cabotegravir should be used with caution and with increased monitoring for side effects in patients with severe renal dysfunction or ESRD.', '2', '"Product Information. Cabenuva (cabotegravir-rilpivirine)." ViiV Healthcare ULC  (2021):|"Product Information. Vocabria (cabotegravir)." ViiV Healthcare  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34705, 0, 'Calcifediol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34706, 0, 'Calcifediol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34707, 0, 'Calcifediol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34708, 0, 'Calcifediol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34709, 0, 'Butorphanol', 'Gastrointestinal Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the gastrointestinal tract and decrease peristalsis, which can lead to elevated intraluminal pressure, spasm, and constipation following prolonged use.  In patients with severe or acute inflammatory bowel disease, the decrease in colonic motility may induce toxic megacolon.  Therapy with opioids should be administered cautiously in patients with gastrointestinal obstruction, constipation, inflammatory bowel disease, or recent gastrointestinal tract surgery.  Gastrointestinal effects appear to be the most pronounced with morphine.', '3', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|White MJ, Berghausen EJ, Dumont SW, Tsueda K, Schroeder JA, Vogel RL, Heine MF, Huang KC "Side effects during continuous epidural infusion of morphine and fentanyl." Can J Anaesth 39 (1992):  576-82|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Thorn SE, Wattwil M, Kallander A "Effects of epidural morphine and epidural bupivacaine on gastroduodenal motility during the fasted state and after food intake." Acta Anaesthesiol Scand 38 (1994):  57-62|Bennett MWR, Shah MV, Bembridge JL "A comparison of the effect on gastric emptying of alfentanil or morphine given during anaesthesia for minor surgery." Anaesthesia 49 (1994):  155-6|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34710, 0, 'Butorphanol', 'Dysentery', 'Narcotic (opioid) analgesic agents may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella, Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  These agents decrease gastrointestinal motility, which may delay the excretion of infective gastroenteric organisms and/or their toxins.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  Therapy with opioids should be avoided or administered cautiously in patients with infectious diarrhea, particularly that due to pseudomembranous enterocolitis or enterotoxin-producing bacteria or if accompanied by high fever, pus, or blood in the stool.', '3', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Bellville JW, Forrest WH, Elashoff J, Laska E "Evaluating side effects of analgesics in a cooperative clinical study." Clin Pharmacol Ther 9 (1968):  303-13|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|White MJ, Berghausen EJ, Dumont SW, Tsueda K, Schroeder JA, Vogel RL, Heine MF, Huang KC "Side effects during continuous epidural infusion of morphine and fentanyl." Can J Anaesth 39 (1992):  576-82|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Thorn SE, Wattwil M, Kallander A "Effects of epidural morphine and epidural bupivacaine on gastroduodenal motility during the fasted state and after food intake." Acta Anaesthesiol Scand 38 (1994):  57-62|Bennett MWR, Shah MV, Bembridge JL "A comparison of the effect on gastric emptying of alfentanil or morphine given during anaesthesia for minor surgery." Anaesthesia 49 (1994):  155-6|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34711, 0, 'Butorphanol', 'Liver Diseases', 'Narcotic (opioid) analgesic agents are extensively metabolized by the liver, and several of them (e.g., codeine, hydrocodone, meperidine, methadone, morphine, propoxyphene) have active metabolites that are further converted to inactive substances.  The serum concentrations of these agents and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with liver disease.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '3', 'Yue QY, Hasselstrom J, Svensson JO, Sawe J "Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine." Br J Clin Pharmacol 31 (1991):  635-42|Pond SM, Tong T, Benowitz NL, et al. "Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects." Clin Pharmacol Ther 30 (1981):  183-8|Neal EA, Meffin PJ, Gregory PB, Blaschke TF "Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis." Gastroenterology 77 (1979):  96-102|Bower S, Sear JW, Roy RC, Carter RF "Effects of different hepatic pathologies on disposition of alfentanil in anaesthetized patients." Br J Anaesth 68 (1992):  462-5|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Mazoit J-X, Sandouk P, Zetlaoui P, Scherrmann J-M "Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects." Anesth Analg 66 (1987):  293-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Osborne R, Joel S, Trew D, Slevin M "Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucoronide." Clin Pharmacol Ther 47 (1990):  12-9|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Yun CH, Wood M, Wood AJ, Guengerich FP "Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4: an explanation of the variable elimination clearance." Anesthesiology 77 (1992):  467-74|Cone EJ, Darwin WD, Gorodetzky CW "Comparative metabolism of codeine in man, rat, dog, guinea-pig and rabbit: identification of four new metabolites." J Pharm Pharmacol 31 (1979):  314-7|McHorse TS, Klotz U, Wilkinson G, Schenker S "Impaired elimination of meperidine in patients with liver disease." Trans Assoc Am Physicians 87 (1974):  281-7|Hasselstrom J, Eriksson S, Persson A, Rane A, Svensson JO, Sawe J "The metabolism and bioavailability of morphine in patients with severe liver cirrhosis." Br J Clin Pharmacol 29 (1990):  289-97|Novick DM, Kreek MJ, Arns PA, et al. "Effect of severe alcoholic liver disease on the disposition of methadone in maintenance patients." Alcohol Clin Exp Res 9 (1985):  349|Kreek MJ, Fanizza AM, et al. "Methadone disposition in patients with chronic liver disease." Clin Pharmacol Ther 30 (1981):  353-62|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|Goromaru T, Matsuura H, Yoshimura N, Miyawaki T, Sameshima T, Miyao J, Furuta T, Baba S "Identification and quantitative determination of fentanyl metabolites in patients by gas chromatography--mass spectrometry." Anesthesiology 61 (1984):  73-7|Haberer JP, Schoeffler P, Couderc E, Duvaldestin P "Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis." Br J Anaesth 54 (1982):  1267-70|McClain DA, Hug CC, Jr "Intravenous fentanyl kinetics." Clin Pharmacol Ther 28 (1980):  106-14|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM "CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone." Clin Pharmacol Ther 54 (1993):  463-72|Cone EJ, Darwin WD, Gorodetzky CW, Tan T "Comparative metabolism of hydrocodone in man, rat, guinea pig, rabbit, and dog." Drug Metab Dispos 6 (1978):  488-93|Hasselstrom J, Sawe J "Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations." Clin Pharmacokinet 24 (1993):  344-54|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Giacomini KM, Giacomini JC, Gibson TP, Levy G "Propoxyphene and norpropoxyphene plasma concentrations after oral propoxyphene in cirrhotic patients with and without surgically constructed portacaval shunt." Clin Pharmacol Ther 28 (1980):  417-24|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Chen ZR, Somogy AA, Reynolds G, Bochner F "Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers." Br J Clin Pharmacol 31 (1991):  381-90|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Hagen N, Thirlwell MP, Dhaliwal HS, Babul N, Harsanyi Z, Darke AC "Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone." J Clin Pharmacol 35 (1995):  37-44|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Beckett AH, Vaughan DP, Essien EE "N-Oxidation--an important route in the metabolism of methadone in man." J Pharm Pharmacol 24 (1972):  244|Beckett AH, Taylor JF, Casy AF, Hassan MM "The biotransformation of methadone in man: synthesis and identification of a major metabolite." J Pharm Pharmacol 20 (1968):  754-62|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|Dershwitz M, Randel GI, Rosow CE, Fragen RJ, Connors PM, Librojo ES, Shaw DL, Peng AW, Jamerson BD "Initial clinical experience with remifentanil, a new opioid metabolized by esterases." Anesth Analg 81 (1995):  619-23|Dershwitz M, Hoke JF, Rosow CE, Michalowski P, Connors PM, Muir KT, Dienstag JL "Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease." Anesthesiology 84 (1996):  812-20|Westmoreland CL, Hoke JF, Sebel PS, Hug CC Jr, Muir KT "Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery." Anesthesiology 79 (1993):  893-903|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34712, 0, 'Butorphanol', 'Premature Birth', 'The use of narcotic (opioid) analgesic agents is contraindicated in premature infants.  These agents may cross the immature blood-brain barrier to a greater extent than in adults, resulting in disproportionate respiratory depression.', '3', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Multum Information Services, Inc. Expert Review Panel"', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34713, 0, 'Butorphanol', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '"Product Information. Ultram (tramadol)." McNeil Pharmaceutical  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Apadaz (acetaminophen-benzhydrocodone)." KemPharm, Inc  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34714, 0, 'Butorphanol', 'Myocardial Infarction', 'Opiate partial agonists may increase systemic and pulmonary arterial pressure and systemic vascular resistance, particularly when given by intravenous administration.  Data are available for pentazocine and butorphanol.  Therapy with opiate partial agonists should be administered cautiously and only if the benefit justifies the risk in patients with acute myocardial infarction (especially if accompanied by hypertension or left ventricular failure) or coronary insufficiency.', '3', '"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34715, 0, 'Butorphanol', 'Substance-Related Disorders', 'Opiate partial agonists have the potential to cause dependence and abuse, particularly in patients with a history of drug abuse.  Tolerance as well as physical and psychological dependence can develop after prolonged use, and abrupt cessation or a significant reduction in dosage may precipitate withdrawal symptoms.  Because of their opiate antagonistic effect, withdrawal symptoms may also occur if opiate partial agonists are administered to patients with an opiate dependence or in whom substantial amounts of narcotics have recently been administered.  Therapy with opiate partial agonists is not recommended in patients who are physically dependent on narcotics.  Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with opiate partial agonists.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of opiate therapy should be undertaken gradually using a dosage-tapering schedule.', '3', 'Miser AW, Chayt KJ, Sandlund JT, Cohen PS, Dothage JA, Miser JS "Narcotic withdrawal syndrome in young adults after the therapeutic use of opiates." Am J Dis Child 140 (1986):  603-4|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34716, 0, 'Butorphanol', 'Intracranial Hypertension', 'The hypoventilation associated with administration of opiate partial agonists can induce cerebral hypoxia and vasodilatation with resultant increase in intracranial pressure.  Unless mechanical ventilation is provided, extreme caution is advised when opiate partial agonists are given to patients head injury, intracranial lesions, or a preexisting elevated CSF pressure.  Also, clinicians treating such patients should be aware that opiate partial agonists may interfere with the evaluation of CNS function, especially with respect to consciousness levels, respiratory status, and pupillary changes.', '3', '"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34717, 0, 'Butorphanol', 'Respiratory Insufficiency', 'Opiate partial agonists may produce respiratory depression by decreasing respiratory drive and increasing airway resistance.  A "ceiling effect" has been noted for these agents, and increasing doses do not produce proportional or further respiratory depression.  However, the duration of effect is prolonged.  At therapeutic analgesic dosages, the respiratory effects are usually not clinically important except in patients with preexisting pulmonary impairment.  Therapy with opiate partial agonists should be avoided or administered with extreme caution and initiated at reduced dosages in patients with severe CNS or respiratory depression; acute alcohol intoxication; sleep apnea; hypoxia, anoxia, or hypercapnia; upper airway obstruction; chronic pulmonary insufficiency; a limited ventilatory reserve; or other respiratory disorders.  In the presence of excessive respiratory secretions, the use of opiate partial agonists may also be problematic because they decrease ciliary activity and reduce the cough reflex.  Caution is also advised in patients who may be at increased risk for respiratory depression, such as comatose patients or those with head injury, intracranial lesions, or intracranial hypertension.  Clinical monitoring of pulmonary function is recommended, and equipment for resuscitation should be immediately available if parenteral routes are used.  Naloxone may be administered to reverse clinically significant respiratory depression.  However, in the case of buprenorphine, naloxone may not be effective due to buprenorphine''s slow rate of dissociation from mu receptors.', '3', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34718, 0, 'Butorphanol', 'Hypertension', 'Butorphanol may increase blood pressure and rarely causes severe hypertension.  Therapy with butorphanol should be administered cautiously in hypertensive patients, particularly when given before surgery or anesthesia.', '2', '"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34719, 0, 'Butorphanol', 'Hypotension', 'Butorphanol may rarely induce vasodilation and hypotension with syncope during the first hour following intranasal administration, particularly in patients with a history of similar reactions to opioid analgesic agents.  Therapy with butorphanol should be administered cautiously in patients with circulatory shock, hypovolemia, or a predisposition to hypotension.', '2', '"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34720, 0, 'Butorphanol', 'Adrenal Insufficiency', 'Patients with Addison''s disease may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  Conversely, these agents may cause or potentiate adrenal insufficiency.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with adrenocortical insufficiency.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Olinvyk (oliceridine)." Trevena Inc  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34721, 0, 'Butorphanol', 'Gallbladder Diseases', 'Narcotic (opioid) analgesic agents increase smooth muscle tone in the biliary tract, which can lead to spasm and elevated biliary tract pressure, especially in the sphincter of Oddi.  Biliary effects appear to be the most pronounced with morphine, although they do not always occur with therapeutic doses.  Therapy with opioids should be administered cautiously in patients with biliary or gallbladder disease.', '2', 'Jones RM, Fiddian-Green R, Knight PR "Narcotic-induced choledochoduodenal sphincter spasm reversed by glucagon." Anesth Analg 59 (1980):  946-7|Hey VM, Ostick DG, Mazumder JK, Lord WD "Pethidine, metoclopramide and the gastro-oesophageal sphincter." Anaesthesia 36 (1981):  173-6|Lang DW, Pilon RN "Naloxone reversal of morphine-induced biliary colic." Anesth Analg 59 (1980):  619-20|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|McCammon RL, Viegas OJ, Stoelting RK, Dryden GE "Naloxone reversal of choledochoduodenal sphincter spasm associated with narcotic administration." Anesthesiology 48 (1978):  437|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Zsigmond EK, Vieira ZEG, Duarte B, Renigers SA, Hirota K "Double-blind placebo-controlled ultrasonographic confirmation of constriction of the common bile duct by morphine." Int J Clin Pharmacol Ther Toxicol 31 (1993):  506-9|Ford MJ, Kellett RJ, Busuttil A, Finlayson ND "Dextropropoxyphene and jaundice." Br Med J 2 (1977):  674|Daikos GK, Kosmidis JC "Propoxyphene jaundice." JAMA 232 (1975):  835|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34722, 0, 'Butorphanol', 'Hypothyroidism', 'Patients with hypothyroidism may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  These agents may also exacerbate the effects of hypothyroidism such as lethargy, impaired mentation, depression, and constipation.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with uncontrolled hypothyroidism or myxedema.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34723, 0, 'Butorphanol', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', 'Findlay JW, Butz RF, Welch RM "Codeine kinetics as determined by radioimmunoassay." Clin Pharmacol Ther 22 (1977):  439-46|Barnes JN, Williams AJ, Tomson MJ, et al. "Dihydrocodeine in renal failure: further evidence for an important role of the kidney in the handling of opioid drugs." Br Med J (Clin Res Ed) 290 (1985):  740-2|Matske GR, Chan GL, Abraham PA "Codeine dosage in renal failure." Clin Pharm 5 (1986):  15-6|Guy DR, Awni WM, Findlay JW, et al. "Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease." Clin Pharmacol Ther 43 (1988):  63-71|Charuvastra VC, Ouren J "Renal failure and treatment of a methadone maintenance patient." Med J Aust 09/24/77 (1977):  433-4|Verbeeck RK, Branch RA, Wilkinson GR "Drug metabolites in renal failure: pharmacokinetic and clinical implications." Clin Pharmacokinet 6 (1981):  329-45|Drayer DE "Active drug metabolites and renal failure." Am J Med 62 (1977):  486-9|Drayer DE "Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure." Clin Pharmacokinet 1 (1976):  426-43|Parab PV, Ritschel WA, Coyle DE, et al. "Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 9 (1988):  187-99|Hill HF, Coda BA, Tanaka A, Schaffer R "Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects." Anesth Analg 72 (1991):  330-6|Poyhia R, Seppala T, Olkkola KT, Kalso E "The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects." Br J Clin Pharmacol 33 (1992):  617-21|Wolff J, Bigler D, Christensen CB, et al. "Influence of renal function on the elimination of morphine and morphine glucoronides." Eur J Clin Pharmacol 34 (1988):  353-7|Covington EC, Gonsalves-Ebrahim L, Currie KO, et al. "Severe respiratory depression from patient-controlled analgesia in renal failure." Psychosomatics 30 (1989):  226-8|Poyhia R, Olkkola KT, Seppala T, Kalso E "The pharmacokinetics of oxycodone after intravenous injection in adults." Br J Clin Pharmacol 32 (1991):  516-8|Glare PA, Walsh TD "Clinical pharmacokinetics of morphine." Ther Drug Monit 13 (1991):  1-23|Gram LF, Schou J, Way WL, et al. "delta-Propoxyphene kinetics after single oral and intravenous doses in man." Clin Pharmacol Ther 26 (1979):  473-82|Bechtel WD, Sinterhauf K "Plasma level and renal excretion of [3H] codeine phosphate in man and in the dog." Arzneimittelforschung 28 (1978):  308-11|Wolfert AI, Sica DA "Narcotic usage in renal failure." Int J Artif Organs 11 (1988):  411-5|Inturrisi CE "Disposition of narcotics in patients with renal disease." Am J Med 62 (1977):  528-9|Chan K, Jennings F, Orme ML "Pharmacokinetics of low-dose intravenous pethidine in patients with renal dysfunction." J Clin Pharmacol 27 (1987):  516-22|Chauvin M, Sandouk P, Scherrmann JM, Farinotti R, Strumza P, Duvaldestin P "Morphine pharmacokinetics in renal failure." Anesthesiology 66 (1987):  327-31|Aitkenhead AR, Vater M, Achola K, Cooper CM, Smith G "Pharmacokinetics of single-dose i.v. morphine in normal volunteers and patients with end-stage renal failure." Br J Anaesth 56 (1984):  813-9|Sawe J, Odar-Cederlof I "Kinetics of morphine in patients with renal failure." Eur J Clin Pharmacol 32 (1987):  377-82|Baselt RC, Casarett LJ "Urinary excretion of methadone in man." Clin Pharmacol Ther 13 (1972):  64-70|Kreek MJ, Schecter AJ, Gutjahr CL, et al. "Methadone use in patients with chronic renal failure." Drug Alcohol Depend 5 (1980):  197-205|Leow KP, Smith MT, Williams B, Cramond T "Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer." Clin Pharmacol Ther 52 (1992):  487-95|Leow KP, Smith MT, Watt JA, Williams BE, Cramond T "Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration." Ther Drug Monit 14 (1992):  479-84|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Dixon R, Crews T, Inturrisi C, Foley K "Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain." Res Commun Chem Pathol Pharmacol 41 (1983):  3-17|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Hanna MH, D''Costa F, Peat SJ, Fung C, Venkat N, Zilkha TR, Davies S "Morphine-6-glucuronide disposition in renal impairment." Br J Anaesth 70 (1993):  511-4|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Gibson TP, Giacomini KM, Briggs WA, Whitman W, Levy G "Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient." Clin Pharmacol Ther 27 (1980):  665-70|Flanagan RJ, Johnston A, White AS, Crome P "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage." Br J Clin Pharmacol 28 (1989):  463-9|Giacomini KM, Gibson TP, Levy G "Plasma protein binding of d-propoxyphene in normal subjects and anephric patients." J Clin Pharmacol 18 (1978):  106-9|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|Dhonneur G, Gilton A, Sandouk P, Scherrmann JM, Duvaldestin P "Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine - the influence of renal failure." Anesthesiology 81 (1994):  87-93|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34724, 0, 'Butorphanol', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', 'Kaiko RF, Foley KM, Grabinski PY, et al. "Central nervous system excitatory effects of meperidine in cancer patients." Ann Neurol 13 (1983):  180-5|Goetting MG, Thirman MJ "Neurotoxicity of meperidine." Ann Emerg Med 14 (1985):  1007-9|Mauro VF, Bonfiglio MF, Spunt AL "Meperidine-induced seizure in a patient without renal dysfunction or sickle cell anemia." Clin Pharm 5 (1986):  837-9|Reutens DC, Stewart-Wynne EG "Norpethidine induced myoclonus in a patient with renal failure." J Neurol Neurosurg Psychiatry 52 (1989):  1450-1|Armstrong PJ, Bersten A "Normeperidine toxicity." Anesth Analg 65 (1986):  536-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|"Product Information. MS Contin (morphine)." Purdue Frederick Company  (2002):|Babul N, Darke AC "Putative role of hydromorphone metabolites in myoclonus." Pain 51 (1992):  260-1|Hagmeyer KO, Mauro LS, Mauro VF "Meperidine-related seizures associated with patient-controlled analgesia pumps." Ann Pharmacother 27 (1993):  29-32|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|Sebel PS, Bovill JG "Fentanyl and convulsions." Anesth Analg 62 (1983):  858-9|Rao TL, Mummaneni N, El-Etr AA "Convulsions: an unusual response to intravenous fentanyl administration." Anesth Analg 61 (1982):  1020-1|Goroszeniuk T, Albin M, Jones RM "Generalized grand mal seizure after recovery from uncomplicated fentanyl-etomidate anesthesia." Anesth Analg 65 (1986):  979-81|Hoien AO "Another case of grand mal seizure after fentanyl administration." Anesthesiology 60 (1984):  387-8|Safwat AM, Daniel D "Grand mal seizure after fentanyl administration." Anesthesiology 59 (1983):  78|Smith NT, Benthuysen JL, Bickford RG, Sanford TJ, Blasco T, Duke PC, Head N, Dec-Silver H "Seizures during opioid anesthetic induction--are they opioid-induced rigidity?" Anesthesiology 71 (1989):  852-62|Benthuysen JL, Stanley TH "Concerning the possible nature of reported fentanyl seizures." Anesthesiology 62 (1985):  205|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|Stone PA, Macintyre PE, Jarvis DA "Norpethidine toxicity and patient controlled analgesia." Br J Anaesth 71 (1993):  738-40|Sjogren P, Dragsted L, Christensen CB "Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure." Acta Anaesthesiol Scand 37 (1993):  780-2|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|Strong WE, Matson M "Probable seizure after alfentanil." Anesth Analg 68 (1989):  692-3|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34725, 0, 'Butorphanol', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', 'Kreek MJ, Hartman N "Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity." Ann N Y Acad Sci 398 (1982):  151-72|Petersen TK, Husted SE, Rybro L, et al. "Urinary retention during I.M. and extradural morphine analgesia." Br J Anaesth 54 (1982):  1175-8|"Product Information. Calcidrine (codeine)." Abbott Pharmaceutical  (2002):|"Product Information. Demerol (meperidine)." Sanofi Winthrop Pharmaceuticals  (2002):|"Product Information. Dolophine (methadone)." Lilly, Eli and Company  (2002):|"Product Information. Roxanol (morphine)." Roxane Laboratories Inc  (2002):|Petros JG, Mallen JK, Howe K, Rimm EB, Robillard RJ "Patient-controlled analgesia and postoperative urinary retention after open appendectomy." Surg Gynecol Obstet 177 (1993):  172-5|"Product Information. Levo-Dromoran (levorphanol)." Roche Laboratories  (2001):|"Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company  (2001):|"Product Information. Darvon (propoxyphene)." Lilly, Eli and Company  (2001):|"Product Information. Duragesic Transdermal System (fentanyl)." Janssen Pharmaceutica, Titusville, NJ.|"Product Information. Sublimaze (fentanyl)." Janssen Pharmaceuticals  (2001):|"Product Information. Fentanyl Oralet (fentanyl)." Abbott Pharmaceutical, Abbott Park, IL.|American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association;  (1994):|"Product Information. Alfenta (alfentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. Sufenta (sufentanil)." Janssen Pharmaceuticals  (2001):|"Product Information. OxyContin (oxycodone)." Purdue Frederick Company  (2001):|"Product Information. Ultiva (remifentanil)." Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):|"Product Information. Kadian (morphine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Vicoprofen (hydrocodone-ibuprofen)." Knoll Pharmaceutical Company  (2001):|"Product Information. Stadol (butorphanol nasal)." Bristol-Myers Squibb  (2001):|"Product Information. Nubain (nalbuphine)." Endo Laboratories LLC  (2001):|"Product Information. Buprenex (buprenorphine)." Reckitt and Colman Pharmaceuticals Inc  (2001):|"Product Information. Talwin NX (pentazocine)." Sanofi Winthrop Pharmaceuticals  (2001):|"Product Information. Stadol (butorphanol)." Allscrips Pharmaceutical Company  (2001):|"Product Information. Dalgan (dezocine)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Opium (opium)." Lilly, Eli and Company  (2022):|"Product Information. Numorphan (oxymorphone)." Endo Laboratories LLC  (2001):|"Product Information. Orlaam (levomethadyl acetate)." Roxane Laboratories Inc  (2001):|"Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34726, 15638, 'Calcitriol', 'Arrhythmias, Cardiac', 'Vitamin D analogs function to increase serum calcium concentrations and can exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34727, 15638, 'Calcitriol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34728, 15638, 'Calcitriol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34729, 15638, 'Calcitriol', 'Kidney Diseases', 'Ergocalciferol, cholecalciferol, and calcifediol undergo renal biotransformation during metabolic activation.  Renal impairment can alter metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as dihydrotachysterol (hepatic activation) and calcitriol (active form) may be considered in patients with compromised renal function.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34730, 15638, 'Calcitriol', 'Diseases requiring dialysis', 'Calcitriol increases inorganic phosphate levels in serum and caution should be used in patients with renal impairment to maintain adequate phosphorus levels and avoid ectopic calcification.  A non-aluminum phosphate-binding compound and a low phosphate diet should be used to control serum phosphorus levels in patients undergoing dialysis.', '2', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34731, 15638, 'Calcitriol', 'Liver Diseases', 'Vitamin D analogs are fat soluble and oral formulations require bile for adequate intestinal absorption.  Hepatic and/or biliary dysfunction decrease the absorption of vitamin D analogs.  Metabolites of vitamin D analogs are primarily excreted in bile and feces.  Ergocalciferol, cholecalciferol, and dihydrotachysterol undergo hepatic hydroxylation during metabolic activation.  Hepatic impairment can alter the metabolic and therapeutic activity of certain vitamin D analogs.  Alternative vitamin D analogs such as calcifediol (requires renal activation) and calcitriol (active form) may be considered in patients with compromised hepatic function.', '2', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34732, 15654, 'Calcipotriol (topical)', 'Hypercalcemia', 'The use of calcipotriene topical preparations is contraindicated in patients with demonstrated hypercalcemia or evidence of vitamin D toxicity.  Calcipotriene is a synthetic vitamin D3 analog.  Systemic absorption of topically applied calcipotriene ranges from less than 1% for the scalp solution to 5% to 6% for the ointment.  Calcipotriene has been reported to be 100 to 200 times less potent in its effects on calcium utilization than natural vitamin D, which facilitates the absorption of calcium in the intestine.  Transient, rapidly reversible elevation of serum calcium has been reported following the topical administration of calcipotriene.  If elevation in serum calcium outside the normal range occurs, treatment should be discontinued until normal calcium levels are restored.  Patients should be advised to contact their physician if they experience early symptoms of hypercalcemia such as weakness, fatigue, somnolence, headache, anorexia, dry mouth, metallic taste, nausea, vomiting, abdominal cramps, constipation, diarrhea, vertigo, tinnitus, ataxia, exanthema, muscle pain, bone pain, and irritability.', '3', 'Hardman KA, Heath DA, Nelson HM "Hypercalcaemia associated with calcipotriol (Dovonex) treatment." BMJ 306 (1993):  896|Berth-Jones J, Bourke JF, Iqbal SJ, Hutchinson PE "Urine calcium excretion during treatment of psoriasis with topical calcipotriol." Br J Dermatol 129 (1993):  411-4|Bourke JF, Berth-Jones J, Iqbal SJ, Hutchinson PE "High-dose topical calcipotriol in the treatment of extensive psoriasis vulgaris." Br J Dermatol 129 (1993):  74-6|Dubertret L, Wallach D, Souteyrand P, Perussel M, Kalis B, Meynadier J, Chevrant-Breton J, Beylot C, Bazex JA, Jurgensen HJ "Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris. A randomized, double-blind, right/left comparative, vehicle- controlled study." J Am Acad Dermatol 27 (1992):  983-8|Dwyer C, Chapman RS "Calcipotriol and hypercalcaemia." Lancet 338 (1991):  764-5|Mortensen L, Kragballe K, Wegmann E, Schifter S, Risteli J, Charles P "Treatment of psoriasis vulgaris with topical calcipotriol has no short-term effect on calcium or bone metabolism. A randomized, double- blind, placebo-controlled study." Acta Derm Venereol 73 (1993):  300-4|Murdoch D, Clissold SP "Calcipotriol. A review of its pharmacological properties and therapeutic use in psoriasis vulgaris." Drugs 43 (1992):  415-29|"Product Information. Dovonex (calcipotriene topical)." Westwood Squibb Pharmaceutical Corporation', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34733, 15658, 'Calcipotriol (topical)', 'Hypercalcemia', 'The use of calcipotriene topical preparations is contraindicated in patients with demonstrated hypercalcemia or evidence of vitamin D toxicity.  Calcipotriene is a synthetic vitamin D3 analog.  Systemic absorption of topically applied calcipotriene ranges from less than 1% for the scalp solution to 5% to 6% for the ointment.  Calcipotriene has been reported to be 100 to 200 times less potent in its effects on calcium utilization than natural vitamin D, which facilitates the absorption of calcium in the intestine.  Transient, rapidly reversible elevation of serum calcium has been reported following the topical administration of calcipotriene.  If elevation in serum calcium outside the normal range occurs, treatment should be discontinued until normal calcium levels are restored.  Patients should be advised to contact their physician if they experience early symptoms of hypercalcemia such as weakness, fatigue, somnolence, headache, anorexia, dry mouth, metallic taste, nausea, vomiting, abdominal cramps, constipation, diarrhea, vertigo, tinnitus, ataxia, exanthema, muscle pain, bone pain, and irritability.', '3', 'Hardman KA, Heath DA, Nelson HM "Hypercalcaemia associated with calcipotriol (Dovonex) treatment." BMJ 306 (1993):  896|Berth-Jones J, Bourke JF, Iqbal SJ, Hutchinson PE "Urine calcium excretion during treatment of psoriasis with topical calcipotriol." Br J Dermatol 129 (1993):  411-4|Bourke JF, Berth-Jones J, Iqbal SJ, Hutchinson PE "High-dose topical calcipotriol in the treatment of extensive psoriasis vulgaris." Br J Dermatol 129 (1993):  74-6|Dubertret L, Wallach D, Souteyrand P, Perussel M, Kalis B, Meynadier J, Chevrant-Breton J, Beylot C, Bazex JA, Jurgensen HJ "Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris. A randomized, double-blind, right/left comparative, vehicle- controlled study." J Am Acad Dermatol 27 (1992):  983-8|Dwyer C, Chapman RS "Calcipotriol and hypercalcaemia." Lancet 338 (1991):  764-5|Mortensen L, Kragballe K, Wegmann E, Schifter S, Risteli J, Charles P "Treatment of psoriasis vulgaris with topical calcipotriol has no short-term effect on calcium or bone metabolism. A randomized, double- blind, placebo-controlled study." Acta Derm Venereol 73 (1993):  300-4|Murdoch D, Clissold SP "Calcipotriol. A review of its pharmacological properties and therapeutic use in psoriasis vulgaris." Drugs 43 (1992):  415-29|"Product Information. Dovonex (calcipotriene topical)." Westwood Squibb Pharmaceutical Corporation', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34734, 15659, 'Calcipotriol (topical)', 'Hypercalcemia', 'The use of calcipotriene topical preparations is contraindicated in patients with demonstrated hypercalcemia or evidence of vitamin D toxicity.  Calcipotriene is a synthetic vitamin D3 analog.  Systemic absorption of topically applied calcipotriene ranges from less than 1% for the scalp solution to 5% to 6% for the ointment.  Calcipotriene has been reported to be 100 to 200 times less potent in its effects on calcium utilization than natural vitamin D, which facilitates the absorption of calcium in the intestine.  Transient, rapidly reversible elevation of serum calcium has been reported following the topical administration of calcipotriene.  If elevation in serum calcium outside the normal range occurs, treatment should be discontinued until normal calcium levels are restored.  Patients should be advised to contact their physician if they experience early symptoms of hypercalcemia such as weakness, fatigue, somnolence, headache, anorexia, dry mouth, metallic taste, nausea, vomiting, abdominal cramps, constipation, diarrhea, vertigo, tinnitus, ataxia, exanthema, muscle pain, bone pain, and irritability.', '3', 'Hardman KA, Heath DA, Nelson HM "Hypercalcaemia associated with calcipotriol (Dovonex) treatment." BMJ 306 (1993):  896|Berth-Jones J, Bourke JF, Iqbal SJ, Hutchinson PE "Urine calcium excretion during treatment of psoriasis with topical calcipotriol." Br J Dermatol 129 (1993):  411-4|Bourke JF, Berth-Jones J, Iqbal SJ, Hutchinson PE "High-dose topical calcipotriol in the treatment of extensive psoriasis vulgaris." Br J Dermatol 129 (1993):  74-6|Dubertret L, Wallach D, Souteyrand P, Perussel M, Kalis B, Meynadier J, Chevrant-Breton J, Beylot C, Bazex JA, Jurgensen HJ "Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris. A randomized, double-blind, right/left comparative, vehicle- controlled study." J Am Acad Dermatol 27 (1992):  983-8|Dwyer C, Chapman RS "Calcipotriol and hypercalcaemia." Lancet 338 (1991):  764-5|Mortensen L, Kragballe K, Wegmann E, Schifter S, Risteli J, Charles P "Treatment of psoriasis vulgaris with topical calcipotriol has no short-term effect on calcium or bone metabolism. A randomized, double- blind, placebo-controlled study." Acta Derm Venereol 73 (1993):  300-4|Murdoch D, Clissold SP "Calcipotriol. A review of its pharmacological properties and therapeutic use in psoriasis vulgaris." Drugs 43 (1992):  415-29|"Product Information. Dovonex (calcipotriene topical)." Westwood Squibb Pharmaceutical Corporation', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34735, 25461, 'Calcipotriol (topical)', 'Hypercalcemia', 'The use of calcipotriene topical preparations is contraindicated in patients with demonstrated hypercalcemia or evidence of vitamin D toxicity.  Calcipotriene is a synthetic vitamin D3 analog.  Systemic absorption of topically applied calcipotriene ranges from less than 1% for the scalp solution to 5% to 6% for the ointment.  Calcipotriene has been reported to be 100 to 200 times less potent in its effects on calcium utilization than natural vitamin D, which facilitates the absorption of calcium in the intestine.  Transient, rapidly reversible elevation of serum calcium has been reported following the topical administration of calcipotriene.  If elevation in serum calcium outside the normal range occurs, treatment should be discontinued until normal calcium levels are restored.  Patients should be advised to contact their physician if they experience early symptoms of hypercalcemia such as weakness, fatigue, somnolence, headache, anorexia, dry mouth, metallic taste, nausea, vomiting, abdominal cramps, constipation, diarrhea, vertigo, tinnitus, ataxia, exanthema, muscle pain, bone pain, and irritability.', '3', 'Hardman KA, Heath DA, Nelson HM "Hypercalcaemia associated with calcipotriol (Dovonex) treatment." BMJ 306 (1993):  896|Berth-Jones J, Bourke JF, Iqbal SJ, Hutchinson PE "Urine calcium excretion during treatment of psoriasis with topical calcipotriol." Br J Dermatol 129 (1993):  411-4|Bourke JF, Berth-Jones J, Iqbal SJ, Hutchinson PE "High-dose topical calcipotriol in the treatment of extensive psoriasis vulgaris." Br J Dermatol 129 (1993):  74-6|Dubertret L, Wallach D, Souteyrand P, Perussel M, Kalis B, Meynadier J, Chevrant-Breton J, Beylot C, Bazex JA, Jurgensen HJ "Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris. A randomized, double-blind, right/left comparative, vehicle- controlled study." J Am Acad Dermatol 27 (1992):  983-8|Dwyer C, Chapman RS "Calcipotriol and hypercalcaemia." Lancet 338 (1991):  764-5|Mortensen L, Kragballe K, Wegmann E, Schifter S, Risteli J, Charles P "Treatment of psoriasis vulgaris with topical calcipotriol has no short-term effect on calcium or bone metabolism. A randomized, double- blind, placebo-controlled study." Acta Derm Venereol 73 (1993):  300-4|Murdoch D, Clissold SP "Calcipotriol. A review of its pharmacological properties and therapeutic use in psoriasis vulgaris." Drugs 43 (1992):  415-29|"Product Information. Dovonex (calcipotriene topical)." Westwood Squibb Pharmaceutical Corporation', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34736, 29077, 'Calcipotriol (topical)', 'Hypercalcemia', 'The use of calcipotriene topical preparations is contraindicated in patients with demonstrated hypercalcemia or evidence of vitamin D toxicity.  Calcipotriene is a synthetic vitamin D3 analog.  Systemic absorption of topically applied calcipotriene ranges from less than 1% for the scalp solution to 5% to 6% for the ointment.  Calcipotriene has been reported to be 100 to 200 times less potent in its effects on calcium utilization than natural vitamin D, which facilitates the absorption of calcium in the intestine.  Transient, rapidly reversible elevation of serum calcium has been reported following the topical administration of calcipotriene.  If elevation in serum calcium outside the normal range occurs, treatment should be discontinued until normal calcium levels are restored.  Patients should be advised to contact their physician if they experience early symptoms of hypercalcemia such as weakness, fatigue, somnolence, headache, anorexia, dry mouth, metallic taste, nausea, vomiting, abdominal cramps, constipation, diarrhea, vertigo, tinnitus, ataxia, exanthema, muscle pain, bone pain, and irritability.', '3', 'Hardman KA, Heath DA, Nelson HM "Hypercalcaemia associated with calcipotriol (Dovonex) treatment." BMJ 306 (1993):  896|Berth-Jones J, Bourke JF, Iqbal SJ, Hutchinson PE "Urine calcium excretion during treatment of psoriasis with topical calcipotriol." Br J Dermatol 129 (1993):  411-4|Bourke JF, Berth-Jones J, Iqbal SJ, Hutchinson PE "High-dose topical calcipotriol in the treatment of extensive psoriasis vulgaris." Br J Dermatol 129 (1993):  74-6|Dubertret L, Wallach D, Souteyrand P, Perussel M, Kalis B, Meynadier J, Chevrant-Breton J, Beylot C, Bazex JA, Jurgensen HJ "Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris. A randomized, double-blind, right/left comparative, vehicle- controlled study." J Am Acad Dermatol 27 (1992):  983-8|Dwyer C, Chapman RS "Calcipotriol and hypercalcaemia." Lancet 338 (1991):  764-5|Mortensen L, Kragballe K, Wegmann E, Schifter S, Risteli J, Charles P "Treatment of psoriasis vulgaris with topical calcipotriol has no short-term effect on calcium or bone metabolism. A randomized, double- blind, placebo-controlled study." Acta Derm Venereol 73 (1993):  300-4|Murdoch D, Clissold SP "Calcipotriol. A review of its pharmacological properties and therapeutic use in psoriasis vulgaris." Drugs 43 (1992):  415-29|"Product Information. Dovonex (calcipotriene topical)." Westwood Squibb Pharmaceutical Corporation', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34737, 1854, 'Calcium carbonate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34738, 1877, 'Calcium carbonate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34739, 15624, 'Calcium carbonate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34740, 15646, 'Calcium carbonate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34741, 15649, 'Calcium carbonate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34742, 15670, 'Calcium carbonate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34743, 15883, 'Calcium carbonate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34744, 23997, 'Calcium carbonate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34745, 24230, 'Calcium carbonate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34746, 24308, 'Calcium carbonate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34747, 28880, 'Calcium carbonate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34748, 1854, 'Calcium carbonate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34749, 1877, 'Calcium carbonate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34750, 15624, 'Calcium carbonate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34751, 15646, 'Calcium carbonate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34752, 15649, 'Calcium carbonate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34753, 15670, 'Calcium carbonate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34754, 15883, 'Calcium carbonate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34755, 23997, 'Calcium carbonate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34756, 24230, 'Calcium carbonate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34757, 24308, 'Calcium carbonate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34758, 28880, 'Calcium carbonate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34759, 1854, 'Calcium carbonate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34760, 1877, 'Calcium carbonate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34761, 15624, 'Calcium carbonate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34762, 15646, 'Calcium carbonate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34763, 15649, 'Calcium carbonate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34764, 15670, 'Calcium carbonate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34765, 15883, 'Calcium carbonate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34766, 23997, 'Calcium carbonate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34767, 24230, 'Calcium carbonate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34768, 24308, 'Calcium carbonate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34769, 28880, 'Calcium carbonate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34770, 1854, 'Calcium carbonate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34771, 1877, 'Calcium carbonate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34772, 15624, 'Calcium carbonate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34773, 15646, 'Calcium carbonate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34774, 15649, 'Calcium carbonate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34775, 15670, 'Calcium carbonate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34776, 15883, 'Calcium carbonate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34777, 23997, 'Calcium carbonate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34778, 24230, 'Calcium carbonate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34779, 24308, 'Calcium carbonate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34780, 28880, 'Calcium carbonate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34781, 1854, 'Calcium carbonate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34782, 1877, 'Calcium carbonate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34783, 15624, 'Calcium carbonate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34784, 15646, 'Calcium carbonate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34785, 15649, 'Calcium carbonate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34786, 15670, 'Calcium carbonate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34787, 15883, 'Calcium carbonate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34788, 23997, 'Calcium carbonate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34789, 24230, 'Calcium carbonate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34790, 24308, 'Calcium carbonate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34791, 28880, 'Calcium carbonate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34792, 13907, 'Adalimumab', 'Infections', 'There have been reports of serious infections, including sepsis and opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis with TNF blockers.  Treatment with these agents should not be initiated in patients with an active infection, including clinically important localized infections.  Caution and close monitoring is recommended when considering their use in patients with a history of recurrent infections, underlying conditions which may predispose them to infections, or chronic, latent, or localized infections.  Administration of these agents should be discontinued if a patient develops a serious infection or sepsis.', '3', '"Product Information. Remicade (infliximab)." Centocor Inc  (2001):|"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):|"Product Information. Cimzia (certolizumab)." UCB Pharma Inc  (2008):|"Product Information. Simponi (golimumab)." Centocor Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34793, 20565, 'Adalimumab', 'Infections', 'There have been reports of serious infections, including sepsis and opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis with TNF blockers.  Treatment with these agents should not be initiated in patients with an active infection, including clinically important localized infections.  Caution and close monitoring is recommended when considering their use in patients with a history of recurrent infections, underlying conditions which may predispose them to infections, or chronic, latent, or localized infections.  Administration of these agents should be discontinued if a patient develops a serious infection or sepsis.', '3', '"Product Information. Remicade (infliximab)." Centocor Inc  (2001):|"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):|"Product Information. Cimzia (certolizumab)." UCB Pharma Inc  (2008):|"Product Information. Simponi (golimumab)." Centocor Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34794, 20566, 'Adalimumab', 'Infections', 'There have been reports of serious infections, including sepsis and opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis with TNF blockers.  Treatment with these agents should not be initiated in patients with an active infection, including clinically important localized infections.  Caution and close monitoring is recommended when considering their use in patients with a history of recurrent infections, underlying conditions which may predispose them to infections, or chronic, latent, or localized infections.  Administration of these agents should be discontinued if a patient develops a serious infection or sepsis.', '3', '"Product Information. Remicade (infliximab)." Centocor Inc  (2001):|"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):|"Product Information. Cimzia (certolizumab)." UCB Pharma Inc  (2008):|"Product Information. Simponi (golimumab)." Centocor Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34795, 30662, 'Adalimumab', 'Infections', 'There have been reports of serious infections, including sepsis and opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis with TNF blockers.  Treatment with these agents should not be initiated in patients with an active infection, including clinically important localized infections.  Caution and close monitoring is recommended when considering their use in patients with a history of recurrent infections, underlying conditions which may predispose them to infections, or chronic, latent, or localized infections.  Administration of these agents should be discontinued if a patient develops a serious infection or sepsis.', '3', '"Product Information. Remicade (infliximab)." Centocor Inc  (2001):|"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):|"Product Information. Cimzia (certolizumab)." UCB Pharma Inc  (2008):|"Product Information. Simponi (golimumab)." Centocor Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34796, 32403, 'Adalimumab', 'Infections', 'There have been reports of serious infections, including sepsis and opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis with TNF blockers.  Treatment with these agents should not be initiated in patients with an active infection, including clinically important localized infections.  Caution and close monitoring is recommended when considering their use in patients with a history of recurrent infections, underlying conditions which may predispose them to infections, or chronic, latent, or localized infections.  Administration of these agents should be discontinued if a patient develops a serious infection or sepsis.', '3', '"Product Information. Remicade (infliximab)." Centocor Inc  (2001):|"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):|"Product Information. Cimzia (certolizumab)." UCB Pharma Inc  (2008):|"Product Information. Simponi (golimumab)." Centocor Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34797, 13907, 'Adalimumab', 'Neoplasms', 'In clinical trials malignancies have been observed in patients receiving TNF-blockers agents.  Patients with psoriasis should be monitored for non-melanoma skin cancers (NMSCs), particularly those patients who have had prior prolonged phototherapy treatment.  Melanoma and Merkel cell carcinoma have been reported in patients treated with TNF blocker therapy.  Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer.  Postmarketing cases of fatal hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with TNF blockers.  Caution should be exercised when considering these agents in the treatment of patients with a history of malignancies or in continuing treatment in patients who develop malignancies while receiving these agents.', '3', '"Product Information. Remicade (infliximab)." Centocor Inc  (2001):|"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):|"Product Information. Cimzia (certolizumab)." UCB Pharma Inc  (2008):|"Product Information. Simponi (golimumab)." Centocor Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34798, 20565, 'Adalimumab', 'Neoplasms', 'In clinical trials malignancies have been observed in patients receiving TNF-blockers agents.  Patients with psoriasis should be monitored for non-melanoma skin cancers (NMSCs), particularly those patients who have had prior prolonged phototherapy treatment.  Melanoma and Merkel cell carcinoma have been reported in patients treated with TNF blocker therapy.  Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer.  Postmarketing cases of fatal hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with TNF blockers.  Caution should be exercised when considering these agents in the treatment of patients with a history of malignancies or in continuing treatment in patients who develop malignancies while receiving these agents.', '3', '"Product Information. Remicade (infliximab)." Centocor Inc  (2001):|"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):|"Product Information. Cimzia (certolizumab)." UCB Pharma Inc  (2008):|"Product Information. Simponi (golimumab)." Centocor Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34799, 20566, 'Adalimumab', 'Neoplasms', 'In clinical trials malignancies have been observed in patients receiving TNF-blockers agents.  Patients with psoriasis should be monitored for non-melanoma skin cancers (NMSCs), particularly those patients who have had prior prolonged phototherapy treatment.  Melanoma and Merkel cell carcinoma have been reported in patients treated with TNF blocker therapy.  Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer.  Postmarketing cases of fatal hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with TNF blockers.  Caution should be exercised when considering these agents in the treatment of patients with a history of malignancies or in continuing treatment in patients who develop malignancies while receiving these agents.', '3', '"Product Information. Remicade (infliximab)." Centocor Inc  (2001):|"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):|"Product Information. Cimzia (certolizumab)." UCB Pharma Inc  (2008):|"Product Information. Simponi (golimumab)." Centocor Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34800, 30662, 'Adalimumab', 'Neoplasms', 'In clinical trials malignancies have been observed in patients receiving TNF-blockers agents.  Patients with psoriasis should be monitored for non-melanoma skin cancers (NMSCs), particularly those patients who have had prior prolonged phototherapy treatment.  Melanoma and Merkel cell carcinoma have been reported in patients treated with TNF blocker therapy.  Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer.  Postmarketing cases of fatal hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with TNF blockers.  Caution should be exercised when considering these agents in the treatment of patients with a history of malignancies or in continuing treatment in patients who develop malignancies while receiving these agents.', '3', '"Product Information. Remicade (infliximab)." Centocor Inc  (2001):|"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):|"Product Information. Cimzia (certolizumab)." UCB Pharma Inc  (2008):|"Product Information. Simponi (golimumab)." Centocor Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34801, 32403, 'Adalimumab', 'Neoplasms', 'In clinical trials malignancies have been observed in patients receiving TNF-blockers agents.  Patients with psoriasis should be monitored for non-melanoma skin cancers (NMSCs), particularly those patients who have had prior prolonged phototherapy treatment.  Melanoma and Merkel cell carcinoma have been reported in patients treated with TNF blocker therapy.  Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer.  Postmarketing cases of fatal hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with TNF blockers.  Caution should be exercised when considering these agents in the treatment of patients with a history of malignancies or in continuing treatment in patients who develop malignancies while receiving these agents.', '3', '"Product Information. Remicade (infliximab)." Centocor Inc  (2001):|"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):|"Product Information. Cimzia (certolizumab)." UCB Pharma Inc  (2008):|"Product Information. Simponi (golimumab)." Centocor Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34802, 13907, 'Adalimumab', 'Neurotoxicity Syndromes', 'The use of TNF blocking agents has been associated with rare cases of CNS manifestations of systemic vasculitis, seizure and new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disorders, including multiple sclerosis and optic neuritis, and peripheral demyelinating disorders, including Guillain-Barr syndrome.  Care should be exercised when considering the use of these agents in patients with neurologic disorders and discontinuing the agent is recommended if these disorders develop during therapy.', '3', '"Product Information. Remicade (infliximab)." Centocor Inc  (2001):|"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):|"Product Information. Cimzia (certolizumab)." UCB Pharma Inc  (2008):|"Product Information. Simponi (golimumab)." Centocor Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34803, 20565, 'Adalimumab', 'Neurotoxicity Syndromes', 'The use of TNF blocking agents has been associated with rare cases of CNS manifestations of systemic vasculitis, seizure and new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disorders, including multiple sclerosis and optic neuritis, and peripheral demyelinating disorders, including Guillain-Barr syndrome.  Care should be exercised when considering the use of these agents in patients with neurologic disorders and discontinuing the agent is recommended if these disorders develop during therapy.', '3', '"Product Information. Remicade (infliximab)." Centocor Inc  (2001):|"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):|"Product Information. Cimzia (certolizumab)." UCB Pharma Inc  (2008):|"Product Information. Simponi (golimumab)." Centocor Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34804, 20566, 'Adalimumab', 'Neurotoxicity Syndromes', 'The use of TNF blocking agents has been associated with rare cases of CNS manifestations of systemic vasculitis, seizure and new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disorders, including multiple sclerosis and optic neuritis, and peripheral demyelinating disorders, including Guillain-Barr syndrome.  Care should be exercised when considering the use of these agents in patients with neurologic disorders and discontinuing the agent is recommended if these disorders develop during therapy.', '3', '"Product Information. Remicade (infliximab)." Centocor Inc  (2001):|"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):|"Product Information. Cimzia (certolizumab)." UCB Pharma Inc  (2008):|"Product Information. Simponi (golimumab)." Centocor Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34805, 30662, 'Adalimumab', 'Neurotoxicity Syndromes', 'The use of TNF blocking agents has been associated with rare cases of CNS manifestations of systemic vasculitis, seizure and new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disorders, including multiple sclerosis and optic neuritis, and peripheral demyelinating disorders, including Guillain-Barr syndrome.  Care should be exercised when considering the use of these agents in patients with neurologic disorders and discontinuing the agent is recommended if these disorders develop during therapy.', '3', '"Product Information. Remicade (infliximab)." Centocor Inc  (2001):|"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):|"Product Information. Cimzia (certolizumab)." UCB Pharma Inc  (2008):|"Product Information. Simponi (golimumab)." Centocor Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34806, 32403, 'Adalimumab', 'Neurotoxicity Syndromes', 'The use of TNF blocking agents has been associated with rare cases of CNS manifestations of systemic vasculitis, seizure and new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disorders, including multiple sclerosis and optic neuritis, and peripheral demyelinating disorders, including Guillain-Barr syndrome.  Care should be exercised when considering the use of these agents in patients with neurologic disorders and discontinuing the agent is recommended if these disorders develop during therapy.', '3', '"Product Information. Remicade (infliximab)." Centocor Inc  (2001):|"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):|"Product Information. Cimzia (certolizumab)." UCB Pharma Inc  (2008):|"Product Information. Simponi (golimumab)." Centocor Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34807, 13907, 'Adalimumab', 'Tuberculosis', 'Cases of reactivation of tuberculosis or new tuberculosis infections have been observed in patients receiving TNF blocking agents, including patients who have previously received treatment for latent or active tuberculosis.  Cases of active tuberculosis have also occurred in patients being treated with these agents during treatment for latent tuberculosis.  Prior to initiating TNF blocking agents, patients should be screened for latent tuberculosis infection with a tuberculin skin test and periodically during therapy.  Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy with TNF blocking agents.  Anti-tuberculosis therapy should also be considered prior to initiation of therapy in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection.  Tuberculosis should be strongly considered in patients who develop a new infection during treatment, especially in patients who have previously or recently traveled to countries with a high prevalence of tuberculosis, or who have had close contact with a person with active tuberculosis.', '3', '"Product Information. Remicade (infliximab)." Centocor Inc  (2001):|"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):|"Product Information. Cimzia (certolizumab)." UCB Pharma Inc  (2008):|"Product Information. Simponi (golimumab)." Centocor Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34808, 20565, 'Adalimumab', 'Tuberculosis', 'Cases of reactivation of tuberculosis or new tuberculosis infections have been observed in patients receiving TNF blocking agents, including patients who have previously received treatment for latent or active tuberculosis.  Cases of active tuberculosis have also occurred in patients being treated with these agents during treatment for latent tuberculosis.  Prior to initiating TNF blocking agents, patients should be screened for latent tuberculosis infection with a tuberculin skin test and periodically during therapy.  Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy with TNF blocking agents.  Anti-tuberculosis therapy should also be considered prior to initiation of therapy in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection.  Tuberculosis should be strongly considered in patients who develop a new infection during treatment, especially in patients who have previously or recently traveled to countries with a high prevalence of tuberculosis, or who have had close contact with a person with active tuberculosis.', '3', '"Product Information. Remicade (infliximab)." Centocor Inc  (2001):|"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):|"Product Information. Cimzia (certolizumab)." UCB Pharma Inc  (2008):|"Product Information. Simponi (golimumab)." Centocor Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34809, 20566, 'Adalimumab', 'Tuberculosis', 'Cases of reactivation of tuberculosis or new tuberculosis infections have been observed in patients receiving TNF blocking agents, including patients who have previously received treatment for latent or active tuberculosis.  Cases of active tuberculosis have also occurred in patients being treated with these agents during treatment for latent tuberculosis.  Prior to initiating TNF blocking agents, patients should be screened for latent tuberculosis infection with a tuberculin skin test and periodically during therapy.  Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy with TNF blocking agents.  Anti-tuberculosis therapy should also be considered prior to initiation of therapy in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection.  Tuberculosis should be strongly considered in patients who develop a new infection during treatment, especially in patients who have previously or recently traveled to countries with a high prevalence of tuberculosis, or who have had close contact with a person with active tuberculosis.', '3', '"Product Information. Remicade (infliximab)." Centocor Inc  (2001):|"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):|"Product Information. Cimzia (certolizumab)." UCB Pharma Inc  (2008):|"Product Information. Simponi (golimumab)." Centocor Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34810, 30662, 'Adalimumab', 'Tuberculosis', 'Cases of reactivation of tuberculosis or new tuberculosis infections have been observed in patients receiving TNF blocking agents, including patients who have previously received treatment for latent or active tuberculosis.  Cases of active tuberculosis have also occurred in patients being treated with these agents during treatment for latent tuberculosis.  Prior to initiating TNF blocking agents, patients should be screened for latent tuberculosis infection with a tuberculin skin test and periodically during therapy.  Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy with TNF blocking agents.  Anti-tuberculosis therapy should also be considered prior to initiation of therapy in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection.  Tuberculosis should be strongly considered in patients who develop a new infection during treatment, especially in patients who have previously or recently traveled to countries with a high prevalence of tuberculosis, or who have had close contact with a person with active tuberculosis.', '3', '"Product Information. Remicade (infliximab)." Centocor Inc  (2001):|"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):|"Product Information. Cimzia (certolizumab)." UCB Pharma Inc  (2008):|"Product Information. Simponi (golimumab)." Centocor Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34811, 32403, 'Adalimumab', 'Tuberculosis', 'Cases of reactivation of tuberculosis or new tuberculosis infections have been observed in patients receiving TNF blocking agents, including patients who have previously received treatment for latent or active tuberculosis.  Cases of active tuberculosis have also occurred in patients being treated with these agents during treatment for latent tuberculosis.  Prior to initiating TNF blocking agents, patients should be screened for latent tuberculosis infection with a tuberculin skin test and periodically during therapy.  Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy with TNF blocking agents.  Anti-tuberculosis therapy should also be considered prior to initiation of therapy in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection.  Tuberculosis should be strongly considered in patients who develop a new infection during treatment, especially in patients who have previously or recently traveled to countries with a high prevalence of tuberculosis, or who have had close contact with a person with active tuberculosis.', '3', '"Product Information. Remicade (infliximab)." Centocor Inc  (2001):|"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):|"Product Information. Cimzia (certolizumab)." UCB Pharma Inc  (2008):|"Product Information. Simponi (golimumab)." Centocor Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34812, 13907, 'Adalimumab', 'Heart Failure', 'Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers.  Cases of worsening CHF have also been observed with adalimumab.  Adalimumab has not been formally studied in patients with CHF; however, in clinical trials of another TNF blocker, a higher rate of serious CHF-related adverse reactions was observed.  Exercise caution when using adalimumab in patients who have heart failure and monitor them carefully.', '2', '"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34813, 20565, 'Adalimumab', 'Heart Failure', 'Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers.  Cases of worsening CHF have also been observed with adalimumab.  Adalimumab has not been formally studied in patients with CHF; however, in clinical trials of another TNF blocker, a higher rate of serious CHF-related adverse reactions was observed.  Exercise caution when using adalimumab in patients who have heart failure and monitor them carefully.', '2', '"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34814, 20566, 'Adalimumab', 'Heart Failure', 'Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers.  Cases of worsening CHF have also been observed with adalimumab.  Adalimumab has not been formally studied in patients with CHF; however, in clinical trials of another TNF blocker, a higher rate of serious CHF-related adverse reactions was observed.  Exercise caution when using adalimumab in patients who have heart failure and monitor them carefully.', '2', '"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34815, 30662, 'Adalimumab', 'Heart Failure', 'Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers.  Cases of worsening CHF have also been observed with adalimumab.  Adalimumab has not been formally studied in patients with CHF; however, in clinical trials of another TNF blocker, a higher rate of serious CHF-related adverse reactions was observed.  Exercise caution when using adalimumab in patients who have heart failure and monitor them carefully.', '2', '"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34816, 32403, 'Adalimumab', 'Heart Failure', 'Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers.  Cases of worsening CHF have also been observed with adalimumab.  Adalimumab has not been formally studied in patients with CHF; however, in clinical trials of another TNF blocker, a higher rate of serious CHF-related adverse reactions was observed.  Exercise caution when using adalimumab in patients who have heart failure and monitor them carefully.', '2', '"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34817, 13907, 'Adalimumab', 'Pulmonary Disease, Chronic Obstructive', 'In controlled trials of other TNF blockers, other than adalimumab, in adult patients at higher risk for malignancies (i.e., patients with COPD with a significant smoking history and cyclophosphamide-treated patients with Wegener''s granulomatosis), a greater portion of malignancies occurred in the TNF blocker group compared to the control group.', '2', '"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34818, 20565, 'Adalimumab', 'Pulmonary Disease, Chronic Obstructive', 'In controlled trials of other TNF blockers, other than adalimumab, in adult patients at higher risk for malignancies (i.e., patients with COPD with a significant smoking history and cyclophosphamide-treated patients with Wegener''s granulomatosis), a greater portion of malignancies occurred in the TNF blocker group compared to the control group.', '2', '"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34819, 20566, 'Adalimumab', 'Pulmonary Disease, Chronic Obstructive', 'In controlled trials of other TNF blockers, other than adalimumab, in adult patients at higher risk for malignancies (i.e., patients with COPD with a significant smoking history and cyclophosphamide-treated patients with Wegener''s granulomatosis), a greater portion of malignancies occurred in the TNF blocker group compared to the control group.', '2', '"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34820, 30662, 'Adalimumab', 'Pulmonary Disease, Chronic Obstructive', 'In controlled trials of other TNF blockers, other than adalimumab, in adult patients at higher risk for malignancies (i.e., patients with COPD with a significant smoking history and cyclophosphamide-treated patients with Wegener''s granulomatosis), a greater portion of malignancies occurred in the TNF blocker group compared to the control group.', '2', '"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34821, 32403, 'Adalimumab', 'Pulmonary Disease, Chronic Obstructive', 'In controlled trials of other TNF blockers, other than adalimumab, in adult patients at higher risk for malignancies (i.e., patients with COPD with a significant smoking history and cyclophosphamide-treated patients with Wegener''s granulomatosis), a greater portion of malignancies occurred in the TNF blocker group compared to the control group.', '2', '"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34822, 13907, 'Adalimumab', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, thrombocytopenia, and pancytopenia, some with a fatal outcome, have been reported in patients treated with TNF blocking agents.  Caution should be exercised when treating patients who have ongoing or a history of significant hematologic abnormalities.  Discontinuation of therapy should be considered in patients with confirmed significant hematologic abnormalities.', '2', '"Product Information. Remicade (infliximab)." Centocor Inc  (2001):|"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):|"Product Information. Cimzia (certolizumab)." UCB Pharma Inc  (2008):|"Product Information. Simponi (golimumab)." Centocor Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34823, 20565, 'Adalimumab', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, thrombocytopenia, and pancytopenia, some with a fatal outcome, have been reported in patients treated with TNF blocking agents.  Caution should be exercised when treating patients who have ongoing or a history of significant hematologic abnormalities.  Discontinuation of therapy should be considered in patients with confirmed significant hematologic abnormalities.', '2', '"Product Information. Remicade (infliximab)." Centocor Inc  (2001):|"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):|"Product Information. Cimzia (certolizumab)." UCB Pharma Inc  (2008):|"Product Information. Simponi (golimumab)." Centocor Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34824, 20566, 'Adalimumab', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, thrombocytopenia, and pancytopenia, some with a fatal outcome, have been reported in patients treated with TNF blocking agents.  Caution should be exercised when treating patients who have ongoing or a history of significant hematologic abnormalities.  Discontinuation of therapy should be considered in patients with confirmed significant hematologic abnormalities.', '2', '"Product Information. Remicade (infliximab)." Centocor Inc  (2001):|"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):|"Product Information. Cimzia (certolizumab)." UCB Pharma Inc  (2008):|"Product Information. Simponi (golimumab)." Centocor Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34825, 30662, 'Adalimumab', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, thrombocytopenia, and pancytopenia, some with a fatal outcome, have been reported in patients treated with TNF blocking agents.  Caution should be exercised when treating patients who have ongoing or a history of significant hematologic abnormalities.  Discontinuation of therapy should be considered in patients with confirmed significant hematologic abnormalities.', '2', '"Product Information. Remicade (infliximab)." Centocor Inc  (2001):|"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):|"Product Information. Cimzia (certolizumab)." UCB Pharma Inc  (2008):|"Product Information. Simponi (golimumab)." Centocor Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34826, 32403, 'Adalimumab', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, thrombocytopenia, and pancytopenia, some with a fatal outcome, have been reported in patients treated with TNF blocking agents.  Caution should be exercised when treating patients who have ongoing or a history of significant hematologic abnormalities.  Discontinuation of therapy should be considered in patients with confirmed significant hematologic abnormalities.', '2', '"Product Information. Remicade (infliximab)." Centocor Inc  (2001):|"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):|"Product Information. Cimzia (certolizumab)." UCB Pharma Inc  (2008):|"Product Information. Simponi (golimumab)." Centocor Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34827, 13907, 'Adalimumab', 'Hepatitis B', 'The use of TNF blockers has been associated with reactivation of hepatitis B, in some cases fatal, in patients who were previously infected with the hepatitis B virus (HBV).  Therefore, screening for viral hepatitis should be performed in accordance with published guidelines before starting therapy with these agents.  Monitor patients at risk or with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation.  Prescribers should exercise caution in prescribing TNF blockers in patients previously infected with HBV.  It is recommended to monitor patients with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation during and for several months following therapy.  In patients who develop HBV reactivation, therapy should be stopped and antiviral therapy with appropriate supportive treatment should be initiated.  The safety of resuming these agents after HBV reactivation is controlled is not known.  Therefore, prescribers should weigh the risks and benefits when considering resumption of therapy.', '2', '"Product Information. Remicade (infliximab)." Centocor Inc  (2001):|"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):|"Product Information. Cimzia (certolizumab)." UCB Pharma Inc  (2008):|"Product Information. Simponi (golimumab)." Centocor Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34828, 20565, 'Adalimumab', 'Hepatitis B', 'The use of TNF blockers has been associated with reactivation of hepatitis B, in some cases fatal, in patients who were previously infected with the hepatitis B virus (HBV).  Therefore, screening for viral hepatitis should be performed in accordance with published guidelines before starting therapy with these agents.  Monitor patients at risk or with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation.  Prescribers should exercise caution in prescribing TNF blockers in patients previously infected with HBV.  It is recommended to monitor patients with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation during and for several months following therapy.  In patients who develop HBV reactivation, therapy should be stopped and antiviral therapy with appropriate supportive treatment should be initiated.  The safety of resuming these agents after HBV reactivation is controlled is not known.  Therefore, prescribers should weigh the risks and benefits when considering resumption of therapy.', '2', '"Product Information. Remicade (infliximab)." Centocor Inc  (2001):|"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):|"Product Information. Cimzia (certolizumab)." UCB Pharma Inc  (2008):|"Product Information. Simponi (golimumab)." Centocor Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34829, 20566, 'Adalimumab', 'Hepatitis B', 'The use of TNF blockers has been associated with reactivation of hepatitis B, in some cases fatal, in patients who were previously infected with the hepatitis B virus (HBV).  Therefore, screening for viral hepatitis should be performed in accordance with published guidelines before starting therapy with these agents.  Monitor patients at risk or with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation.  Prescribers should exercise caution in prescribing TNF blockers in patients previously infected with HBV.  It is recommended to monitor patients with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation during and for several months following therapy.  In patients who develop HBV reactivation, therapy should be stopped and antiviral therapy with appropriate supportive treatment should be initiated.  The safety of resuming these agents after HBV reactivation is controlled is not known.  Therefore, prescribers should weigh the risks and benefits when considering resumption of therapy.', '2', '"Product Information. Remicade (infliximab)." Centocor Inc  (2001):|"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):|"Product Information. Cimzia (certolizumab)." UCB Pharma Inc  (2008):|"Product Information. Simponi (golimumab)." Centocor Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34830, 30662, 'Adalimumab', 'Hepatitis B', 'The use of TNF blockers has been associated with reactivation of hepatitis B, in some cases fatal, in patients who were previously infected with the hepatitis B virus (HBV).  Therefore, screening for viral hepatitis should be performed in accordance with published guidelines before starting therapy with these agents.  Monitor patients at risk or with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation.  Prescribers should exercise caution in prescribing TNF blockers in patients previously infected with HBV.  It is recommended to monitor patients with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation during and for several months following therapy.  In patients who develop HBV reactivation, therapy should be stopped and antiviral therapy with appropriate supportive treatment should be initiated.  The safety of resuming these agents after HBV reactivation is controlled is not known.  Therefore, prescribers should weigh the risks and benefits when considering resumption of therapy.', '2', '"Product Information. Remicade (infliximab)." Centocor Inc  (2001):|"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):|"Product Information. Cimzia (certolizumab)." UCB Pharma Inc  (2008):|"Product Information. Simponi (golimumab)." Centocor Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34831, 32403, 'Adalimumab', 'Hepatitis B', 'The use of TNF blockers has been associated with reactivation of hepatitis B, in some cases fatal, in patients who were previously infected with the hepatitis B virus (HBV).  Therefore, screening for viral hepatitis should be performed in accordance with published guidelines before starting therapy with these agents.  Monitor patients at risk or with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation.  Prescribers should exercise caution in prescribing TNF blockers in patients previously infected with HBV.  It is recommended to monitor patients with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation during and for several months following therapy.  In patients who develop HBV reactivation, therapy should be stopped and antiviral therapy with appropriate supportive treatment should be initiated.  The safety of resuming these agents after HBV reactivation is controlled is not known.  Therefore, prescribers should weigh the risks and benefits when considering resumption of therapy.', '2', '"Product Information. Remicade (infliximab)." Centocor Inc  (2001):|"Product Information. Humira (adalimumab)." Abbott Pharmaceutical  (2003):|"Product Information. Cimzia (certolizumab)." UCB Pharma Inc  (2008):|"Product Information. Simponi (golimumab)." Centocor Inc  (2009):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34832, 3595, 'Calcium acetate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34833, 7723, 'Calcium acetate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34834, 15668, 'Calcium acetate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34835, 3595, 'Calcium acetate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34836, 7723, 'Calcium acetate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34837, 15668, 'Calcium acetate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34838, 3595, 'Calcium acetate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34839, 7723, 'Calcium acetate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34840, 15668, 'Calcium acetate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34841, 3595, 'Calcium acetate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34842, 7723, 'Calcium acetate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34843, 15668, 'Calcium acetate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34844, 3595, 'Calcium acetate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34845, 7723, 'Calcium acetate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34846, 15668, 'Calcium acetate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34847, 1872, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34848, 1876, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34849, 1879, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34850, 1906, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34851, 1947, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34852, 3939, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34853, 4042, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34854, 8090, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34855, 10403, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34856, 11625, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34857, 13595, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34858, 13710, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34859, 15419, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34860, 15682, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34861, 15725, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34862, 15726, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34863, 21356, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34864, 21365, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34865, 21833, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34866, 22182, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34867, 24198, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34868, 25869, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34869, 26187, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34870, 27022, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34871, 30248, 'Calcium citrate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34872, 1872, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34873, 1876, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34874, 1879, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34875, 1906, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34876, 1947, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34877, 3939, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34878, 4042, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34879, 8090, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34880, 10403, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34881, 11625, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34882, 13595, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34883, 13710, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34884, 15419, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34885, 15682, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34886, 15725, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34887, 15726, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34888, 21356, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34889, 21365, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34890, 21833, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34891, 22182, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34892, 24198, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34893, 25869, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34894, 26187, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34895, 27022, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34896, 30248, 'Calcium citrate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34897, 1872, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34898, 1876, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34899, 1879, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34900, 1906, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34901, 1947, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34902, 3939, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34903, 4042, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34904, 8090, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34905, 10403, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34906, 11625, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34907, 13595, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34908, 13710, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34909, 15419, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34910, 15682, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34911, 15725, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34912, 15726, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34913, 21356, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34914, 21365, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34915, 21833, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34916, 22182, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34917, 24198, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34918, 25869, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34919, 26187, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34920, 27022, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34921, 30248, 'Calcium citrate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34922, 1872, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34923, 1876, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34924, 1879, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34925, 1906, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34926, 1947, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34927, 3939, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34928, 4042, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34929, 8090, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34930, 10403, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34931, 11625, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34932, 13595, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34933, 13710, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34934, 15419, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34935, 15682, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34936, 15725, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34937, 15726, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34938, 21356, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34939, 21365, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34940, 21833, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34941, 22182, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34942, 24198, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34943, 25869, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34944, 26187, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34945, 27022, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34946, 30248, 'Calcium citrate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34947, 1872, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34948, 1876, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34949, 1879, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34950, 1906, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34951, 1947, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34952, 3939, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34953, 4042, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34954, 8090, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34955, 10403, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34956, 11625, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34957, 13595, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34958, 13710, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34959, 15419, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34960, 15682, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34961, 15725, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34962, 15726, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34963, 21356, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34964, 21365, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34965, 21833, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34966, 22182, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34967, 24198, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34968, 25869, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34969, 26187, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34970, 27022, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34971, 30248, 'Calcium citrate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34972, 202, 'Calcium gluconate', 'Hyperphosphatemia', 'Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body.  Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment).  Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  These complexes are eliminated in the feces.  Clinical monitoring of serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34973, 202, 'Calcium gluconate', 'Cardiac Conduction System Disease', 'Calcium is involved in cardiac muscle contraction and electrical impulse conduction.  Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease.  Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias.  Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34974, 202, 'Calcium gluconate', 'Malabsorption Syndromes', 'Calcium is absorbed from the intestinal tract by active transport and passive diffusion.  Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium.  Calcium is available in oral and parenteral formulations.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34975, 202, 'Calcium gluconate', 'Kidney Diseases', 'Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment.  Hyperphosphatemia occurs during renal failure.  Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract.  Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure.  Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34976, 202, 'Calcium gluconate', 'Sarcoidosis', 'Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis.  Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma.  Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.', '3', '"Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins|"Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34977, 17544, 'Canagliflozin', 'Liver Diseases', 'Sodium-glucose cotransporter 2 (SGLT2) inhibitors ertugliflozin and canagliflozin are not recommended for use in patients with severe hepatic impairment due to lack of clinical data.  Dapagliflozin has not been studied in patients with severe hepatic impairment and caution is recommended.  Dosage adjustments are not necessary in patients with mild or moderate hepatic impairment.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34978, 17545, 'Canagliflozin', 'Liver Diseases', 'Sodium-glucose cotransporter 2 (SGLT2) inhibitors ertugliflozin and canagliflozin are not recommended for use in patients with severe hepatic impairment due to lack of clinical data.  Dapagliflozin has not been studied in patients with severe hepatic impairment and caution is recommended.  Dosage adjustments are not necessary in patients with mild or moderate hepatic impairment.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34979, 20920, 'Canagliflozin', 'Liver Diseases', 'Sodium-glucose cotransporter 2 (SGLT2) inhibitors ertugliflozin and canagliflozin are not recommended for use in patients with severe hepatic impairment due to lack of clinical data.  Dapagliflozin has not been studied in patients with severe hepatic impairment and caution is recommended.  Dosage adjustments are not necessary in patients with mild or moderate hepatic impairment.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34980, 20921, 'Canagliflozin', 'Liver Diseases', 'Sodium-glucose cotransporter 2 (SGLT2) inhibitors ertugliflozin and canagliflozin are not recommended for use in patients with severe hepatic impairment due to lack of clinical data.  Dapagliflozin has not been studied in patients with severe hepatic impairment and caution is recommended.  Dosage adjustments are not necessary in patients with mild or moderate hepatic impairment.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34981, 24578, 'Canagliflozin', 'Liver Diseases', 'Sodium-glucose cotransporter 2 (SGLT2) inhibitors ertugliflozin and canagliflozin are not recommended for use in patients with severe hepatic impairment due to lack of clinical data.  Dapagliflozin has not been studied in patients with severe hepatic impairment and caution is recommended.  Dosage adjustments are not necessary in patients with mild or moderate hepatic impairment.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34982, 24579, 'Canagliflozin', 'Liver Diseases', 'Sodium-glucose cotransporter 2 (SGLT2) inhibitors ertugliflozin and canagliflozin are not recommended for use in patients with severe hepatic impairment due to lack of clinical data.  Dapagliflozin has not been studied in patients with severe hepatic impairment and caution is recommended.  Dosage adjustments are not necessary in patients with mild or moderate hepatic impairment.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34983, 17544, 'Canagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34984, 17545, 'Canagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34985, 20920, 'Canagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34986, 20921, 'Canagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34987, 24578, 'Canagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34988, 24579, 'Canagliflozin', 'Kidney Diseases', 'The glucose lowering effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors is decreased in patients with worsening renal function.  Additionally, patients with renal impairment function (eGFR less than 60 mL/min/1.73 m2) the elderly, and patients on loop diuretics may be more likely to experience adverse reactions related to volume depletion such as hypotension and acute kidney injury during therapy.  Renal function should be evaluated prior to treatment initiation and monitored regularly in at-risk patients.  Assess volume status and correct volume depletion before initiating therapy.  The use of SGLT-2 inhibitors in patients undergoing dialysis is contraindicated.  In both patients with and without type 2 diabetes, beneficial effects in chronic kidney disease and heart failure have been observed with SGLT2 inhibitor therapy.  The manufacturer''s product labeling should be consulted for indication specific renal dosing for SGLT2 inhibitors.', '3', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34989, 17544, 'Canagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34990, 17545, 'Canagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34991, 20920, 'Canagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34992, 20921, 'Canagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34993, 24578, 'Canagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34994, 24579, 'Canagliflozin', 'Hypotension', 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors cause intravascular volume contraction which may lead to symptomatic hypotension after treatment initiation especially in the elderly, in patients with impaired renal function, patients with low systolic blood pressure, or those using diuretics .  Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.', '2', '"Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals  (2013):|"Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb  (2014):|"Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim  (2014):|"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34995, 17544, 'Canagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34996, 17545, 'Canagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34997, 20920, 'Canagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34998, 20921, 'Canagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (34999, 24578, 'Canagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (35000, 24579, 'Canagliflozin', 'Infections', 'An increase in the risk of genital mycotic infections has been reported with the use of a sodium-glucose cotransporter 2 (SGLT-2) inhibitors.  Care should be exercised when using this agent in patients who have a history of genital mycotic infections or who are uncircumcised as these patients are more likely to develop genital mycotic infections.  Monitor and treat appropriately.', '2', '"Product Information. Steglatro (ertugliflozin)." Merck & Co., Inc  (2017):', 'DDInter', 0);